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Chapter 1
Optimal Nutrition in the Paediatric Intensive Care Unit
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Optimal Nutrition in the Paediatric ICU 
Current Opinion in Clinical Nutrition and Metabolic Care 2016;19:131-137
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INTRODUCTION 
 
Nutrition is essential for adequate growth and development in all children. In times of critical 
illness, the acute metabolic stress response temporarily inhibits these processes in favour of 
the teleological impulse to survive. Alongside this, optimal nutrition deserves a prominent 
position in intensive care therapy because critically ill children are at high risk of developing 
nutritional deficiencies due to limited body reserves of fat and protein while energy 
expenditure is higher. In several studies, nutritional deficits in critically ill children were 
associated with increased catabolism,1-3 nutritional status deterioration,4-7 and worse clinical 
outcomes.8,9 Although these studies were not designed to provide causal relations between 
nutritional deficiencies and clinical outcomes, these associations form the basis of presumed 
benefit of aggressive feeding strategies to achieve optimal nutrition in critically ill children.  
 
DEFINING OPTIMAL NUTRITION 
 
When applying a nutritional intervention, one should take into account the phases of illness, 
since an intervention could be beneficial during one phase, yet have detrimental effects when 
applied in another phase. The first phase of critical illness is the acute phase, in which children 
admitted to the paediatric intensive care unit (PICU) require (increasing) vital organ support. 
After the acute phase comes the stable phase, characterised by stabilisation or weaning from 
vital organ support, followed by the recovery phase, in which the child is no longer in need of 
vital organ support. During the evolution of these phases of illness, metabolic, immunologic 
and endocrine alterations occur, which require different nutritional needs.10  
To define optimal nutrition, a distinction can be made between surrogate and clear 
clinical outcome parameters. A stepwise approach can be used to describe these surrogate 
(step 1, 2, 3) and clinical (step 4 and 5) outcome parameters (Figure 1). A summary of these 
outcome parameters is given in Table 1.  
 
 
 
 
Figure 1: Stepwise approach defining optimal nutrition 
 
ICER = incremental cost-effectiveness ratio. 
 
STEP 1: BIOCHEMICAL  INDICES 
 
Biochemical changes predominantly found in the acute phase of critical illness are 
characterisations of a hypercatabolic state, while in the stable and recovery phase they might 
reflect the child’s nutritional status. Biochemical indices that can be obtained at the bedside 
include plasma concentrations of glucose, albumin, triglycerides, fatty acids, trace elements, 
and vitamins. Other indices such as amino acid levels, nitrogen balance, and stable isotope 
tracer investigations are not easily obtained. 
 
Amino acid concentrations 
A few recent studies analysed the amino acid profiles of critically ill children after an 
intervention. A sub-analysis (n=100) of a large randomised controlled trial (RCT) in critically ill 
children post-cardiac surgery showed amino acid profiles at different time points under 
conditions of two different glycemic control strategies.11 Both increased as well as decreased 
amino acid profiles were observed at baseline and time profiles also differed considerably. 
Higher total amino acid concentrations were found in neonates and in non-survivors. Whether 
these differences in specific amino acids reflected nutritional status or catabolism remains 
unclear. Furthermore, several studies on critically ill infants, with a limited number of patients, 
have shown that amino acid profiles can be affected by modulating both enteral and 
parenteral nutrition.2,12-14 Whether plasma amino acid levels can be used to estimate protein 
catabolism and to guide nutritional interventions is currently under debate. Recent findings 
show that low blood amino acid levels are the result of increased availability of glucagon, 
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which stimulates hepatic amino acid breakdown and ureagenesis, and is even intensified by 
exogenous amino acid administration.15-17 
 
Nitrogen balances 
Commonly used methods to calculate protein turnover are nitrogen balance and stable 
isotope tracer infusion. Although nitrogen balance is predominantly used, this method 
requires an adaptation period which is extremely difficult to establish in critically ill children. 
In a systematic review of 9 studies, a correlation between energy and protein intake and 
protein balance in critically ill children on mechanical ventilation was shown. A minimum 
intake of 1.5 g/kg/day protein and 57 kcal/kg/day energy was associated with a protein 
anabolic state (Figure 2).3  
 
Figure 2: Protein balance associated with the corresponding level of A, protein intake 
(Spearman r=0.729; p=0.011) and B, energy intake (r=0.721; p=0.012) in critically ill children 
(adapted with permission from Bechard LJ et al.3) 
 
 
 
Stable isotopes 
In contrast with nitrogen balance studies, stable isotope tracer studies only require a steady 
state for a period of hours instead of days. In stable isotopes studies in critically ill infants and 
adolescents, high protein intake (3 g/kg protein) compared with 1.5 g/kg protein provided net 
positive protein balance.1,2 However, in septic adolescents this beneficial effect was offset by 
enhanced endogenous glucose production and lipolysis, which raised concerns of an increased 
insulin resistance.1  
 
Glucose homeostasis 
One of the measurements that can easily be obtained at the bedside is blood glucose 
concentration, which is influenced by macronutrient intake and metabolism, and is regulated 
by hormones. Hyperglycaemia frequently occurs during the acute phase of critical illness and 
is a complication commonly feared among paediatricians. In a recent RCT with the acronym 
 
 
 
“PEPaNIC” (Paediatric Early versus Late Parenteral Nutrition in Critical Illness), in which 
critically ill children were randomly allocated to early initiation (<24 hours) of supplemental 
parenteral nutrition (PN) or withholding PN during the first week, the risk of hypoglycaemia 
was increased in the Late-PN group.18 Both the correct definition of hypoglycaemia and the 
long-term consequences of a brief period of low glucose levels without clinical signs remain 
uncertain.19-23 In contrast, hyperglycaemia above 145 mg/dL (above 8 mmol/L) has 
consistently been associated with increased morbidity and mortality.24,25 A meta-analysis of 4 
trials in critically ill children revealed that tight blood glucose control did not decrease 
mortality, but reduced new infections, at the expense of higher incidence of hypoglycemia.26  
 
Lipids 
Dyslipidaemia during critical illness is characterised by increased plasma triglycerides, free 
fatty acids, and very-low-density lipoproteins (VLDL) on the one hand and a decreased 
cholesterol content of both high- and low-density lipoproteins (HDL, LDL) on the other. A 
number of factors may decrease the clearance rate of lipids and increase the level of serum 
triglycerides: malnutrition (lower levels of lipoprotein lipase), the lipolytic effect of drugs (like 
steroids), lipid-containing drugs (like propofol, amphotericin B), metabolic stress, and organ 
dysfunction. Upper limits for plasma triglycerides are used to guide optimal lipid provision: for 
infants a level of  >250 mg/dL (>2.9 mmol/L) and for older children >400 mg/dL (>4.6 mmol/L). 
Providing lipids allows a high energy supply, facilitates the prevention of high glucose infusion 
rates, and is indispensable for the supply of essential fatty acids. However, the optimal 
composition remains a topic of discussion. Although immunomodulation with different fatty 
acid compositions has gained widespread interest, studies in critically ill children are scarce. 
In critically ill children, enteral nutrition (EN) enriched with eicosapentaenoic acid and γ-
linolenic acid effectively modulated plasma phospholipid fatty acid concentrations, 
theoretically reflecting an anti-inflammatory profile.27 The use of soybean oil emulsions, which 
have been the primary choice for years, was associated with compromised immune function 
and PN associated liver disease. Although a recent systematic review did not find significant 
evidence that a combined lipid emulsion offers any benefit as compared with a soybean oil 
emulsion,28 pure soybean oil emulsions may provide less balanced nutrition than combined 
lipid emulsions.29 If a child depends on PN longer than a few days, recently updated European 
guidelines recommends replacing pure soybean oil emulsions by combined lipid emulsions 
with or without fish oil.29 Fish oil based or combined lipid emulsions are capable of changing 
the fatty acid plasma profile and antioxidant defense system in children.30  
Overall, there are several studies that have looked at plasma levels of macronutrients 
during critical illness as well as their changes after a nutritional intervention. In clinical 
practice, advanced biochemical indices are hard to obtain, which makes them less suitable to 
guide daily nutritional management. However, biochemical indices are important scientific 
outcome measures to give more insight into the underlying mechanisms of nutritional 
interventions. When using these outcomes, one should keep in mind that an improved 
biochemical outcome does not necessarily translate into  better outcomes for the patient. 
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Therefore, if possible, findings from studies using biochemical outcomes should be related to 
short- and long-term clinical outcomes. 
 
STEP 2: BODY COMPOSITION 
 
Anthropometry 
Changes in nutritional status are traditionally assessed by alterations in body composition, 
predominantly with the use of anthropometric measurements including weight, height, and 
head circumference. Alternatively, mid-upper arm circumference can be used to identify 
undernutrition or to estimate a child’s weight.31,32  
To diagnose undernutrition and overweight in children, Z-scores for weight-for-age, 
weight-for-length, length-for-age, and body mass index (BMI)-for-age are commonly used. Z-
scores can be based on the World Health Organisation child growth standards, or on country 
or syndrome-specific growth charts. Children with a Z-score <-2 are considered 
undernourished in most studies. A few studies have reported the relationship between altered 
body composition, measured with anthropometric variables, and outcomes. In a study of 385 
children admitted to a PICU, 45% were undernourished on admission, which was associated 
with an increased duration of mechanical ventilation (6.3 vs 5.1 days).33 Several other studies 
showed an association between undernutrition and multi-organ failure, mortality, prolonged 
PICU stay, and duration of mechanical ventilation.34-36 Currently, it is not clear whether 
overweight or obesity is associated with the impaired outcome on the PICU.37-41  
There is a scarcity of data addressing the evolution of body composition during 
admission and at follow-up, and the effect of nutrition hereon. In an observational study of 
293 critically ill children, the nutritional status deteriorated from admission to discharge, but 
recovered within 6 months after discharge.42 Lower enteral intake was associated with 
deterioration of the nutritional status.4-7 In a study of 325 children who stayed at least 4 days 
at the PICU, 19% were acutely undernourished on admission.43 In a subgroup of 223 children, 
the proportion of acutely undernourished children at discharge (26%) was not significantly 
different from that on admission (22%).43 In this study, no association was found between the 
amount of energy intake or route of nutrition and clinical outcomes, but this study was not 
designed to find these differences.43 In a recent study, faltering growth – defined as a 
deceleration of >1 Z-score within 3 months – during the first year after PICU admission was 
associated with a longer length of PICU stay.44 However, the role of nutrition during PICU stay 
was not investigated in this study.    
 
Dual X-ray absorptiometry, bioelectrical impedance analysis, air plethysmography 
In the PICU, other methods to measure nutritional status such as dual X-ray absorptiometry 
(DXA), bioelectrical impedance analysis (BIA), and air plethysmography are still rarely 
performed due to the practical and logistic limitations of these measurements. In one study, 
in which 592 children with burns were studied, DXA was used on admission and discharge. A 
higher loss of bone mineral density was found in obese children whereas normal weighing 
 
 
 
patients showed no major change during this time. All children gained whole body fat during 
hospital stay and the loss of lean body mass was nearly equal in both groups.45 Recently, the 
prognostic value of a phase angle measurement by use of BIA (which is a measure of 
undernutrition) was investigated in children admitted following congenital heart defect 
surgery. A lower phase angle on admission to the PICU and at day 2 was associated with a 
PICU stay longer than 4 days,46 suggesting that this can possibly be used as a very early 
outcome measure to predict short-term clinical outcomes. 
It can be concluded from the literature that undernutrition on admission to a PICU is 
associated with impaired outcomes. So far, it is unknown whether short-term changes in body 
composition predispose for long-term sustained body composition alterations. Furthermore, 
it is unknown if and how nutritional interventions during PICU stay can alter the course of a 
nutritional status, as there are no studies investigating a causal relation. If a nutritional status 
would be modifiable, it is unknown whether preventing deterioration of it actually leads to 
improved clinical, long-term outcomes. Thus, the value of body composition as a measure of 
outcome is still unclear.  
 
STEP 3: ORGAN FUNCTION 
 
Optimal nutrition might enhance recovery of organ functions (nerve, muscle, hormonal 
function, lung, liver, skin). 
 
Muscle strength 
The reported incidence of muscle weakness in critically ill children varies from 1.7% to 
30%.47,48 Muscle mass, as measured by the thickness of the femoral quadriceps,  decreased 
up to 13% during PICU stay.49 Muscle and nerve dysfunction exacerbated by critical illness 
already begins within hours of PICU admission,50 and was associated with functional disability 
in adults,51,52 and with both a longer need for mechanical ventilation and longer length of PICU 
stay in children.53 After the acute phase, handgrip strength can be tested in children aged 4 
years and older to investigate muscle function. In observational studies in hospitalized non-
critically ill children, there was an independent association between inflammation and 
handgrip strength.54 In critically ill mice and adults, PN was not capable of preventing muscle 
wasting.16 In fact, early administration of PN increased muscle weakness and reduced 
autophagic quality control of myofibres.55 The absence of an effect of PN on muscle wasting 
might be explained by increased hepatic amino acids breakdown, mediated by higher 
glucagon availability, which is enhanced by amino acid administration.16 Currently, it is 
unknown whether nutrition can affect muscle mass or function in critically ill children. 
 
Hormonal function 
One of the hormonal axes affected by critical illness is the thyroid axis, leading to non-thyroidal 
illness syndrome (NTI), which is characterised by an increased peripheral inactivation of 
thyroid hormone. The severity of NTI was associated with a prolonged duration of PICU stay 
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Changes in nutritional status are traditionally assessed by alterations in body composition, 
predominantly with the use of anthropometric measurements including weight, height, and 
head circumference. Alternatively, mid-upper arm circumference can be used to identify 
undernutrition or to estimate a child’s weight.31,32  
To diagnose undernutrition and overweight in children, Z-scores for weight-for-age, 
weight-for-length, length-for-age, and body mass index (BMI)-for-age are commonly used. Z-
scores can be based on the World Health Organisation child growth standards, or on country 
or syndrome-specific growth charts. Children with a Z-score <-2 are considered 
undernourished in most studies. A few studies have reported the relationship between altered 
body composition, measured with anthropometric variables, and outcomes. In a study of 385 
children admitted to a PICU, 45% were undernourished on admission, which was associated 
with an increased duration of mechanical ventilation (6.3 vs 5.1 days).33 Several other studies 
showed an association between undernutrition and multi-organ failure, mortality, prolonged 
PICU stay, and duration of mechanical ventilation.34-36 Currently, it is not clear whether 
overweight or obesity is associated with the impaired outcome on the PICU.37-41  
There is a scarcity of data addressing the evolution of body composition during 
admission and at follow-up, and the effect of nutrition hereon. In an observational study of 
293 critically ill children, the nutritional status deteriorated from admission to discharge, but 
recovered within 6 months after discharge.42 Lower enteral intake was associated with 
deterioration of the nutritional status.4-7 In a study of 325 children who stayed at least 4 days 
at the PICU, 19% were acutely undernourished on admission.43 In a subgroup of 223 children, 
the proportion of acutely undernourished children at discharge (26%) was not significantly 
different from that on admission (22%).43 In this study, no association was found between the 
amount of energy intake or route of nutrition and clinical outcomes, but this study was not 
designed to find these differences.43 In a recent study, faltering growth – defined as a 
deceleration of >1 Z-score within 3 months – during the first year after PICU admission was 
associated with a longer length of PICU stay.44 However, the role of nutrition during PICU stay 
was not investigated in this study.    
 
Dual X-ray absorptiometry, bioelectrical impedance analysis, air plethysmography 
In the PICU, other methods to measure nutritional status such as dual X-ray absorptiometry 
(DXA), bioelectrical impedance analysis (BIA), and air plethysmography are still rarely 
performed due to the practical and logistic limitations of these measurements. In one study, 
in which 592 children with burns were studied, DXA was used on admission and discharge. A 
higher loss of bone mineral density was found in obese children whereas normal weighing 
 
 
 
patients showed no major change during this time. All children gained whole body fat during 
hospital stay and the loss of lean body mass was nearly equal in both groups.45 Recently, the 
prognostic value of a phase angle measurement by use of BIA (which is a measure of 
undernutrition) was investigated in children admitted following congenital heart defect 
surgery. A lower phase angle on admission to the PICU and at day 2 was associated with a 
PICU stay longer than 4 days,46 suggesting that this can possibly be used as a very early 
outcome measure to predict short-term clinical outcomes. 
It can be concluded from the literature that undernutrition on admission to a PICU is 
associated with impaired outcomes. So far, it is unknown whether short-term changes in body 
composition predispose for long-term sustained body composition alterations. Furthermore, 
it is unknown if and how nutritional interventions during PICU stay can alter the course of a 
nutritional status, as there are no studies investigating a causal relation. If a nutritional status 
would be modifiable, it is unknown whether preventing deterioration of it actually leads to 
improved clinical, long-term outcomes. Thus, the value of body composition as a measure of 
outcome is still unclear.  
 
STEP 3: ORGAN FUNCTION 
 
Optimal nutrition might enhance recovery of organ functions (nerve, muscle, hormonal 
function, lung, liver, skin). 
 
Muscle strength 
The reported incidence of muscle weakness in critically ill children varies from 1.7% to 
30%.47,48 Muscle mass, as measured by the thickness of the femoral quadriceps,  decreased 
up to 13% during PICU stay.49 Muscle and nerve dysfunction exacerbated by critical illness 
already begins within hours of PICU admission,50 and was associated with functional disability 
in adults,51,52 and with both a longer need for mechanical ventilation and longer length of PICU 
stay in children.53 After the acute phase, handgrip strength can be tested in children aged 4 
years and older to investigate muscle function. In observational studies in hospitalized non-
critically ill children, there was an independent association between inflammation and 
handgrip strength.54 In critically ill mice and adults, PN was not capable of preventing muscle 
wasting.16 In fact, early administration of PN increased muscle weakness and reduced 
autophagic quality control of myofibres.55 The absence of an effect of PN on muscle wasting 
might be explained by increased hepatic amino acids breakdown, mediated by higher 
glucagon availability, which is enhanced by amino acid administration.16 Currently, it is 
unknown whether nutrition can affect muscle mass or function in critically ill children. 
 
Hormonal function 
One of the hormonal axes affected by critical illness is the thyroid axis, leading to non-thyroidal 
illness syndrome (NTI), which is characterised by an increased peripheral inactivation of 
thyroid hormone. The severity of NTI was associated with a prolonged duration of PICU stay 
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in critically ill children with meningococcal sepsis.56 In critically ill adults with low or no 
macronutrient intake, NTI was further aggravated.57 In a small RCT among critically ill children 
with severe burns, initiating EN after 48 hours resulted in lower T3 concentrations, compared 
to when EN was initiated within 24 hours.58 In a mixed group of critically ill children, a fasting 
response mimicked by tight glycaemic control resulted in a more pronounced peripheral 
inactivation of thyroid hormone.59 This aggravated peripheral inactivation was associated with 
a higher likelihood of an earlier live discharge from the PICU, suggesting that enhancement of 
the early catabolic response to critical illness might be beneficial. Regarding the somatotropic 
axis, tight glycaemic control in critically ill children led to increased blood growth hormone 
concentrations and decreased bioavailable insulin-like growth factor-1, possibly partly due to 
increased peripheral growth hormone resistance.60 In contrast with all other hypothalamus-
pituitary-peripheral axes, the hypothalamus-pituitary-adrenal axis shows a pattern of typically 
high cortisol levels, with low levels of adrenocorticotropic hormone. Although nutrition can 
influence the cortisol concentration in healthy individuals, in critically ill adults, early 
administration of PN did not result in elevated cortisol levels, compared to when PN was 
postponed beyond the first week of admission to the intensive care unit.61  
The studies addressing tight glycaemic control in critically ill children showed that a 
metabolic/nutritional intervention is capable of altering hormone levels. To what extend the 
hormonal axes of critically ill children can be affected by nutrient intake has not been explored 
yet. 
 
Lung function 
In regard to lung function in mechanically ventilated children, weaning from mechanical 
ventilation is dependent on several pathophysiological conditions, such as neuromuscular 
incompetence, diaphragmatic muscle weakness, and nutritional disorder. Currently, no 
studies exist that have shown nutritional status or nutritional strategies to affect either lung 
function or weaning parameters. 
 
Liver function 
Abnormal blood levels of liver enzymes often indicate liver dysfunction and are routinely used 
in clinical practice. The PEPaNIC RCT showed that withholding PN during the first week in PICU 
(Late-PN) resulted in lower peak plasma concentrations of gamma-glutamyl transpeptidase 
(γ-GT) and alkaline phosphatase (ALP), and in higher plasma total bilirubin concentration, as 
compared with Early-PN.18 Alkaline aminotransferase (ALAT) and aspartate aminotransferase 
(ASAT) were unaffected by PN.18 However, when the plasma concentrations of γ-GT, ALP, 
ALAT, and ASAT were analysed per day, there we no differences between the randomised 
groups.62 Daily plasma bilirubin concentrations were elevated by Late-PN but were 
comparable to those of the Early-PN group when PN was started after 1 week.62 Further 
evaluation of these findings revealed that, during the first week, the prevalence of cholestasis 
(3.8%-4.9%) and hepatitis (0.8%-2.2%) were low, and unaffected by PN.62 A mild elevation of 
 
 
 
plasma bilirubin at day 1, between 0.20 mg/dL and 0.76 mg/dL, was associated with a lower 
risk of mortality.62 
 
Wound healing 
In case of burn injury, skin healing is an important treatment outcome. Recovery is 
characterised by catabolic and hypermetabolic responses that may persist for up to 2 years. 
Only 1 study with a small group (18 children, 20-40% total body surface burned) showed that 
an increase of dietary protein intake from 1.1 to 2.9 g/kg/day might enhance skin healing.63 
So far, however, no RCTs in children with burns have studied the influence of nutritional 
strategies on skin healing. 
It can be concluded that studies which relate nutrition to organ function are scarce. 
These outcome parameters could be of interest, as some organ dysfunctions persist in the 
long-term, which could impair the daily functioning and quality of life of PICU-survivors.  
 
STEP 4: SHORT-TERM CLINICAL OUTCOMES 
 
In the past decades, the advancement of new techniques has led to a decline in mortality rates 
of PICU patients to <5% in developed countries.18,64 Subsequently, measures of morbidity have 
become more important. Other short-term clinical outcome measures are length of stay (PICU 
or hospital), duration of mechanical ventilation, incidence of new infections and other 
complications. Numerous studies showed a clear association between malnutrition and these 
outcomes. Some recent studies suggested that early nutritional support might influence the 
short-term outcomes. In a retrospective study of 306 children between 8 and 18 years of age 
with traumatic brain injury, a shorter time to initiation of nutritional support was associated 
with a decreased length of stay, and a shorter time to reach full caloric intake was associated 
with improved neurological status at discharge.65 A multicentre retrospective study, 
performed in 5105 critically ill children with a PICU length of stay of ≥4 days, showed that 
children who received at least 25% of targeted energy intake enterally over the first 48 hours 
of admission, were less likely to die than those who did not.66 Recently, in two multicentre 
prospective cohort studies in children older than 1 month who required mechanical 
ventilation longer than 48 hours, it was shown that higher enteral intake (67% of targeted 
intake) and delivery of more than 60% of prescribed protein intake were associated with lower 
60-day mortality.8,9 It should be noted that all abovementioned studies were observational, 
which includes a risk of confounding, as both nutritional intake and clinical outcome can be 
affected by the severity of illness, medication, age, and many other variables. One small RCT 
has been performed in children with severe burns, investigating initiation of EN within 24 
hours versus after 48 hours, in which no effect on clinical outcomes was found.58 However, 
this study might have been underpowered. Overall, it is widely accepted, but based on 
predominantly observational studies, that early initiation of EN and higher enteral intake is 
preferred.  
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in critically ill children with meningococcal sepsis.56 In critically ill adults with low or no 
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a higher likelihood of an earlier live discharge from the PICU, suggesting that enhancement of 
the early catabolic response to critical illness might be beneficial. Regarding the somatotropic 
axis, tight glycaemic control in critically ill children led to increased blood growth hormone 
concentrations and decreased bioavailable insulin-like growth factor-1, possibly partly due to 
increased peripheral growth hormone resistance.60 In contrast with all other hypothalamus-
pituitary-peripheral axes, the hypothalamus-pituitary-adrenal axis shows a pattern of typically 
high cortisol levels, with low levels of adrenocorticotropic hormone. Although nutrition can 
influence the cortisol concentration in healthy individuals, in critically ill adults, early 
administration of PN did not result in elevated cortisol levels, compared to when PN was 
postponed beyond the first week of admission to the intensive care unit.61  
The studies addressing tight glycaemic control in critically ill children showed that a 
metabolic/nutritional intervention is capable of altering hormone levels. To what extend the 
hormonal axes of critically ill children can be affected by nutrient intake has not been explored 
yet. 
 
Lung function 
In regard to lung function in mechanically ventilated children, weaning from mechanical 
ventilation is dependent on several pathophysiological conditions, such as neuromuscular 
incompetence, diaphragmatic muscle weakness, and nutritional disorder. Currently, no 
studies exist that have shown nutritional status or nutritional strategies to affect either lung 
function or weaning parameters. 
 
Liver function 
Abnormal blood levels of liver enzymes often indicate liver dysfunction and are routinely used 
in clinical practice. The PEPaNIC RCT showed that withholding PN during the first week in PICU 
(Late-PN) resulted in lower peak plasma concentrations of gamma-glutamyl transpeptidase 
(γ-GT) and alkaline phosphatase (ALP), and in higher plasma total bilirubin concentration, as 
compared with Early-PN.18 Alkaline aminotransferase (ALAT) and aspartate aminotransferase 
(ASAT) were unaffected by PN.18 However, when the plasma concentrations of γ-GT, ALP, 
ALAT, and ASAT were analysed per day, there we no differences between the randomised 
groups.62 Daily plasma bilirubin concentrations were elevated by Late-PN but were 
comparable to those of the Early-PN group when PN was started after 1 week.62 Further 
evaluation of these findings revealed that, during the first week, the prevalence of cholestasis 
(3.8%-4.9%) and hepatitis (0.8%-2.2%) were low, and unaffected by PN.62 A mild elevation of 
 
 
 
plasma bilirubin at day 1, between 0.20 mg/dL and 0.76 mg/dL, was associated with a lower 
risk of mortality.62 
 
Wound healing 
In case of burn injury, skin healing is an important treatment outcome. Recovery is 
characterised by catabolic and hypermetabolic responses that may persist for up to 2 years. 
Only 1 study with a small group (18 children, 20-40% total body surface burned) showed that 
an increase of dietary protein intake from 1.1 to 2.9 g/kg/day might enhance skin healing.63 
So far, however, no RCTs in children with burns have studied the influence of nutritional 
strategies on skin healing. 
It can be concluded that studies which relate nutrition to organ function are scarce. 
These outcome parameters could be of interest, as some organ dysfunctions persist in the 
long-term, which could impair the daily functioning and quality of life of PICU-survivors.  
 
STEP 4: SHORT-TERM CLINICAL OUTCOMES 
 
In the past decades, the advancement of new techniques has led to a decline in mortality rates 
of PICU patients to <5% in developed countries.18,64 Subsequently, measures of morbidity have 
become more important. Other short-term clinical outcome measures are length of stay (PICU 
or hospital), duration of mechanical ventilation, incidence of new infections and other 
complications. Numerous studies showed a clear association between malnutrition and these 
outcomes. Some recent studies suggested that early nutritional support might influence the 
short-term outcomes. In a retrospective study of 306 children between 8 and 18 years of age 
with traumatic brain injury, a shorter time to initiation of nutritional support was associated 
with a decreased length of stay, and a shorter time to reach full caloric intake was associated 
with improved neurological status at discharge.65 A multicentre retrospective study, 
performed in 5105 critically ill children with a PICU length of stay of ≥4 days, showed that 
children who received at least 25% of targeted energy intake enterally over the first 48 hours 
of admission, were less likely to die than those who did not.66 Recently, in two multicentre 
prospective cohort studies in children older than 1 month who required mechanical 
ventilation longer than 48 hours, it was shown that higher enteral intake (67% of targeted 
intake) and delivery of more than 60% of prescribed protein intake were associated with lower 
60-day mortality.8,9 It should be noted that all abovementioned studies were observational, 
which includes a risk of confounding, as both nutritional intake and clinical outcome can be 
affected by the severity of illness, medication, age, and many other variables. One small RCT 
has been performed in children with severe burns, investigating initiation of EN within 24 
hours versus after 48 hours, in which no effect on clinical outcomes was found.58 However, 
this study might have been underpowered. Overall, it is widely accepted, but based on 
predominantly observational studies, that early initiation of EN and higher enteral intake is 
preferred.  
18 
CHAPTER 1
 
 
 
If caloric targets cannot be reached by EN, supplemental PN is routinely used in the 
PICU.67 In a previous observational study, the use of PN was associated with higher mortality.8 
Recent systematic reviews showed that there is a scarcity of RCTs investigating PN in critically 
ill children using clinical outcomes.68,69 Currently, 1 large RCT has been done to investigate the 
effects of PN. In 2016, the short-term clinical results from the multicentre, international RCT 
“PEPaNIC” were published.18 In this study, 1440 critically ill children, with an expected PICU 
stay longer than 24 hours, and expected insufficient EN longer than 24 hours were randomized 
into “Early-PN” (initiation of PN within 24 hours) or “Late-PN” (withholding PN during the first 
week) if the exclusion criteria were not met. This study was executed in the PICUs of Leuven 
(Belgium), Rotterdam (The Netherlands), and Edmonton (Canada). The children were aged 
from term newborns to 17 years. Children in the Early-PN group received PN to supplement 
EN until the amount of calories delivered enterally was above 80% of target. In the Late-PN 
group, a dextrose 5%/saline mixture was administered intravenously until EN was above 80% 
of target to match the amount of fluid administered to children in the Early-PN group. At day 
8, PN was also started in the Late-PN group if EN was still insufficient. Initiation and incline of 
EN were similar in the treatment groups and all children received intravenous vitamins, 
minerals, and trace elements if EN was under 80% of target.  
In this study,18 Late-PN was clinically superior to Early-PN on relevant outcome 
measures: among others, it reduced the incidence of new infections and shortened length of 
PICU and hospital stay. There was no significant difference in mortality. However, the 
incidence of hypoglycaemia (<40 mg/dL [<2.2 mmol/L]) was higher in the Late-PN group. 
Furthermore, a post hoc secondary analysis from this study showed that higher doses of amino 
acids, but not lipids or glucose, were associated with an increased risk of acquiring new 
infections, a longer duration of PICU dependency, and a longed need for mechanical 
ventilatory support.70 
Aside from the position this trial took in the new guidelines, another major 
contribution was that it provided firm support for the role of nutrition as therapeutic 
intervention for critically ill children. Interestingly, children with the highest risk of 
malnutrition benefitted the most from Late-PN regarding the primary outcomes.18 
Furthermore, term neonates had a larger reduction in length of PICU stay with Late-PN than 
older children.18 Since the clinical short-term outcomes were not analysed in detail in these 
subgroups, many questions remained unanswered. Hence, concerns were raised by 
nutritional experts on the efficacy and safety of withholding PN for a week in undernourished 
children and neonates.71-75 Furthermore, concerns were raised on possible weight 
deterioration due to reduced nutritional intake.71 Thus, this RCT provided important answers 
and showed that nutrition can impact clinical outcome, yet also raised new questions, which 
need to be addressed. 
From the current literature, it can be concluded that early (within 48 hours) and higher 
(67% of goal) enteral intake is associated with better short-term outcomes, although evidence 
for causality is lacking. Adequate EN can be achieved by the choice of an appropriate route of 
enteral feeding, by the timing of the start of EN, by administering protein-energy enriched 
 
 
 
formula and by overcoming the common barriers to start or continue EN.76,77 Based on 1 RCT 
it can be concluded that withholding PN during the first week results in improved short-term 
outcomes. There is a need for more RCTs investigating the effect of nutritional intervention 
on short-term outcome parameters.  
 
STEP 5: LONG-TERM AND SOCIETAL HEALTH-RELATED ECONOMIC OUTCOMES 
 
Physical outcomes 
Children who are discharged from the PICU and hospital often suffer for years from sustained 
morbidity.78,79 Children with oesophageal atresia showed impaired growth up to the age of 8 
years, which was normalised at age 12 years.80 On the contrary, children with congenital 
diaphragmatic hernia showed impaired growth up to age 12 years.81 Furthermore, post-PICU 
patients are at risk of developing chronic kidney disease. Among children who developed 
acute kidney injury during PICU stay, 10% were diagnosed with chronic kidney disease 1 to 3 
years after critical illness.82 Long-term prevalence of persistent critical illness-induced muscle 
weakness was described up to 30% in children who developed muscle weakness during PICU 
stay.83 
Recently, a 6-month and 3-year follow-up of post-PICU patients revealed that mortality 
increased from 4% at discharge from PICU to 8% at 6 months and 10% at 3 years.79 New 
morbidity, defined as a change in Functional Status Scale score of ≥3, also increased during 
follow-up from 5% at discharge from PICU to 7% at 6 months and 10% at 3 years.79 These 
findings point out that the burden of critical illness is not limited to the PICU or hospital period, 
and stresses the importance of long-term follow-up. 
 
Neuropsychological outcomes 
Nutrition is one of many factors that can affect brain structure and function, cognition, and 
academic performance.84,85 The brain is particularly vulnerable to an inadequate diet in the 
phase of rapid growth in the last trimester of gestation and the first 2 years after birth.86 A 
recent systematic review showed that PICU survivors have significantly lower scores in at least 
1 cognitive domain compared to healthy controls.87 This cognitive impairment was associated 
with low socioeconomic status and signs of more severe illness, such as high oxygen 
requirements, need for mechanical ventilation, sedation, and pain medications.87 A younger 
age at critical illness and/or older age at follow-up were associated with cognitive 
impairment,87 which could be explained by a phenomenon called ‘growing into deficit’: brain 
damage evoked earlier in childhood could have a cumulative effect on neurodevelopment, 
since more cognitive skills are demanded with increasing age, making neurocognitive deficits 
more pronounced.  
Furthermore, a literature review showed that paediatric critical illness decreased 
health-related quality of life.88 These findings in the general PICU population were also present 
in specific subgroups of post-PICU patients. Children who were treated with extracorporeal 
membrane oxygenation showed a lower health-related quality of life, behavioural problems, 
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If caloric targets cannot be reached by EN, supplemental PN is routinely used in the 
PICU.67 In a previous observational study, the use of PN was associated with higher mortality.8 
Recent systematic reviews showed that there is a scarcity of RCTs investigating PN in critically 
ill children using clinical outcomes.68,69 Currently, 1 large RCT has been done to investigate the 
effects of PN. In 2016, the short-term clinical results from the multicentre, international RCT 
“PEPaNIC” were published.18 In this study, 1440 critically ill children, with an expected PICU 
stay longer than 24 hours, and expected insufficient EN longer than 24 hours were randomized 
into “Early-PN” (initiation of PN within 24 hours) or “Late-PN” (withholding PN during the first 
week) if the exclusion criteria were not met. This study was executed in the PICUs of Leuven 
(Belgium), Rotterdam (The Netherlands), and Edmonton (Canada). The children were aged 
from term newborns to 17 years. Children in the Early-PN group received PN to supplement 
EN until the amount of calories delivered enterally was above 80% of target. In the Late-PN 
group, a dextrose 5%/saline mixture was administered intravenously until EN was above 80% 
of target to match the amount of fluid administered to children in the Early-PN group. At day 
8, PN was also started in the Late-PN group if EN was still insufficient. Initiation and incline of 
EN were similar in the treatment groups and all children received intravenous vitamins, 
minerals, and trace elements if EN was under 80% of target.  
In this study,18 Late-PN was clinically superior to Early-PN on relevant outcome 
measures: among others, it reduced the incidence of new infections and shortened length of 
PICU and hospital stay. There was no significant difference in mortality. However, the 
incidence of hypoglycaemia (<40 mg/dL [<2.2 mmol/L]) was higher in the Late-PN group. 
Furthermore, a post hoc secondary analysis from this study showed that higher doses of amino 
acids, but not lipids or glucose, were associated with an increased risk of acquiring new 
infections, a longer duration of PICU dependency, and a longed need for mechanical 
ventilatory support.70 
Aside from the position this trial took in the new guidelines, another major 
contribution was that it provided firm support for the role of nutrition as therapeutic 
intervention for critically ill children. Interestingly, children with the highest risk of 
malnutrition benefitted the most from Late-PN regarding the primary outcomes.18 
Furthermore, term neonates had a larger reduction in length of PICU stay with Late-PN than 
older children.18 Since the clinical short-term outcomes were not analysed in detail in these 
subgroups, many questions remained unanswered. Hence, concerns were raised by 
nutritional experts on the efficacy and safety of withholding PN for a week in undernourished 
children and neonates.71-75 Furthermore, concerns were raised on possible weight 
deterioration due to reduced nutritional intake.71 Thus, this RCT provided important answers 
and showed that nutrition can impact clinical outcome, yet also raised new questions, which 
need to be addressed. 
From the current literature, it can be concluded that early (within 48 hours) and higher 
(67% of goal) enteral intake is associated with better short-term outcomes, although evidence 
for causality is lacking. Adequate EN can be achieved by the choice of an appropriate route of 
enteral feeding, by the timing of the start of EN, by administering protein-energy enriched 
 
 
 
formula and by overcoming the common barriers to start or continue EN.76,77 Based on 1 RCT 
it can be concluded that withholding PN during the first week results in improved short-term 
outcomes. There is a need for more RCTs investigating the effect of nutritional intervention 
on short-term outcome parameters.  
 
STEP 5: LONG-TERM AND SOCIETAL HEALTH-RELATED ECONOMIC OUTCOMES 
 
Physical outcomes 
Children who are discharged from the PICU and hospital often suffer for years from sustained 
morbidity.78,79 Children with oesophageal atresia showed impaired growth up to the age of 8 
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increased from 4% at discharge from PICU to 8% at 6 months and 10% at 3 years.79 New 
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academic performance.84,85 The brain is particularly vulnerable to an inadequate diet in the 
phase of rapid growth in the last trimester of gestation and the first 2 years after birth.86 A 
recent systematic review showed that PICU survivors have significantly lower scores in at least 
1 cognitive domain compared to healthy controls.87 This cognitive impairment was associated 
with low socioeconomic status and signs of more severe illness, such as high oxygen 
requirements, need for mechanical ventilation, sedation, and pain medications.87 A younger 
age at critical illness and/or older age at follow-up were associated with cognitive 
impairment,87 which could be explained by a phenomenon called ‘growing into deficit’: brain 
damage evoked earlier in childhood could have a cumulative effect on neurodevelopment, 
since more cognitive skills are demanded with increasing age, making neurocognitive deficits 
more pronounced.  
Furthermore, a literature review showed that paediatric critical illness decreased 
health-related quality of life.88 These findings in the general PICU population were also present 
in specific subgroups of post-PICU patients. Children who were treated with extracorporeal 
membrane oxygenation showed a lower health-related quality of life, behavioural problems, 
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and neurocognitive impairments with a normal intelligence quotient (IQ) years after critical 
illness.89-91 Children who survived meningococcal septic shock syndrome, cardiac arrest, 
cardiac surgery or heart transplantation also had neuropsychological problems.92-95 The long-
term ‘legacy’ of critical illness was traditionally presumed to be unmodifiable during the 
course of critical care. This is in contrast to a large long-term follow-up performed in children 
who were randomised to standard or tight glycaemic control during PICU admission 4 years 
earlier. The post-PICU patients had a full-scale IQ reduction of 9 points and scored worse on 
executive functioning, memory, behaviour, and neurological condition compared with siblings 
and age-matched unrelated healthy controls.20 More interestingly, tight glycaemic control in 
these patients improved motor coordination and cognitive flexibility. Tight glycaemic control 
mimicked a fasting response due to the low circulating levels of glucose, as was shown by the 
suppressed somatotropic and thyrotrophic axes.59,60 This mimicked fasting response explained 
part of the benefit of tight glycaemic control. Hence, interfering with nutrition and metabolism 
during critical illness has the potential to affect long-term outcomes.  
 
Health-economic outcomes 
Along with the long-term consequences of critical illness for children and their families, there 
is also a societal burden. This burden includes the costs of treatments during PICU admission 
as well as the lifetime – direct and indirect – health-related costs. There are hardly any studies 
about the health-economical aspects of nutritional support in critically ill children. Costs of 
nutrition itself are a small fraction of total PICU costs. The most important attribution to total 
PICU costs is the length of stay, which is highly related to infectious complications.96 Reducing 
PN, an independent risk factor for acquisition of new infections, could inherently substantially 
cut PICU costs.97  
To show that nutritional and metabolic interventions can indeed affect both clinical 
and economic consequences, studies on tight glycaemic control can, again, be used as an 
example. In a large multicentre study, tight glycaemic control led to an average reduction in 
12-month costs of approximately £10,000 for the non-cardiac surgery subgroup.98 These 
potential cost savings from a tight glycaemic control policy are important in understanding the 
possible impact of optimal therapy on financial resources.   
Overall, PICU survivors are confronted with long-term significant physical and 
neuropsychological morbidity, which seems to increase over time. Whether this long-term 
‘legacy’ can be influenced by nutritional interventions is being investigated after the PEPaNIC 
trial. As presently, more critically ill children survive post-PICU, optimal long-term outcomes 
are the ultimate goal. Furthermore, as the costs of nutritional support are relatively low, with 
potentially significant clinical effects, nutritional interventions are likely to be cost-effective. 
Thus, future nutritional studies should preferably include a long-term follow-up and cost-
effectiveness assessment. 
 
 
  
 
 
 
CURRENT NUTRITIONAL PRACTICES IN PICUS 
 
Most recommendations on nutritional management in current international guidelines are 
based on expert opinion, observational studies, or studies with surrogate endpoints.74,99 This 
lack of evidence is also reflected in the variety of nutritional management in practice. Recent 
surveys across the world have investigated the current nutritional practices in PICUs. All of 
them concluded that nutritional practices varied widely between PICUs.67,100-102 Presence of a 
nutritional protocol ranged from 31% to 52%.67,100-102 Energy requirements were estimated 
using a variety of methods, particularly the Schofield equation, World Health Organization 
recommendations, dietary reference index, and based on total fluid requirements.67,100 EN 
was intended to be started early (within 24 to 48 hours) in 30% to 60% of the PICUs, preferably 
via the gastric route (in more than 80% of the PICUs).67,100,101 In all surveys, the most reported 
reasons for stopping EN were suspected gastrointestinal intolerance (based on gastric residual 
volumes, abdominal symptoms/distension, vomiting), hemodynamic instability, suspected 
necrotising enterocolitis, and after cardiac arrest.67,100-102 When EN was insufficient, in 13% to 
42% of the PICUs, PN would be started within 24 hours;67,100,101 in approximately 55% of the 
PICUs, PN would be started within 48 hours.67,101  
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Table 1: Summary of surrogate and clinical outcome parameters 
 
Parameter Variables and major outcomes Remarks 
Biochemical 
indices 
Plasma amino acid profiles: differ 
according to disease phase, age and 
survival status. Can be affected by 
(par)enteral intake and insulin. 
Difficult to achieve in routine 
clinical care. 
Nitrogen balance and stable isotope 
studies: higher protein intake 
increases net protein balance. 
Require a steady state, 
difficult to achieve in routine 
clinical care. 
Body composition Z-scores of weight and BMI: 
undernutrition is associated with 
longer duration of mechanical 
ventilation, multi-organ failure, 
prolonged PICU stay, and mortality. 
Weight and height are 
difficult to measure and 
estimates are used regularly.  
 
Lower enteral intake is associated 
with nutritional status deterioration. 
Effect of PN on the course of 
nutritional status is 
unknown. 
DXA: a higher loss of bone mineral 
density was found in obese children 
with burns. Lower phase angle is 
associated with prolonged PICU stay. 
Difficult to achieve in PICU 
setting. 
Organ function Handgrip strength related to 
inflammation and undernutrition on 
admission. 
Can be tested after critical 
illness, age ≥4 years. 
Lower T3 if EN was initiated >48 hours 
compared to <24 hours in children 
with burns. 
One RCT in children with 
burns. 
 Withholding PN during the first week 
elevated plasma bilirubin 
concentration. Mild elevation of 
plasma bilirubin is associated with 
lower mortality. 
One large RCT. 
Short-term 
outcomes 
Mortality: relation with the adequacy 
of EN  and amount of protein. Length 
of hospital stay and neurological 
status at discharge after traumatic 
brain injury: associated with earlier 
nutritional support. 
 
Observational studies, no 
evidence for causality. 
 
 
 
Table 1 continued   
Parameter Variables and major outcomes Remarks 
Short-term 
outcomes 
In children with burns: initiation of EN 
<24 vs >48 hours: no difference in 
clinical outcome. 
One small RCT. 
 
 Length of stay, new infections, 
duration of ventilation: decreased by 
withholding PN during the first week. 
One large RCT. 
Long-term 
outcomes 
Improved neurocognitive outcome, 
primarily motor coordination and 
cognitive flexibility 4 years after tight 
glycaemic control in PICU. 
Only RCTs on tight glycaemic 
control; no studies done 
comparing nutritional 
strategies.  
Health-economics: reduction in 12-
month costs by tight glycaemic 
control in the non-cardiac subgroup. 
No cost-effectiveness studies 
on nutrition. 
Difficult to calculate total 
financial impact. 
BMI = body mass index; DXA = dual X-ray absorptiometry; EN = enteral nutrition; PICU = paediatric intensive care 
unit; PN = parenteral nutrition; RCT = randomised controlled trial. 
 
CONCLUSION 
 
Most nutritional studies in critically ill children were not designed to prove causal relationships 
between nutritional interventions and clinical outcomes or used surrogate measures of 
outcome, such as biochemical changes. Subsequently, current international guidelines on 
nutritional intake are predominantly based on small trials with surrogate outcome 
parameters.  
Understanding the characteristics of the different phases of the acute stress response 
is essential in defining an optimal strategy concerning enteral and parenteral nutritional 
support. Recent research has shown that an optimal nutritional strategy depends on the phase 
of illness, and is influenced by the choice of an appropriate route of feeding, by the timing of 
(par)enteral nutrition, and by overcoming the common barriers to start EN, which is the 
preferred route of feeding in the early phase of the disease.  
Prospective randomised studies are needed with nutritional and/or metabolic 
interventions to establish an optimal feeding strategy for critically ill children. These studies 
should be adequately powered, with clinical short-term outcomes, and preferably include a 
long-term follow-up and cost-effectiveness assessment.   
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long-term follow-up and cost-effectiveness assessment.   
 
24 
CHAPTER 1
 
 
 
OUTLINE OF THIS THESIS 
 
The aim of this thesis was to provide more insight into optimal nutrition for critically ill 
children, and into potential nutritional opportunities to reduce healthcare costs in the PICU. 
In this thesis, both the clinical consequences and the health-economic consequences of 
paediatric critical illness are  addressed, focusing on the role of PN.  
 
The main hypotheses that we tested were as follows: 
Withholding PN during the first week in critically ill children… 
- is effective and safe in neonates and undernourished children; 
- does not negatively affect nutritional status; 
- is effective and safe in the long-term; 
- is a cost-saving strategy comprising more than merely omitting the costs of PN itself. 
 
The large multicentre PEPaNIC RCT has shown that Late-PN was clinically superior to Early-PN 
in critically ill children. Due to the results of the PEPaNIC RCT, Early-PN was de-implemented 
locally. However, it was unknown to what extent delaying PN was adopted worldwide. This 
thesis starts with the results from our online survey to investigate the de-implementation of 
early initiation of PN in PICUs worldwide, and to identify factors that facilitated or hampered 
de-implementation (Chapter 2). In this thesis, short-term outcomes of Late-PN versus Early-
PN in critically ill neonates (Chapter 3) and critically ill undernourished children (Chapter 4) 
are explored. In order to further investigate the safety of tolerating a low macronutrient 
intake, the change in weight during PICU admission in both treatment groups is described 
(Chapter 5). In recent years, there has been more focus on the long-term consequences of 
paediatric critical illness. In this thesis, the long-term neuropsychological development of PICU 
survivors of the PEPaNIC trial are described (Chapter 6). Besides the clinical consequences of 
critical illness, there is also an economic burden. In Chapter 7, the cost-effectiveness of Late-
PN versus Early-PN is addressed, and the impact of preventing new infections by Late-PN on 
the total direct healthcare costs is explored. Finally, this thesis concludes with a discussion of 
the results and aims for future research (Chapter 8). An English and Dutch summary of the 
major findings that are presented in this thesis can be found in Chapter 9. 
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ABSTRACT 
 
Background 
Initiating parenteral nutrition (PN) within 24 hours in critically ill children is inferior to 
withholding PN during the first week, as was found in the PEPaNIC study. The aims of this 
study were to investigate de-implementation of early initiation of PN at PICUs worldwide, and 
to identify factors influencing de-implementation. 
 
Methods 
A cross-sectional online survey was conducted (May-October 2017), consisting of 41 questions 
addressing current PN practices, the degree of de-implementation, and factors affecting de-
implementation. 
 
Results  
We analysed 81 responses from 39 countries. Of these 81 respondents, 53 (65%) were aware 
of the findings of the PEPaNIC study, and 43 (53%) have read the article. In these 43 PICUs, PN 
was completely withheld during the first week in 10 PICUs, of which 5 already withheld PN 
(12%), and 5 de-implemented early initiation of PN (12%). Partial de-implementation was 
reported by 17 (40%) and no de-implementation by 16 (37%). Higher de-implementation rates 
were observed when the interpreted level of evidence and grade of recommendation of 
PEPaNIC was high. Predominant reasons for retaining early initiation of PN were concerns on 
withholding amino acids, the safety in undernourished children and neonates, and the long-
term consequences. Furthermore, the respondents were waiting for updated guidelines. 
 
Conclusions  
One year after the publication of the PEPaNIC trial, only two-thirds of the respondents was 
aware of the study results. Within this group, early initiation of PN was de-implemented 
completely in 12% of the PICUs, while 40% asserted partial de-implementation. Increasing the 
awareness, addressing the intervention-specific questions and more frequently revising 
international guidelines might help to accelerate de-implementation of ineffective,  unproven 
or harmful healthcare.   
 
 
 
INTRODUCTION 
 
Optimal nutrition is considered essential to improve outcome in the paediatric intensive care 
unit (PICU) but large well-designed randomised, controlled trials (RCTs) with clinically relevant 
outcome measures are lacking.68,69 The limited evidence leads to a wide variation in nutritional 
practices between individual intensivists, PICUs and countries. This variation includes timing 
of and thresholds for the initiation of parenteral nutrition (PN), as measured by a worldwide 
survey with a point-prevalence.67 According to this survey completed in 2014, in 20% of the 
PICUs, PN was initiated within 24 hours after admission, and in 55% of the PICUs within 48 
hours.67 The international guidelines at that time were based on small studies with surrogate 
outcome measures, observations, and expert opinion, and could not provide clear 
recommendations on the timing of initiating PN in critically ill children.103,104 In 2016, the 
results of the large, international, multicentre RCT ‘PEPaNIC’ (Paediatric Early versus Late PN 
in Critically Illness) were published.18 This RCT showed that administering PN within 24 hours 
after PICU admission (Early-PN; the standard therapy) was clinically inferior to withholding PN 
during the first week of PICU admission (Late-PN).18 Withholding PN during the first week 
prevented new infections, shortened intensive care dependency, the duration of mechanical 
ventilation and hospital stay. Based on the impact of these findings, and the scarcity of 
evidence for the early use of PN in PICUs, one could expect that currently, initiation of 
supplemental PN is delayed until after the first week of critical illness in the majority of PICUs. 
 De-implementation or de-adoption is described as ‘reducing or stopping low-value, 
ineffective, harmful or unproven care’.105-107  However, rational and quantitative evidence are 
only part of the driving forces for decision making and only 49% of the interventions is 
supported or contradicted by the available evidence.105,108 Little is known about the factors 
that influence the extend and pace of de-implementation.106,109 Moreover, currently, only 10% 
of the de-implementation research has focused on paediatric healthcare.107  
 In this study, we explored the degree of early de-implementation of initiating PN in the 
first week in PICUs and barriers for de-implementation with a survey among physicians and 
dieticians across PICUs worldwide. 
 
MATERIALS AND METHODS 
 
This electronic (LimeSurvey GmbH version 2.06lts) cross-sectional survey was conducted 
between May and October 2017. It consisted of 41 questions and was provided in English, 
French and Spanish. The full questionnaire used for this survey can be found as online 
supplement to this article (Appendix). In brief, the survey was developed to collect 
information in different echelons. The first part collected general information of the 
respondents and responding PICUs, the second part focused on the current practice of PN in 
the responding PICU, and the third part investigated the awareness of the results of the 
PEPaNIC trial. Subsequently, the respondents who had read the findings of this study prior to 
our survey were requested to participate in the final part of the survey in which they were 
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asked to grade the quality of evidence of the PEPaNIC trial according to the Scottish 
Intercollegiate Guidelines Network (SIGN) system that was provided in the survey.110 Finally, 
they were asked whether and how the PEPaNIC results has changed the current practice of 
initiating PN in their PICU, and which factors have influenced the degree of de-implementation 
in their PICU. 
The survey was piloted by independent clinicians in two different centres (Erasmus 
MC-Sophia Children’s Hospital, Rotterdam, the Netherlands and the University Hospital of 
Leuven, Belgium) to test the clarity, relevance and clinical sensibility of the questionnaire, and 
the questionnaire was adapted accordingly. Data from this pilot were not included in the final 
analyses and survey results. The survey was electronically distributed among members of the 
World Federation of Pediatric Intensive and Critical Care Societies (WFPICCS) by newsletter 
and Twitter, and to specific members of the European Society of Paediatric and Neonatal 
Intensive Care (ESPNIC). Reminders were sent three times with six-week intervals. If more 
than one questionnaire was present for a PICU, the answers were weighed by the inverse of 
the number of completed questionnaires per centre in order to process conflicting statements 
within one PICU, without disrupting the weight of the answers per PICU.  
Main outcome was the degree of de-implementation (fidelity), with complete de-
implementation defined as withholding PN until day 8 of PICU admission. Partial de-
implementation was defined as postponed initiation of PN (but still initiated prior to day 8 in 
PICU) and/or decreased amount of PN as compared with nutritional practices before the 
results from PEPaNIC, or only administering PN during the first week in specific patient groups. 
Secondary outcomes were supporting factors and barriers for de-implementation.  
Statistical analysis was performed using IBM SPSS statistics version 24. All answers 
were categorical, and were expressed as numbers and proportions.   
 
RESULTS 
 
Response 
Since the survey was distributed via Twitter, ESPNIC and WFPICCS, with unknown number of 
PICUs in their databases, the exact number of invited PICUs is unknown. A total of 88 
completed questionnaires were received, of which one was removed because the respondent 
worked in a Neonatal Intensive Care Unit. From the remaining 87 questionnaires, the answers 
of nine respondents from three centres needed to be pooled per centre by weighing the 
answers according to the number of completed questionnaires per centre. The 3 pooled 
responses per centre were kept for analyses, and the individual responses were removed 
(Figure 1). Finally, responses from 81 PICUs in 39 countries on 6 continents were analysed 
(Figure 2). Of the respondents, 74% were (paediatric) intensivists, 12% were dieticians or 
nutritionists, 6% were paediatricians, 5% were nurses or nurse practitioners, and 3% were 
anaesthesiologists.  
 
 
 
 
 
Figure 1: Flowchart of the responses and build-up of the survey 
 
NICU = neonatal intensive care unit; PN = parenteral nutrition. 
 
 
Of the responding PICUs, 39 (48%) were located in Europe, 14 (17%) in South America, 
12 (15%) in North America, and 12 (15%) in Asia (Table 1). The majority of the PICUs had 251-
750 paediatric admissions per year (Table 1). All PICU demographics are displayed in table 1. 
 
Current PN practices in PICUs 
In 50 of the 81 PICUs (62%), a nutritional protocol regarding PN was present. Most of the 
protocols were based on international guidelines (27 of 50, 54%), 8 of 50 (16%) on national 
guidelines, and 15 of 50 (30%) on the opinion of the staff. Respondents from 10 of the 81 
PICUs (12%) would always start PN if enteral nutrition (EN) is insufficient, and 4 (5%) would 
never start PN. In 43 of the 81 PICUs (53%), supplemental PN would be started if enteral 
nutrition covered less than 80% of the target goals, at 20 (25%) of the PICUs if EN covered less 
than 50%, and 4 (5%) of the PICUs handled another threshold. PN administration via peripheral 
intravenous access was possible in 58 of the 81 PICUs (72%).  
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Figure 1: Flowchart of the responses and build-up of the survey 
 
NICU = neonatal intensive care unit; PN = parenteral nutrition. 
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12 (15%) in North America, and 12 (15%) in Asia (Table 1). The majority of the PICUs had 251-
750 paediatric admissions per year (Table 1). All PICU demographics are displayed in table 1. 
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never start PN. In 43 of the 81 PICUs (53%), supplemental PN would be started if enteral 
nutrition covered less than 80% of the target goals, at 20 (25%) of the PICUs if EN covered less 
than 50%, and 4 (5%) of the PICUs handled another threshold. PN administration via peripheral 
intravenous access was possible in 58 of the 81 PICUs (72%).  
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Figure 2: Participating PICUs: 81 responses from 39 countries (in blue), covering six 
continents 
 
Created with: https://www.amcharts.com/visited_countries/ 
 
 
Regarding the timing of PN initiation, amino acids would be started within 48 hours when a 
child was (expected to be) intolerable to EN in 37 of the 81 PICUs (46%). Initiation of amino 
acids was postponed beyond the first week in 4 of the 81 PICUs (5%; Figure 3). Lipids would 
be started within 48 hours in 34 of the 81 PICUs (42%; Figure 3). Lipids would be initiated 
beyond the first week in 4 of the 81 PICUs (5%; Figure 3). Targeted glucose intake during the 
first 12-24 hours varied between 1-4 mg/kg/min and 8-10 mg/kg/min. In most cases, 4-6 
mg/kg/min was targeted in children who weighed less than 10 kilograms (38 of 81 PICUs, 47%), 
1-4 mg/kg/min in children who weighed 10-30 kilograms (50 of 81 PICUs, 62%) and also in 
children weighing more than 30 kilograms (62 of 81 PICUs, 77%). Of the 81 respondents, 73 
(90%) would administer vitamins and trace elements routinely. 
 
  
 
 
 
Table 1: Characteristics of the responding paediatric intensive care units 
 
Characteristic No. of PICUs (n=81) 
Continent   
Europe 39 (48%) 
South America 14 (17%) 
Asia 12 (15%) 
North America 12 (15%) 
Africa 2 (3%) 
Oceania 2 (3%) 
Hospital type   
University children’s hospital 37 (46%) 
University hospital 24 (30%) 
General hospital 18 (21%) 
Other 2 (3%) 
Type of PICU   
Multidisciplinary/mixed 75 (93%) 
Medical 4 (5%) 
Cardiac 1 (1%) 
Surgical  1 (1%) 
Combination of PICU   
Not combined  66 (82%) 
With neonatal ICU 10 (12%) 
With adult ICU 4 (5%) 
With adult and neonatal ICU 1 (1%) 
Size of PICU   
1-10 beds 33 (41%) 
11-20 beds 28 (35%) 
21-30 beds 16 (50%) 
>30 beds 4 (6%) 
Paediatric admissions (patients/year)   
1-250 7 (9%) 
251-500 29 (36%) 
501-750 18 (22%) 
751-1000 7 (9%) 
1001-1250 7 (9%) 
>1250 13 (16%) 
Mechanically ventilated patients   
<25 % 9 (11%) 
25-50 % 31 (38%) 
50-75 % 25 (31%) 
>75 % 16 (20%) 
PICU = paediatric intensive care unit; ICU = intensive care unit. 
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Figure 3: Time to initiate parenteral nutrition when enteral nutrition is (expected to be) 
insufficient 
 
 
PICU = paediatric intensive care unit. 
De-implementation of initiating PN early during critical illness 
Fifty-three of the 81 respondents (65%) answered to be familiar with the results from the 
PEPaNIC trial, and 43 (53%) reported to have read the original article. Those who have read 
the article were larger PICUs and all multidisciplinary/mixed, and reported higher proportions 
of mechanically ventilated patients (Appendix). The majority of those who have read the 
article would start PN if EN was <50%, whereas the majority of those who have not read the 
article would start PN if EN was <80% of target (Appendix). Furthermore, those who have read 
the article would start amino acids more often within 48 hours than those who did not read 
the article (Appendix).  
Of the 43 respondents who have read the article, 9 (21%) interpreted the level of 
evidence of the PEPaNIC trial as level 1, 25 (58%) as level 2, and 9 (21%) as level 3. 
Furthermore, 8 (19%) of these 43 respondents interpreted the grade of recommendation as 
A (shall be recommended), 17 (39%) as B (should be recommended), and 18 (42%) as 0 
(can/may be recommended). These 43 respondents all completed the final part of the survey 
questions on de-implementation of early PN initiation in their PICU (Figure 1). Complete de-
implementation of early PN initiation, due to the results of PEPaNIC, was reported by 12% (5 
of 43) and another 5 (12%) declared to already withhold PN during the first week prior to 
PEPaNIC (Figure 4). Partial de-implementation was asserted by 17 (40%) of the respondents 
(Figure 4). Of these 17 respondents, 16 reported to give PN during the first week only in 
specific patient groups (11 to neonates, 11 to undernourished children, and 4 to other, 
unspecified patients), and 3 respondents declared to have postponed the timing of initiation 
and/or decreasing the amount of amino acids or lipids. Sixteen (37%) of the 43 PICUs reported 
 
 
 
no de-implementation, and continued to administer PN early during PICU admission. Ten of 
these PICUs would start PN within 48 hours after admission, of which 6 within 24 hours.  
 
Figure 4: De-implementation of parenteral nutrition during the first week of paediatric 
critical illness 
 
 
PICU = paediatric intensive care unit; PN = parenteral nutrition. 
 
Associations between PICU/respondent characteristics and de-implementation 
The degree of de-implementation within the characteristics of the PICUs/respondents is 
described in table 2. Higher proportions of complete de-implementation were observed in 
PICUs from which the respondent rated the level of evidence and grade of recommendation 
high as compared with those PICUs who rated them lower (Table 2). 
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Table 2: Distribution of the degree of de-implementation within the characteristics of the 
43 PICUs/respondents who have answered part D of the questionnaire 
 
 Characteristic 
No de-
implementation 
Partial de-
implementation 
Complete de-
implementation 
Already 
withheld PN 
Continent          
Europe 2 (9%) 8 (36%) 8 (36%) 2 (9%) 
South America 2 (25%) 4 (50%) 0 (0%) 2 (25%) 
Asia 2 (100%) 0 0%) 0 (0%) 0 (0%) 
North America 3 (39%) 3 (38%) 1 (13%) 1 (13%) 
Africa 1 (50%) 1 (50%) 0 (0%) 0 (0%) 
Oceania 0 (0%) 1 (100%) 0 (0%) 0 (0%) 
Combination of PICU        
Not combined  14 (40%) 15 (43%) 3 (9%) 3 (9%) 
With neonatal ICU 2 (40%) 2 (40%) 0 (0%) 1 (20%) 
With adult ICU 0 (0%) 0 (0%) 2 (67%) 1 (33%) 
With adult and neonatal ICU 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Size of PICU         
1-10 beds 5 (42%) 4 (33%) 1 (8%) 2 (7%) 
11-20 beds 5 (31%) 6 (38%) 3 (19%) 2 (13%) 
21-30 beds 6 (50%) 5 (42%) 1 (8%) 0 (0%) 
>30 beds 0 (0%) 2 (67%) 0 (0%) 1 (33%) 
Experience of respondent (years)        
1-5 0 (0%) 3 (50%) 2 (33%) 1 (17%) 
6-10 5 (71%) 2 (29%) 0 (0%) 0 (0%) 
11-20 6 (46%) 3 (23%) 1 (8%) 3 (23%) 
>20 5 (29%) 9 (53%) 2 (12%) 1 (6%) 
Nutritional protocol present        
Yes 12 (41%) 10 (35%) 4 (14%) 3 (10%) 
No 2 (29%) 7 (50%) 1 (7%) 2 (14%) 
Rated level of evidence         
4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
3 7 (78%) 2 (22%) 0 (0%) 0 (0%) 
2 7 (28%) 11 (44%) 2 (8%) 5 (20%) 
1 2 (22%) 4 (44%) 3 (33%) 0 (0%) 
Rated grade of recommendation        
Good Practice Points 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
0 10 (56%) 6 (33%) 0 (0%) 2 (11%) 
B 3 (18%) 9 (53%) 2 (12%) 3 (18%) 
A 3 (38%) 2 (25%) 3 (38%) 0 (0%) 
PICU = paediatric intensive care unit; ICU = intensive care unit; PN = parenteral nutrition. 
 
  
 
 
 
Table 3: Barriers for de-implementation (>1 answer per PICU possible) in the 33 PICUs that 
have partially or not de-implemented early administration of PN 
 
Barrier 
 
No of PICUs 
(n=33) 
Safety issues  
Not convinced of the safety and/or efficacy in undernourished children 17 
Convinced that critically ill children need amino acids in the acute phase of illness 15 
Not convinced of the safety and/or efficacy in neonates 11 
Convinced that critically ill children need lipids in the acute phase of illness 6 
Not convinced of the safety in general 4 
Convinced that critically ill children need more glucose in the acute phase of illness 2 
Confirmation of results  
Waiting for replicating studies 11 
Waiting for updated international guidelines a 11 
Waiting for long-term results 8 
Don’t consider these results to be cost-effective 1 
Structural reasons  
Non-consensus within staff 9 
Other b 5 
Lack of nutritional protocol 2 
Because of logistic reasons (i.e. arrangements with pharmacy)  1 
Total number of reasons 103 
PICU = paediatric intensive care unit; PN = parenteral nutrition. 
a Respondents from Europe: n=7, North America: n=2, South America: n=2 and Africa: n=1. 
b Provided answers: the PEPaNIC results are not generalizable to our PICU: n=3; PN is administrated rarely in our 
centre: n=1; we are currently changing our PN strategies: n=1. 
 
Barriers for de-implementation 
As familiarity of study results are a condition of studying de-implementation, we started off 
with making this distinction. Of the respondents, only 65% was familiar with the PEPaNIC study 
and only 43 (53%) had actually read the article. Of these 43, 33 respondents reported no or 
partial de-implementation and were asked for reasons not to adopt withholding PN during the 
first week (Figure 1). The most distinct arguments were those that addressed the safety of 
postponing PN. The perception that withholding PN would be harmful to children who were 
undernourished on admission (barrier for 17 respondents, 52%) and neonates (barrier for 11 
respondents, 33%) were important barriers. Another major concern was the conviction that 
parenteral amino acids should be provided during the acute phase of critical illness 
(mentioned by 15 respondents, 46%). Further arguments represented the need for additional 
confirmation of the results from the PEPaNIC trial: waiting for replicating studies (11 
respondents; 33%), waiting for updated international guidelines (11 respondents; 33%), and 
waiting for long-term outcomes (8 respondents; 24%) (Table 3). Interestingly, 9 (27%) 
respondents reported that the results from the PEPaNIC trial were discussed within their staff 
but this had not led to de-implementation of early PN initiation because of lack of consensus 
(Table 3). 
	 37
DE-IMPLEMENTATION	OF	EARLY	PN	IN	PICUS
2
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(mentioned by 15 respondents, 46%). Further arguments represented the need for additional 
confirmation of the results from the PEPaNIC trial: waiting for replicating studies (11 
respondents; 33%), waiting for updated international guidelines (11 respondents; 33%), and 
waiting for long-term outcomes (8 respondents; 24%) (Table 3). Interestingly, 9 (27%) 
respondents reported that the results from the PEPaNIC trial were discussed within their staff 
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DISCUSSION 
 
This survey showed that nutritional practices continue to vary greatly among PICUs worldwide 
as was previously reported.67 Despite the dearth of evidence in the field of nutritional support 
in the PICU, in the current survey only about two-thirds of the respondents asserted to be 
familiar with the results from the PEPaNIC trial and approximately half had read the article. 
Among these respondents, PN was completely withheld during the first week in almost a 
quarter of the PICUs, and most PICUs had partially de-implemented early PN initiation, which 
meant predominantly that early PN would only be given to specific patient groups. Reported 
barriers for de-implementation were predominantly based on the conviction that PN during 
the first week of critical illness is necessary in neonates and undernourished children, and 
especially amino acids were viewed to be essential.  
Although this de-implementation rate might be considered low, it is to be expected 
given the relative short time between publication of PEPaNIC and the survey (approximately 
1 year). It has been shown that it takes more than a decade from publication to 
implementation into practice.111,112 An important first step in this process is to create 
awareness of new insights.113 Interestingly, our survey pointed out that even if the existing 
evidence in the field is scarce and new results from a large, international study are published 
in a high-impact, open access journal, only two-thirds of the PICUs was aware of these results.  
Besides awareness of new results, (de-)implementation depends on inhibiting and 
supporting factors. Previous studies have identified the following influences: believe in the 
benefits for the targeted population, financial implications, organizational structure, 
caregiver’s motivation to change current practice, feasibility, quality of the evidence, 
credibility of the working group, relevance and generalizability of the research.114-117 Indeed, 
most of these factors were mentioned in our survey as arguments not to change current 
practice. We will discuss those barriers/facilitators that could guide us to enhance early de-
implementation. 
In our survey, 76% still administered PN during the first week to all critically ill children 
or specific patient groups, because they believed in the benefit of early initiation of PN. 
Despite the fact that early-PN appeared to be even more harmful in neonates than in older 
children, and more harmful in children at the highest risk of malnutrition, as was already 
reported in the PEPaNIC article,18 neonates and undernourished children were predominant 
barriers. After the survey, additional detailed subgroup analyses of neonates and 
undernourished children were published, which showed that withholding PN was clinically 
beneficial in these patients as well.118,119 Concerns on withholding PN in critically ill children 
might be explained by several assumptions. Since undernourishment on admission has been 
associated with worse clinical outcomes, it is assumed that providing (parenteral) nutrition 
can improve clinical outcomes by promoting anabolism. In small RCTs, higher provision of 
energy and protein/amino acids resulted in a positive protein balance.3,120 Subsequently, it 
was assumed that this would also lead to improved clinical outcomes. These assumptions 
regarding PN might have reduced the faith in the controversial results from the PEPaNIC study, 
 
 
 
which is also reflected in a number of respondents who requested for repeat studies. 
Currently, we could identify one single centre RCT on ClinicalTrials.gov, which is designed to 
randomize 80 critically ill children to receive supplemental PN within 12 or 96 hours after 
admission.121 However, for clinicians working in combined adult/paediatric ICUs, PEPaNIC 
could have been considered as a repeat study. Withholding PN for a week in critically ill adults 
has been included in the ‘choosing wisely campaign’, a list made by specialty societies of 
possible unnecessary healthcare recommendations.122 This might explain why PN was 
completely withheld in critically ill children during the first week in all of the combined 
adult/paediatric ICUs. Additionally, since evidence for withholding PN during the first week in 
critically ill adults has already been published first in 2011,123 the time between evidence from 
research and de-implementation in practice might play a role. Furthermore, a significant 
proportion of the respondents mentioned the request for updated guidelines. When the 
survey was distributed, the most recent international guidelines were developed in 2005 and 
2009. In the meantime, these guidelines have been updated by the leading expert nutrition 
societies,74,99 which means that the time between previous and current versions of the 
guidelines was 8 to 13 years. The fact that updated guidelines were awaited by a significant 
proportion of respondents stresses the importance of up-to-date guidelines. Hence, more 
frequent updates of the international guidelines might enhance (de-)implementation. 
Despite the factors that hamper de-implementation, we have observed a shift in the 
timing of initiation of PN in critically ill children. In 2013, a worldwide survey was conducted, 
addressing nutritional practices in the PICU.67 In this survey, the majority (55%) of the PICUs 
reported to start PN within 48 hours, and 20% within 24 hours. Furthermore, PN was 
completely withheld in only 3.5% of the PICUs before the PEPaNIC results were published.67 
Comparing these results to the results of our study, there seems to be a shift towards initiation 
of PN between day 2 to 7 and an increase in complete de-implementation of early PN, 
although this cannot be concluded confidently as the responding PICUs were not exactly the 
same.  
Limiting the delay in de-implementation is of particular importance in case of harm by 
an intervention ─ which was the case in early-PN ─ or cost-ineffectiveness. Based on our results 
and existing literature, de-implementation might be accelerated by increasing awareness, 
gaining trust on the efficacy and safety of stopping the intervention, and facilitating up-to-
date international guidelines. An important aspect to take into account is that the personal 
willingness and readiness to change a practice differs widely, which is illustrated by the ‘theory 
of the diffusion of innovation’ by Rogers et al.113 According to this theory, the PICUs who had 
de-implemented early PN in our survey could be the ‘Early Adopters’, who generally have the 
highest degree of opinion leadership.113 Hence, the next step to increase awareness and gain 
support, demands the Innovators and Early Adopters to distribute the knowledge within their 
networks. Furthermore, the concerns on the efficacy and safety of stopping the intervention 
(in our case withholding PN) should be addressed if possible. Since the launch of this survey, 
several secondary analyses have investigated the main concerns, such as the harm associated 
with administration of amino acids,70 the efficacy and safety of withholding PN in 
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undernourished children119 and neonates,118 the long-term effects on physical and 
neuropsychological functions,124 and the cost-effectiveness of withholding PN.125 All these 
new findings were supportive for de-implementation of early-PN. Additionally, underlying 
mechanisms are currently explored.126 Finally, since many clinical practices depend on the 
international opinion, de-implementation might be accelerated if the international guidelines 
would be revised more frequently in order to cover the most up-to-date evidence.  
The strength of our study is the widespread responses worldwide. However, some 
limitations should also be addressed. First, responses from 81 PICUs are a small fraction of all 
PICUs worldwide. Possibly, only physicians interested in nutrition might have responded to 
our survey, which poses a risk of selection bias. Second, some answers from the respondents 
could potentially have been socially desirable, as this survey has been conducted by the 
PEPaNIC study group. Furthermore, some respondents gave inconsistent answers. We have 
analysed all answers as provided by the respondent to avoid incorrect interpretation. And 
third, with this survey, we have measured theoretical de-implementation based upon the 
answers of the respondents, without measuring real PN practices. A previous survey 
addressing nutritional practices in PICUs, in which the questionnaire was followed by a point-
prevalence, illustrated that the respondents often overestimated their practices.67 
 
CONCLUSIONS 
 
One year after the publication of the PEPaNIC trial, only two-thirds of the respondents was 
aware of the study results. Within this group, complete de-implementation of starting PN in 
the first week of critical illness was done in 12% of the PICUs worldwide, and partial de-
implementation was done in 40% of the PICUs. Another 12% of PICUs already withheld PN 
during the first week. Important barriers for not de-implementing early PN were concerns on 
the efficacy and safety of withholding PN, and waiting for updated international guidelines. 
Increasing the awareness, addressing the intervention-specific questions and more frequently 
revising the international guidelines might help to accelerate de-implementation of 
ineffective,  unproven or harmful healthcare. 
 
 
 
APPENDIX 
 
Supplementary Methods 1: Questionnaire 
Part A: General information     
1. What is your country of work? 
2. What is the name of your institution?  
3. What type of hospital do you work in?   
 general       
 university       
  university-children’s    
 other, specify  
4. What is your profession?     
 (paediatric) intensivist  
 anaesthesiologist    
 paediatrician   
 surgeon   
 dietician/nutritionist  
 nurse/nurse practitioner 
 other, specify  
5. How many years of experience do you have working in a PICU?  
 1-5      
 6-10        
 11-20        
 >20    
6. What type of a PICU do you work in?  
 multidisciplinary/mixed   
 surgical    
 cardiac     
 medical    
 other, specify  
7. Is the PICU combined with an adult ICU or a neonatal ICU?   
 not combined   
 neonatal  
 adult  
 Both neonatal and adult  
8. What is the number of paediatric ICU beds in your unit (until age 18 years)?          
 1-10      
 11-20        
 21-30        
 >30    
9. What is the average number of paediatric admissions per year in your unit (until age 18 years)?  
 1-250   
 251-500  
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 501-750   
 751-1000   
 1001-1250   
 >1250 
10. What is the average proportion of mechanically (invasive) ventilated paediatric patients per 
year in your unit (until age 18 years)?  
 <25%  
 25-50%     
 >50-75%   
 >75%     
 
Part B: Parenteral nutrition in your PICU 
Please fill in your current practice regarding PN for critically ill paediatric patients. 
 
1. Is there a nutritional protocol regarding PN used in your PICU?  
Yes / No 
If Yes  after C, answer D1 
If No  after C, answer D2 
2. What is the basis of your nutritional protocol? 
 International guideline  go to B3 
 National guideline  go to B4 
 Opinion of the staff  go to B4 
3. Which guideline? 
 European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Society for 
Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) 
 American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) 
 Adult international guideline 
4. How much glucose is administered during the first 12-24 hours of admission:  
- <10 kg         1-4 mg/kg/min (1.4-5.8 g/kg/day)  4-6 mg/kg/min (5.8-8.6 g/kg/day)  6-8 
mg/kg/min (8.6-11.5 g/kg/day)  8-10 mg/kg/min (11.5-14.4 g/kg/day) 
- 10-30 kg      1-4 mg/kg/min (1.4-5.8 g/kg/day)  4-6 mg/kg/min (5.8-8.6 g/kg/day)  6-8 
mg/kg/min (8.6-11.5 g/kg/day)  8-10 mg/kg/min (11.5-14.4 g/kg/day) 
- >30 kg    1-4 mg/kg/min (1.4-5.8 g/kg/day)  4-6 mg/kg/min (5.8-8.6 g/kg/day)  6-8 
mg/kg/min (8.6-11.5 g/kg/day)  8-10 mg/kg/min (11.5-14.4 g/kg/day) 
5. At what point would you start amino acids in a child (expected to be) intolerable to enteral 
feeds?  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days     
6. At what point would you start lipids in a child (expected to be) intolerable to enteral feeds?  
 < 24 hours  
 < 48 hours  
 
 
 
 2-4 days     
 4-7 days  
 >7 days     
7. When enteral nutrition is provided but is insufficient to meet target goals, would PN be added?  
 No   
 Yes, always   
 Yes, if enteral nutrition covers < 80% of target calories  
 Yes, if enteral nutrition covers < 50% of target calories  
 Other    
8. If PN is given in combination with enteral nutrition: at what moment (percentage of nutritional 
target achieved by enteral nutrition) is PN stopped?  
 If enteral nutrition covers 100% of target calories  
 If enteral nutrition covers > 80% of target calories  
 If enteral nutrition covers > 50% of target calories  
 Other    
9. How is PN provided in your institution? 
 Pharmacy-customised, age/weight specific  
 Commercial mixed bags  
 Other 
10. Is it possible to administer PN without a central venous line?  Yes / No 
11. Do you routinely administer vitamins and trace elements?  Yes / No 
 
Part C: Awareness of the Early versus Late PN in Critically Ill Children (PEPaNIC) study 
The results of the international, multicentre, randomised, controlled trial Paediatric Early versus Late 
Parenteral Nutrition in Critical Illness (PEPaNIC) have been published in the New England Journal of 
Medicine in March 2016. 
 
1. Are you familiar with the results of this study? Yes / No 
2. Did you read this article before you filled out this survey? Yes / No  
3. Did you read the supplemental material before you filled out this survey? Yes / No 
4. How would you rate the level of evidence?  
 1 (high to excellent)  
 2 (moderate to high)  
 3 (low)  
 4 (expert opinion)  
5. How would you rate the grade of recommendation?  
 A (shall be recommended)  
 B (should be recommended)  
 0 (can/may be recommended)  
 GPP (Good Practice Points) 
 
Part D1: Change in Nutritional Practice 
In the PEPaNIC study, in children who were allocated to the Late-PN group, during the first week of 
critical illness, PN was withheld completely (meaning: low amounts of glucose (<2 mg/kg/min), no 
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amino acids and no lipids were administered). Late-PN resulted in lower percentage of new infections 
and shorter duration of PICU stay compared to Early-PN. 
 
1. Has the local nutritional protocol of your PICU, concerning the initiation or amount of PN, been 
changed due to the results of this study?  
  No change. We already withheld PN during the first week  go to D9, after D: go to E4  
  No change. We still administer PN during the first week in all children   go to D9 
  Yes,  we have changed our practice. We now withhold PN during the first week  go D6 & 
D8, after D: go to E4  
  Yes, we have changed our protocol partially or only in specific patients. We withhold or 
decreased component(s) of PN  go to D2 
2. Please specify: during the first week of critical illness in children… (multiple choice) 
  We still administer PN in the first week only in specific patient groups (i.e. neonates, 
malnourished children, specific diseases)  go to D3 
 We withhold or decrease only some of the macronutrients (glucose, amino acids, lipids)  
go to D5 
  Other, namely ….  go to D5 
3. Which patient group(s) continued receiving PN during the first week? (multiple choice) 
  neonates (<1 month) 
  malnourished children 
  other 
4. At which day was/is PN started in this patient group?  
Neonates: 
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
Malnourished children:  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
Other:  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
 go to D9 
5. Did you change the administration of parenteral amino acids during the first week due to the 
results of this study? (multiple choice) 
 No  go to D7 
 
 
 
 Yes, we have changed the timing of initiation of amino acids  go to D6 
 Yes, we have changed the amount of amino acids  go to D7  
6. At which day were amino acids started before the change in protocol:  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
7. Did you change the administration of parenteral lipids during the first week due to the results of 
this study? (multiple choice) 
 No  go to D9 
 Yes, we have changed the timing of initiation of lipids  go to D8 
 Yes, we have changed the amount of lipids  go to D9  
8. At which day were parenteral lipids started before the change in protocol:  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
9. Did you lower the amount of glucose administered intravenously during the first week due to the 
results of this study? Yes / No  
10. Keeping the results of the study in mind,  when a child deteriorates clinically after the first week 
(i.e. sepsis), would you then discontinue PN? Yes / No.  
 
Part D2: Change in Nutritional Practice 
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amino acids and no lipids were administered). Late-PN resulted in lower percentage of new infections 
and shorter duration of PICU stay compared to Early-PN. 
 
1. Has the local nutritional practice of your PICU, concerning the initiation or amount of PN, been 
changed due to the results of this study?  
  No change. We already withheld PN during the first week  go to D9, after D: go to E4  
  No change. We still administer PN during the first week in all children   go to D9 
  Yes,  we have changed our practice. We now withhold PN during the first week  go D6 & 
D8, after D: go to E4  
  Yes, we have changed our practice partially or only in specific patients. We withhold or 
decreased component(s) of PN  go to D2 
2. Please specify: during the first week of critical illness in children… (multiple choice) 
  We still administer PN in the first week only in specific patient groups (i.e. neonates, 
malnourished children, specific diseases)  go to D3 
 We withhold or decrease only some of the macronutrients (glucose, amino acids, lipids)  
go to D5 
  Other, namely ….  go to D5 
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3. Which patient group(s) continued receiving PN during the first week? (multiple choice) 
  neonates (<1 month) 
  malnourished children 
  other 
4. At which day was/is PN started in this patient group?  
Neonates: 
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
Malnourished children:  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
Other:  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
 go to D9 
5. Did you change the administration of parenteral amino acids during the first week due to the 
results of this study? (multiple choice) 
 No  go to D7 
 Yes, we have changed the timing of initiation of amino acids  go to D6 
 Yes, we have changed the amount of amino acids  go to D7  
6. At which day were amino acids started before the change in practice:  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
7. Did you change the administration of parenteral lipids during the first week due to the results of 
this study? (multiple choice) 
 No  go to D9 
 Yes, we have changed the timing of initiation of lipids  go to D8 
 Yes, we have changed the amount of lipids  go to D9 
8. At which day were parenteral lipids started before the change in practice:  
 < 24 hours  
 < 48 hours  
 2-4 days     
 
 
 
 4-7 days  
 >7 days 
9. Did you lower the amount of glucose administered intravenously during the first week due to the 
results of this study? Yes / No  
10. Keeping the results of the study in mind,  when a child deteriorates clinically after the first week 
(i.e. sepsis), would you then discontinue PN? Yes / No.  
 
Part E: Reasons for not implementing Late-PN 
1. What is/are reason(s) for not withholding PN in your PICU during the first week of critical illness in 
children? (multiple choice) 
 waiting for replicating studies 
 not convinced of the safety  
 not convinced of the safety and/or efficacy in neonates 
 not convinced of the safety and/or efficacy in malnourished children 
 convinced that critically ill children need amino acids in the acute phase of illness 
 convinced that critically ill children need more glucose in the acute phase of illness 
 convinced that critically ill children need lipids in the acute phase of illness 
 waiting for long-term results. 
 don’t consider these results to be cost-effective 
 waiting for updated international guidelines 
 lack of nutritional protocol 
 non-consensus within staff 
 Because of logistic reasons (i.e. arrangements with pharmacy) ( go to E2) 
 Other, namely ….. 
All answers (except logistic reasons)go to E4 
2. When enteral nutrition is insufficient to meet nutritional targets, do you intend to withhold PN 
during the first week of critical illness in the future?   
   No, I intend to start PN as soon as possible  
   Yes, I intend to withhold PN for less than 7 days in the future ( go to E3)    
   Yes, I intend to withhold PN during the first week in the future ( go to E4)   
3. At which day do you intend to start PN in the future?  
 < 24 hours  
 < 48 hours  
 2-4 days     
 4-7 days  
 >7 days 
4. Do you have any comments on this survey? (not mandatory) 
5. If you would like to be informed about the results of this survey, please fill in your name and email-
address. (not mandatory) 
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Supplementary Table 1: Characteristics and nutritional practices of PICUs of which the respondent 
had read the article versus those who have not read the article 
 
Characteristic / nutritional practice 
Have read the article 
(n=43) 
Did not read the article 
(n=38) 
Continent    
Europe 22 (51.2%) 17 (44.7%) 
South America 8 (18.6%) 6 (15.8%) 
Asia 2 (4.7%) 10 (26.3%) 
North America 8 (18.6%) 4 (10.5%) 
Africa 2 (4.7%) 0 (0%) 
Oceania 1 (2.3%) 1 (2.6%) 
Hospital type   
University children’s hospital 26 (60.5%) 11 (28.9%) 
University hospital 10 (23.3%) 14 (36.8%) 
General hospital 6 (14.0%) 12 (31.6%) 
Other 1 (2.3%) 1 (2.6%) 
Type of PICU   
Multidisciplinary/mixed 43 (100%) 32 (84.2%) 
Medical 0 (0%) 4 (10.5%) 
Cardiac 0 (0%) 1 (2.6%) 
Surgical 0 (0%) 1 (2.6%) 
Combination of PICU   
Not combined  35 (81.4%) 31 (81.6%) 
With neonatal ICU 5 (11.6%) 5 (13.2%) 
With adult ICU 3 (7.0%) 1 (2.6%) 
With adult and neonatal ICU 0 (0%) 1 (2.6%) 
Size of PICU   
1-10 beds 12 (27.9%) 21 (55.3%) 
11-20 beds 16 (37.2%) 12 (31.6%) 
21-30 beds 12 (27.9%) 4 (10.5%) 
>30 beds 3 (7.0%) 1 (2.6%) 
Paediatric admissions (patients/year)  
1-250 3 (7.0%) 4 (10.5%) 
251-500 13 (30.2%) 16 (42.1%) 
501-750 9 (20.9%) 9 (23.7%) 
751-1000 4 (9.3%) 3 (7.9%) 
1001-1250 5 (11.6%) 2 (5.3%) 
>1250 9 (20.9%) 4 (10.5%) 
Mechanically ventilated patients  
<25% 6 (14.0%) 3 (7.9%) 
25-50% 13 (30.2%) 18 (47.4%) 
50-75% 14 (32.6%) 11 (28.9%) 
>75% 
 
 
 
 
10 (23.3%) 
 
 
 
 
6 (15.8%) 
 
 
 
 
 
 
 
Supplementary table 1 continued   
Characteristic / nutritional practice 
Have read the article 
(n=43) 
Did not read the article 
(n=38) 
Add PN if EN is insufficient   
No 2 (4.7%) 2 (5.3%) 
Yes, if EN <50% 13 (30.2%) 7 (18.4%) 
Yes, if EN <80% 21 (4.7%) 22 (57.9%) 
Yes, always 5 (11.6%) 5 (13.2%) 
Other 2 (4.7%) 2 (5.3%) 
Start amino acids   
<24 hours 12 (27.9%) 9 (23.7) 
<48 hours 5 (11.6%) 11 (28.9%) 
2-4 days 12 (27.9%) 9 (23.7%) 
4-7 days 10 (23.3%) 7 (18.4%) 
>7 days 4 (9.3%) 0 (0.0%) 
Start lipids   
<24 hours 9 (20.9%) 5 (13.2%) 
<48 hours 9 (20.9%) 11 (28.9%) 
2-4 days 11 (25.6%) 10 (26.3%) 
4-7 days 11 (25.6%) 11 (28.9%) 
>7 days 3 (7.0%) 1 (2.6%) 
PICU = paediatric intensive care unit; ICU = intensive care unit; PN = parenteral nutrition. 
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Supplementary table 1 continued   
Characteristic / nutritional practice 
Have read the article 
(n=43) 
Did not read the article 
(n=38) 
Add PN if EN is insufficient   
No 2 (4.7%) 2 (5.3%) 
Yes, if EN <50% 13 (30.2%) 7 (18.4%) 
Yes, if EN <80% 21 (4.7%) 22 (57.9%) 
Yes, always 5 (11.6%) 5 (13.2%) 
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<24 hours 9 (20.9%) 5 (13.2%) 
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2-4 days 11 (25.6%) 10 (26.3%) 
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ABSTRACT 
 
Background  
Previous randomised studies showed that withholding parenteral nutrition (PN) for 1 week of 
critical illness was superior to early initiation (<24-48 h) of PN in children and adults. However, 
neonates are considered more susceptible to macronutrient deficits. We investigated the 
effect of withholding PN  for 1 week in critically ill, term neonates. 
 
Methods  
We previously did a randomised, controlled study (PEPaNIC) of children aged up to 17 years 
admitted to paediatric intensive care units (ICUs) in three hospitals in Belgium, Canada, and 
the Netherlands randomly assigned (1:1) to either standard care of PN initiated early within 
24 hours of admission to an ICU or Late-PN (where supplemental PN was withheld for 1 week 
after admission to the ICU. In this preplanned, secondary subanalysis of PEPaNIC, we looked 
at data from critically ill, term neonate participants (gestational age ≥37 weeks) aged up to 28 
days (studied in overlapping age groups of ≤4 weeks, ≤1 week, and <1 day— i.e., age at 
admission). In both the Early-PN and Late-PN groups, enteral nutrition was initiated as soon 
as possible and increased according to local protocols. Outcome assessors and investigators 
not directly involved in the paediatric ICU were not informed of treatment allocation. The 
primary endpoints were incidence of new infections and duration of paediatric ICU 
dependency (quantified as the number of days in the paediatric ICU and likelihood of earlier 
live discharge from the ICU), analysed based on intention to treat. Multivariable analyses were 
adjusted for the following risk factors: centre, Paediatric Logistic Organ Dysfunction score, 
Paediatric Index of Mortality 2 score, diagnosis group, and weight-for-age Z scores on 
admission. Secondary safety outcomes were mortality (at 90 days, during the intervention, in 
the paediatric ICU, and in the hospital) and hypoglycaemic incidents during the intervention. 
All patients in the respective groups were included in the safety analysis. 
 
Findings  
Between June 18, 2012, and July 27, 2015, we included 209 participants in this substudy, 145 
of whom were aged up to and including 1 week and 45 aged younger than 1 day. In neonates 
aged up to and including 4 weeks, Late-PN increased the likelihood of earlier live discharge 
from the paediatric ICU compared with Early-PN (adjusted hazard ratio [HR] 1.61, 95% CI 1.19–
2.20; p=0.0021) but did not affect the risk of infection. The risk of infection in neonates aged 
up to and including 1 week and younger than 1 day was lower with Late-PN than with Early-
PN (adjusted odds ratios [OR] 0.36, 95% CI 0.15–0.83, p=0.017; and 0.10, 0.01–0.64, p=0.015, 
respectively). For neonates aged up to and including 1 week, the likelihood of an earlier live 
discharge from the ICU was higher with Late-PN (adjusted HR 1.69, 95% CI 1.16–2.46; 
p=0.0063). For neonates younger than 1 day, adjusted HR was 1.95 (95% CI 0.93–4.12; 
p=0.078). Mortality at all studied time-points was similar between the groups for all ages; 
however, in neonates aged up to and including 4 weeks and aged up to and including 1 week, 
 
 
 
the risk of hypoglycaemia was higher with Late-PN (23% vs 14%; adjusted OR 3.05, 95% CI 
1.27–7.35, p=0.013; and 24% vs 14%; 3.57, 1.23–10.45, p=0.019, respectively). 
 
Interpretation  
In critically ill, term neonates, withholding PN for 1 week was clinically superior to standard 
care of Early-PN for short-term outcomes. However, withholding PN for 1 week significantly 
increased the risk of developing hypoglycaemia, which necessitates long-term follow-up of 
these children before Late-PN can be confidently recommended for this vulnerable patient 
group.
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from the paediatric ICU compared with Early-PN (adjusted hazard ratio [HR] 1.61, 95% CI 1.19–
2.20; p=0.0021) but did not affect the risk of infection. The risk of infection in neonates aged 
up to and including 1 week and younger than 1 day was lower with Late-PN than with Early-
PN (adjusted odds ratios [OR] 0.36, 95% CI 0.15–0.83, p=0.017; and 0.10, 0.01–0.64, p=0.015, 
respectively). For neonates aged up to and including 1 week, the likelihood of an earlier live 
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p=0.078). Mortality at all studied time-points was similar between the groups for all ages; 
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the risk of hypoglycaemia was higher with Late-PN (23% vs 14%; adjusted OR 3.05, 95% CI 
1.27–7.35, p=0.013; and 24% vs 14%; 3.57, 1.23–10.45, p=0.019, respectively). 
 
Interpretation  
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care of Early-PN for short-term outcomes. However, withholding PN for 1 week significantly 
increased the risk of developing hypoglycaemia, which necessitates long-term follow-up of 
these children before Late-PN can be confidently recommended for this vulnerable patient 
group.
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INTRODUCTION 
 
Findings from recent multicentre, randomised, controlled trials showed that withholding 
parenteral nutrition (PN) to supplement insufficient enteral nutrition (EN) for patients in the 
first week in an intensive care unit (ICU) led to better clinical and health-economic outcomes 
than initiating PN early (<24-48 h), both in adults and in children.18,123,125,127 Preplanned 
secondary analyses of these studies suggested that the early administration of amino acids 
rather than glucose or lipids was associated with the harm caused by early supplementation 
of PN.70,128 In these trials, there was an age-dependent effect, with the largest benefit of 
withholding PN occurring in children and term neonates.18,123 However, withholding 
supplemental PN in neonates for a week, especially amino acids, contradicts with current 
advice.103 Neonates are susceptible to acquiring macronutrient deficits because of their low 
stores of glycogen and fat combined with increased energy and protein requirements to 
sustain growth. Therefore, recommendations for macronutrient intake are higher for 
neonates than for older children and adults, and early supplementation with PN is often more 
strongly promoted in neonates than in older children.103 Concerns raised by experts regarding 
withholding PN in neonates have primarily focused on the risk of developing hypoglycaemia 
and amino acid deficits.71-73 
We previously did a randomised, controlled study (PEPaNIC)18 that investigated the 
effect of withholding PN in the first week of intensive care versus early PN within 24 hours on 
outcomes in children admitted to a paediatric ICU. In this secondary analysis of the PEPaNIC 
study, we investigated the efficacy and safety of withholding supplemental PN for 1 week in 
all neonates enrolled in the trial. We analysed the effects on patients aged up to and including 
4 weeks, up to and including 1 week, and younger than 1 day. Because of the major concerns 
raised by experts in the field regarding withholding PN, we further investigated the effect on 
neonates who did not tolerate any EN during the first week in the paediatric ICU. Finally, we 
investigated whether early amino acid administration might be associated with harm in 
neonates as has been observed in children.70 
 
METHODS 
 
Study design and participants 
PEPaNIC included 1440 critically ill children aged from term newborns (gestational age ≥37 
weeks) to 17 years, with a medium-to-high risk of malnutrition who were admitted to three 
paediatric ICUs in Belgium (Leuven), Canada (Edmonton), and the Netherlands (Rotterdam) 
from June 18, 2012, to July 27, 2015. The study protocol has been reported previously in 
detail.18,129 This preplanned secondary analysis included critically ill, term newborn babies 
aged up to 28 days who participated in PEPaNIC (Appendix).18 The institutional ethical review 
boards of the participating centres in Leuven (ML8052), Rotterdam (NL38772.000.12) and 
Edmonton (Pro00038098) approved the study. Written informed consent was obtained from 
participants’ parents or legal guardians. 
 
 
 
Randomisation and masking 
Participants were randomly assigned (1:1) to either withholding supplemental PN for the first 
week after admission to the paediatric ICU (Late-PN) or to standard care of initiating PN within 
24 hours of admission (Early-PN) when EN alone was insufficient. In both groups, EN was 
initiated as soon as possible and increased according to local protocols. Outcome assessors 
and investigators not directly involved in the paediatric ICU were not informed of treatment 
allocation. 
 
Procedures 
PN was provided at a dose and of a composition that varied according to local guidelines and 
was not provided as an all-in-one product. For patients assigned to Early-PN, this was initiated 
within 24 hours after admission to the paediatric ICU as supplementation if EN provided less 
than 80% of the target to reach the local age-specific and weight-specific caloric targets. In 
patients assigned to Late0-PN, PN was withheld during the first week in the ICU. To match the 
fluid administration of the Early-PN group, taking into account the volume of EN delivered, a 
mixture of dextrose 5% and saline was provided. To prevent refeeding syndrome, patients 
from both groups received intravenous micronutrients (trace elements, minerals, and 
vitamins) early in similar amounts, until EN reached 80% of caloric targets. For patients from 
both groups who were still in the ICU after a week and who were not yet receiving 80% of the 
caloric target enterally, PN was administered to reach the targets. If a central venous line was 
not or was no longer in place for clinical purposes, any required PN was delivered via a 
peripheral line. Blood glucose control with insulin for neonates differed according to local 
protocols. In Leuven, insulin infusion was started to target blood glucose concentrations of 
2.7-4.4 mmol/L. In Rotterdam, neonates received insulin infusion to target blood glucose 
concentrations of 4.0-8.0 mmol/L. In Edmonton, patients received insulin infusion when blood 
glucose concentrations exceeded 10.0 mmol/L. Blood glucose concentrations were checked 
hourly after every change in macronutrient intake or insulin administration until three 
consecutive measurements were within the normal range.18,129 This analysis investigated 
outcomes in three overlapping age groups (≤4 weeks, ≤1 week, and <1 day). Neonates with 
no or minimal EN were defined as those who had stayed in the paediatric ICU for at least 7 
days, and were unable to receive EN or had only received trophic feeding (<40 mL per day) 
during the first week, with a maximum of 80 mL per week. 
 
Outcomes 
The primary efficacy endpoints were the incidence of infections acquired in the paediatric ICU 
and duration of paediatric ICU dependency (quantified as the crude number of days in the 
paediatric ICU and likelihood of earlier live discharge from the ICU). Secondary efficacy 
outcomes were duration of mechanical ventilation (crude number of days and likelihood of 
earlier live weaning from ventilation), maximum plasma urea concentration, duration of 
hospital stay (crude number of days and likelihood of earlier live discharge from hospital), and 
direct health-care costs.125 The assessment of infections acquired in the paediatric ICU was 
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stores of glycogen and fat combined with increased energy and protein requirements to 
sustain growth. Therefore, recommendations for macronutrient intake are higher for 
neonates than for older children and adults, and early supplementation with PN is often more 
strongly promoted in neonates than in older children.103 Concerns raised by experts regarding 
withholding PN in neonates have primarily focused on the risk of developing hypoglycaemia 
and amino acid deficits.71-73 
We previously did a randomised, controlled study (PEPaNIC)18 that investigated the 
effect of withholding PN in the first week of intensive care versus early PN within 24 hours on 
outcomes in children admitted to a paediatric ICU. In this secondary analysis of the PEPaNIC 
study, we investigated the efficacy and safety of withholding supplemental PN for 1 week in 
all neonates enrolled in the trial. We analysed the effects on patients aged up to and including 
4 weeks, up to and including 1 week, and younger than 1 day. Because of the major concerns 
raised by experts in the field regarding withholding PN, we further investigated the effect on 
neonates who did not tolerate any EN during the first week in the paediatric ICU. Finally, we 
investigated whether early amino acid administration might be associated with harm in 
neonates as has been observed in children.70 
 
METHODS 
 
Study design and participants 
PEPaNIC included 1440 critically ill children aged from term newborns (gestational age ≥37 
weeks) to 17 years, with a medium-to-high risk of malnutrition who were admitted to three 
paediatric ICUs in Belgium (Leuven), Canada (Edmonton), and the Netherlands (Rotterdam) 
from June 18, 2012, to July 27, 2015. The study protocol has been reported previously in 
detail.18,129 This preplanned secondary analysis included critically ill, term newborn babies 
aged up to 28 days who participated in PEPaNIC (Appendix).18 The institutional ethical review 
boards of the participating centres in Leuven (ML8052), Rotterdam (NL38772.000.12) and 
Edmonton (Pro00038098) approved the study. Written informed consent was obtained from 
participants’ parents or legal guardians. 
 
 
 
Randomisation and masking 
Participants were randomly assigned (1:1) to either withholding supplemental PN for the first 
week after admission to the paediatric ICU (Late-PN) or to standard care of initiating PN within 
24 hours of admission (Early-PN) when EN alone was insufficient. In both groups, EN was 
initiated as soon as possible and increased according to local protocols. Outcome assessors 
and investigators not directly involved in the paediatric ICU were not informed of treatment 
allocation. 
 
Procedures 
PN was provided at a dose and of a composition that varied according to local guidelines and 
was not provided as an all-in-one product. For patients assigned to Early-PN, this was initiated 
within 24 hours after admission to the paediatric ICU as supplementation if EN provided less 
than 80% of the target to reach the local age-specific and weight-specific caloric targets. In 
patients assigned to Late0-PN, PN was withheld during the first week in the ICU. To match the 
fluid administration of the Early-PN group, taking into account the volume of EN delivered, a 
mixture of dextrose 5% and saline was provided. To prevent refeeding syndrome, patients 
from both groups received intravenous micronutrients (trace elements, minerals, and 
vitamins) early in similar amounts, until EN reached 80% of caloric targets. For patients from 
both groups who were still in the ICU after a week and who were not yet receiving 80% of the 
caloric target enterally, PN was administered to reach the targets. If a central venous line was 
not or was no longer in place for clinical purposes, any required PN was delivered via a 
peripheral line. Blood glucose control with insulin for neonates differed according to local 
protocols. In Leuven, insulin infusion was started to target blood glucose concentrations of 
2.7-4.4 mmol/L. In Rotterdam, neonates received insulin infusion to target blood glucose 
concentrations of 4.0-8.0 mmol/L. In Edmonton, patients received insulin infusion when blood 
glucose concentrations exceeded 10.0 mmol/L. Blood glucose concentrations were checked 
hourly after every change in macronutrient intake or insulin administration until three 
consecutive measurements were within the normal range.18,129 This analysis investigated 
outcomes in three overlapping age groups (≤4 weeks, ≤1 week, and <1 day). Neonates with 
no or minimal EN were defined as those who had stayed in the paediatric ICU for at least 7 
days, and were unable to receive EN or had only received trophic feeding (<40 mL per day) 
during the first week, with a maximum of 80 mL per week. 
 
Outcomes 
The primary efficacy endpoints were the incidence of infections acquired in the paediatric ICU 
and duration of paediatric ICU dependency (quantified as the crude number of days in the 
paediatric ICU and likelihood of earlier live discharge from the ICU). Secondary efficacy 
outcomes were duration of mechanical ventilation (crude number of days and likelihood of 
earlier live weaning from ventilation), maximum plasma urea concentration, duration of 
hospital stay (crude number of days and likelihood of earlier live discharge from hospital), and 
direct health-care costs.125 The assessment of infections acquired in the paediatric ICU was 
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based on an a priori-drafted protocol, which made use of data on prescribed antibiotics and 
clinical infection and inflammation (appendix).18,129 ICU dependency was defined as requiring 
or at-risk for requiring vital organ support. Total direct health-care costs were explored from 
a hospital perspective in the Belgian and Dutch study populations, because these healthcare 
systems are reasonably comparable.125 Secondary safety endpoints were 90-day mortality, 
death during the first week, mortality in the paediatric ICU, and hospital mortality, as well as 
incidence of hypoglycaemia (i.e., plasma glucose concentration <40 mg/dL [2.2 mmol/L]). For 
the patients in Leuven who had an episode of hypoglycaemia, time-to-recovery from 
hypoglycaemia was also investigated. 
 
Statistical analysis 
Data were analysed based on intention to treat for the whole group of neonates aged up to 
and including 4 weeks and those aged up to and including 1 week. The main outcomes were 
also analysed separately in neonates younger than 1 day and in neonates who had received 
no or minimal enteral nutrition during the first week. The original PEPaNIC trial was a priori 
statistically powered to detect a difference in new infections, as in the adult EPaNIC trial,123 
and stratified for age according to the groups younger than 1 year, and 1 year and older. 
Because the sample size of the present subanalysis depended on the number of neonates 
included in PEPaNIC, we did a retrospective power analysis based on observed differences for 
risk of new infection as primary endpoint, rather than an a-priori sample size calculation. 
 We reported variables as frequencies (%), mean (SD), or median (IQR) as appropriate, 
and did univariable and multivariable analyses. The multivariable analyses included logistic 
and linear regression for dichotomous and continuous outcomes, respectively, and Cox 
proportional hazard analysis for time-to-event outcomes with data censored at 90 days. A 
competing risk analysis was used for duration outcomes, with data of non-survivors censored 
at 91 days. Multivariable analyses were adjusted for the predefined baseline risk factors of 
centre, Paediatric Logistic Organ Dysfunction (PELOD) score, Paediatric Index of Mortality 2 
(PIM2) score, diagnosis group (medical, surgical-cardiac, or surgical other), and weight-for-age 
Z scores on admission;130,131 in a sensitivity analysis they were also adjusted for age in 
neonates aged up to and including 4 weeks. Results are reported as odds ratios (OR), hazard 
ratios (HR), or beta values (β), and corresponding 95% CI. No corrections were made for 
multiple testing. 
 To investigate which macronutrient might be accountable for any potential harm, we 
did an explanatory analysis in neonates aged up to and including 4 weeks and aged up to and 
including 1 week of the independent associations between average daily total doses of each 
macronutrient class (ie, glucose, lipids, and amino acids) up to each of the first 7 days in the 
paediatric ICU and clinical outcomes with use of multivariable Cox proportional hazard 
analysis censored at 90 days, adjusted for the predefined baseline risk factors listed earlier. 
This method has been previously described in detail.70 Briefly, because PEPaNIC investigated 
the effect on outcome of Late-PN versus Early-PN over the first 7 days after admission to a 
paediatric ICU, with doses titrated differently for each macronutrient as crude g/kg per day, 
 
 
 
we analysed independent associations between clinical outcomes and average daily total 
doses of each macronutrient up to each of the 7 days for neonates aged up to and including 4 
weeks and aged up to and including 1 week who were still in the ICU on those respective days 
(Appendix). Associations of each of these average doses with the likelihoods of acquiring a 
new infection in the ICU (time to first new infection, with left-truncation), earlier live discharge 
from the ICU, and earlier live weaning from mechanical ventilation were studied. No 
corrections for multiple comparisons were done. We considered two-sided p values of less 
than 0.05 as statistically significant for all analyses. Analyses were done with SPSS Statistics 
v.21 or JMP Pro-13.1. An independent data and safety monitoring board oversaw the original 
trial.18 
 
Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and final responsibility for the decision to submit for publication. 
 
RESULTS  
 
Patients 
This subanalysis included 209 term neonates aged up to and including 4 weeks (of 917 
screened for eligibility), of which 145 neonates aged up to and including 1 week, of which 45 
neonates aged younger than 1 day (Appendix). Macronutrient intake per day up to day 7 in 
the paediatric ICU, illustrating protocol adherence, is in the appendix. In neonates aged up to 
and including 4 weeks and those aged up to and including 1 week, the PIM2 score was 
significantly higher in the Early-PN groups than in the Late-PN groups, reflecting a higher risk 
of mortality (Table 1).  
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In neonates younger than 1 day, the PELOD scores were significantly higher in the Early-PN 
group than in the Late-PN group (Table 1), which also contained a higher proportion of 
patients with congenital diaphragmatic hernia and a lower proportion of patients with 
gastroschisis than the late parenteral nutrition group (Appendix). In the subgroup of neonates 
without enteral nutrition, baseline characteristics were similar, but with similar 
disproportionate distribution of diagnoses (Appendix). 
 In univariable analysis, late parenteral nutrition reduced the risk of acquiring a new 
infection in all age groups (Tables 2, 3, 4). In multivariable analysis, this effect of Late-PN was 
only maintained in neonates aged up to and including 1 week and younger than 1 day (Tables 
2, 3, 4). Statistical power (one-tailed test, α 0.05) retrospectively calculated for the observed 
differences in risk of new infection in univariable analysis was 79.6%, 92.3%, and 95.4% for 
neonates aged up to and including 4 weeks and aged up to and including 1 week, and younger 
than 1 day, respectively. Starting from the observed risk of new infection in the Early-PN, the 
minimally demonstrable risk reduction versus the observed absolute risk reduction (one-
tailed) with Late-PN for new infections in the paediatric ICU, accepting an α of 0.05 and a 
power of 80%, was -14.5% versus -14.4% in neonates aged up to and including 4 weeks,-18.1% 
versus -21.7% in those aged up to and including 1 week, and -36.5% versus -45.3% in those 
younger than 1 day. Late-PN also shortened the duration of paediatric ICU dependency, with 
a higher likelihood of an earlier live discharge at any time in neonates aged up to and including 
4 weeks and aged up to and including 1 week (Tables 2, 3). Further adjustments for age in 
neonates aged up to and including 4 weeks did not affect the main outcomes (Appendix).  
 Mortality was similar for Late-PN versus Early-PN in all age groups (Tables 2, 3, 4). The 
risk of having an episode of hypoglycaemia was significantly higher with Late-PN versus Early-
PN for neonates aged up to and including 4 weeks and those aged up to and including 1 week 
(Tables 2, 3). Further adjustment for age in neonates aged up to and including 4 weeks did not 
affect the safety outcomes (Appendix). 83 hypoglycaemic episodes were further analysed 
(Appendix). This analysis showed that none of the episodes was symptomatic, and 94% 
occurred during insulin administration. Time to recovery from hypoglycaemia was equally fast 
in both treatment groups after a median of approximately 58 min, and in 84% of the cases at 
the first glucose check. However, this outcome could be analysed only in neonates in Belgium 
(n=60) because the exact time of glucose measurements had not been recorded by bedside 
glucometers used in other centres.  
In all age groups, the need for mechanical ventilation was shorter with Late-PN, with a 
higher likelihood of being weaned alive from the ventilator at any time, than with Early-PN 
(Tables 2, 3, 4). In neonates aged up to and including 4 weeks and aged up to and including 1 
week, plasma urea concentrations and direct health-care costs were lower in the Late-PN 
group compared with the Early-PN (Tables 2, 3).  
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In neonates younger than 1 day, the PELOD scores were significantly higher in the Early-PN 
group than in the Late-PN group (Table 1), which also contained a higher proportion of 
patients with congenital diaphragmatic hernia and a lower proportion of patients with 
gastroschisis than the late parenteral nutrition group (Appendix). In the subgroup of neonates 
without enteral nutrition, baseline characteristics were similar, but with similar 
disproportionate distribution of diagnoses (Appendix). 
 In univariable analysis, late parenteral nutrition reduced the risk of acquiring a new 
infection in all age groups (Tables 2, 3, 4). In multivariable analysis, this effect of Late-PN was 
only maintained in neonates aged up to and including 1 week and younger than 1 day (Tables 
2, 3, 4). Statistical power (one-tailed test, α 0.05) retrospectively calculated for the observed 
differences in risk of new infection in univariable analysis was 79.6%, 92.3%, and 95.4% for 
neonates aged up to and including 4 weeks and aged up to and including 1 week, and younger 
than 1 day, respectively. Starting from the observed risk of new infection in the Early-PN, the 
minimally demonstrable risk reduction versus the observed absolute risk reduction (one-
tailed) with Late-PN for new infections in the paediatric ICU, accepting an α of 0.05 and a 
power of 80%, was -14.5% versus -14.4% in neonates aged up to and including 4 weeks,-18.1% 
versus -21.7% in those aged up to and including 1 week, and -36.5% versus -45.3% in those 
younger than 1 day. Late-PN also shortened the duration of paediatric ICU dependency, with 
a higher likelihood of an earlier live discharge at any time in neonates aged up to and including 
4 weeks and aged up to and including 1 week (Tables 2, 3). Further adjustments for age in 
neonates aged up to and including 4 weeks did not affect the main outcomes (Appendix).  
 Mortality was similar for Late-PN versus Early-PN in all age groups (Tables 2, 3, 4). The 
risk of having an episode of hypoglycaemia was significantly higher with Late-PN versus Early-
PN for neonates aged up to and including 4 weeks and those aged up to and including 1 week 
(Tables 2, 3). Further adjustment for age in neonates aged up to and including 4 weeks did not 
affect the safety outcomes (Appendix). 83 hypoglycaemic episodes were further analysed 
(Appendix). This analysis showed that none of the episodes was symptomatic, and 94% 
occurred during insulin administration. Time to recovery from hypoglycaemia was equally fast 
in both treatment groups after a median of approximately 58 min, and in 84% of the cases at 
the first glucose check. However, this outcome could be analysed only in neonates in Belgium 
(n=60) because the exact time of glucose measurements had not been recorded by bedside 
glucometers used in other centres.  
In all age groups, the need for mechanical ventilation was shorter with Late-PN, with a 
higher likelihood of being weaned alive from the ventilator at any time, than with Early-PN 
(Tables 2, 3, 4). In neonates aged up to and including 4 weeks and aged up to and including 1 
week, plasma urea concentrations and direct health-care costs were lower in the Late-PN 
group compared with the Early-PN (Tables 2, 3).  
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Figure 1: Association of average total macronutrient doses in each of the first 7 days in 
paediatric intensive care unit with clinical outcomes 
 
Data are hazard ratios (HR; 95% Cis) per g macronutrient/kg added. The figure shows associations of average 
daily doses of the individual macronutrients up to each of the 7 days with the likelihood of (A) acquiring a new 
infection in the PICU, (B) earlier live PICU discharge, and (C) earlier live weaning from mechanical ventilation. 
Results were obtained after adjustment for centre, Paediatric Logistic Organ Dysfunction (PELOD) score, 
Paediatric Index of Mortality 2 (PIM2) score, diagnosis group and weight-for-age Z-scores on admission. A HR >1 
indicates a higher likelihood of acquiring a new infection (indicating harm), but a higher likelihood of live weaning 
from mechanical ventilation and of live PICU discharge (indicating benefit), and vice versa for a HR <1. N 
represents the number of patients still in the PICU on the day of analysis. The dotted lines represent a neutral 
relationship in form of HRs being equal to 1 (border between harm and benefit).  
PICU = paediatric intensive care unit. 
 
 
DISCUSSION 
 
Withholding supplemental PN for 1 week in critically ill, term neonates admitted to a 
paediatric ICU was superior to Early-PN given within 24 hours from a clinical and health-
economical perspective. Late-PN resulted in fewer nosocomial infections in neonates aged up 
to and including 1 week and younger than 1 day, and in a shorter dependency on intensive 
care and mechanical ventilation for all studied age groups of neonates. The benefits of Late-
PN were noted irrespective of centre, disease severity, risk of mortality, diagnosis and 
nutritional status upon admission. In neonates younger than 1 day, the benefits and large 
treatment effects observed should be interpreted with the small sample size and differences 
in diagnoses in consideration, although the direction of the effect was also consistently in 
favour of Late-PN.  
Taking statistical power into consideration, the benefits of withholding PN during 
critical illness occurred for term neonates in agreement with findings for older children and 
adults.18,123 This observation contrasted with concerns that have been raised by experts that 
neonates are more susceptible to macronutrient deficits.71-73 A pathophysiological 
explanation would help to support the clinical findings and abate remaining concerns. 
Underlying mechanisms of the clinical benefits of withholding PN cannot be determined by 
our study and remain speculative. However, a role for better activation of autophagy - a 
process essential for innate immunity, cellular damage control and preservation of 
endogenous energy supply during critical illness - seems plausible.132,133 Whereas autophagy 
is activated during fasting, both during the physiological transition from foetal to neonatal life 
as well as during critical illness-related anorexia, it is inhibited with Early-PN.132,133 
Furthermore, production of ketone bodies as fuel for the brain is facilitated in foetuses by 
brown adipose tissue.134 Thus, efficient ketone body production and upregulated autophagy 
could provide strategies to manage a macronutrient deficit during acute critical illness in the 
neonatal period. Such resilience to a macronutrient deficit might also account for why the 
results in the group of critically ill, term neonates incapable of receiving any EN during the first 
week seemed to achieve similar benefits as noted with Late-PN in the whole group of 
neonates. However, the small number of patients did not allow us to draw any firm 
conclusions. 
Safety aspects of Late-PN need to be considered. We showed that, although Late-PN 
did not affect mortality, it did increase the incidence of hypoglycaemia, which necessitates 
caution when applied to this vulnerable patient group. Neonates receiving no or minimal EN 
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and healthy newborn babies are contradictory and remain a subject of debate.19,21-23 Critically 
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negative effects of hypoglycaemia on neurocognitive functioning.20 However, real-time 
continuous glucose monitoring was unavailable in all centres and thus unnoticed 
hypoglycaemic periods up to 1 hour cannot be excluded. Whether the hypoglycaemic 
incidents in our Late-PN group affected long-term neurocognitive outcome is yet to be 
established. A long-term follow-up of the patients is currently ongoing. 
In line with a secondary analysis of all children included in the PEPaNIC trial,70 we 
showed in a similar explanatory analysis that higher amounts of amino acids, rather than 
glucose or lipids, were associated with prolonged need for mechanical ventilation and 
intensive care in critically ill term neonates, a population that required mechanical ventilation 
and intensive care for a longer time than the older patients in the PEPaNIC trial. Current advice 
for amino acid intake is based on studies investigating nitrogen balance as outcome 
measure.74,136 Based on exclusively preterm neonatal research, amino acid intake in neonates 
is advised to be started as soon as possible after birth to avoid the metabolic derangement 
caused by the interruption of continuous feeding that is present in utero.137 Higher amounts 
of amino acids indeed result in positive nitrogen balances and an anabolic state, though at the 
cost of higher urea concentrations and higher amino acid oxidation rates.3,138,139 Furthermore, 
no long-term beneficial effects of early high amino acid administration were noted.140 Thus, 
the optimum amount of amino acid administration in preterm neonates is under debate.140 
Although findings in preterm neonates cannot be extrapolated to term neonates, they raise 
questions about the presumed beneficial effect of early high amounts of amino acids in 
critically ill, term neonates. In that regard, our present data call for caution, as higher amino 
acid doses appeared to be associated with delayed recovery and with higher plasma urea 
concentrations, highlighting the need for addressing causality in an adequately powered 
randomised trial.  
One strength of our study was the randomised design in a large group of critically ill 
neonates. Another asset is the clinically relevant outcome measures, unique for nutritional 
studies in this population. Important limitations are the insufficient power in some of the sub-
analyses, and the observational design of the explanatory macronutrient dose analyses. 
Another major limitation was that the baseline characteristics differed between the 
randomisation groups. However, we corrected for this during the multivariable analyses. A 
final limitation is the absence of data on (long-term) growth. 
 
CONCLUSIONS 
 
Withholding PN for 1 week during critical illness in term neonates, while administering 
micronutrients during this time, is superior to early initiation of PN from a short-term clinical 
and health-economical perspective. However, withholding PN for 1 week significantly 
increased the risk of developing hypoglycaemia, necessitating frequent monitoring of blood 
glucose concentrations. Long-term effects of hypoglycaemia need to be investigated before 
Late-PN can be confidently recommended for this vulnerable patient group. 
 
 
APPENDIX 
 
Methods S1: Protocol for scoring of infections      
Data export  
All patients receiving antimicrobial agents were identified by the data manager, who provided 
an export of all patient numbers with all the information on antimicrobial agents given as well 
as the duration of such treatment.  
 
Identification of patients with infections 
The infectious disease specialists, who were blinded for treatment allocation, selected all 
patients receiving antimicrobial agents for more than 48 hours, after excluding all patients 
who received prophylaxis. Each patient who fulfilled the criteria for infection, as well as the 
type of infection, was identified as such based on thorough review of the medical record. 
Patients for whom antimicrobials where initiated prior to paediatric ICU admission or within 
the first 48 hours of admission while the criteria for infection were fulfilled, were labelled as 
“having an infection upon admission”. When antimicrobial agents were initiated after 
randomization and beyond the first 48 hours in the paediatric ICU, and were given for more 
than 48 hours while the criteria for infection were fulfilled, the patient was labelled as “having 
a new infection”.18 
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Methods S2: Stepwise transformation of the given doses of glucose, lipid, and amino acids 
and association with clinical outcomes 
 
 
In a first step, doses of glucose, lipid, and amino acids as the crude grams per kilogram per day 
that were given on each of the first 7 days in paediatric ICU were used to calculate average 
doses of glucose, lipid, and amino acids administered up to each of the first 7 days in paediatric 
ICU for all patients who were still in paediatric ICU on these respective days. 
In a second step, associations of these average doses up to each of the first 7 days in 
paediatric ICU with the clinical endpoints (time to the first new infection acquired in the 
paediatric ICU, the time to live discharge from paediatric ICU accounting for mortality as a 
competing risk, and the time to live weaning from mechanical ventilatory support) were 
determined with Cox proportional hazard analyses, adjusting for centre, Paediatric Logistic 
Organ Dysfunction (PELOD) score, Paediatric Index of Mortality 2 (PIM2) score, diagnosis 
group and weight-for-age Z-scores on admission. 
This procedure was performed for total doses and repeated for enteral doses and 
parenteral doses of glucose, lipid, and amino acids. 
 
 
Figure S1: Consort flow diagram 
 
DNR = do not resuscitate, ICU = intensive care unit, PICU = paediatric intensive care unit.
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Table S2: Diagnoses of neonates aged <1 day 
 
Diagnosis Early-PN 
(n=28) 
Late-PN 
(n=17) 
P-value 
Surgical    
    Abdominal / Thoracic surgery    
            Congenital Diaphragmatic Hernia 17 (61%) 5 (29%) 0.041 
            Gastroschisis 3 (11%) 6 (35%) 0.045 
            Other 1 (3%) 2 (12%) 0.30 
    Cardiac surgery 3 (11%) 1 (6%) 0.58 
Non-surgical    
    Cardiac 3 (11%) 1 (6%) 0.58 
    Other 1 (3%) 2 (12%) 0.30 
PN = parenteral nutrition. 
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Table S2: Diagnoses of neonates aged <1 day 
 
Diagnosis Early-PN 
(n=28) 
Late-PN 
(n=17) 
P-value 
Surgical    
    Abdominal / Thoracic surgery    
            Congenital Diaphragmatic Hernia 17 (61%) 5 (29%) 0.041 
            Gastroschisis 3 (11%) 6 (35%) 0.045 
            Other 1 (3%) 2 (12%) 0.30 
    Cardiac surgery 3 (11%) 1 (6%) 0.58 
Non-surgical    
    Cardiac 3 (11%) 1 (6%) 0.58 
    Other 1 (3%) 2 (12%) 0.30 
PN = parenteral nutrition. 
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Table S3: Baseline characteristics of neonates needing intensive care for at least 7 days who 
did not receive enteral nutrition in the first week in paediatric ICU  
 
 Early-PN  
(n=23) 
Late-PN  
(n=15) 
P-value 
Male 15 (65%) 19 (67%) 0.93 
Age at randomisation (days) 0 (0-5) 1 (0-6) 0.48 
Gestational Age (weeks) 38 (38-39) 38 (37-39) 0.54 
Birth Weight (gram) 3100 (2777-3500) 3080 (2700-3330) 0.33 
Weight z-scorea -0.56 (-1.30;0.41) -0.85 (-1.26-0.01) 0.73 
PELOD score 21 (12-32) 22 (12-32) 1.00 
PIM2 score -1.95 (-2.36;-0.00) -0.77 (-2.90;-0.08) 0.70 
Risk of mortality (%)b 12.4 (8.6-50.0) 31.6 (5.2-48.0) 0.70 
Diagnostic group 
    Medical  
    Surgical cardiac 
    Surgical other 
 
2 (9%) 
8 (35%) 
13 (56%) 
 
1 (7%) 
7 (47%) 
7 (47%) 
0.76 
Mechanical ventilation on admission 23 (100%) 15 (100%) - 
Haemodynamic support on admission 18 (78%) 19 (67%) 0.43 
ICU = intensive care unit, PN = parenteral nutrition. 
a Neonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score.  
b Based on PIM2 score =([exp (PIM2)]/[1+exp (PIM2)])*100%. 
 
 
 
 
Table S4: Outcomes of neonates needing intensive care for at least 7 days who did not 
receive enteral nutrition in the first week in paediatric ICU 
 
Diagnosis Early-PN 
(n=23) 
Late-PN 
(n=15) 
P-value 
Surgical    
    Abdominal / thoracic surgery    
            Congenital Diaphragmatic Hernia 12 (52%) 3 (20%) 0.047 
            Gastroschisis 1 (4%) 3 (20%) 0.12 
            Other 0 (0%) 1 (7%) 0.21 
    Cardiac surgery 8 (35%) 7 (47%) 0.46 
Non-surgical    
    Cardiac 2 (9%) 0 (%) 0.24 
    Other 0 (0%) 1 (7%) 0.21 
ICU = intensive care unit, PN = parenteral nutrition. 
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Table S3: Baseline characteristics of neonates needing intensive care for at least 7 days who 
did not receive enteral nutrition in the first week in paediatric ICU  
 
 Early-PN  
(n=23) 
Late-PN  
(n=15) 
P-value 
Male 15 (65%) 19 (67%) 0.93 
Age at randomisation (days) 0 (0-5) 1 (0-6) 0.48 
Gestational Age (weeks) 38 (38-39) 38 (37-39) 0.54 
Birth Weight (gram) 3100 (2777-3500) 3080 (2700-3330) 0.33 
Weight z-scorea -0.56 (-1.30;0.41) -0.85 (-1.26-0.01) 0.73 
PELOD score 21 (12-32) 22 (12-32) 1.00 
PIM2 score -1.95 (-2.36;-0.00) -0.77 (-2.90;-0.08) 0.70 
Risk of mortality (%)b 12.4 (8.6-50.0) 31.6 (5.2-48.0) 0.70 
Diagnostic group 
    Medical  
    Surgical cardiac 
    Surgical other 
 
2 (9%) 
8 (35%) 
13 (56%) 
 
1 (7%) 
7 (47%) 
7 (47%) 
0.76 
Mechanical ventilation on admission 23 (100%) 15 (100%) - 
Haemodynamic support on admission 18 (78%) 19 (67%) 0.43 
ICU = intensive care unit, PN = parenteral nutrition. 
a Neonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score.  
b Based on PIM2 score =([exp (PIM2)]/[1+exp (PIM2)])*100%. 
 
 
 
 
Table S4: Outcomes of neonates needing intensive care for at least 7 days who did not 
receive enteral nutrition in the first week in paediatric ICU 
 
Diagnosis Early-PN 
(n=23) 
Late-PN 
(n=15) 
P-value 
Surgical    
    Abdominal / thoracic surgery    
            Congenital Diaphragmatic Hernia 12 (52%) 3 (20%) 0.047 
            Gastroschisis 1 (4%) 3 (20%) 0.12 
            Other 0 (0%) 1 (7%) 0.21 
    Cardiac surgery 8 (35%) 7 (47%) 0.46 
Non-surgical    
    Cardiac 2 (9%) 0 (%) 0.24 
    Other 0 (0%) 1 (7%) 0.21 
ICU = intensive care unit, PN = parenteral nutrition. 
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Table S6: Episodes of hypoglycaemia 
 
 Early-PN  
(n=35) 
Late-PN  
(n=48) 
Univariable  
P-value 
Lowest level of blood glucose – mg/dL 37 (33.3-38) 34.5 (29-37) 0.032 
Time-to-recovery from hypoglycaemiaa – minutes  58 (45-88) 58.5 (48-76) 0.27 
Level of blood glucose at recovery– mg/dL 73 (54-94) 58.5 (48-76) 0.065 
PN = parenteral nutrition. 
aOnly in Belgian neonates (n=60). 
 
 
 
Table S7-1A: Multivariable linear regression analysis determining significant and independent 
associations between baseline risk factors and acquiring new infections in the neonates aged 
≤4 weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.54 (0.27-1.08) 0.082 
Centre Rotterdam vs Leuven 2.02 (0.50-8.16) 0.32 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 2.29 (0.66-7.96) 0.19 
Diagnosis group Surgical other vs medical 2.19 (0.74-6.50) 0.16 
PELOD score (per point added) 1.02 (0.97-1.08) 0.43 
PIM2 score (per point added) 1.42 (1.10-1.84) 0.0073 
Weight for age Z-score (per Z-score added)a  0.94 (0.68-1.29) 0.94 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
Table S7-1B: Multivariable linear regression analysis determining significant and independent 
associations between baseline risk factors including age and acquiring new infections in the 
neonates aged ≤4 weeks 
 
Variable  Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN  0.55 (0.27-1.10) 0.092 
Age (per day added)  0.99 (0.93-1.05) 0.68 
Centre Rotterdam vs Leuven  1.91 (0.46-7.97) 0.38 
Centre Edmonton vs Leuven  0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical  2.23 (0.63-7.85) 0.21 
Diagnosis group Surgical other vs medical  1.95 (0.58-6.57) 0.28 
PELOD score (per point added)  1.02 (0.97-1.08) 0.48 
PIM2 score (per point added)  1.41 (1.08-1.83) 0.012 
Weight for age Z-score (per Z-score added) a  0.92 (0.66-1.29) 0.63 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
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Table S7-2A: Multivariable linear regression analysis determining significant and independent 
associations between baseline risk factors and time-to-live discharge from the PICU in the 
neonates aged ≤4 weeks 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.61 (1.19-2.20) 0.0021 
Centre Rotterdam vs Leuven 0.83 (0.45-1.54) 0.56 
Centre Edmonton vs Leuven 1.43 (0.19-10.55) 0.73 
Diagnosis group Surgery cardiac vs medical 1.29 (0.77-2.16) 0.34 
Diagnosis group Surgical other vs medical 1.02 (0.67-1.56) 0.93 
PELOD score (per point added) 0.99 (0.96-1.01) 0.24 
PIM2 score (per point added) 0.74 (0.65-0.84) <0.0001 
Weight for age Z-score (per Z-score added)a 1.06 (0.93-1.22) 0.39 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
 
Table S7-2B: Multivariable linear regression analysis determining significant and independent 
associations between baseline risk factors including age and time-to-live discharge from the 
PICU in the neonates aged ≤4 weeks 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.59 (1.17-2.16) 0.0031 
Age (per day added) 1.01 (0.99-1.04) 0.30 
Centre Rotterdam vs Leuven 0.90 (0.48-1.69) 0.74 
Centre Edmonton vs Leuven 1.41 (0.19-10.41) 0.74 
Diagnosis group Surgery cardiac vs medical 1.36 (0.80-2.30) 0.26 
Diagnosis group Surgical other vs medical 1.17 (0.71-1.94) 0.53 
PELOD score (per point added) 0.99 (0.96-1.01) 0.31 
PIM2 score (per point added) 0.75 (0.65-0.85) <0.0001 
Weight for age Z-score (per Z-score added) a 1.08 (0.94-1.25) 0.28 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
 
 
 
Table S7-3A: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life weaning from ventilatory support in the 
neonates aged ≤4 weeks 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.62 (1.19-2.21) 0.0020 
Centre Rotterdam vs Leuven 0.77 (0.41-1.46) 0.42 
Centre Edmonton vs Leuven 0.87 (0.12-6.45) 0.89 
Diagnosis group Surgery cardiac vs medical 1.17 (0.70-2.00) 0.55 
Diagnosis group Surgical other vs medical 1.18 (0.79-1.78) 0.42 
PELOD score (per point added) 0.99 (1.00-1.02) 0.60 
PIM2 score (per point added) 0.68 (0.59-0.78) <0.0001 
Weight for age Z-score (per Z-score added) a 1.06 (0.93-1.22) 0.39 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score 
. 
 
 
 
 
Table S7-3B: Multivariable linear regression analysis determining significant and independent 
associations between risk factors including age and time-to-life weaning from ventilatory 
support in the neonates aged ≤4 weeks 
 
Variable  Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.60 (1.18-2.18) 0.0027 
Age (per day added) 1.01 (0.98-1.03) 0.71 
Centre Rotterdam vs Leuven 0.80 (0.42-1.53) 0.49 
Centre Edmonton vs Leuven 0.88 (0.12-6.47) 0.90 
Diagnosis group Surgery cardiac vs medical 1.18 (0.70-1.98) 0.54 
Diagnosis group Surgical other vs medical 1.22 (0.75-1.98) 0.42 
PELOD score (per point added) 0.99 (0.97-1.02) 0.63 
PIM2 score (per point added) 0.68 (0.59-0.78) <0.0001 
Weight for age Z-score (per Z-score added)a 1.06 (0.93-1.22) 0.39 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
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Table S7-4A: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and death during the first week in the neonates aged ≤4 
weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.71 (0.09-5.61) 0.74 
Centre Rotterdam vs Leuven 1.03 (0.05-20.67) 0.99 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 1.51 (0.08-29.14) 0.78 
Diagnosis group Surgical other vs medical 1.29 (0.06-29.42) 0.87 
PELOD score (per point added) 1.05 (0.94-1.16) 0.42 
PIM2 score (per point added) 3.55 (1.59-7.94) 0.0020 
Weight for age Z-score (per Z-score added)a 1.82 (0.67-4.93) 0.24 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
 
 
Table S7-4B: Multivariable linear regression analysis determining significant and independent 
associations between risk factors including age and death during the first week in the neonates 
aged ≤4 weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.81 (0.08-7.85) 0.86 
Age (per day added) 0.97 (0.78-1.21) 0.77 
Centre Rotterdam vs Leuven 0.72 (0.02-34.75) 0.87 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 1.19 (0.04-34.74) 0.92 
Diagnosis group Surgical other vs medical 1.26 (0.06-28.64) 0.89 
PELOD score (per point added) 1.05 (0.94-1.17) 0.41 
PIM2 score (per point added) 3.57 (1.56-8.15) 0.0025 
Weight for age Z-score (per Z-score added)a 1.71 (0.58-5.05) 0.33 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
 
Table S7-5A: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and 90 day mortality in the neonates aged ≤4 weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.41 (0.13-1.30) 0.13 
Centre Rotterdam vs Leuven 0.83 (0.10-7.08) 0.86 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 0.59 (0.09-4.01) 0.59 
Diagnosis group Surgical other vs medical 0.56 (0.08-3.86) 0.55 
PELOD score (per point added) 1.05 (0.98-1.14) 0.17 
PIM2 score (per point added) 1.92 (1.33-2.78) 0.00052 
Weight for age Z-score (per Z-score added)a 1.03 (0.60-1.78) 0.91 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
 
 
 
Table S7-5B: Multivariable linear regression analysis determining significant and independent 
associations between risk factors including age and 90 day mortality in the neonates aged ≤4 
weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.40 (0.12-1.28) 0.12 
Age (per day added) 1.01 (0.92-1.11) 0.78 
Centre Rotterdam vs Leuven 0.91 (0.10-8.53) 0.94 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 0.64 (0.09-4.59) 0.66 
Diagnosis group Surgical other vs medical 0.60 (0.08-4.54) 0.62 
PELOD score (per point added) 1.05 (0.98-1.14) 0.17 
PIM2 score (per point added) 1.95 (1.33-2.86) 0.00064 
Weight for age Z-score (per Z-score added)a 1.06 (0.60-1.86) 0.85 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
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Table S7-6A: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and hypoglycaemia in the neonates aged ≤4 weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 3.05 (1.27-7.35) 0.013 
Centre Rotterdam vs Leuven 0.12 (0.03-0.59) 0.0087 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 0.69 (0.17-2.88) 0.61 
Diagnosis group Surgical other vs medical 0.96 (0.24-3.87) 0.95 
PELOD score (per point added) 1.03 (0.96-1.09) 0.42 
PIM2 score (per point added) 1.25 (0.94-1.67) 0.13 
Weight for age Z-score (per Z-score added)a 0.88 (0.60-1.29) 0.51 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
 
 
 
Table S7-6B: Multivariable linear regression analysis determining significant and independent 
associations between risk factors including age and hypoglycaemia in the neonates aged ≤4 
weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 3.32 (1.36-8.08) 0.0082 
Age (per day added) 0.94 (0.88-1.01) 0.081 
Centre Rotterdam vs Leuven 0.09 (0.02-0.46) 0.0042 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 0.52 (0.11-2.36) 0.39 
Diagnosis group Surgical other vs medical 0.54 (0.12-2.52) 0.44 
PELOD score (per point added) 1.02 (0.96-1.09) 0.47 
PIM2 score (per point added) 1.15 (0.85-1.55) 0.37 
Weight for age Z-score (per Z-score added)a 0.77 (0.51-1.17) 0.22 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
 aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
Table S7-7: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and acquiring new infections in the neonates aged ≤1 week 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.36 (0.15-0.83) 0.017 
Centre Rotterdam vs Leuven 1.77 (0.19-16.42) 0.61 
Diagnosis group Surgery cardiac vs medical 1.65 (0.21-12.7) 0.63 
Diagnosis group Surgical other vs medical 1.70 (0.41-7.06) 0.47 
PELOD score (per point added) 1.03 (0.96-1.10) 0.41 
PIM2 score (per point added) 1.21 (0.89-1.64) 0.22 
Weight for age Z-score (per Z-score added)a 0.98 (0.66-1.46) 0.92 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
 
 
 
 
Table S7-8: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life discharge from PICU in the neonates aged ≤1 
week 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.69 (1.16-2.46) 0.0063 
Centre Rotterdam vs Leuven 0.57 (0.18-1.79) 0.33 
Diagnosis group Surgery cardiac vs medical 0.98 (0.38-2.56) 0.97 
Diagnosis group Surgical other vs medical 1.00 (0.54-1.88) 0.99 
PELOD score (per point added) 0.97 (0.93-1.01) 0.97 
PIM2 score (per point added) 0.78 (0.66-0.91) 0.0018 
Weight for age Z-score (per Z-score added)a 1.07 (0.90-1.27) 0.44 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
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Table S7-6A: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and hypoglycaemia in the neonates aged ≤4 weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 3.05 (1.27-7.35) 0.013 
Centre Rotterdam vs Leuven 0.12 (0.03-0.59) 0.0087 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 0.69 (0.17-2.88) 0.61 
Diagnosis group Surgical other vs medical 0.96 (0.24-3.87) 0.95 
PELOD score (per point added) 1.03 (0.96-1.09) 0.42 
PIM2 score (per point added) 1.25 (0.94-1.67) 0.13 
Weight for age Z-score (per Z-score added)a 0.88 (0.60-1.29) 0.51 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
 
 
 
Table S7-6B: Multivariable linear regression analysis determining significant and independent 
associations between risk factors including age and hypoglycaemia in the neonates aged ≤4 
weeks 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 3.32 (1.36-8.08) 0.0082 
Age (per day added) 0.94 (0.88-1.01) 0.081 
Centre Rotterdam vs Leuven 0.09 (0.02-0.46) 0.0042 
Centre Edmonton vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 0.52 (0.11-2.36) 0.39 
Diagnosis group Surgical other vs medical 0.54 (0.12-2.52) 0.44 
PELOD score (per point added) 1.02 (0.96-1.09) 0.47 
PIM2 score (per point added) 1.15 (0.85-1.55) 0.37 
Weight for age Z-score (per Z-score added)a 0.77 (0.51-1.17) 0.22 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
 aNeonates <1 week: birthweight-for-gestational age Z-score, neonates ≥1 week: weight-for-age Z-score. 
 
 
 
Table S7-7: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and acquiring new infections in the neonates aged ≤1 week 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.36 (0.15-0.83) 0.017 
Centre Rotterdam vs Leuven 1.77 (0.19-16.42) 0.61 
Diagnosis group Surgery cardiac vs medical 1.65 (0.21-12.7) 0.63 
Diagnosis group Surgical other vs medical 1.70 (0.41-7.06) 0.47 
PELOD score (per point added) 1.03 (0.96-1.10) 0.41 
PIM2 score (per point added) 1.21 (0.89-1.64) 0.22 
Weight for age Z-score (per Z-score added)a 0.98 (0.66-1.46) 0.92 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
 
 
 
 
Table S7-8: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life discharge from PICU in the neonates aged ≤1 
week 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.69 (1.16-2.46) 0.0063 
Centre Rotterdam vs Leuven 0.57 (0.18-1.79) 0.33 
Diagnosis group Surgery cardiac vs medical 0.98 (0.38-2.56) 0.97 
Diagnosis group Surgical other vs medical 1.00 (0.54-1.88) 0.99 
PELOD score (per point added) 0.97 (0.93-1.01) 0.97 
PIM2 score (per point added) 0.78 (0.66-0.91) 0.0018 
Weight for age Z-score (per Z-score added)a 1.07 (0.90-1.27) 0.44 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
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Table S7-9: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life weaning from ventilatory support in the 
neonates aged ≤1 week 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.61 (1.10-2.35) 0.014 
Centre Rotterdam vs Leuven 0.48 (0.15-1.57) 0.23 
Diagnosis group Surgery cardiac vs medical 0.77 (0.30-2.01) 0.60 
Diagnosis group Surgical other vs medical 0.97 (0.52-1.81) 0.92 
PELOD score (per point added) 0.98 (0.94-1.02) 0.28 
PIM2 score (per point added) 0.69 (0.58-0.82) <0.0001 
Weight for age Z-score (per Z-score added)a 1.07 (0.91-1.27) 0.41 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
 
 
 
Table S7-10: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and death during first week in the neonates aged ≤1 week 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.47 (0.04-5.83) 0.56 
Centre Rotterdam vs Leuven 7.44 (0.07-773.75) 0.40 
Diagnosis group Surgery cardiac vs medical 7.22 (0.07-712.22) 0.40 
Diagnosis group Surgical other vs medical 1.01 (0.05-22.39) 1.00 
PELOD score (per point added) 1.05 (0.94-1.17) 0.37 
PIM2 score (per point added) 2.76 (1.28-5.95) 0.01 
Weight for age Z-score (per Z-score added)a 1.94 (0.62-6.02) 0.25 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
  
 
 
 
Table S7-11: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and 90 day mortality in the neonates aged ≤1 week 
 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.31 (0.07-1.44) 0.13 
Centre Rotterdam vs Leuven 5.01 (0.20-123.47) 0.32 
Diagnosis group Surgery cardiac vs medical 2.58 (0.14-48.32) 0.53 
Diagnosis group Surgical other vs medical 0.74 (0.08-6.79) 0.79 
PELOD score (per point added) 1.09 (0.99-1.20) 0.077 
PIM2 score (per point added) 1.92 (1.22-3.02) 0.0050 
Weight for age Z-score (per Z-score added)a 0.93 (0.44-1.97) 0.86 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
 
 
 
Table S7-12: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and hypoglycaemia in the neonates aged ≤1 week 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 3.57 (1.23-10.45) 0.019 
Centre Rotterdam vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 0.00 (0.00-.) 1.00 
Diagnosis group Surgical other vs medical 0.35 (0.06-2.10) 0.25 
PELOD score (per point added) 0.98 (0.89-1.07) 0.57 
PIM2 score (per point added) 1.28 (0.88-1.86) 0.20 
Weight for age Z-score (per Z-score added)a 0.83 (0.50-1.36) 0.45 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
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Table S7-9: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life weaning from ventilatory support in the 
neonates aged ≤1 week 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.61 (1.10-2.35) 0.014 
Centre Rotterdam vs Leuven 0.48 (0.15-1.57) 0.23 
Diagnosis group Surgery cardiac vs medical 0.77 (0.30-2.01) 0.60 
Diagnosis group Surgical other vs medical 0.97 (0.52-1.81) 0.92 
PELOD score (per point added) 0.98 (0.94-1.02) 0.28 
PIM2 score (per point added) 0.69 (0.58-0.82) <0.0001 
Weight for age Z-score (per Z-score added)a 1.07 (0.91-1.27) 0.41 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
 
 
 
Table S7-10: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and death during first week in the neonates aged ≤1 week 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.47 (0.04-5.83) 0.56 
Centre Rotterdam vs Leuven 7.44 (0.07-773.75) 0.40 
Diagnosis group Surgery cardiac vs medical 7.22 (0.07-712.22) 0.40 
Diagnosis group Surgical other vs medical 1.01 (0.05-22.39) 1.00 
PELOD score (per point added) 1.05 (0.94-1.17) 0.37 
PIM2 score (per point added) 2.76 (1.28-5.95) 0.01 
Weight for age Z-score (per Z-score added)a 1.94 (0.62-6.02) 0.25 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
  
 
 
 
Table S7-11: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and 90 day mortality in the neonates aged ≤1 week 
 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.31 (0.07-1.44) 0.13 
Centre Rotterdam vs Leuven 5.01 (0.20-123.47) 0.32 
Diagnosis group Surgery cardiac vs medical 2.58 (0.14-48.32) 0.53 
Diagnosis group Surgical other vs medical 0.74 (0.08-6.79) 0.79 
PELOD score (per point added) 1.09 (0.99-1.20) 0.077 
PIM2 score (per point added) 1.92 (1.22-3.02) 0.0050 
Weight for age Z-score (per Z-score added)a 0.93 (0.44-1.97) 0.86 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
 
 
 
Table S7-12: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and hypoglycaemia in the neonates aged ≤1 week 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 3.57 (1.23-10.45) 0.019 
Centre Rotterdam vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 0.00 (0.00-.) 1.00 
Diagnosis group Surgical other vs medical 0.35 (0.06-2.10) 0.25 
PELOD score (per point added) 0.98 (0.89-1.07) 0.57 
PIM2 score (per point added) 1.28 (0.88-1.86) 0.20 
Weight for age Z-score (per Z-score added)a 0.83 (0.50-1.36) 0.45 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
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Table S7-13: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and acquiring new infections in the neonates aged <1 day 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.10 (0.01-0.64) 0.015 
Centre Rotterdam vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 2.96 (0.10-92.62) 0.54 
Diagnosis group Surgical other vs medical 0.57 (0.07-4.98) 0.61 
PELOD score (per point added) 1.00 (0.86-1.17) 0.98 
PIM2 score (per point added) 1.06 (0.64-1.75) 0.83 
Weight for age Z-score (per Z-score added)a 1.37 (0.66-2.84) 0.40 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
Table S7-14: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life discharge from PICU in the neonates aged <1 day 
 
Variable  Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.95 (0.93-4.12) 0.078 
Centre Rotterdam vs Leuven 0.08 (0.003-2.07) 0.13 
Diagnosis group Surgery cardiac vs medical 1.89 (0.34-10.47) 0.47 
Diagnosis group Surgical other vs medical 2.38 (0.64-8.92) 0.20 
PELOD score (per point added) 0.93 (0.82-1.05) 0.25 
PIM2 score (per point added) 0.87 (0.66-1.14) 0.31 
Weight for age Z-score (per Z-score added)a 1.06 (0.78-1.46) 0.70 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
Table S7-15 Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life weaning from ventilatory support in the 
neonates aged <1 day 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 2.63 (1.23-5.63) 0.013 
Centre Rotterdam vs Leuven 0.09 (0.003-2.16) 0.14 
Diagnosis group Surgery cardiac vs medical 1.75 (0.32-9.55) 0.52 
Diagnosis group Surgical other vs medical 2.47 (0.69-8.87) 0.17 
PELOD score (per point added) 0.95 (0.84-1.08) 0.44 
PIM2 score (per point added) 0.74 (0.54-1.01) 0.060 
Weight for age Z-score (per Z-score added)a 1.02 (0.74-1.40) 0.91 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
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Table S7-13: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and acquiring new infections in the neonates aged <1 day 
 
Variable Odds ratio (95% CI) P-value 
Randomisation Late vs Early PN 0.10 (0.01-0.64) 0.015 
Centre Rotterdam vs Leuven 0.00 (0.00-.) 1.00 
Diagnosis group Surgery cardiac vs medical 2.96 (0.10-92.62) 0.54 
Diagnosis group Surgical other vs medical 0.57 (0.07-4.98) 0.61 
PELOD score (per point added) 1.00 (0.86-1.17) 0.98 
PIM2 score (per point added) 1.06 (0.64-1.75) 0.83 
Weight for age Z-score (per Z-score added)a 1.37 (0.66-2.84) 0.40 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
Table S7-14: Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life discharge from PICU in the neonates aged <1 day 
 
Variable  Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 1.95 (0.93-4.12) 0.078 
Centre Rotterdam vs Leuven 0.08 (0.003-2.07) 0.13 
Diagnosis group Surgery cardiac vs medical 1.89 (0.34-10.47) 0.47 
Diagnosis group Surgical other vs medical 2.38 (0.64-8.92) 0.20 
PELOD score (per point added) 0.93 (0.82-1.05) 0.25 
PIM2 score (per point added) 0.87 (0.66-1.14) 0.31 
Weight for age Z-score (per Z-score added)a 1.06 (0.78-1.46) 0.70 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
 
 
Table S7-15 Multivariable linear regression analysis determining significant and independent 
associations between risk factors and time-to-life weaning from ventilatory support in the 
neonates aged <1 day 
 
Variable Hazard ratio (95% CI) P-value 
Randomisation Late vs Early PN 2.63 (1.23-5.63) 0.013 
Centre Rotterdam vs Leuven 0.09 (0.003-2.16) 0.14 
Diagnosis group Surgery cardiac vs medical 1.75 (0.32-9.55) 0.52 
Diagnosis group Surgical other vs medical 2.47 (0.69-8.87) 0.17 
PELOD score (per point added) 0.95 (0.84-1.08) 0.44 
PIM2 score (per point added) 0.74 (0.54-1.01) 0.060 
Weight for age Z-score (per Z-score added)a 1.02 (0.74-1.40) 0.91 
PN = parenteral nutrition, PELOD = Paediatric Logistic Organ Dysfunction, PIM2 = Paediatric Index of Mortality 2. 
aBirthweight-for-gestational age Z-score. 
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ABSTRACT 
 
Importance  
Undernourishment has been associated with poor outcomes of critical illness in children. The 
impact of withholding parenteral nutrition (PN) for 1 week in undernourished critically ill children 
is unknown.  
 
Objective  
To assess the outcome effects of withholding PN for 1 week in undernourished critically ill 
children.  
 
Design, setting and participants  
This is a secondary analysis of the randomised controlled trial Paediatric Early versus Late 
Parenteral Nutrition in Intensive Care Unit (n=1440), which focused on the subgroup of paediatric 
intensive care unit (PICU) patients identified as undernourished upon admission. Children 
included in the Paediatric Early versus Late Parenteral Nutrition in Intensive Care Unit 
randomised controlled trial were enrolled between June 18, 2012, and July 27, 2015. 
Undernourishment was defined as weight-for-age Z-score less than -2 in children aged younger 
than1 year, and body mass index-for-age Z-score less than -2 in children 1 year or older. Data 
analysis was conducted from August 3 2017, to July 6 2018.  
 
Intervention  
Patients were randomised to initiation of supplemental PN within 24 hours (Early-PN) or after 1 
week (Late-PN) when enteral nutrition was insufficient. 
 
Main outcomes and measures 
Primary endpoints were risk of new infections acquired in PICU and time to live PICU discharge, 
assessed via multivariable logistic regression and Cox proportional hazard analyses, adjusted for 
risk factors.  
 
Results  
A total of 289 of 1440 children (20%) were identified as undernourished, of whom 150 of 717 
patients (20.9%) in the Late-PN group and 139 of 723 (19.2%) were in the Early-PN group. On 
admission, characteristics were similar among the treatment groups. Mean weight Z-scores were 
-3.33 (SD 1.18) in the Late-PN group and -3.21 (SD 1.09) in the Early-PN group. Compared with 
well-nourished PICU patients, undernourishment on admission was associated with lower 
likelihood of an earlier live PICU discharge (adjusted hazard ratio 0.86; 95% CI 0.75-0.99; p=0.03). 
 
 
 
Among undernourished PICU patients, Late-PN reduced the risk of new infections by 11.0% 
(adjusted odds ratio 0.39; 95% CI 0.19-0.78; p=0.008), and shortened the duration of PICU stay 
with a median of 2 days (earlier live PICU discharge: adjusted hazard ratio 1.37; 95% CI 1.06-1.75; 
p=0.01). The safety outcomes mortality, incidence of hypoglycaemia during the first week, and 
incidence of weight deterioration during PICU stay were similar between the treatment groups.  
 
Conclusion and relevance 
In undernourished critically ill children, withholding PN for 1 week was clinically superior to Early-
PN.  
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ABSTRACT 
 
Importance  
Undernourishment has been associated with poor outcomes of critical illness in children. The 
impact of withholding parenteral nutrition (PN) for 1 week in undernourished critically ill children 
is unknown.  
 
Objective  
To assess the outcome effects of withholding PN for 1 week in undernourished critically ill 
children.  
 
Design, setting and participants  
This is a secondary analysis of the randomised controlled trial Paediatric Early versus Late 
Parenteral Nutrition in Intensive Care Unit (n=1440), which focused on the subgroup of paediatric 
intensive care unit (PICU) patients identified as undernourished upon admission. Children 
included in the Paediatric Early versus Late Parenteral Nutrition in Intensive Care Unit 
randomised controlled trial were enrolled between June 18, 2012, and July 27, 2015. 
Undernourishment was defined as weight-for-age Z-score less than -2 in children aged younger 
than1 year, and body mass index-for-age Z-score less than -2 in children 1 year or older. Data 
analysis was conducted from August 3 2017, to July 6 2018.  
 
Intervention  
Patients were randomised to initiation of supplemental PN within 24 hours (Early-PN) or after 1 
week (Late-PN) when enteral nutrition was insufficient. 
 
Main outcomes and measures 
Primary endpoints were risk of new infections acquired in PICU and time to live PICU discharge, 
assessed via multivariable logistic regression and Cox proportional hazard analyses, adjusted for 
risk factors.  
 
Results  
A total of 289 of 1440 children (20%) were identified as undernourished, of whom 150 of 717 
patients (20.9%) in the Late-PN group and 139 of 723 (19.2%) were in the Early-PN group. On 
admission, characteristics were similar among the treatment groups. Mean weight Z-scores were 
-3.33 (SD 1.18) in the Late-PN group and -3.21 (SD 1.09) in the Early-PN group. Compared with 
well-nourished PICU patients, undernourishment on admission was associated with lower 
likelihood of an earlier live PICU discharge (adjusted hazard ratio 0.86; 95% CI 0.75-0.99; p=0.03). 
 
 
 
Among undernourished PICU patients, Late-PN reduced the risk of new infections by 11.0% 
(adjusted odds ratio 0.39; 95% CI 0.19-0.78; p=0.008), and shortened the duration of PICU stay 
with a median of 2 days (earlier live PICU discharge: adjusted hazard ratio 1.37; 95% CI 1.06-1.75; 
p=0.01). The safety outcomes mortality, incidence of hypoglycaemia during the first week, and 
incidence of weight deterioration during PICU stay were similar between the treatment groups.  
 
Conclusion and relevance 
In undernourished critically ill children, withholding PN for 1 week was clinically superior to Early-
PN.  
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INTRODUCTION 
 
The prevalence of undernourishment in children on admission to the paediatric intensive care 
unit (PICU) has been shown to be up to 24%.42 Undernourishment on admission to the PICU has 
been associated with increased mortality and morbidity such as infectious complications, longer 
need for mechanical ventilation and prolonged hospital stay.33,35,36 Observational cohort studies 
have shown that higher nutritional intake is associated with an improvement of nutritional 
status,4-7 although the role of parenteral nutrition (PN) herein has not been investigated.141 
Assumptions have been made that an earlier and increased nutrition delivery might prevent 
deterioration of nutritional status, and subsequently improve clinical outcome.3 This strategy is 
promoted more vigorously in undernourished patients where macronutrient deficiency is 
presumed to be more detrimental during acute illness.74   
Recently, the Paediatric Early versus Late Parenteral Nutrition in Intensive Care Unit 
(PEPaNIC) randomized controlled trial (RCT), including 1440 critically ill children, showed that 
withholding PN for 1 week (Late-PN) resulted in fewer new infections and reduced the duration 
of PICU stay as compared with initiating PN at day 1 (Early-PN).18 These clinical benefits were 
even larger in children who were at high risk of developing undernutrition, reflected by a high 
score on the Screening Tool for Risk on Nutritional Status and Growth (STRONGkids).142 However, 
withholding PN for 1 week in undernourished critically ill children, unable to advance past low 
volumes of enteral nutrition (EN), raised concerns among experts.71,74,75 Recently updated 
guidelines advise to start supplemental PN earlier in undernourished children than in well-
nourished children if enteral intake is insufficient.74,136 This secondary analysis of the PEPaNIC 
RCT investigated the impact of withholding supplemental PN in a subgroup of critically ill children 
who were acutely undernourished on admission to the PICU.  
 
METHODS 
 
Patients and procedure 
These analyses were performed for children in the 3 PICUs (Belgium, The Netherlands and 
Canada) who participated in the PEPaNIC RCT (recruitment from June 18, 2012 to July 27, 2015). 
This study has followed the Consolidated Standards of 6 Reporting Trials (CONSORT) reporting 
guideline. The full study protocol has been reported previously.18,129 Briefly, 1440 critically ill 
children (term newborns to age 17 year) with a score on the STRONGkids of 2 or higher were 
included. This score ranges from 0 to 5, with a higher score indicating a higher risk of developing 
undernutrition. The children were randomly assigned to Late-PN (withholding PN during the first 
week) or Early-PN (initiation of PN at day 1), if EN was <80% of target, and was expected to be 
insufficient for at least 24 hours. Children in the Late-PN group received a mixture of dextrose 5% 
and saline to match the amount of fluid administered to those in the Early-PN group. After the 
 
 
 
first week, PN was also started in the Late-PN group if EN was less than 80% of caloric target. 
Initiation and incline of EN was similar between the treatment groups.18,129 Both groups received 
parenteral micronutrients (vitamins, minerals and trace elements) from day 2 onwards if EN was  
less than 80% of the target.18,129 Furthermore, blood glucose control with insulin according to 
local targets was identical in both groups.18,129 In Leuven, Belgium, target range for blood glucose 
concentrations was 50 to 80 mg/dL (to convert blood glucose concentrations to millimoles per 
litre, multiply by 0.0555) in infants aged younger than 1 year and 70 to 100 mg/dL (to convert 
blood glucose concentrations to millimoles per litre, multiply by 0.0555) in older children. In 
Rotterdam, The Netherlands, target range for blood glucose concentration was 72 to 144 mg/dL 
(to convert blood glucose concentrations to millimoles per litre, multiply by 0.0555), except for 
patients with traumatic brain injury in which a range of 108 to 144 mg/dL (to convert blood 
glucose concentrations to millimoles per litre, multiply by 0.0555) was targeted. In Edmonton, 
Canada, insulin was administered to target blood glucose concentration less than 180 mg/dL (to 
convert blood glucose concentrations to millimoles per litre, multiply by 0.0555). After every 
change in macronutrient intake or amount of administered insulin, blood glucose concentration 
was checked hourly, either within routine laboratory check or by use of bedside glucose meters, 
until 3 consecutive measurements were within the targeted range. If a central venous line was 
not or no longer in place for clinical purposes, any required PN was delivered via a peripheral 
line.  
Outcome assessors and investigators were not directly involved in the PICU and were 
blinded to the treatment allocation.  
The institutional ethical review boards of the participating centres in Leuven Belgium 
(ML8052), Rotterdam, The Netherlands (NL38772.000.12) and Edmonton, Canada 
(Pro00038098) approved the study, which was performed in accordance with the 1964 
Declaration of Helsinki and its amendments. Written informed consent was obtained from the 
parents or legal guardians. 
For the current secondary analysis, a subgroup of acutely undernourished children on 
admission was identified. The broad age range of the patients in our study population did not 
allow us to use the same definition in all children. Therefore, acute undernutrition was defined 
as weight-for-age Z-score less than -2 in children aged younger than 1 year, and BMI-for-age Z-
score less than -2 in children aged 1 year or older.131,143 Severe acute undernutrition was defined 
as WFA Z-score <-3 in children aged <1 year, and BFA Z-score <-3 in children aged ≥1 year.131,143  
 
Outcomes 
Primary outcomes were the incidence of new infections during the PICU stay, and length of the 
PICU stay accounting for mortality as a competing risk.129 Discharge from PICU was defined as 
ready for discharge from PICU (i.e. no longer need for, or at risk of, vital organ support).129 
Secondary outcomes were 7-day mortality (i.e. during the intervention window), death during 
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PICU stay, death during hospital stay, and 90-day mortality, incidence of hypoglycaemia (blood 
glucose <40 mg/dl [to convert blood glucose concentrations to millimoles per litre, multiply by 
0.0555]) during the first week, incidence of weight Z-score deterioration during PICU stay 
(defined as a negative change in weight Z-score from admission to PICU discharge), duration of 
mechanical ventilatory support,  and length of hospital stay.  
 
Statistical analyses 
The analyses were done based on intention-to-treat. Variables are reported as proportions, mean 
(SD) if normally distributed or as median (interquartile range) if not-normally distributed. 
Proportions were analysed univariably using χ2 test, means with t-test and medians with Mann 
Whitney U test. PICU stay, hospital stay and duration of mechanical ventilation were investigated 
univariably as the crude number of days, and multivariably as the likelihood of an earlier 
discharge from PICU alive, likelihood of an earlier discharge from hospital alive and likelihood of 
an earlier weaning from mechanical ventilation alive, respectively. The results on time to PICU 
discharge alive, time to hospital discharge alive and time to weaning from mechanical ventilation 
alive can potentially be biased by the rate of mortality. Therefore, these multivariable time-to-
event effect sizes were calculated with the use of Cox proportional hazard analysis, with data of 
survivors censored at 90 days, and data of non-survivors was set beyond all survivors at 91 days 
to account for mortality as competing risk. The multivariable analyses of dichotomized outcomes 
were performed using logistic regression. Odds ratios or hazard ratios with 95% confidence 
intervals were calculated. Multivariable analyses were adjusted for the baseline risk factors 
centre, age, diagnosis group, STRONGkids category,142 Paediatric Logistic Organ Dysfunction 
score,144 and Paediatric Index of Mortality 2 score.145 
P-values 0.05 or less were considered statistically significant and all tests were 2-sided. 
All analyses were performed with IBM SPSS Statistics, version 21 (IBM Corp). Z-scores were 
calculated with the use of Growth Analyzer Research Calculation Tool, version 4.146 
 
RESULTS 
 
Patients undernourished on PICU admission 
In total, 289 of 1440 children (20%) were acutely undernourished on admission, among which 
150 of 717 patients  (20.9%) were assigned to the Late-PN group, and 139 of 723 patients (19.2%) 
were assigned to the Early-PN group (Figure 1). The incidence of undernourishment on admission 
was similar in all centres, 21.3% in Leuven, Belgium, 19.5% in Rotterdam, The Netherlands, and 
21.9% in Edmonton, Canada  (p=0.70). In total, 18.5% of the children with a medium risk score 
on the STRONGkids tool were undernourished versus 38.9% of the children with a high risk score 
(p<0.001). Baseline characteristics for the undernourished children were similar for the Late-PN 
group and the Early-PN group (Table 1). The weight Z-score on PICU admission was -3.33 (SD 
 
 
 
1.18) in the Late-PN group and -3.21 (SD 1.09) in the Early-PN group (Table 1). Enteral energy and 
macronutrient doses were similar in both treatment groups; whereas, parenteral energy and 
macronutrient doses differed between the treatment groups, which showed adherence to the 
protocol (Appendix). At the time PN was initiated in the Early-PN group, more than 95% of 
critically ill children received less than 50% of caloric targets enterally.147,148 During the 
intervention period, 55 children (35.7%) in the Late-PN group, and 43 children (30.9%) in the 
Early-PN group did not receive any EN (p=0.30). 
 
Figure 1: Flow diagram of children with and without undernourishment on PICU admission 
 
DNR = do not resuscitate; PICU = paediatric intensive care unit; NICU = neonatal intensive care unit; STRONGkids = 
Screening Tool for Risk on Nutritional Status and Growth, range from 0 to 5, with a score of 0 indicating low risk of 
malnutrition, a score of 1 to 3 indicating medium risk, and a score of 4 to 5 indicating high risk.  
Acutely undernourished is defined as weight-for-age Z-score <-2 (if <1 year), or BMI-for-age Z-score <-2 (if ≥1 
year).131,143 Severely acutely undernourished  is defined as weight-for-age Z-score <-3 (if <1 year), or BMI-for-age Z-
score <-3 (if ≥1 year).131,143 
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Undernourished versus well-nourished children 
Comparison of baseline characteristics between undernourished and well-nourished children 
showed that the group of undernourished children was younger, contained a higher proportion 
of respiratory diagnoses and lower proportion of neurosurgical diagnoses on PICU admission, and 
comprised a lower proportion of children needing mechanical hemodynamic support (Appendix).  
Being undernourished on admission was not associated with an increased risk of acquiring 
a new infection in the PICU, but was associated with both a prolonged duration of PICU stay and 
hospital stay with a median difference of 2 days and a lower likelihood of an earlier discharge 
from PICU alive (adjusted hazard ratio 0.86; 95% CI 0.75-0.99; p=0.03), as well as a lower 
likelihood of an earlier discharge from hospital alive (adjusted hazard ratio 0.83; 95% CI 0.73-
0.96; p=0.01) (Appendix).  
Undernourishment on admission was associated with a lower 7-day mortality, but a 
higher incidence of hypoglycaemia during the first week as compared with well-nourished 
children. Death during PICU stay and hospital stay, and 90-day mortality were not associated with 
undernourishment on admission (Appendix). 
 
Late-PN versus Early-PN in children undernourished upon PICU admission 
In children who were undernourished on admission to the PICU, Late-PN reduced the risk of new 
infections with an absolute 11.0% (22.3% vs. 11.3%, p=0.02), with an adjusted odds ratio for new 
infections of 0.39 (95% CI 0.19-0.78; p=0.01). Late-PN also shortened the duration of PICU 
dependency with a median of 2 days in undernourished children (6 vs 4 days; p=0.01), with a 
higher likelihood of an earlier discharge from PICU alive (adjusted hazard ratio 1.37; 95% CI 1.06-
1.75; p=0.01; Table 2). 
Safety outcomes mortality at all investigated time-points and the incidence of 
hypoglycaemia did not differ between Late-PN and Early-PN in the undernourished children 
(Table 2). The duration of mechanical ventilatory support was shorter in the Late-PN group, with 
a higher likelihood of being weaned alive earlier from mechanical ventilation (adjusted hazard 
ratio 1.39; 95% CI 1.09-1.77; p=0.008; Table 2). Late-PN also shortened the duration of hospital 
stay with a median of 4 days, with a higher likelihood of an earlier discharge alive (adjusted hazard 
ratio 1.37; 95% CI 1.07-1.75; p=0.01; Table 2). In a subgroup of 100 undernourished critically ill 
children with weight Z-scores on admission and at discharge from the PICU available, of which 48 
in the Late-PN group and 52 in the Early-PN group, the incidence of weight Z-score deterioration 
was not different between the treatment groups (Table 2). A sensitivity analysis, assuming that 
all patients who died in the PICU had acquired a new infection during their PICU stay, supported 
our results; Late-PN reduced the risk of new infections with an absolute 9.7% (23.7% vs. 14.0%, 
p=0.03), with an adjusted odds ratio for new infections of 0.46 (95% CI 0.24-0.91; p=0.03). 
  
 
 
 
Table 1: Baseline characteristics of children undernourished on admission 
 
Characteristic Early-PN  
(n=139) 
Late-PN  
(n=150) 
P-value  
Male 88 (63.3) 85 (56.7) 0.28 
Age at randomisation, median (IQR), y 0.43 (0.25-2.36) 0.46 (0.21-3.46) 0.69 
High STRONGkids category 27 (19.4) 31 (20.7) 0.88 
Weight Z-score, mean (SD)a -3.21 (1.09) -3.33 (1.18) 0.37 
Severely undernourished on admissionb 61 (43.9) 76 (50.7) 0.25 
PELOD score, median (IQR) 21 (11-32) 21 (12-31) 0.99 
PIM2 score, mean (SD) -2.46 (1.52) -2.47 (1.69) 0.93 
Risk of Mortality, median (IQR), %c 6.3 (2.8-22.8) 6.7 (2.5-15.7) 0.58 
Diagnostic group    0.72 
  Surgical   
  Abdominal 7 (5.0) 10 (6.7) 
  Burns 0 (0.0) 0 (0.0) 
  Cardiac 58 (41.7) 66 (44.0) 
  Neurologic 6 (4.3) 6 (4.0) 
  Thoracic 3 (2.2) 2 (1.3) 
  Transplant 0 (0.0) 2 (1.3) 
  Trauma/orthopedic 8 (5.8) 9 (6.0) 
  Other 5 (3.6) 1 (0.7) 
 Medical   
  Cardiac 6 (4.3) 6 (4.0) 
  Gastro-intestinal/hepatic) 0 (0.0) 2 (1.3) 
  Hematologic/oncologic 1 (0.7) 1 (0.7) 
  Neurologic 11 (7.9) 9 (6.0) 
  Renal 0 (0.0) 0 (0.0) 
  Respiratory 29 (20.9) 28 (18.7) 
  Other 5 (3.6) 8 (5.3) 
Syndrome or genetic abnormality    0.36 
   No 96 (69.1) 94 (62.7) 
  Yes 36 (25.9) 43 (28.7) 
  Suspected 7 (5.0) 13 (8.7) 
Mechanical ventilatory support on PICU admission 124 (89.2) 127 (84.7) 0.30 
Inotrope or vasopressor medication on PICU admission 57 (41.0) 69 (46.0) 0.41 
Mechanical hemodynamic support on PICU admission 0 (0.0) 3 (2.0) 0.25 
PELOD = Paediatric Logistic Organ Dysfunction, range from 0 to 71, with higher scores indicating more severe illness; 
PICU = paediatric intensive care unit; PIM2 = Paediatric Index of Mortality 2, with higher scores indicating a higher 
risk of mortality; PN = parenteral nutrition; STRONGkids = Screening Tool for Risk on Nutritional Status and Growth, 
range from 0 to 5, with a score of 0 indicating low risk of malnutrition, a score of 1 to 3 indicating medium risk, and 
a score of 4 to 5 indicating high risk. 
a<1 year: weight-for-age Z-score, ≥1 year: BMI-for-age Z-score.131,143 
bSevere undernutrition defined as: <1 year: weight-for-age Z-score <-3, ≥1 year: BMI-for-age Z-score <-3.131,143 
cBased on PIM2 score =([exp (PIM2)]/[1+exp (PIM2)])*100%. 
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children with weight Z-scores on admission and at discharge from the PICU available, of which 48 
in the Late-PN group and 52 in the Early-PN group, the incidence of weight Z-score deterioration 
was not different between the treatment groups (Table 2). A sensitivity analysis, assuming that 
all patients who died in the PICU had acquired a new infection during their PICU stay, supported 
our results; Late-PN reduced the risk of new infections with an absolute 9.7% (23.7% vs. 14.0%, 
p=0.03), with an adjusted odds ratio for new infections of 0.46 (95% CI 0.24-0.91; p=0.03). 
  
 
 
 
Table 1: Baseline characteristics of children undernourished on admission 
 
Characteristic Early-PN  
(n=139) 
Late-PN  
(n=150) 
P-value  
Male 88 (63.3) 85 (56.7) 0.28 
Age at randomisation, median (IQR), y 0.43 (0.25-2.36) 0.46 (0.21-3.46) 0.69 
High STRONGkids category 27 (19.4) 31 (20.7) 0.88 
Weight Z-score, mean (SD)a -3.21 (1.09) -3.33 (1.18) 0.37 
Severely undernourished on admissionb 61 (43.9) 76 (50.7) 0.25 
PELOD score, median (IQR) 21 (11-32) 21 (12-31) 0.99 
PIM2 score, mean (SD) -2.46 (1.52) -2.47 (1.69) 0.93 
Risk of Mortality, median (IQR), %c 6.3 (2.8-22.8) 6.7 (2.5-15.7) 0.58 
Diagnostic group    0.72 
  Surgical   
  Abdominal 7 (5.0) 10 (6.7) 
  Burns 0 (0.0) 0 (0.0) 
  Cardiac 58 (41.7) 66 (44.0) 
  Neurologic 6 (4.3) 6 (4.0) 
  Thoracic 3 (2.2) 2 (1.3) 
  Transplant 0 (0.0) 2 (1.3) 
  Trauma/orthopedic 8 (5.8) 9 (6.0) 
  Other 5 (3.6) 1 (0.7) 
 Medical   
  Cardiac 6 (4.3) 6 (4.0) 
  Gastro-intestinal/hepatic) 0 (0.0) 2 (1.3) 
  Hematologic/oncologic 1 (0.7) 1 (0.7) 
  Neurologic 11 (7.9) 9 (6.0) 
  Renal 0 (0.0) 0 (0.0) 
  Respiratory 29 (20.9) 28 (18.7) 
  Other 5 (3.6) 8 (5.3) 
Syndrome or genetic abnormality    0.36 
   No 96 (69.1) 94 (62.7) 
  Yes 36 (25.9) 43 (28.7) 
  Suspected 7 (5.0) 13 (8.7) 
Mechanical ventilatory support on PICU admission 124 (89.2) 127 (84.7) 0.30 
Inotrope or vasopressor medication on PICU admission 57 (41.0) 69 (46.0) 0.41 
Mechanical hemodynamic support on PICU admission 0 (0.0) 3 (2.0) 0.25 
PELOD = Paediatric Logistic Organ Dysfunction, range from 0 to 71, with higher scores indicating more severe illness; 
PICU = paediatric intensive care unit; PIM2 = Paediatric Index of Mortality 2, with higher scores indicating a higher 
risk of mortality; PN = parenteral nutrition; STRONGkids = Screening Tool for Risk on Nutritional Status and Growth, 
range from 0 to 5, with a score of 0 indicating low risk of malnutrition, a score of 1 to 3 indicating medium risk, and 
a score of 4 to 5 indicating high risk. 
a<1 year: weight-for-age Z-score, ≥1 year: BMI-for-age Z-score.131,143 
bSevere undernutrition defined as: <1 year: weight-for-age Z-score <-3, ≥1 year: BMI-for-age Z-score <-3.131,143 
cBased on PIM2 score =([exp (PIM2)]/[1+exp (PIM2)])*100%. 
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Late-PN versus Early-PN in children severely undernourished upon PICU admission 
In the Late-PN group, 76 of 717 children (10.6%) were severely undernourished, and 61 of 723 
children (8.4%) in the Early-PN group (Figure 1). Among severely undernourished children, the 
baseline characteristics were similar between the treatment groups (Appendix). In severely 
undernourished children, Late-PN shortened the duration of PICU stay significantly with a median 
difference of 1 day, both in univariable and multivariable analyses corrected for baseline risk 
factors (Table 3). The percentage of severely undernourished children with a new infection was 
10.5% in the group receiving Late-PN, as compared with 18.0% in the group receiving Early-PN, 
although this difference was not statistically significant. The safety outcomes were not 
significantly different between the treatment groups (Table 3). 
 
DISCUSSION 
 
Overall, we found that approximately 20% of the children in the PEPaNIC study were acutely 
undernourished on PICU admission and that these children performed worse with a lower 
likelihood of earlier discharge from PICU alive as well as from the hospital as compared with well-
nourished children. The undernourished children benefited from withholding PN during the first 
week of critical illness  compared to initiating PN at the first day, as illustrated by a decreased risk 
of new infections, a shorter dependency on intensive care and an accelerated discharge from the 
hospital alive. The benefits of Late-PN were noticeable irrespective of centre, age, disease 
severity, risk of mortality, diagnosis group, and STRONGkids score on admission. Late-PN did not 
affect the safety outcomes mortality and incidence of hypoglycaemia, and was not associated 
with weight deterioration in the undernourished critically ill children.  
The association between undernourishment and worse clinical outcome, as in our study 
demonstrated by longer duration of PICU and hospital stay, has previously been described.33,35,36 
However, baseline characteristics and diagnoses on admission in undernourished children 
differed from those in well-nourished children, which could have explained these differences in 
outcomes. Therefore, we cannot rule out that other factors played a role in the clinical outcome 
of children who are undernourished on admission. 
The large proportion of undernourished children on admission to the PICU, as well as the 
ongoing weight loss during PICU admission agree with previous studies.4,43 However, the 
beneficial effect of withholding PN during the first week of critical illness in these undernourished 
children contrasts with concerns raised by experts.71,75,136 The effect sizes of Late-PN versus Early-
PN in the undernourished group were even higher than in the main trial cohort, which is in line 
with the larger effect size in critically ill children with a high STRONGkids score.18 In a small 
subgroup of severely undernourished children, Late-PN resulted in a significant higher likelihood 
of earlier discharge from PICU alive as compared with Early-PN. Although the proportions of new 
infections were in line with those found in the main trial cohort,18 the risk of acquiring a new 
 
 
 
infection was not statistically different between the randomization arms, probably owing to lack 
of power in this small subgroup. Although speculative, a possible explanation for these somewhat 
counterintuitive results of withholding PN in undernourished children, who are considered to be 
vulnerable for low nutritional intake, could be an attenuated immunosuppression. 
Undernourished children already have an altered immune system.149 Moreover, critical illness 
induces further immunosuppression,150 and Early-PN may potentially reduce immune 
function.151-153 An important function of the immune system is autophagy, an adaptive response 
to critical illness in order to control the cellular damage. In rabbits132 and critically ill adults,55 
Late-PN enhanced autophagy as compared with Early-PN. Hence, possibly, undernourished 
critically ill children may have an immune response which differs from well-nourished critically ill 
children making them even more susceptible for the benefits of withholding PN during the acute 
phase. 
In contrast to the data from our randomised study, in non-randomised observational 
cohort studies a lower nutritional intake, with or without PN, was associated with excessive 
weight deterioration.4-7 We cannot exclude that the different results between these 
observational studies and our study are related to the parenteral route of nutrition for which we 
randomised, although EN in our study was provided equally to both groups, both in timing of 
initiation as well as amounts. Nonetheless, we should consider the possibility that parenteral 
nutritional support during the acute phase of critical illness in children is not capable to influence 
the children’s nutritional status assessed with anthropometric measurements. Hence, the 
deterioration of the nutritional status during acute critical illness appears primarily determined 
by the diagnosis and disease severity with which the child presents to the PICU and appears 
unaffected by parenteral nutritional support during the acute phase. The inflammatory response 
during critical illness possibly needs to be resolved before the child can transit into an anabolic 
state.154 Future research is warranted to determine when a patient transits from the acute phase 
to a stable or even recovery phase and whether and how in these phases parenteral nutritional 
support is able to improve the nutritional status and long-term outcomes of the patient.10 
However, our findings are reassuring with respect to the concerns raised by experts about 
the consequence of Late-PN in undernourished critically ill children.71,74,75 Late-PN was effective, 
and did not negatively affect mortality, hypoglycaemia or change in weight Z-score as compared 
with Early-PN. Hence, there appears to be no support for early supplementation of PN during 
acute critical illness to improve outcomes or to reverse or prevent weight deterioration in the 
PICU in undernourished critically ill children. 
Our study has some limitations. First, in children younger than 2 years with a history of 
being born prematurely, we were unable to use corrected ages to calculate weight-for-age and 
body mass index-for-age Z-scores. Consequently, the proportion of undernourished children may 
be overestimated, although such overestimation would be equal in both treatment groups owing 
to the randomised design. Second, weight measured in the PICU is highly influenced by factors 
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such as fluid overload, tubes, and splints. Therefore, a change in weight during admission does 
not always reflect a change in lean body mass. Other measurements, such as mid-upper arm 
circumference, might be a more reliable measure, as this is less affected by fluid change and 
extracorporeal items attached to the child. Despite these challenges to reliably measure the 
change in nutritional status, the inaccuracies in the anthropometric data will most likely be 
distributed equally in both treatment groups, owing to the randomised design. Furthermore, the 
amount of administered fluid was similar in the 2 groups. Third, as longitudinal anthropometric 
measurements were only available in part of the undernourished children, there may be a 
selection bias. Fourth, we only presented short-term outcome measures. Follow-up of our 
patients, which is currently ongoing, has to point out the long-term effects of withholding PN.  
 
CONCLUSIONS 
 
Critically ill children who are undernourished on PICU admission have a lower likelihood of an 
earlier discharge from PICU and hospital alive as compared with well-nourished children. 
Withholding PN during the first week in these acutely undernourished critically ill children was 
clinically superior to supplementing PN early, with a lower risk of new infections and a higher 
likelihood of an earlier discharge alive. Withholding PN during the first week was not associated 
with weight deterioration during PICU stay. 
 
 
 
APPENDIX 
 
Methods S1: Protocol for scoring of infections     
Data export 
All patients receiving antimicrobial agents were identified by the data manager, who provided an 
export of all patient numbers with all the information on antimicrobial agents given as well as 
the duration of such treatment.  
  
Identification of patients with infections 
The infectious disease specialists, who were blinded for treatment allocation, selected all 
patients receiving antimicrobial agents for more than 48h, after excluding all patients who 
received prophylaxis. Each patient who fulfilled the criteria for infection, as well as the type of 
infection, was identified as such based on thorough review of the medical record.155 Patients for 
whom antimicrobials where initiated prior to PICU admission or within the first 48 hours of 
admission while the criteria for infection were fulfilled, were labelled as “having an infection 
upon admission”. When antimicrobial agents were initiated after randomization and beyond the 
first 48 hours in the PICU, and were given for more than 48 hours while the criteria for infection 
were fulfilled, the patient was labelled as “having a new infection”.18,155
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Table S4: Baseline characteristics of children severely undernourisheda on admission in the 
Early-PN and Late-PN group 
 
Characteristic Early-PN (n=61) Late-PN (n=76) P-value  
Male 43 (70.5) 52 (68.4) 0.79 
Age at randomisation, median (IQR), y 0.37 (0.21-0.63) 0.40 (0.20-2.52) 0.34 
High STRONGkids category  15 (24.6) 17 (22.4) 0.76 
Weight Z-score, mean (SD)b -4.19 (0.94) -4.17 (1.13) 0.90 
PELOD score, median (IQR) 14 (6.5-32) 21.5 (12-31) 0.72 
PIM2 score, mean (SD) -2.79 (1.47) -2.47 (2.03) 0.30 
Risk of Mortality, median (IQR), (%)c 5.6 (2.0-20.3) 5.7 (2.5-16.6) 0.62 
Diagnostic group    0.51 
  Surgical   
  Abdominal 4 (6.6) 8 (10.5) 
  Burns 0 (0) 0 (0) 
  Cardiac 27 (44.3) 30 (39.5) 
  Neurologic 1 (1.6) 4 (5.3) 
  Thoracic 1 (1.6) 0 (0) 
  Transplant 0 (0) 0 (0) 
  Trauma/orthopedic 3 (4.9) 5 (6.6) 
  Other 3 (4,1) 1 (1.3) 
 Medical   
  Cardiac 2 (3.3) 2 (2,6) 
  Gastro-intestinal/hepatic 0 (0) 1 (1.3) 
  Hematologic/oncologic 0 (0) 0 (0) 
  Neurologic 5 (8.2) 5 (6.6) 
  Renal 0 (0) 0 (0) 
  Respiratory 15 (24.6) 16 (21.1) 
  Other 0 (0) 4 (5.3) 
Syndrome or genetic abnormality    0.18 
   No 42 (68.9) 42 (55.3) 
  Yes 17 (27.9) 27 (35.5) 
  Suspected 2 (3.3) 7 (9.2) 
Mechanical ventilatory support on PICU admission 53 (86.9) 64 (84.2) 0.66 
Inotrope or vasopressor medication on PICU admission 26 (42.6) 32 (42.1) 0.95 
Mechanical hemodynamic support on PICU admission 0 (0) 1 (1.3) 0.37 
PELOD = Paediatric Logistic Organ Dysfunction, range from 0 to 71, with higher scores indicating more severe illness; 
PIM2 = Paediatric Index of Mortality 2, with higher scores indicating a higher risk of mortality; PN = parenteral 
nutrition; STRONGkids = Screening Tool for Risk on Nutritional Status and Growth, range from 0 to 5, with a score of 
0 indicating low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score of 4 to 5 indicating high 
risk. 
aSeverely acutely undernourished defined as weight-for-age Z-score <-3 if <1 year, or BMI-for-age Z-score <-3 if ≥1 
year.131,143 
b<1 year: weight-for-age Z-score, ≥1 year: BMI-for-age Z-score.131,143 
cBased on PIM2 score =([exp (PIM2)]/[1+exp (PIM2)])*100%. 
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Table S4: Baseline characteristics of children severely undernourisheda on admission in the 
Early-PN and Late-PN group 
 
Characteristic Early-PN (n=61) Late-PN (n=76) P-value  
Male 43 (70.5) 52 (68.4) 0.79 
Age at randomisation, median (IQR), y 0.37 (0.21-0.63) 0.40 (0.20-2.52) 0.34 
High STRONGkids category  15 (24.6) 17 (22.4) 0.76 
Weight Z-score, mean (SD)b -4.19 (0.94) -4.17 (1.13) 0.90 
PELOD score, median (IQR) 14 (6.5-32) 21.5 (12-31) 0.72 
PIM2 score, mean (SD) -2.79 (1.47) -2.47 (2.03) 0.30 
Risk of Mortality, median (IQR), (%)c 5.6 (2.0-20.3) 5.7 (2.5-16.6) 0.62 
Diagnostic group    0.51 
  Surgical   
  Abdominal 4 (6.6) 8 (10.5) 
  Burns 0 (0) 0 (0) 
  Cardiac 27 (44.3) 30 (39.5) 
  Neurologic 1 (1.6) 4 (5.3) 
  Thoracic 1 (1.6) 0 (0) 
  Transplant 0 (0) 0 (0) 
  Trauma/orthopedic 3 (4.9) 5 (6.6) 
  Other 3 (4,1) 1 (1.3) 
 Medical   
  Cardiac 2 (3.3) 2 (2,6) 
  Gastro-intestinal/hepatic 0 (0) 1 (1.3) 
  Hematologic/oncologic 0 (0) 0 (0) 
  Neurologic 5 (8.2) 5 (6.6) 
  Renal 0 (0) 0 (0) 
  Respiratory 15 (24.6) 16 (21.1) 
  Other 0 (0) 4 (5.3) 
Syndrome or genetic abnormality    0.18 
   No 42 (68.9) 42 (55.3) 
  Yes 17 (27.9) 27 (35.5) 
  Suspected 2 (3.3) 7 (9.2) 
Mechanical ventilatory support on PICU admission 53 (86.9) 64 (84.2) 0.66 
Inotrope or vasopressor medication on PICU admission 26 (42.6) 32 (42.1) 0.95 
Mechanical hemodynamic support on PICU admission 0 (0) 1 (1.3) 0.37 
PELOD = Paediatric Logistic Organ Dysfunction, range from 0 to 71, with higher scores indicating more severe illness; 
PIM2 = Paediatric Index of Mortality 2, with higher scores indicating a higher risk of mortality; PN = parenteral 
nutrition; STRONGkids = Screening Tool for Risk on Nutritional Status and Growth, range from 0 to 5, with a score of 
0 indicating low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score of 4 to 5 indicating high 
risk. 
aSeverely acutely undernourished defined as weight-for-age Z-score <-3 if <1 year, or BMI-for-age Z-score <-3 if ≥1 
year.131,143 
b<1 year: weight-for-age Z-score, ≥1 year: BMI-for-age Z-score.131,143 
cBased on PIM2 score =([exp (PIM2)]/[1+exp (PIM2)])*100%. 
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Table S5: Baseline characteristics of children well-nourished on admission in the Early-PN and 
Late-PN group 
 
Characteristic Early-PN  
(n=565) 
Late-PN  
(n=545) 
P-value  
Male 315 (55.8) 319 (58.5) 0.35 
Age at randomisation, median (IQR), years 1.81 (0.28-6.32) 1.77 (0.19-7.32) 0.77 
High STRONGkids category) 51 (9.0) 40 (7.3) 0.31 
Weight Z-score, mean (SD)a -0.07 (1.13) -0.01 (1.37) 0.44 
PELOD score, median (IQR) 21 (11-31) 21 (11-31) 0.98 
PIM2 score, mean (SD) -2.49 (1.75) -2.58 (1.73) 0.37 
Risk of Mortality, median (IQR), (%)b 5.8 (2.4-18.8) 5.5 (2.5-16.2) 0.51 
Diagnostic group    0.83 
  Surgical   
  Abdominal 45 (8.0) 47 (8.6) 
  Burns 3 (0.5) 4 (0.7) 
  Cardiac 221 (39.1) 202 (37.1) 
  Neurologic 56 (9.9) 45 (8.3) 
  Thoracic 30 (5.3) 25 (4.6) 
  Transplant 7 (1.2) 15 (2.8) 
  Trauma/orthopedic 19 (3.4) 17 (3.1) 
  Other 16 (2.8) 26 (4.8) 
 Medical   
  Cardiac 23 (4.1) 25 (4.6) 
  Gastro-intestinal/hepatic 2 (0.4) 2 (0.4) 
  Hematologic/oncologic 7 (1.2) 6 (1.1) 
  Neurologic 35 (6.2) 41 (7.5) 
  Renal 1 (0.2) 1 (0.2) 
  Respiratory 65 (11.5) 58 (10.6) 
  Other 35 (6.2) 31 (5.7) 
Syndrome or genetic abnormality    0.24 
   No 479 (84.8) 480 (88.2) 
  Yes 63 (11.2) 46 (8.5) 
  Suspected 23 (4.1) 18 (3.3) 
Mechanical ventilatory support on PICU admission 501 (88.7) 479 (87.9) 0.69 
Inotrope or vasopressor medication on PICU admission 234 (41.4) 221 (40.6) 0.77 
Mechanical hemodynamic support on PICU admission 17 (3.0) 22 (4.0) 0.35 
PELOD = Paediatric Logistic Organ Dysfunction, range from 0 to 71, with higher scores indicating more severe illness; 
PIM2 = Paediatric Index of Mortality 2, with higher scores indicating a higher risk of mortality; PN = parenteral 
nutrition; STRONGkids = Screening Tool for Risk on Nutritional Status and Growth, range from 0 to 5, with a score of 
0 indicating low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score of 4 to 5 indicating high 
risk.  
aWell-undernourished defined as weight-for-age Z-score ≥2 if <1 year, or BMI-for-age Z-score ≥2 if ≥1 year.131,143   
b<1 year: weight-for-age Z-score, ≥1 year: BMI-for-age Z-score.131,143 
cBased on PIM2 score =([exp (PIM2)]/[1+exp (PIM2)])*100%. 
 
 
 Ta
bl
e 
S6
: O
ut
co
m
es
 o
f L
at
e-
PN
 v
er
su
s E
ar
ly
-P
N 
in
 w
el
l-n
ou
ris
he
d 
ch
ild
re
n 
 PE
LO
D 
= 
Pa
ed
ia
tr
ic 
Lo
gi
st
ic 
Or
ga
n 
Dy
sf
un
ct
io
n,
 ra
ng
e 
fro
m
 0
 to
 7
1,
 w
ith
 h
ig
he
r s
co
re
s i
nd
ica
tin
g 
m
or
e 
se
ve
re
 il
ln
es
s; 
PI
M
2 
= 
Pa
ed
ia
tr
ic 
In
de
x o
f M
or
ta
lit
y 
2,
 w
ith
 
hi
gh
er
 s
co
re
s 
in
di
ca
tin
g 
a 
hi
gh
er
 r
isk
 o
f m
or
ta
lit
y;
 P
IC
U 
= 
pa
ed
ia
tr
ic 
in
te
ns
iv
e 
ca
re
 u
ni
t; 
PN
 =
 p
ar
en
te
ra
l n
ut
rit
io
n;
 S
TR
ON
Gk
id
s 
= 
Sc
re
en
in
g 
To
ol
 fo
r 
Ri
sk
 o
n 
Nu
tr
iti
on
al
 S
ta
tu
s a
nd
 G
ro
w
th
, r
an
ge
 fr
om
 0
 to
 5
, w
ith
 a
 sc
or
e 
of
 0
 in
di
ca
tin
g 
lo
w
 ri
sk
 o
f m
al
nu
tr
iti
on
, a
 sc
or
e 
of
 1
 to
 3
 in
di
ca
tin
g 
m
ed
iu
m
 ri
sk
, a
nd
 a
 sc
or
e 
of
 4
 
to
 5
 in
di
ca
tin
g 
hi
gh
 ri
sk
. 
a O
dd
s r
at
io
 (O
R)
 o
r H
az
ar
d 
ra
tio
 (H
R)
, a
dj
us
te
d 
fo
r b
as
el
in
e 
ris
k 
fa
ct
or
s c
en
te
r, 
ag
e,
 d
ia
gn
os
is 
gr
ou
p,
 P
EL
OD
 sc
or
e,
 P
IM
2 
sc
or
e,
 a
nd
 S
TR
ON
Gk
id
s c
at
eg
or
y,
 w
ith
 
co
rr
es
po
nd
in
g 
95
%
 C
on
fid
en
ce
 In
te
rv
al
 (C
I).
  
b T
he
se
 v
al
ue
s a
re
 a
dj
us
te
d 
OR
s, 
th
e 
ot
he
r v
al
ue
s a
re
 a
dj
us
te
d 
HR
s.
Ou
tc
om
e 
Ea
rly
-P
N 
(n
=5
65
) 
La
te
-P
N 
(n
=5
45
) 
P-
va
lu
e 
Ad
ju
st
ed
 O
R 
or
 H
R 
(9
5%
 C
I)a
 
 P
-v
al
ue
a 
Pr
im
ar
y 
en
dp
oi
nt
 
Ne
w
 in
fe
ct
io
ns
 
10
2 
(1
8.
1)
 
59
 (1
0.
8)
 
0.
00
1 
0.
53
 (0
.3
7-
0.
77
)b  
0.
00
1 
Du
ra
tio
n 
of
 P
IC
U 
st
ay
 —
 m
ed
ia
n 
(IQ
R)
, d
 
4 
(2
-8
) 
3 
(2
-7
) 
0.
03
 
1.
16
 (1
.0
3-
1.
31
) 
0.
02
 
Se
co
nd
ar
y 
sa
fe
ty
 e
nd
po
in
t 
De
at
h 
du
rin
g 
fir
st
 w
ee
k 
19
 (3
.4
) 
14
 (2
.6
) 
0.
44
 
0.
55
 (0
.2
2-
1.
40
)b  
0.
21
 
De
at
h 
du
rin
g 
PI
CU
 st
ay
 
30
 (5
.3
) 
23
 (4
.2
) 
0.
40
 
0.
69
 (0
.3
4-
1.
37
)b  
0.
29
 
De
at
h 
du
rin
g 
ho
sp
ita
l s
ta
y 
38
 (6
.7
) 
27
 (5
.0
) 
0.
21
 
0.
62
 (0
.3
4-
1.
14
)b  
0.
12
 
90
-d
ay
 m
or
ta
lit
y 
39
 (6
.9
) 
26
 (4
.8
) 
0.
13
 
0.
56
 (0
.3
0-
1.
05
)b  
0.
07
 
Hy
po
gl
yc
ae
m
ia
 (b
lo
od
 g
lu
co
se
 <
40
 m
g/
dl
) d
ur
in
g 
fir
st
 w
ee
k 
af
te
r 
ra
nd
om
isa
tio
n 
22
 (3
.9
) 
45
 (8
.3
) 
0.
00
2 
3.
19
 (1
.7
7-
5.
73
)b  
<0
.0
01
 
W
ei
gh
t Z
-s
co
re
 d
et
er
io
ra
tio
n 
10
7 
(5
9.
1)
 
10
8 
(5
7.
8)
 
0.
79
 
0.
96
 (0
.6
3-
1.
47
)b  
0.
85
 
Se
co
nd
ar
y 
ef
fic
ac
y 
en
dp
oi
nt
 
Du
ra
tio
n 
of
 m
ec
ha
ni
ca
l v
en
til
at
or
y 
su
pp
or
t –
 m
ed
ia
n 
 (I
Q
R)
, d
 
2 
(1
-6
) 
2 
(1
-4
) 
0.
07
 
0.
11
 (0
.9
8-
1.
25
) 
0.
11
 
Du
ra
tio
n 
of
 h
os
pi
ta
l s
ta
y 
– 
m
ed
ia
n 
(IQ
R)
, d
 
11
 (6
-2
2)
 
10
-6
-2
1)
 
0.
09
 
1.
12
 (0
.9
9-
1.
26
) 
0.
08
 
	 111
	LATE	VS	EARLY	PN	IN	CRITICALLY	ILL	UNDERNOURISHED	CHILDREN
4
 
 
 
Table S5: Baseline characteristics of children well-nourished on admission in the Early-PN and 
Late-PN group 
 
Characteristic Early-PN  
(n=565) 
Late-PN  
(n=545) 
P-value  
Male 315 (55.8) 319 (58.5) 0.35 
Age at randomisation, median (IQR), years 1.81 (0.28-6.32) 1.77 (0.19-7.32) 0.77 
High STRONGkids category) 51 (9.0) 40 (7.3) 0.31 
Weight Z-score, mean (SD)a -0.07 (1.13) -0.01 (1.37) 0.44 
PELOD score, median (IQR) 21 (11-31) 21 (11-31) 0.98 
PIM2 score, mean (SD) -2.49 (1.75) -2.58 (1.73) 0.37 
Risk of Mortality, median (IQR), (%)b 5.8 (2.4-18.8) 5.5 (2.5-16.2) 0.51 
Diagnostic group    0.83 
  Surgical   
  Abdominal 45 (8.0) 47 (8.6) 
  Burns 3 (0.5) 4 (0.7) 
  Cardiac 221 (39.1) 202 (37.1) 
  Neurologic 56 (9.9) 45 (8.3) 
  Thoracic 30 (5.3) 25 (4.6) 
  Transplant 7 (1.2) 15 (2.8) 
  Trauma/orthopedic 19 (3.4) 17 (3.1) 
  Other 16 (2.8) 26 (4.8) 
 Medical   
  Cardiac 23 (4.1) 25 (4.6) 
  Gastro-intestinal/hepatic 2 (0.4) 2 (0.4) 
  Hematologic/oncologic 7 (1.2) 6 (1.1) 
  Neurologic 35 (6.2) 41 (7.5) 
  Renal 1 (0.2) 1 (0.2) 
  Respiratory 65 (11.5) 58 (10.6) 
  Other 35 (6.2) 31 (5.7) 
Syndrome or genetic abnormality    0.24 
   No 479 (84.8) 480 (88.2) 
  Yes 63 (11.2) 46 (8.5) 
  Suspected 23 (4.1) 18 (3.3) 
Mechanical ventilatory support on PICU admission 501 (88.7) 479 (87.9) 0.69 
Inotrope or vasopressor medication on PICU admission 234 (41.4) 221 (40.6) 0.77 
Mechanical hemodynamic support on PICU admission 17 (3.0) 22 (4.0) 0.35 
PELOD = Paediatric Logistic Organ Dysfunction, range from 0 to 71, with higher scores indicating more severe illness; 
PIM2 = Paediatric Index of Mortality 2, with higher scores indicating a higher risk of mortality; PN = parenteral 
nutrition; STRONGkids = Screening Tool for Risk on Nutritional Status and Growth, range from 0 to 5, with a score of 
0 indicating low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score of 4 to 5 indicating high 
risk.  
aWell-undernourished defined as weight-for-age Z-score ≥2 if <1 year, or BMI-for-age Z-score ≥2 if ≥1 year.131,143   
b<1 year: weight-for-age Z-score, ≥1 year: BMI-for-age Z-score.131,143 
cBased on PIM2 score =([exp (PIM2)]/[1+exp (PIM2)])*100%. 
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ABSTRACT 
 
Background and aims  
Critically ill children are at increased risk of weight deterioration in the paediatric intensive care 
unit (PICU). Whether early initiation of parenteral nutrition (PN) prevents weight deterioration is 
unknown. The aims of this study were to assess the effect of withholding supplemental PN during 
the first week on weight Z-score change in PICU and to evaluate the association between weight 
Z-score change in the PICU and clinical outcomes. 
 
Methods  
This is a secondary analysis of the Paediatric Early versus Late Parenteral Nutrition in Intensive 
Care Unit (PEPaNIC) randomised controlled trial (n=1440), which focused on the subgroup of 
patients with longitudinal weight Z-scores available on admission and on the last day in PICU. 
Patients were randomly allocated to initiation of supplemental PN after one week (Late-PN) or 
within 24 hours (Early-PN) when enteral nutrition was insufficient. The effect of Late-PN versus 
Early-PN on the change in weight Z-score was investigated, adjusted for risk factors. Moreover, 
the association between weight Z-score change and clinical outcomes was explored, adjusted for 
risk factors. 
 
Results  
Longitudinal weight Z-scores were available for 470 patients. Enteral nutrition intake was equal 
in the Early-PN and Late-PN group. Less weight Z-score deterioration during PICU stay was 
associated with a lower risk of new infections (adjusted OR per Z-score increase 0.72 [0.55-0.96], 
p=0.02), and with a higher likelihood of an earlier discharge from PICU alive (adjusted HR per Z-
score increase 1.22 [1.10-1.37], p<0.001). During PICU-stay, the change in weight Z-score did not 
differ among both groups (Late-PN median 0.00 [-0.34-0.12] vs Early-PN median -0.03 [-0.48-
0.01], adjusted β=0.10 [-0.05-0.25], p=0.18).  
 
Conclusions 
Weight deterioration during the PICU stay was associated with worse clinical outcomes. 
Withholding supplemental PN during the first week did not aggravate weight Z-score 
deterioration during PICU stay. 
 
 
INTRODUCTION 
 
Critically ill children admitted to the paediatric intensive care unit (PICU) are at increased risk for 
deterioration of their nutritional status.4,5,7,42,156 Although increased nutritional intake is 
associated with improved nutritional status, the role of parenteral nutrition (PN) is unknown. 
Recently, the “Paediatric Early versus Late Parenteral Nutrition in Intensive Care Unit (PEPaNIC)” 
randomised controlled trial showed that withholding supplemental PN during the first week of 
intensive care (Late-PN) resulted in, among others, fewer new infections and a reduced duration 
of PICU stay as compared with initiating PN at day 1 (Early-PN).18 Since the nutritional intake was 
lower in the Late-PN group because of delaying PN, this strategy might have impacted the 
nutritional status of these children. Therefore, we aimed to investigate the effect of withholding 
supplemental PN for 1 week on the change in weight Z-score during PICU stay as compared with 
early initiation of PN, and whether weight Z-score deterioration during PICU stay is associated 
with worse clinical outcome.  
 
Materials and Methods 
Study design 
This is a secondary analysis of the PEPaNIC randomised controlled trial in a subgroup of children 
with anthropometric measurements available on admission and on the last day in PICU. The trial 
was conducted at the University Hospitals Leuven, Belgium; Erasmus MC–Sophia Children’s 
Hospital, Rotterdam, the Netherlands; and Stollery Children’s Hospital, Edmonton, AB, Canada 
between 2012 and 2015.The full study protocol has been reported previously, trial registration 
number is NCT01536275 (clinicaltrials.gov).18,129 Briefly, 1440 critically ill children (term 
newborns to 17 years old) were randomly assigned 1:1 to Late-PN or Early-PN, if enteral nutrition 
(EN) was <80% of target. Early administration of PN was standard of care at that time in the 
participating hospitals. Patients with a low risk of malnutrition on the Screening Tool for Risk on 
Nutritional Status and Growth (STRONGkids) were excluded. Patients in the Late-PN group 
received a dextrose 5%/saline infusion to match the administered fluid of those in the Early-PN 
group. Initiation and incline of EN and intravenous administration of micronutrients were similar 
in both groups. After the first week, patients in both groups received supplemental PN if EN was 
<80% of target. The institutional ethical review boards of the participating centres approved the 
study. Written informed consent was obtained from the parents or legal guardians. 
 
Definitions and outcomes 
Change in weight Z-score was calculated from admission to the last day in PICU. Weight was 
measured to the nearest 0.01 kg using calibrated scales. The broad age range of our patients did 
not allow us to use the same measure of weight Z-score for all children. Therefore, weight Z-score 
was defined as weight-for-age Z-score157 in children <1 year old and BMI-for-age Z-score157 in 
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children ≥1 year old, as was done previously.119 In neonates, birthweight-for-gestational age Z-
scores130 were used until the age of 7 days to account for physiologic weight loss during the first 
week of life. Clinical outcomes were the risk of new infections during PICU stay, and the likelihood 
of an earlier discharge from PICU alive, with the duration of PICU stay censored at 90 days, and 
the duration of PICU stay of non-survivors set beyond that of all survivors at 91 days, to account 
for mortality as a competing risk. Discharge from PICU was a priori defined as ready for discharge 
from PICU (i.e. no longer in need, or at risk, of vital organ support).  
 
Statistical analysis 
Variables are reported as proportions, mean (±SD) or median (IQR) as appropriate. Proportions 
were analysed univariably using χ2 test, means with t-test and medians with Mann-Whitney test. 
The effect of Late PN on change in weight Z-score was analysed using linear regression, adjusted 
for the baseline risk factors centre, age, diagnosis group (aggregated to 4 groups based on 
stratification groups), STRONGkids category, Paediatric Logistic Organ Dysfunction (PELOD) 
score, Paediatric Index of Mortality 2 (PIM2) score, and weight Z-score on admission. The 
associations between change in weight Z-score and the risk of new infections or the likelihood of 
earlier discharge from PICU alive were analysed using logistic regression and Cox proportional 
hazard analyses, respectively, adjusted for the baseline risk factors mentioned above. Weight 
was measured to the nearest 0.01 kg using calibrated scales. Beta values (β), odds ratios (OR) and 
hazard ratios (HR) with corresponding 95% confidence intervals were calculated. 
P-values ≤0.05 were considered statistically significant. All analyses were performed with 
IBM SPSS Statistics version 21. Z-scores were calculated with use of Growth Analyzer Research 
Calculation Tool version 4, and Fenton 2013 Preterm Growth Chart version 6. 
 
RESULTS 
 
Anthropometric measurements on admission and at the last day in PICU were available for 470 
Dutch children (Figure 1), equally divided between the randomisation groups and with similar 
baseline characteristics in the Late-PN and Early-PN groups (Table 1).  
  
 
 
Figure 1: CONSORT flow diagram 
 
PN = parenteral nutrition. 
 
 
The total caloric intake during the first week differed significantly between the treatment groups 
due to differences in PN, whereas enteral intake was similar between the groups, according to 
the trial protocol (Table 2). Patients who were included in the analyses differed from those not 
included: they were younger, had a higher proportion of children with a high STRONGkids score, 
a lower PELOD score, a higher proportion of emergency admission, comprised more respiratory 
diagnoses and less cardiac surgery, and a lower proportion of inotrope or vasopressor medication 
on admission (Table 1). There were no significant differences between the Dutch children who 
were included and those excluded from the analyses (data not shown), which indicates that the 
observed baseline differences could be attributed to selection of centre rather than selection 
bias. 
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In the children included in this secondary analyses, Late-PN reduced the risk of new 
infections compared to Early-PN (Late-PN 12.4% vs Early-PN 21.6%, p=0.01; adjusted OR 0.47 
[0.28-0.79], p=0.004; Figure 2). The duration of PICU stay was significantly shorter in the Late-
PN group (median 4 days [3-9]) than in the Early-PN group (median 6 days [2-13]; p=0.04). 
Furthermore, the likelihood of an earlier discharge from PICU alive was higher among children 
in the Late-PN group than those in the Early-PN group (adjusted HR 1.30 [1.08-1.57], p=0.005; 
Figure 2).  
Less weight Z-score deterioration during PICU stay was associated with a lower risk of 
new infections (adjusted OR per Z-score increase 0.72 [0.55-0.96], p=0.02; Table 3, Figure 2), 
and with a higher likelihood of an earlier discharge from PICU alive (adjusted HR per Z-score 
increase 1.22 [1.10-1.37], p<0.001; Table 4; Figure 2).The median change in weight Z-score 
from admission to the last day in PICU was not significantly different between the treatment 
groups (Late-PN median 0.00 [-0.34-0.12] vs Early-PN median -0.03 [-0.48-0.01], univariable 
p=0.19; adjusted β 0.10 [-0.05-0.25], p=0.18, Figure 2).  
 
Table 3: Association of the change in weight Z-score with the risk of acquiring new 
infections in PICU 
 
New infections was coded as: 0 = no new infection, 1 = new infection.  
PELOD = Paediatric Logistic Organ Dysfunction; PICU = paediatric intensive care unit; PIM2 = Paediatric Index of 
Mortality 2; PN = parenteral nutrition;  STRONGkids = Screening Tool for Risk on Nutritional Status and Growth. 
 
Since the duration of PICU stay differed between the treatment groups, we 
additionally investigated the average change in weight Z-score per day in PICU, which was a 
median of 0.00 (-0.06-0.01) in the Late-PN group and 0.00 (-0.05-0.00) in the Early-PN group 
(univariable p=0.50; adjusted β 0.03 [-0.04-0.10], p=0.35). Change in weight Z-score within 
children aged <1 year was not different between the Late-PN and Early-PN groups (Late-PN 
median -0.01 [ -0.39;0.08] vs Early-PN median -0.10 [ -0.53;0.08], univariable p=0.37; adjusted 
β 0.04 [ -0.13;0.20), p=0.68]. Within children aged ≥1 year, we also did not find a difference in 
change in weight Z-score between Late-PN and Early-PN (Late-PN median -0.001 [ -0.26;0.20] 
Variable 
Univariable Multivariable 
OR 95% CI P-value OR 95% CI P-value 
Change in weight Z-score 0.75 0.57-0.99 0.04 0.72 0.55-0.96 0.02 
PELOD score    1.05 1.02-0.08 0.003 
PIM2 score    1.16 0.96-1.40 0.12 
STRONGkids category    1.59 0.86-2.92 0.14 
Age    1.03 0.98-1.08 0.25 
Diagnosis group Cardiac surgery (reference)    - - - 
Diagnosis group Surgery other    0.67 0.33-1.35 0.26 
Diagnosis group Medical Neurologic    0.24 0.07-0.83 0.02 
Diagnosis group Medical other    0.65 0.31-1.34 0.24 
Weight Z-score on admission    0.95 0.81-1.11 0.50 
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In the children included in this secondary analyses, Late-PN reduced the risk of new 
infections compared to Early-PN (Late-PN 12.4% vs Early-PN 21.6%, p=0.01; adjusted OR 0.47 
[0.28-0.79], p=0.004; Figure 2). The duration of PICU stay was significantly shorter in the Late-
PN group (median 4 days [3-9]) than in the Early-PN group (median 6 days [2-13]; p=0.04). 
Furthermore, the likelihood of an earlier discharge from PICU alive was higher among children 
in the Late-PN group than those in the Early-PN group (adjusted HR 1.30 [1.08-1.57], p=0.005; 
Figure 2).  
Less weight Z-score deterioration during PICU stay was associated with a lower risk of 
new infections (adjusted OR per Z-score increase 0.72 [0.55-0.96], p=0.02; Table 3, Figure 2), 
and with a higher likelihood of an earlier discharge from PICU alive (adjusted HR per Z-score 
increase 1.22 [1.10-1.37], p<0.001; Table 4; Figure 2).The median change in weight Z-score 
from admission to the last day in PICU was not significantly different between the treatment 
groups (Late-PN median 0.00 [-0.34-0.12] vs Early-PN median -0.03 [-0.48-0.01], univariable 
p=0.19; adjusted β 0.10 [-0.05-0.25], p=0.18, Figure 2).  
 
Table 3: Association of the change in weight Z-score with the risk of acquiring new 
infections in PICU 
 
New infections was coded as: 0 = no new infection, 1 = new infection.  
PELOD = Paediatric Logistic Organ Dysfunction; PICU = paediatric intensive care unit; PIM2 = Paediatric Index of 
Mortality 2; PN = parenteral nutrition;  STRONGkids = Screening Tool for Risk on Nutritional Status and Growth. 
 
Since the duration of PICU stay differed between the treatment groups, we 
additionally investigated the average change in weight Z-score per day in PICU, which was a 
median of 0.00 (-0.06-0.01) in the Late-PN group and 0.00 (-0.05-0.00) in the Early-PN group 
(univariable p=0.50; adjusted β 0.03 [-0.04-0.10], p=0.35). Change in weight Z-score within 
children aged <1 year was not different between the Late-PN and Early-PN groups (Late-PN 
median -0.01 [ -0.39;0.08] vs Early-PN median -0.10 [ -0.53;0.08], univariable p=0.37; adjusted 
β 0.04 [ -0.13;0.20), p=0.68]. Within children aged ≥1 year, we also did not find a difference in 
change in weight Z-score between Late-PN and Early-PN (Late-PN median -0.001 [ -0.26;0.20] 
Variable 
Univariable Multivariable 
OR 95% CI P-value OR 95% CI P-value 
Change in weight Z-score 0.75 0.57-0.99 0.04 0.72 0.55-0.96 0.02 
PELOD score    1.05 1.02-0.08 0.003 
PIM2 score    1.16 0.96-1.40 0.12 
STRONGkids category    1.59 0.86-2.92 0.14 
Age    1.03 0.98-1.08 0.25 
Diagnosis group Cardiac surgery (reference)    - - - 
Diagnosis group Surgery other    0.67 0.33-1.35 0.26 
Diagnosis group Medical Neurologic    0.24 0.07-0.83 0.02 
Diagnosis group Medical other    0.65 0.31-1.34 0.24 
Weight Z-score on admission    0.95 0.81-1.11 0.50 
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vs Early-PN median -0.002 [-0.33;0.003], univariable p=0.28; adjusted β 0.19 [ -0.07;0.46], 
p=0.16). 
 
Table 4: Association of the change in weight Z-score with the likelihood of an earlier 
discharge from PICU alive 
 
PELOD = Paediatric Logistic Organ Dysfunction; PICU = paediatric intensive care unit; PIM2 = Paediatric Index of 
Mortality 2; PN = parenteral nutrition;  STRONGkids = Screening Tool for Risk on Nutritional Status and Growth. 
 
 
DISCUSSION 
 
In this secondary analysis of the PEPaNIC trial, we found in the subgroup of children with 
available longitudinal anthropometric data that less weight Z-score deterioration during PICU 
stay was associated with a lower risk of new infections and with a higher likelihood of an 
earlier discharge from PICU alive. However, these associations should be interpreted with 
caution, as cause and consequence within these associations remains unclear (i.e. acquiring a 
new infection might lead to weight Z-score deterioration). Furthermore, withholding 
supplemental PN during the first week, and thus accepting low macronutrient intakes, did not 
affect weight Z-score during PICU stay compared to early supplemental PN. The effect of 
supplemental PN on the change in weight has not been investigated with a randomised design 
before. In several observational studies, less nutritional intake during the first 2 weeks or 
during the entire PICU or hospital admission was associated with deterioration of the child’s 
nutritional status.4,6,7 However, due to the observational design of these studies, their results 
could be confounded. Moreover, in these studies, the total caloric intake from EN and PN was 
investigated. In our study, we found that withholding supplemental PN did not aggravate 
weight Z-score deterioration while it decreased the risk of new infections and reduced the 
duration of PICU stay.  
These results question the value of weight Z-score change to guide the effect of 
nutritional therapy in the acute phase of critical illness. Possibly, weight Z-score deterioration 
could be considered an expression of illness severity. Consensus statements on diagnosing 
Variable 
Univariable Multivariable 
HR 95% CI P-value HR 95% CI P-value 
Change in weight Z-score 1.12 1.01-1.24 0.03 1.22 1.10-1.37 <0.001 
PELOD score    0.98 0.97-1.00 0.007 
PIM2 score    0.86 0.80-0.92 <0.001 
STRONGkids category    0.79 0.62-1.00 0.05 
Age    0.98 0.96-1.00 0.06 
Diagnosis group Cardiac surgery (reference)    - - - 
Diagnosis group Surgery other    0.93 0.71-1.22 0.60 
Diagnosis group Medical Neurologic    1.17 0.81-1.69 0.42 
Diagnosis group Medical other    0.78 0.59-1.04 0.09 
Weight Z-score on admission    1.08 1.01-1.14 0.02 
 
 
 
malnutrition recognise disease burden/inflammation to contribute to illness-related 
malnutrition, although the precise role of inflammation is not yet clear.158,159 In case of severe 
inflammation such as critical illness, an adaptive housekeeping process called autophagy is 
essential to control cell damage.160 Early administration of nutrients, in particular of amino 
acids, was found to suppress autophagy.132 In critically ill adults, a fasting response evoked by 
withholding supplemental PN resulted in more efficient activation of autophagy in muscles 
and reduced muscle weakness.55 Hence, in critically ill patients in whom severe inflammation 
is present, increased artificial nutritional support might not be able to prevent nutritional 
status deterioration. Instead, reduction of cell damage during the acute phase of illness, even 
if a reduction of nutritional intake is necessary to achieve this, might contribute to optimal 
muscle and lean body mass preservation. 
Body weight might be distorted by oedema and fluid retention, and is therefore 
difficult to measure reliably in the PICU setting, which warrants caution when interpreting 
these results. However, such inaccuracies in weight measurements were likely similar in both 
groups of our study, due to the randomised design and equal fluid administration. It would 
have been interesting to investigate changes in body composition or muscle tissue between 
the two groups. Possible measurements of body composition could be dual X-ray 
absorptiometry (DXA), bioelectrical impedance (BIA/BIS) or plethysmography. However, all of 
these measurements have some important disadvantages in critically ill children, as the 
children have to be stable enough to be transported, and in case of plethysmography should 
be awake and able to sit.161,162 Despite its limitations, BIA/BIS might be a promising technique 
for future research. Phase angle measurements derived from BIS have recently been 
associated with nutritional status and clinical outcomes in critically ill children.46,163 Currently, 
the effect of nutritional therapies on change in phase angle during PICU stay in relation with 
clinical outcomes is unknown. Other measurements to estimate body composition could be 
mid-upper arm circumference or skinfold thickness, which are both less influenced by oedema 
than weight, and easy to obtain at the bedside.164 Information on muscle wasting and 
structure can be derived from muscle biopsies or imaging. In the EPaNIC study in critically ill 
adults, muscle biopsies taken at day 8 showed that Late-PN allowed more efficient activation 
of autophagic quality control.55 Moreover, in participants of the EPaNIC study, CT images 
made at day 2 and day 9 showed that withholding supplemental PN during the first week of 
critical illness did not affect muscle wasting but improved the quality of the muscle, reflected 
by the decreased amount of adipose tissue within the muscle compartments.57 Whether these 
observations can also be applied to critically ill children in different age categories is unknown. 
In critically ill children, it is difficult to detect an altered muscle structure. The reliability and 
accuracy of ultrasonography to evaluate muscle wasting in critically ill children is 
questionable.49,165 
There are additional limitations to our study that need to be addressed. First, as this 
study comprised a subgroup, there may be a selection bias. However, the observed baseline 
differences could be attributed to selection of centre instead of selection bias. Furthermore, 
the Late-PN and Early-PN groups were comparable at baseline. Therefore, we feel that the 
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could be considered an expression of illness severity. Consensus statements on diagnosing 
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PIM2 score    0.86 0.80-0.92 <0.001 
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inflammation such as critical illness, an adaptive housekeeping process called autophagy is 
essential to control cell damage.160 Early administration of nutrients, in particular of amino 
acids, was found to suppress autophagy.132 In critically ill adults, a fasting response evoked by 
withholding supplemental PN resulted in more efficient activation of autophagy in muscles 
and reduced muscle weakness.55 Hence, in critically ill patients in whom severe inflammation 
is present, increased artificial nutritional support might not be able to prevent nutritional 
status deterioration. Instead, reduction of cell damage during the acute phase of illness, even 
if a reduction of nutritional intake is necessary to achieve this, might contribute to optimal 
muscle and lean body mass preservation. 
Body weight might be distorted by oedema and fluid retention, and is therefore 
difficult to measure reliably in the PICU setting, which warrants caution when interpreting 
these results. However, such inaccuracies in weight measurements were likely similar in both 
groups of our study, due to the randomised design and equal fluid administration. It would 
have been interesting to investigate changes in body composition or muscle tissue between 
the two groups. Possible measurements of body composition could be dual X-ray 
absorptiometry (DXA), bioelectrical impedance (BIA/BIS) or plethysmography. However, all of 
these measurements have some important disadvantages in critically ill children, as the 
children have to be stable enough to be transported, and in case of plethysmography should 
be awake and able to sit.161,162 Despite its limitations, BIA/BIS might be a promising technique 
for future research. Phase angle measurements derived from BIS have recently been 
associated with nutritional status and clinical outcomes in critically ill children.46,163 Currently, 
the effect of nutritional therapies on change in phase angle during PICU stay in relation with 
clinical outcomes is unknown. Other measurements to estimate body composition could be 
mid-upper arm circumference or skinfold thickness, which are both less influenced by oedema 
than weight, and easy to obtain at the bedside.164 Information on muscle wasting and 
structure can be derived from muscle biopsies or imaging. In the EPaNIC study in critically ill 
adults, muscle biopsies taken at day 8 showed that Late-PN allowed more efficient activation 
of autophagic quality control.55 Moreover, in participants of the EPaNIC study, CT images 
made at day 2 and day 9 showed that withholding supplemental PN during the first week of 
critical illness did not affect muscle wasting but improved the quality of the muscle, reflected 
by the decreased amount of adipose tissue within the muscle compartments.57 Whether these 
observations can also be applied to critically ill children in different age categories is unknown. 
In critically ill children, it is difficult to detect an altered muscle structure. The reliability and 
accuracy of ultrasonography to evaluate muscle wasting in critically ill children is 
questionable.49,165 
There are additional limitations to our study that need to be addressed. First, as this 
study comprised a subgroup, there may be a selection bias. However, the observed baseline 
differences could be attributed to selection of centre instead of selection bias. Furthermore, 
the Late-PN and Early-PN groups were comparable at baseline. Therefore, we feel that the 
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results regarding the effect of Late-PN versus Early-PN on the change in weight Z-score are 
reliable. Nevertheless, caution is warranted when generalising these results. Second, in this 
study, we presented short-term outcomes. Recently, the 2 years follow-up of the PEPaNIC 
patients showed no differences in weight, height, body mass index and head circumference Z-
scores between the Late-PN and Early-PN groups.124  Thus, also in the long-term, there seem 
to be no repercussions on growth when PN is withheld during the first week of paediatric 
critical illness.124  
 
CONCLUSIONS 
 
In a large heterogeneous PICU population, weight deterioration during PICU stay was 
associated with worse clinical outcomes. Withholding supplemental PN during the first week 
of critical illness did not aggravate weight Z-score deterioration during PICU-stay. 
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ABSTRACT  
 
Background 
The Paediatric Early versus Late Parenteral Nutrition in Critical Illness (PEPaNIC) multicentre, 
randomised, controlled trial showed that compared with early parenteral nutrition (Early-PN), 
withholding supplemental parenteral nutrition for 1 week in the paediatric intensive care unit 
(PICU; Late-PN) reduced infections and accelerated recovery from critical illness in children. 
We aimed to investigate the long-term impact on physical and neurocognitive development 
of early versus late parenteral nutrition (PN). 
 
Methods 
In this preplanned 2-year follow-up study, all patients included in the PEPaNIC trial (which was 
done in University Hospitals Leuven, Belgium; Erasmus MC–Sophia Children’s Hospital, 
Rotterdam, the Netherlands; and Stollery Children’s Hospital, Edmonton, AB, Canada) were 
approached for possible assessment of physical and neurocognitive development compared 
with healthy children who were matched for age and sex, and who had never been admitted 
to a neonatal ICU or a PICU. Assessed outcomes comprised anthropometric data; health 
status; parent/caregiver-reported executive functions, and emotional and behavioural 
problems; and tests for intelligence, visual-motor integration, alertness, motor coordination, 
inhibitory control, cognitive flexibility, and memory. To address partial responses among the 
children tested, we did multiple data imputation by chained equations before univariable and 
multivariable linear and logistic regression analyses adjusted for risk factors. This trial is 
registered with ClinicalTrials.gov, number NCT01536275. 
 
Findings 
At the 2-years follow-up, 60 (8%) of 717 children who received Late-PN and 63 (9%) of 723 
children who received Early-PN had died (p=0.81). 68 (9%) of 717 children who received Late-
PN and 91 (13%) of 723 children who received Early-PN were too disabled for neurocognitive 
assessment (p=0.059), and 786 patients (395 assigned to Late-PN and 391 assigned to Early-
PN) consented for testing. 786 patients and 405 healthy control children underwent long-term 
outcomes testing between August 4, 2014, and January 19, 2018, and were included in the 
imputation model for subsequent multivariable analyses. Late-PN did not adversely affect 
anthropometric data, health status, or neurological functioning, and improved 
parent/caregiver-reported executive functioning (Late-PN vs Early-PN β estimate –2.258, 95% 
CI –4.012 to –0.504; p=0.011), more specifically inhibition (–3.422, –5.171 to –1.673; 
p=0.0001), working memory (–2.016, –3.761 to –0.270; p=0.023), and meta-cognition (–1.957, 
–3.694 to –0.220; p=0.027). Externalising behavioural problems (β estimate –1.715, 95% CI –
3.325 to –0.106; p=0.036) and visual-motor integration (0.468, 0.087 to 0.850; p=0.016) were 
also improved in the Late-PN group compared with the Early-PN group. After Bonferroni 
correction for multiple comparisons, the effect on inhibitory control remained significant 
(p=0.0001). 
 
 
 
 
Interpretation 
Withholding early PN for 1 week in the PICU did not negatively affect survival, 
anthropometrics, health status, and neurocognitive development, and improved inhibitory 
control 2 years after PICU admission. 
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INTRODUCTION 
 
The Paediatric Early versus Late Parenteral Nutrition in Critical Illness (PEPaNIC) multicentre, 
randomised, controlled trial revealed that withholding parenteral nutrition (PN) for up to 1 
week in the paediatric intensive care unit (PICU), when enteral nutrition (EN) was insufficient, 
was clinically superior to providing full nutrition up to caloric targets with supplemental PN.18 
Indeed, not giving PN during the first week in PICU and thus, in most patients, accepting low 
caloric and macronutrient intake reduced the incidence of new infections and accelerated 
recovery.18 Despite these short-term clinical benefits, concerns have been raised about 
potential adverse long-term consequences of low caloric and macronutrient intake for the 
patients’ length, bodyweight, head circumference, health status and neurocognitive 
development.75,166 To evaluate long-term value for patients, patient-reported outcomes or 
rather, in case of children, parent/caregiver-reported outcomes should also be investigated.167 
Any such adverse patient-centred long-term consequences would discourage withholding PN 
early in the course of paediatric critical illness. Children who have been treated in the PICU 
tend to have adverse long-term developmental and neurocognitive outcomes.168 In view of 
the potential benefits of fasting-induced responses for removal of cell damage and prevention 
of neurodegeneration,169,170 we hypothesised that withholding PN early during the course of 
critical illness in children could also bring about beneficial effects in the long term, in particular 
for neurocognitive development.  
We aimed to investigate whether withholding supplemental PN during the first week 
in PICU, rather than giving PN to reach nutritional targets as soon as possible, while adequately 
providing micronutrients, has an impact on survival, health status, and anthropometrics, 
clinically assessed neurological function, and parent/caregiver-reported and clinically tested 
neurocognitive outcomes at the 2-year follow-up, compared with matched healthy children. 
 
METHODS 
 
Study design and participants 
This study is the preplanned 2-year follow-up of the PEPaNIC trial, in which 1440 critically ill 
children admitted to the participating PICUs (University Hospitals Leuven, Belgium; Erasmus-
MC Sophia Children’s Hospital, Rotterdam, Netherlands; Stollery Children’s Hospital, 
Edmonton, AB, Canada) had been enrolled between 2012 and 2015. The full study protocol 
and acute outcome results have been published.18,129  
Parents or legal guardians had provided written informed consent on admission to the 
PICU to contact them for long-term follow-up testing of their child. Survival status was 
determined by assessment of hospital notes, national registers, or contact with the general 
practitioner or referring paediatrician. All PICU survivors and their parents or caregivers were 
first sent a standardised patient information letter. Subsequently, they were contacted by 
phone to obtain consent for scheduling an appointment for the medical and neurocognitive 
assessment. Participating patients (Appendix) were assessed either at the hospital or at home; 
 
 
 
the latter was offered whenever parents or caregivers considered the burden of coming to the 
hospital too high. Neonates and infants enrolled in the PEPaNIC trial were assessed at the age 
of 2.5 years because the youngest appropriate age for parent/caregiver-reported executive 
functioning (with the Behaviour Rating Inventory of Executive Function [BRIEF] and a general 
intelligence test, Wechsler Preschool and Primary Scale of Intelligence [WPPSI])  is 2.5 years.  
405 healthy control children were recruited for a medical and neurocognitive 
assessment similar to that of the PEPaNIC patients. These children were demographically 
matched to the patients for age and sex. To control as much as possible for genetic, 
socioeconomic, and environmental background, siblings and relatives of the patients were 
preferably recruited into this control group besides unrelated children recruited from the 
same geographical area. Exclusion criteria for the control group were previous admission to a 
neonatal ICU or a PICU, or hospital admission for at least 7 days with need for an intravenous 
line, history of suspicious or established inborn chronic metabolic diseases requiring a specific 
diet, such as diabetes, and history of short bowel syndrome on home PN or other conditions 
that require home PN.  
Written informed consent was obtained from the parents or legal guardians or from 
the adolescent according to local regulations. The institutional review boards at each 
participating site approved this follow-up study (ML8052; NL49708.078; Pro00038098). The 
protocol is available online. 
 
Procedures, randomisation and masking 
In the PEPaNIC trial,18 after having obtained consent, children who were admitted to the PICU 
were randomly allocated (1:1) to receive Early-PN, which was initiating PN within 24 hours of 
PICU admission to supplement EN whenever 80% of targeted calories per age and bodyweight 
categories was not reached, or Late-PN. Late-PN meant that, for up to 1 week, patients 
received a mixture of glucose 5% and sodium chloride 0.9% without other forms of PN (lipid 
or protein infusions) being administered, corresponding to no PN in the majority of children. 
After 1 week, for both groups equally, PN could be administered if necessary. When EN 
covered 80% or more of calculated targets, supplemental PN was discontinued. Total 
macronutrient doses administered on each of the first 7 days in PICU are shown in the 
appendix. EN was initiated early for both groups equally, and all patients received intravenous 
micronutrients until fully enterally fed.  
Outcome assessors were physicians and experienced paediatric psychologists who had 
not been involved in the management of the patients during their stay in the PICU and who 
were strictly blinded for the randomised allocation to either Late-PN or Early-PN. Parents had 
not been masked during the time the child was treated in the PICU and were not actively 
informed about the initial PEPaNIC study results.  
 
Outcomes 
In this 2-year follow-up study, the primary outcomes assessed were growth, physical ability, 
health status, and clinical, neurological, and neurocognitive outcomes. Death and severe 
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INTRODUCTION 
 
The Paediatric Early versus Late Parenteral Nutrition in Critical Illness (PEPaNIC) multicentre, 
randomised, controlled trial revealed that withholding parenteral nutrition (PN) for up to 1 
week in the paediatric intensive care unit (PICU), when enteral nutrition (EN) was insufficient, 
was clinically superior to providing full nutrition up to caloric targets with supplemental PN.18 
Indeed, not giving PN during the first week in PICU and thus, in most patients, accepting low 
caloric and macronutrient intake reduced the incidence of new infections and accelerated 
recovery.18 Despite these short-term clinical benefits, concerns have been raised about 
potential adverse long-term consequences of low caloric and macronutrient intake for the 
patients’ length, bodyweight, head circumference, health status and neurocognitive 
development.75,166 To evaluate long-term value for patients, patient-reported outcomes or 
rather, in case of children, parent/caregiver-reported outcomes should also be investigated.167 
Any such adverse patient-centred long-term consequences would discourage withholding PN 
early in the course of paediatric critical illness. Children who have been treated in the PICU 
tend to have adverse long-term developmental and neurocognitive outcomes.168 In view of 
the potential benefits of fasting-induced responses for removal of cell damage and prevention 
of neurodegeneration,169,170 we hypothesised that withholding PN early during the course of 
critical illness in children could also bring about beneficial effects in the long term, in particular 
for neurocognitive development.  
We aimed to investigate whether withholding supplemental PN during the first week 
in PICU, rather than giving PN to reach nutritional targets as soon as possible, while adequately 
providing micronutrients, has an impact on survival, health status, and anthropometrics, 
clinically assessed neurological function, and parent/caregiver-reported and clinically tested 
neurocognitive outcomes at the 2-year follow-up, compared with matched healthy children. 
 
METHODS 
 
Study design and participants 
This study is the preplanned 2-year follow-up of the PEPaNIC trial, in which 1440 critically ill 
children admitted to the participating PICUs (University Hospitals Leuven, Belgium; Erasmus-
MC Sophia Children’s Hospital, Rotterdam, Netherlands; Stollery Children’s Hospital, 
Edmonton, AB, Canada) had been enrolled between 2012 and 2015. The full study protocol 
and acute outcome results have been published.18,129  
Parents or legal guardians had provided written informed consent on admission to the 
PICU to contact them for long-term follow-up testing of their child. Survival status was 
determined by assessment of hospital notes, national registers, or contact with the general 
practitioner or referring paediatrician. All PICU survivors and their parents or caregivers were 
first sent a standardised patient information letter. Subsequently, they were contacted by 
phone to obtain consent for scheduling an appointment for the medical and neurocognitive 
assessment. Participating patients (Appendix) were assessed either at the hospital or at home; 
 
 
 
the latter was offered whenever parents or caregivers considered the burden of coming to the 
hospital too high. Neonates and infants enrolled in the PEPaNIC trial were assessed at the age 
of 2.5 years because the youngest appropriate age for parent/caregiver-reported executive 
functioning (with the Behaviour Rating Inventory of Executive Function [BRIEF] and a general 
intelligence test, Wechsler Preschool and Primary Scale of Intelligence [WPPSI])  is 2.5 years.  
405 healthy control children were recruited for a medical and neurocognitive 
assessment similar to that of the PEPaNIC patients. These children were demographically 
matched to the patients for age and sex. To control as much as possible for genetic, 
socioeconomic, and environmental background, siblings and relatives of the patients were 
preferably recruited into this control group besides unrelated children recruited from the 
same geographical area. Exclusion criteria for the control group were previous admission to a 
neonatal ICU or a PICU, or hospital admission for at least 7 days with need for an intravenous 
line, history of suspicious or established inborn chronic metabolic diseases requiring a specific 
diet, such as diabetes, and history of short bowel syndrome on home PN or other conditions 
that require home PN.  
Written informed consent was obtained from the parents or legal guardians or from 
the adolescent according to local regulations. The institutional review boards at each 
participating site approved this follow-up study (ML8052; NL49708.078; Pro00038098). The 
protocol is available online. 
 
Procedures, randomisation and masking 
In the PEPaNIC trial,18 after having obtained consent, children who were admitted to the PICU 
were randomly allocated (1:1) to receive Early-PN, which was initiating PN within 24 hours of 
PICU admission to supplement EN whenever 80% of targeted calories per age and bodyweight 
categories was not reached, or Late-PN. Late-PN meant that, for up to 1 week, patients 
received a mixture of glucose 5% and sodium chloride 0.9% without other forms of PN (lipid 
or protein infusions) being administered, corresponding to no PN in the majority of children. 
After 1 week, for both groups equally, PN could be administered if necessary. When EN 
covered 80% or more of calculated targets, supplemental PN was discontinued. Total 
macronutrient doses administered on each of the first 7 days in PICU are shown in the 
appendix. EN was initiated early for both groups equally, and all patients received intravenous 
micronutrients until fully enterally fed.  
Outcome assessors were physicians and experienced paediatric psychologists who had 
not been involved in the management of the patients during their stay in the PICU and who 
were strictly blinded for the randomised allocation to either Late-PN or Early-PN. Parents had 
not been masked during the time the child was treated in the PICU and were not actively 
informed about the initial PEPaNIC study results.  
 
Outcomes 
In this 2-year follow-up study, the primary outcomes assessed were growth, physical ability, 
health status, and clinical, neurological, and neurocognitive outcomes. Death and severe 
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disability precluding neurocognitive testing were a priori defined as safety endpoints. 
Neurocognitive testability was determined by screening of the medical file or clinical 
judgment, before the start of the neurocognitive assessment, by the physician or psychologist 
and confirmed by the parents or caregivers. 
For children who were examined at follow-up, head circumferences, bodyweights, and 
heights were measured. A clinical neurological examination was done to assess gross 
neurological abnormalities. A structured interview with the parents or caregivers assessed 
whether the child had been diagnosed with a somatic or psychiatric illness, or had been 
admitted to a hospital for medical or surgical reasons during the preceding 2 years for healthy 
control children and during the 2 years following the index PICU admission for patients. 
Validated, internationally recognised questionnaires and clinical tests with adequate 
normative data were used to score performance for a broad range of neurocognitive 
functions.20 Patient-reported outcome questionnaires were completed by parents or 
caregivers. They reported executive functioning in their child with the BRIEF preschool version 
for children aged 2.5-5 years or BRIEF for patients aged 6-18 years. Overlapping scales of both 
questionnaires (inhibition, flexibility, emotional control, working memory, and planning and 
organisation), the overlapping index (meta-cognition, comprising the scales working memory 
and planning and organisation), and the total score were reported (T scores, with mean 50 [SD 
10]).171,172 Parents or caregivers completed the Child Behaviour Checklist (CBCL 1.5–5 years or 
CBCL 6–18 years)173,174 to assess emotional and behavioural problems. Internalising, 
externalising, and total problems were analysed (T scores, with mean 50 [SD 10]).173,174  
Clinical tests were used to evaluate neurocognitive functions. General intellectual 
ability was assessed with use of age-appropriate versions of the Wechsler intelligence 
quotient (IQ). WPPSI-III-NL175 was used for children aged between 2.5 years and 5 years 11 
months, the Wechsler Intelligence Scale for Children (WISC-III-NL)176 was used for children 
aged between 6 years and 16 years 11 months, and the Wechsler Adult Intelligence Scale 
(WAIS-IV-NL)177 for adolescents or young adults who were 17 years or older. For all of  these 
tests, total IQ, verbal IQ, and performance IQ scores (test mean 100 [SD 15]) were computed. 
The Beery Developmental Test of Visual–Motor Integration178 was used for children aged 2.5 
years and older to assess the ability to integrate visual and motor functions (total scaled score, 
with test mean 10 [SD 3]). The validated computerised Amsterdam Neuropsychological Tasks 
(ANT) programme was used to measure attention, motor coordination, and executive 
functions in children aged 4 years or older.179 ANT-Baseline Speed was used to evaluate 
alertness (reaction time and SD), ANT-Tapping to assess motor coordination (number of taps), 
and Response Organisation Objects to measure inhibitory control and cognitive flexibility 
(differences in reaction time and in number of errors between tests of increasing demand). 
Memory was assessed with use of 4 tests from the Children’s Memory Scale (CMS) for children 
aged between 5 years and 16 years 11 months.180 CMS-Numbers assessed short-term verbal 
memory span and verbal working memory load (scaled score, with test mean 10 [SD 3]). The 
CMS-Word Pairs assessed short-term and long-term verbal memory, and recognition; CMS-
Picture Locations assessed immediate visual memory; and CMS-Dot Locations assessed 
 
 
 
immediate and delayed visual memory (proportion of correct responses, ranging from 0 to 1). 
The CMS-Learning index represents learning abilities of the child (standard score, with mean 
100 [SD 15]). The extended description of the parent/caregiver-reported outcome 
questionnaires and of the clinical and neuropsychological test battery is available in the 
appendix.  
 
Statistical analysis  
After taking into account estimations for the safety endpoints (death and severe disability 
precluding neurocognitive testing), we estimated that about 30% of the patients among the 
critically ill patients who had been included in the PEPaNIC trial and who were alive and 
testable at the 2-year follow-up would be lost to follow-up, on the basis of earlier 
experience.20 We calculated that such a sample size had >80% power to detect, with a 
certainty of >95%, clinically relevant differences between the 2 randomisation arms, in the 
same order of magnitude as those we had previously documented with blood glucose control 
in the PICU.20 For the healthy control group, we calculated that with a sample size of 405 
children, we would be able to detect, with a power of >80% and certainty of >95%, outcome 
differences between patients and healthy children of the same order of magnitude as those 
previously documented.20    
The inability to fully complete any of the neurocognitive tests would introduce bias in 
univariable analyses of these test results, because this in itself might suggest poor function. 
Hence, to correctly address partial responses, multiple data imputation by chained equations 
was required,181 with use of all available data per individual (Appendix). For tests validated for 
a specific age range (alertness, motor coordination, inhibitory control and flexibility in children 
aged 4 years or older, and memory in children who are between 5 and 16 years old), we 
imputed data within these age ranges only. To avoid bias and instability in this imputation 
model, the percentage of missing data per variable could not exceed 30%181 and to minimise 
loss of statistical power, the number of iterative imputations was set at 31.181 Comparison of 
the observed and imputed values and the imputation predictor are shown in the appendix. 
To analyse the differences in outcomes between PEPaNIC participants and healthy 
control children, and to investigate the long-term outcome differences between patients 
randomly allocated to Late-PN or Early-PN during PICU stay, we did multivariable linear and 
logistic regression analyses on the 31 imputed datasets with the β estimates or odds ratios 
reported as pooled results, preceded by a pooled univariable comparison with use of Fisher’s 
exact test, Student’s t test, or Wilcoxon rank-sum test as appropriate (Appendix). All 
multivariable analyses were adjusted for the following risk factors: age, centre, race,182 sex, 
geographic origin,182 language, hand preference, history of malignancy, diabetes, a predefined 
syndrome (Appendix), and the educational and occupational status of parents (Appendix). For 
the comparison between Late-PN and Early-PN groups, further adjustment was done for 
diagnosis and severity of illness (with the Paediatric Index of Mortality 3 and paediatric logistic 
organ dysfunction scores) on PICU admission, risk of malnutrition, and parental smoking 
behaviour before PICU admission. We calculated p values for interaction between age group 
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disability precluding neurocognitive testing were a priori defined as safety endpoints. 
Neurocognitive testability was determined by screening of the medical file or clinical 
judgment, before the start of the neurocognitive assessment, by the physician or psychologist 
and confirmed by the parents or caregivers. 
For children who were examined at follow-up, head circumferences, bodyweights, and 
heights were measured. A clinical neurological examination was done to assess gross 
neurological abnormalities. A structured interview with the parents or caregivers assessed 
whether the child had been diagnosed with a somatic or psychiatric illness, or had been 
admitted to a hospital for medical or surgical reasons during the preceding 2 years for healthy 
control children and during the 2 years following the index PICU admission for patients. 
Validated, internationally recognised questionnaires and clinical tests with adequate 
normative data were used to score performance for a broad range of neurocognitive 
functions.20 Patient-reported outcome questionnaires were completed by parents or 
caregivers. They reported executive functioning in their child with the BRIEF preschool version 
for children aged 2.5-5 years or BRIEF for patients aged 6-18 years. Overlapping scales of both 
questionnaires (inhibition, flexibility, emotional control, working memory, and planning and 
organisation), the overlapping index (meta-cognition, comprising the scales working memory 
and planning and organisation), and the total score were reported (T scores, with mean 50 [SD 
10]).171,172 Parents or caregivers completed the Child Behaviour Checklist (CBCL 1.5–5 years or 
CBCL 6–18 years)173,174 to assess emotional and behavioural problems. Internalising, 
externalising, and total problems were analysed (T scores, with mean 50 [SD 10]).173,174  
Clinical tests were used to evaluate neurocognitive functions. General intellectual 
ability was assessed with use of age-appropriate versions of the Wechsler intelligence 
quotient (IQ). WPPSI-III-NL175 was used for children aged between 2.5 years and 5 years 11 
months, the Wechsler Intelligence Scale for Children (WISC-III-NL)176 was used for children 
aged between 6 years and 16 years 11 months, and the Wechsler Adult Intelligence Scale 
(WAIS-IV-NL)177 for adolescents or young adults who were 17 years or older. For all of  these 
tests, total IQ, verbal IQ, and performance IQ scores (test mean 100 [SD 15]) were computed. 
The Beery Developmental Test of Visual–Motor Integration178 was used for children aged 2.5 
years and older to assess the ability to integrate visual and motor functions (total scaled score, 
with test mean 10 [SD 3]). The validated computerised Amsterdam Neuropsychological Tasks 
(ANT) programme was used to measure attention, motor coordination, and executive 
functions in children aged 4 years or older.179 ANT-Baseline Speed was used to evaluate 
alertness (reaction time and SD), ANT-Tapping to assess motor coordination (number of taps), 
and Response Organisation Objects to measure inhibitory control and cognitive flexibility 
(differences in reaction time and in number of errors between tests of increasing demand). 
Memory was assessed with use of 4 tests from the Children’s Memory Scale (CMS) for children 
aged between 5 years and 16 years 11 months.180 CMS-Numbers assessed short-term verbal 
memory span and verbal working memory load (scaled score, with test mean 10 [SD 3]). The 
CMS-Word Pairs assessed short-term and long-term verbal memory, and recognition; CMS-
Picture Locations assessed immediate visual memory; and CMS-Dot Locations assessed 
 
 
 
immediate and delayed visual memory (proportion of correct responses, ranging from 0 to 1). 
The CMS-Learning index represents learning abilities of the child (standard score, with mean 
100 [SD 15]). The extended description of the parent/caregiver-reported outcome 
questionnaires and of the clinical and neuropsychological test battery is available in the 
appendix.  
 
Statistical analysis  
After taking into account estimations for the safety endpoints (death and severe disability 
precluding neurocognitive testing), we estimated that about 30% of the patients among the 
critically ill patients who had been included in the PEPaNIC trial and who were alive and 
testable at the 2-year follow-up would be lost to follow-up, on the basis of earlier 
experience.20 We calculated that such a sample size had >80% power to detect, with a 
certainty of >95%, clinically relevant differences between the 2 randomisation arms, in the 
same order of magnitude as those we had previously documented with blood glucose control 
in the PICU.20 For the healthy control group, we calculated that with a sample size of 405 
children, we would be able to detect, with a power of >80% and certainty of >95%, outcome 
differences between patients and healthy children of the same order of magnitude as those 
previously documented.20    
The inability to fully complete any of the neurocognitive tests would introduce bias in 
univariable analyses of these test results, because this in itself might suggest poor function. 
Hence, to correctly address partial responses, multiple data imputation by chained equations 
was required,181 with use of all available data per individual (Appendix). For tests validated for 
a specific age range (alertness, motor coordination, inhibitory control and flexibility in children 
aged 4 years or older, and memory in children who are between 5 and 16 years old), we 
imputed data within these age ranges only. To avoid bias and instability in this imputation 
model, the percentage of missing data per variable could not exceed 30%181 and to minimise 
loss of statistical power, the number of iterative imputations was set at 31.181 Comparison of 
the observed and imputed values and the imputation predictor are shown in the appendix. 
To analyse the differences in outcomes between PEPaNIC participants and healthy 
control children, and to investigate the long-term outcome differences between patients 
randomly allocated to Late-PN or Early-PN during PICU stay, we did multivariable linear and 
logistic regression analyses on the 31 imputed datasets with the β estimates or odds ratios 
reported as pooled results, preceded by a pooled univariable comparison with use of Fisher’s 
exact test, Student’s t test, or Wilcoxon rank-sum test as appropriate (Appendix). All 
multivariable analyses were adjusted for the following risk factors: age, centre, race,182 sex, 
geographic origin,182 language, hand preference, history of malignancy, diabetes, a predefined 
syndrome (Appendix), and the educational and occupational status of parents (Appendix). For 
the comparison between Late-PN and Early-PN groups, further adjustment was done for 
diagnosis and severity of illness (with the Paediatric Index of Mortality 3 and paediatric logistic 
organ dysfunction scores) on PICU admission, risk of malnutrition, and parental smoking 
behaviour before PICU admission. We calculated p values for interaction between age group 
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and randomisation to assess whether patients who were infants (aged <1 years) at 
randomisation behaved differently from older children.  
We did explanatory statistical analyses with further adjustment to investigate whether 
any eventual impact of Late-PN versus Early-PN on the long-term outcomes might have been 
mediated by its acute effects on new PICU infections and duration of PICU stay, and thus 
possibly indirectly also number of post-randomisation hypoglycaemic events or the duration 
of post-randomisation treatments such as mechanical ventilatory support, haemodynamic 
support, antibiotics, corticosteroids, opioids, benzodiazepines, hypnotics, and α2-agonists.  
Data are presented as β estimates and odds ratios with 95% CIs, means and SDs, or 
numbers and proportions, as appropriate.  
Statistical analyses were done with R version 3.4.3, MICE version 2.46.0, and JMP 
version 13.0.0. Two-sided p-values of 0.05 or less were considered statistically significant. 
Bonferroni corrections for the multiple comparisons (n=45) were done as a sensitivity analysis, 
which altered the required level of p value for significance to 0.001 or less.  
This trial is registered with ClinicalTrials.gov, NCT01536275. 
  
 
 
 
RESULTS 
 
Figure 1: CONSORT flow diagram of the study participants 
 
PN = parenteral nutrition, STRONGkids = Screening Tool for Risk on Nutritional Status and Growth. 
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Of the total patient population (n=1440), 60 (8%) of 717 children in the Late-PN group and 63 
(9%) of 723 children in the Early-PN group had died 2 years after admission to a PICU (p=0.81; 
Figure 1). 68 (9%) patients in the Late-PN group and 91 (13%) patients in the Early-PN group 
were identified as too disabled to assess for neurocognitive development (p=0.059). 372 (26%) 
patients survived, but declined participation or could not be reached. No differences in 
reasons for loss to follow-up between randomisation groups were observed (p=0.27). 786 
patients (395 assigned to Late-PN and 391 assigned to Early-PN) and 405 healthy controls 
underwent long-term outcome testing between August 4, 2014 and January 19 2018, and 
were included in the imputation model for subsequent multivariable analyses. Of the healthy 
control children, 332 (82%) were assessed at the hospital compared with 502 (64%) PEPaNIC 
children (p<0.001), with similar proportions for the Early-PN 458 (64%) and Late-PN 461 (64%) 
groups being assessed at the hospital (p=0.79). Demographic and medical characteristics of 
PEPaNIC participants and healthy control children are shown in Table 1. Patients who were 
tested at follow-up were overall comparable to the initial PEPaNIC study population (Table 1).  
Overall, PEPaNIC participants had worse outcomes at the 2-year follow-up for height, 
body weight, and head circumference, for health status, clinically assessed neurological 
functioning, parent/caregiver-reported executive functioning, and emotional and behavioural 
problems, and for clinical tests for intelligence, visual-motor integration, alertness, and 
memory than did healthy control children, assessed via univariable and via multivariable 
comparisons (Table 2; Table 3).  
Patients in the Late-PN group and those in the Early-PN group were similar in terms of 
height, bodyweight, body-mass index, and head circumference, and for health status, and 
clinically assessed neurological functioning in univariable and multivariable analyses (Table 2, 
Table 3) However, in the univariable comparisons, patients in the Late-PN group performed 
better than did those in the Early-PN group on parent/caregiver-reported inhibitory control, 
working memory, meta-cognition, and overall executive functioning, and on clinical tests for 
visual-motor integration, verbal-auditory recognition, and for one motor coordination task 
(synchronous tapping; Table 2). Adjusted for multiple comparisons, the better inhibitory 
control of patients in the Late-PN group than that of patients in the Early-PN group remained 
significant (p=0.0001). After multivariable adjustment for risk factors, parents/caregivers of 
patients in the Late-PN group reported better overall executive functioning than did 
parents/caregivers of patients in the Early-PN group (β estimate –2.258, 95% CI –4.012 to –
0.504; p=0.011), more specifically for inhibition (–3.422, –5.171 to –1.673; p=0.0001), working 
memory (–2.016, –3.761 to –0.270; p=0.023), and metacognition (–1.957, –3.694 to –0.220; 
p=0.027; Table 3; Figure 2). Furthermore, patients in the Late-PN group had fewer 
externalising behavioural problems (–1.715, 95% CI –3.325 to –0.106; p=0.036) as reported by 
parents/caregivers and scored better on visual-motor integration (0.468, 0.087 to 0.850; 
p=0.016) than did patients in the Early-PN group (Table 3; Appendix). 
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Of the total patient population (n=1440), 60 (8%) of 717 children in the Late-PN group and 63 
(9%) of 723 children in the Early-PN group had died 2 years after admission to a PICU (p=0.81; 
Figure 1). 68 (9%) patients in the Late-PN group and 91 (13%) patients in the Early-PN group 
were identified as too disabled to assess for neurocognitive development (p=0.059). 372 (26%) 
patients survived, but declined participation or could not be reached. No differences in 
reasons for loss to follow-up between randomisation groups were observed (p=0.27). 786 
patients (395 assigned to Late-PN and 391 assigned to Early-PN) and 405 healthy controls 
underwent long-term outcome testing between August 4, 2014 and January 19 2018, and 
were included in the imputation model for subsequent multivariable analyses. Of the healthy 
control children, 332 (82%) were assessed at the hospital compared with 502 (64%) PEPaNIC 
children (p<0.001), with similar proportions for the Early-PN 458 (64%) and Late-PN 461 (64%) 
groups being assessed at the hospital (p=0.79). Demographic and medical characteristics of 
PEPaNIC participants and healthy control children are shown in Table 1. Patients who were 
tested at follow-up were overall comparable to the initial PEPaNIC study population (Table 1).  
Overall, PEPaNIC participants had worse outcomes at the 2-year follow-up for height, 
body weight, and head circumference, for health status, clinically assessed neurological 
functioning, parent/caregiver-reported executive functioning, and emotional and behavioural 
problems, and for clinical tests for intelligence, visual-motor integration, alertness, and 
memory than did healthy control children, assessed via univariable and via multivariable 
comparisons (Table 2; Table 3).  
Patients in the Late-PN group and those in the Early-PN group were similar in terms of 
height, bodyweight, body-mass index, and head circumference, and for health status, and 
clinically assessed neurological functioning in univariable and multivariable analyses (Table 2, 
Table 3) However, in the univariable comparisons, patients in the Late-PN group performed 
better than did those in the Early-PN group on parent/caregiver-reported inhibitory control, 
working memory, meta-cognition, and overall executive functioning, and on clinical tests for 
visual-motor integration, verbal-auditory recognition, and for one motor coordination task 
(synchronous tapping; Table 2). Adjusted for multiple comparisons, the better inhibitory 
control of patients in the Late-PN group than that of patients in the Early-PN group remained 
significant (p=0.0001). After multivariable adjustment for risk factors, parents/caregivers of 
patients in the Late-PN group reported better overall executive functioning than did 
parents/caregivers of patients in the Early-PN group (β estimate –2.258, 95% CI –4.012 to –
0.504; p=0.011), more specifically for inhibition (–3.422, –5.171 to –1.673; p=0.0001), working 
memory (–2.016, –3.761 to –0.270; p=0.023), and metacognition (–1.957, –3.694 to –0.220; 
p=0.027; Table 3; Figure 2). Furthermore, patients in the Late-PN group had fewer 
externalising behavioural problems (–1.715, 95% CI –3.325 to –0.106; p=0.036) as reported by 
parents/caregivers and scored better on visual-motor integration (0.468, 0.087 to 0.850; 
p=0.016) than did patients in the Early-PN group (Table 3; Appendix). 
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For overall executive functioning, inhibition, meta-cognition, and externalising problems as 
reported by parents/caregivers, patients in the Late-PN group were not different from healthy 
control children (p values of ≥0.12; Appendix). After further correction for multiple 
comparisons, the better inhibitory control of patients in the Late-PN group than of those in 
the Early-PN group remained significant (p=0.0001; Table 3). Sensitivity analyses for the 
missing-at-random assumption and with imputing worst test scores for the severely disabled 
and thus non-testable children, as presented in the appendix, further supported the 
robustness of these results.  
The effects of Late-PN versus Early-PN were more pronounced in the subgroup of 
patients who were infants at randomisation than in older children (interaction p values of 
≤0.03): β estimates for Late-PN versus Early-PN among infants for parent/caregiver-reported 
overall executive functioning (-3.843, 95% CI -6.361 to -1.325; p=0.0029), meta-cognition (-
3.749, -6.244 to -1.254; p=0.0034), and working memory (-3.594, -6.052 to -1.135; p=0.0043; 
Appendix).  
The impact of Late-PN versus Early-PN on long-term outcomes did not appear to be 
mediated by its acute effects on new PICU infections, duration of PICU stay, exposure to 
hypoglycaemia, or duration of potentially hazardous post-randomisation treatments during 
the PICU stay (Appendix). The use of benzodiazepines and of corticosteroids was 
independently associated with poorer outcomes, whereas treatment with α2 agonists was 
associated with better overall executive functioning and visual-motor integration (Appendix). 
 
DISCUSSION 
 
Two years after inclusion in the PEPaNIC multicentre, randomised, controlled trial, PICU 
survivors had worse developmental outcomes than did healthy control children. However, no 
adverse effect of withholding PN during the first week in the PICU could be detected for 
survival, anthropometrics health status, and neurocognitive development. In fact, omitting 
Early-PN in the PICU improved parent/caregiver-reported executive functioning 2 years later 
compared with Early-PN, in particular resulting in a better inhibitory control. Moreover, of the 
patients who survived, fewer were too disabled to be tested in the Late-PN group than in the 
Early-PN group.  
The long-term legacy of problems in executive functioning, as reported in this Article 
by parents or caregivers of patients admitted to the PICU, has been described previously, 
although mostly limited to the results of clinical neurocognitive testing.20,90 
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For overall executive functioning, inhibition, meta-cognition, and externalising problems as 
reported by parents/caregivers, patients in the Late-PN group were not different from healthy 
control children (p values of ≥0.12; Appendix). After further correction for multiple 
comparisons, the better inhibitory control of patients in the Late-PN group than of those in 
the Early-PN group remained significant (p=0.0001; Table 3). Sensitivity analyses for the 
missing-at-random assumption and with imputing worst test scores for the severely disabled 
and thus non-testable children, as presented in the appendix, further supported the 
robustness of these results.  
The effects of Late-PN versus Early-PN were more pronounced in the subgroup of 
patients who were infants at randomisation than in older children (interaction p values of 
≤0.03): β estimates for Late-PN versus Early-PN among infants for parent/caregiver-reported 
overall executive functioning (-3.843, 95% CI -6.361 to -1.325; p=0.0029), meta-cognition (-
3.749, -6.244 to -1.254; p=0.0034), and working memory (-3.594, -6.052 to -1.135; p=0.0043; 
Appendix).  
The impact of Late-PN versus Early-PN on long-term outcomes did not appear to be 
mediated by its acute effects on new PICU infections, duration of PICU stay, exposure to 
hypoglycaemia, or duration of potentially hazardous post-randomisation treatments during 
the PICU stay (Appendix). The use of benzodiazepines and of corticosteroids was 
independently associated with poorer outcomes, whereas treatment with α2 agonists was 
associated with better overall executive functioning and visual-motor integration (Appendix). 
 
DISCUSSION 
 
Two years after inclusion in the PEPaNIC multicentre, randomised, controlled trial, PICU 
survivors had worse developmental outcomes than did healthy control children. However, no 
adverse effect of withholding PN during the first week in the PICU could be detected for 
survival, anthropometrics health status, and neurocognitive development. In fact, omitting 
Early-PN in the PICU improved parent/caregiver-reported executive functioning 2 years later 
compared with Early-PN, in particular resulting in a better inhibitory control. Moreover, of the 
patients who survived, fewer were too disabled to be tested in the Late-PN group than in the 
Early-PN group.  
The long-term legacy of problems in executive functioning, as reported in this Article 
by parents or caregivers of patients admitted to the PICU, has been described previously, 
although mostly limited to the results of clinical neurocognitive testing.20,90 
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Executive dysfunction comprises problems in complex decision making and goal-oriented 
behaviour with implications for daily life183 and has been associated with externalising 
problems such as antisocial and aggressive behaviour.171,184 Indeed, poor inhibitory control in 
children is known to contribute to impulsive and destructive behaviours that upset or harm 
others.184 Hence, the possible beneficial effects of delaying PN in paediatric critical illness on 
the longer-term parent/caregiver-reported inhibitory function, further supported by better 
scores for other executive functions, externalising behaviour, and visual-motor integration 
(comparisons that lost significance after Bonferroni correction), are relevant. Indeed, the 
consequences for daily life and for the social environment are otherwise difficult to quantify 
by existing clinical neurocognitive tests.  
The most robust protection of executive functioning of delayed PN was observed for 
the ability to suppress immediate responses, as measured by the parent/caregiver-reported 
inhibition score; this finding suggests potential damage induced by Early-PN to frontal lobe 
areas that coordinate inhibition.185 The frontal lobe appears to be particularly vulnerable to 
metabolic insults during critical illness, with inflammation and neuronal damage described, 
which can be partially prevented by avoiding excessive hyperglycaemia.186 A previous 
randomised, controlled trial20 that documented the long-term neurocognitive impact of 
preventing hyperglycaemia in the PICU also found some improvement of executive 
functioning. We speculate that harm induced by Early-PN to executive functioning might also 
be a direct metabolic insult on the developing brains of young children, because it was not 
statistically explained by the acute effects of the intervention, such as increased incidence of 
new infections or delayed recovery, or by other potentially hazardous post-randomisation 
treatments given during the PICU stay, such as use of benzodiazepines. The larger benefit 
observed for critically ill infants than for older children provides support for this speculation. 
Whether other periods of age or development, such as puberty, also represent special 
vulnerability remains to be investigated. 
Unlike our current findings in patients admitted to the PICU early in life, studies in 
other paediatric settings and otherwise healthy children have shown that insufficient rather 
than abundant nutritional intake, both prenatally and during childhood, can result in impaired 
growth and neurocognitive development.84,187 These differing results could be explained by 
the context. Indeed, specifically in the context of critical illness, fasting-induced responses 
brought about during the first days after an insult might generate beneficial effects through 
(autophagy-induced) cell damage removal and prevention of neuronal loss.132,186 The early 
administration of amino acids, the most powerful suppressors of autophagy,132 rather than 
glucose or lipids was found to explain the short-term harm by Early-PN in critically ill 
children.70 However, the exact underlying mechanisms of any long-term effect of not 
forcefully feeding patients early during critical illness remain speculative. Among others, 
alterations in DNA methylation in promoters or bodies of genes involved in neuronal growth, 
axonal guidance, and signal transduction could play a part,188 since such epigenetic changes 
have been previously associated with executive dysfunction.183 Moreover, the potential 
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Executive dysfunction comprises problems in complex decision making and goal-oriented 
behaviour with implications for daily life183 and has been associated with externalising 
problems such as antisocial and aggressive behaviour.171,184 Indeed, poor inhibitory control in 
children is known to contribute to impulsive and destructive behaviours that upset or harm 
others.184 Hence, the possible beneficial effects of delaying PN in paediatric critical illness on 
the longer-term parent/caregiver-reported inhibitory function, further supported by better 
scores for other executive functions, externalising behaviour, and visual-motor integration 
(comparisons that lost significance after Bonferroni correction), are relevant. Indeed, the 
consequences for daily life and for the social environment are otherwise difficult to quantify 
by existing clinical neurocognitive tests.  
The most robust protection of executive functioning of delayed PN was observed for 
the ability to suppress immediate responses, as measured by the parent/caregiver-reported 
inhibition score; this finding suggests potential damage induced by Early-PN to frontal lobe 
areas that coordinate inhibition.185 The frontal lobe appears to be particularly vulnerable to 
metabolic insults during critical illness, with inflammation and neuronal damage described, 
which can be partially prevented by avoiding excessive hyperglycaemia.186 A previous 
randomised, controlled trial20 that documented the long-term neurocognitive impact of 
preventing hyperglycaemia in the PICU also found some improvement of executive 
functioning. We speculate that harm induced by Early-PN to executive functioning might also 
be a direct metabolic insult on the developing brains of young children, because it was not 
statistically explained by the acute effects of the intervention, such as increased incidence of 
new infections or delayed recovery, or by other potentially hazardous post-randomisation 
treatments given during the PICU stay, such as use of benzodiazepines. The larger benefit 
observed for critically ill infants than for older children provides support for this speculation. 
Whether other periods of age or development, such as puberty, also represent special 
vulnerability remains to be investigated. 
Unlike our current findings in patients admitted to the PICU early in life, studies in 
other paediatric settings and otherwise healthy children have shown that insufficient rather 
than abundant nutritional intake, both prenatally and during childhood, can result in impaired 
growth and neurocognitive development.84,187 These differing results could be explained by 
the context. Indeed, specifically in the context of critical illness, fasting-induced responses 
brought about during the first days after an insult might generate beneficial effects through 
(autophagy-induced) cell damage removal and prevention of neuronal loss.132,186 The early 
administration of amino acids, the most powerful suppressors of autophagy,132 rather than 
glucose or lipids was found to explain the short-term harm by Early-PN in critically ill 
children.70 However, the exact underlying mechanisms of any long-term effect of not 
forcefully feeding patients early during critical illness remain speculative. Among others, 
alterations in DNA methylation in promoters or bodies of genes involved in neuronal growth, 
axonal guidance, and signal transduction could play a part,188 since such epigenetic changes 
have been previously associated with executive dysfunction.183 Moreover, the potential 
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involvement of telomere shortening, which has been shown to be accelerated by early 
initiation of PN during paediatric critical illness, should be further investigated.126 
This study has limitations. First, the young age of PEPaNIC patients precluded complete 
and reliable results for certain neurocognitive tests. For these tests, the statistical power and 
thus the odds of identifying a difference between treatment groups was reduced. Second, 
neuroimaging studies were not done. Third, information on physiotherapy in the PICU and on 
the regular ward (i.e., after PICU but before hospital discharge) was not recorded. Fourth, data 
on follow-up consultations and therapies beyond the study protocol were not systematically 
available for all centres and all diagnostic subgroups. Fifth, after conservative Bonferroni 
correction, only the impact of withholding PN early in the PICU on long-term inhibitory control 
remained significant. However, given that inhibition is an important cognitive function 
involved in many aspects of daily life, and given the absence of any harm, this finding is 
relevant for endorsing implementation of withholding early PN in the PICU. 
 
CONCLUSIONS 
 
Patients admitted to the PICU early in life had worse outcomes at the 2-year follow-up for 
anthropometrics, health status, and neurocognitive development than did healthy control 
children. Withholding early PN for 1 week in the PICU did not negatively affect survival, 
anthropometrics, health status and neurocognitive development, and improved inhibitory 
control 2 years later. 
  
 
 
 
APPENDIX 
 
Methods S1: Definition of educational and occupational level of parents 
 
Educational level of parents 
The education level is the average of the paternal and maternal educational level, and 
calculated based upon the 3-point scale subdivisions as made by the Algemene Directie 
Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal Bureau voor de Statistiek (The 
Netherlands; statline.cbs.nl): low (=1), middle (=2) and high (=3) educational level. 
 
Occupational level of parents 
The occupation level is the average of the paternal and maternal occupation level, which is 
calculated based upon the International Isco System 4-point scale for professions 
(http://www.ilo.org/public/english/bureau/stat/isco/). In case one of the parents filled in two 
jobs in the questionnaire, the highest Isco code level was used. In case “unemployed”, 
“disabled”, “student”, or “housewife/houseman” was filled in, an Isco code level of 1 was 
given to that parent. When the parents described their profession as “employee”, “worker”, 
“liberal profession”, or “retired”, they were given an Isco code level of 2. 
 
Methods S2: Definition of “Syndrome” 
A prerandomisation syndrome or illness a priori defined as affecting or possibly affecting 
neurocognitive development, and which is subdivided in the following categories: 
• Genetically confirmed syndrome or pathogenic chromosomal abnormality 
• Clearly defined syndrome, association or malformation without (identified) genetic 
aberration 
• Polymalformative syndrome of unknown aetiology 
• Clear auditory or visual impairment without specified syndrome 
• Congenital hypothyroidism due to thyroid agenesis 
• Brain tumour or tumour with intracranial metastatic disease 
• Paedopsychiatric disorder (e.g. autism spectrum disorder, (treatment for) attention 
deficit hyperactivity disorder) 
• Severe medical disorder, not primarily neurologic, but suspected to alter psychomotor 
and/or mental performance 
• Severe neonatal problem (e.g. severe asphyxia) 
• Severe craniocerebral trauma or near-drowning 
• Severe infectious encephalitis or drug-induced encephalopathy 
• Infectious meningitis, encephalitis or Guillain-Barré 
• Resuscitation and/or need for extracorporeal membrane oxygenation prior to 
randomisation 
• Severe convulsions or stroke prior to randomisation 
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involvement of telomere shortening, which has been shown to be accelerated by early 
initiation of PN during paediatric critical illness, should be further investigated.126 
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and reliable results for certain neurocognitive tests. For these tests, the statistical power and 
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relevant for endorsing implementation of withholding early PN in the PICU. 
 
CONCLUSIONS 
 
Patients admitted to the PICU early in life had worse outcomes at the 2-year follow-up for 
anthropometrics, health status, and neurocognitive development than did healthy control 
children. Withholding early PN for 1 week in the PICU did not negatively affect survival, 
anthropometrics, health status and neurocognitive development, and improved inhibitory 
control 2 years later. 
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jobs in the questionnaire, the highest Isco code level was used. In case “unemployed”, 
“disabled”, “student”, or “housewife/houseman” was filled in, an Isco code level of 1 was 
given to that parent. When the parents described their profession as “employee”, “worker”, 
“liberal profession”, or “retired”, they were given an Isco code level of 2. 
 
Methods S2: Definition of “Syndrome” 
A prerandomisation syndrome or illness a priori defined as affecting or possibly affecting 
neurocognitive development, and which is subdivided in the following categories: 
• Genetically confirmed syndrome or pathogenic chromosomal abnormality 
• Clearly defined syndrome, association or malformation without (identified) genetic 
aberration 
• Polymalformative syndrome of unknown aetiology 
• Clear auditory or visual impairment without specified syndrome 
• Congenital hypothyroidism due to thyroid agenesis 
• Brain tumour or tumour with intracranial metastatic disease 
• Paedopsychiatric disorder (e.g. autism spectrum disorder, (treatment for) attention 
deficit hyperactivity disorder) 
• Severe medical disorder, not primarily neurologic, but suspected to alter psychomotor 
and/or mental performance 
• Severe neonatal problem (e.g. severe asphyxia) 
• Severe craniocerebral trauma or near-drowning 
• Severe infectious encephalitis or drug-induced encephalopathy 
• Infectious meningitis, encephalitis or Guillain-Barré 
• Resuscitation and/or need for extracorporeal membrane oxygenation prior to 
randomisation 
• Severe convulsions or stroke prior to randomisation 
150 
CHAPTER 6
 
 
 
Methods S3: Detailed description of outcome measures 
 
Medical assessment 
Anthropometric data 
Height (in cm), body weight (in kg) and head circumference (in cm) were measured.  
 
Health status  
In an interview with the parents, the need for medical support of all kind during the past two 
years for healthy control children and during the 2 years following the index PICU admission 
for patients, was recorded. The hospital admissions because of surgery or a medical reason, 
and the occurrence of a psychiatric diagnosis were documented.  
 
Clinical neurological examination 
In order to assess whether there were gross neurological abnormalities, during a structured 
clinical neurological examination, signs of major neurologic dysfunction were detected in the 
following domains: interaction/language skills, gross motor function, involuntary movements, 
reflexes, coordination and balance, fine motor function, cranial nerves, and special senses 
(sensory, visual, and auditory function). These were all scored normal or abnormal. An 
abnormal result for each of these domains was given 1 point and the sum was made of all the 
abnormal results, with a range of 0-8. 
 
Neurocognitive testing 
A broad range of neurocognitive functions, including general intellectual functioning, visual-
motor integration, attention, motor coordination, inhibitory control and cognitive flexibility, 
verbal and visual-spatial learning, and memory were evaluated, as previously reported.20 
 
Patient/Parents-reported outcomes (PROs) 
Executive functioning was measured with the Behaviour Rating Inventory of Executive 
Function (BRIEF-P 2.5-5 years, BRIEF 6-18 years), filled out by the parents or caregivers of the 
child. Overlapping scales and indices of both questionnaires (Inhibition, Flexibility, Emotional 
Control, Working Memory, Planning and Organisation, Meta-cognition) and a Total Score were 
analysed (T-scores, with mean 50 and SD 10).171,172 Emotional and behavioural problems were 
assessed by the parent or caregiver with the Child Behaviour Checklist (CBCL 1.5-5 years or 
CBCL 6-18 years).173,174 Internalising, externalising, and total problems were analysed (T-
scores, with mean 50 and SD 10).173,174 
 
Intelligence 
General intellectual ability was assessed with use of age-appropriate versions of the Wechsler 
Intelligence Quotient (IQ) tests. The Wechsler Preschool and Primary Scale of Intelligence 
(WPPSI-III-NL)175 was used for children aged 2.5 years to 5 years 11 months (one version for 
age range 2 years 6 months to 3 years 11 months, and another version for age range 4 years 
 
 
 
to 5 years 11 months), the Wechsler Intelligence Scale for Children (WISC-III-NL)176 was used 
for children aged 6 years to 16 years 11 months, and the Wechsler Adult Intelligence Scale 
(WAIS-IV-NL)177 for adolescents who were 17 years or older. For all these tests Total IQ, Verbal 
IQ, and Performal IQ scores (Test-mean 100, SD 15) were computed. 
 
Visual-motor integration 
We used the Beery Developmental Test of Visual-Motor Integration, 6th Edition (VMI) to 
assess the ability to integrate their visual and motor functions (total Scaled Score, Test-mean 
10, SD 3). This involves eye-hand coordination.178 
 
Alertness, motor-coordination, and executive functions 
To measure alertness, motor-coordination and executive function, the validated Amsterdam 
Neuropsychological Tasks (ANT) program was used.179 The ANT is a computer-aided 
assessment battery of reaction time (RT) tasks that allows for the systematic evaluation of 
information processing capacities.  
Children 4 years and older performed ANT-Baseline Speed (BS), ANT-Tapping (TP), and 
Response Organisation Objects (ROO). The ANT-BS evaluated alertness by measuring simple 
RT to visual stimuli (mean RT and SD of RT were obtained for the right and left hand 
separately). The ANT-TP assessed motor coordination for the right hand, left hand, bimanual 
alternating, and bimanual synchronous. The ANT-ROO measured inhibitory control and 
cognitive flexibility by calculating the differences in RT and the differences in number of errors 
between tests of increasing demand. 
 
Memory 
Auditory/verbal memory and Visual-spatial/non-verbal memory were assessed with use of 
four tests from the Children’s Memory Scale (CMS) for children between 5 and 16 years 11 
months. 180 As to verbal memory, CMS-Numbers assessed short-term verbal memory span 
(forward digit recall) and verbal working memory load (backward digit recall). The CMS-Word 
Pairs (recall a list of word pairs) assessed short-term and long-term verbal memory, and 
recognition. As to non-verbal memory, CMS-Picture Locations (remembering and recall of 
pictures in various locations) assessed immediate visual memory. CMS-Dot Locations 
(remembering and recall of the location of dots) assessed immediate and delayed visual 
memory. For CMS-Numbers, raw scores for verbal memory span, CMS-numbers forward, and 
verbal working memory load, CMS-numbers backward were reported. For CMS-Word Pairs, 
CMS-Picture Locations, and CMS-Dot Locations, proportional scores were analysed 
(proportion of correct responses ranging from 0 to 1, with higher scores reflecting better 
performance). The CMS-Learning index is a standardised score of the sum of the three learning 
trials of the CMS-Word Pairs and the learning trial of the CMS-Dot Locations subtests. The 
range of the score is 50-150, with a higher score representing a better learning ability. 
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Methods S3: Detailed description of outcome measures 
 
Medical assessment 
Anthropometric data 
Height (in cm), body weight (in kg) and head circumference (in cm) were measured.  
 
Health status  
In an interview with the parents, the need for medical support of all kind during the past two 
years for healthy control children and during the 2 years following the index PICU admission 
for patients, was recorded. The hospital admissions because of surgery or a medical reason, 
and the occurrence of a psychiatric diagnosis were documented.  
 
Clinical neurological examination 
In order to assess whether there were gross neurological abnormalities, during a structured 
clinical neurological examination, signs of major neurologic dysfunction were detected in the 
following domains: interaction/language skills, gross motor function, involuntary movements, 
reflexes, coordination and balance, fine motor function, cranial nerves, and special senses 
(sensory, visual, and auditory function). These were all scored normal or abnormal. An 
abnormal result for each of these domains was given 1 point and the sum was made of all the 
abnormal results, with a range of 0-8. 
 
Neurocognitive testing 
A broad range of neurocognitive functions, including general intellectual functioning, visual-
motor integration, attention, motor coordination, inhibitory control and cognitive flexibility, 
verbal and visual-spatial learning, and memory were evaluated, as previously reported.20 
 
Patient/Parents-reported outcomes (PROs) 
Executive functioning was measured with the Behaviour Rating Inventory of Executive 
Function (BRIEF-P 2.5-5 years, BRIEF 6-18 years), filled out by the parents or caregivers of the 
child. Overlapping scales and indices of both questionnaires (Inhibition, Flexibility, Emotional 
Control, Working Memory, Planning and Organisation, Meta-cognition) and a Total Score were 
analysed (T-scores, with mean 50 and SD 10).171,172 Emotional and behavioural problems were 
assessed by the parent or caregiver with the Child Behaviour Checklist (CBCL 1.5-5 years or 
CBCL 6-18 years).173,174 Internalising, externalising, and total problems were analysed (T-
scores, with mean 50 and SD 10).173,174 
 
Intelligence 
General intellectual ability was assessed with use of age-appropriate versions of the Wechsler 
Intelligence Quotient (IQ) tests. The Wechsler Preschool and Primary Scale of Intelligence 
(WPPSI-III-NL)175 was used for children aged 2.5 years to 5 years 11 months (one version for 
age range 2 years 6 months to 3 years 11 months, and another version for age range 4 years 
 
 
 
to 5 years 11 months), the Wechsler Intelligence Scale for Children (WISC-III-NL)176 was used 
for children aged 6 years to 16 years 11 months, and the Wechsler Adult Intelligence Scale 
(WAIS-IV-NL)177 for adolescents who were 17 years or older. For all these tests Total IQ, Verbal 
IQ, and Performal IQ scores (Test-mean 100, SD 15) were computed. 
 
Visual-motor integration 
We used the Beery Developmental Test of Visual-Motor Integration, 6th Edition (VMI) to 
assess the ability to integrate their visual and motor functions (total Scaled Score, Test-mean 
10, SD 3). This involves eye-hand coordination.178 
 
Alertness, motor-coordination, and executive functions 
To measure alertness, motor-coordination and executive function, the validated Amsterdam 
Neuropsychological Tasks (ANT) program was used.179 The ANT is a computer-aided 
assessment battery of reaction time (RT) tasks that allows for the systematic evaluation of 
information processing capacities.  
Children 4 years and older performed ANT-Baseline Speed (BS), ANT-Tapping (TP), and 
Response Organisation Objects (ROO). The ANT-BS evaluated alertness by measuring simple 
RT to visual stimuli (mean RT and SD of RT were obtained for the right and left hand 
separately). The ANT-TP assessed motor coordination for the right hand, left hand, bimanual 
alternating, and bimanual synchronous. The ANT-ROO measured inhibitory control and 
cognitive flexibility by calculating the differences in RT and the differences in number of errors 
between tests of increasing demand. 
 
Memory 
Auditory/verbal memory and Visual-spatial/non-verbal memory were assessed with use of 
four tests from the Children’s Memory Scale (CMS) for children between 5 and 16 years 11 
months. 180 As to verbal memory, CMS-Numbers assessed short-term verbal memory span 
(forward digit recall) and verbal working memory load (backward digit recall). The CMS-Word 
Pairs (recall a list of word pairs) assessed short-term and long-term verbal memory, and 
recognition. As to non-verbal memory, CMS-Picture Locations (remembering and recall of 
pictures in various locations) assessed immediate visual memory. CMS-Dot Locations 
(remembering and recall of the location of dots) assessed immediate and delayed visual 
memory. For CMS-Numbers, raw scores for verbal memory span, CMS-numbers forward, and 
verbal working memory load, CMS-numbers backward were reported. For CMS-Word Pairs, 
CMS-Picture Locations, and CMS-Dot Locations, proportional scores were analysed 
(proportion of correct responses ranging from 0 to 1, with higher scores reflecting better 
performance). The CMS-Learning index is a standardised score of the sum of the three learning 
trials of the CMS-Word Pairs and the learning trial of the CMS-Dot Locations subtests. The 
range of the score is 50-150, with a higher score representing a better learning ability. 
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Methods S4: Imputation 
 
Missing data (excluding the deceased and the severely disabled whereby non-testable 
children) were handled by multiple data imputation with chained equations under a ‘missing 
at random’ assumption. There were no missing data in the baseline variables. Predictors for 
missing values included all covariates listed below, and were retained in the predictor models 
with a minimum correlation of 0.1 with the prediction target. Predictive mean matching189 
was used for numeric variables except for factors with two levels (which were imputed based 
on logistic regression) and factors with more than two levels (for which polytomous 
(unordered) regression was used). A monotonous visiting scheme was used such that variables 
for imputation were visited in increasing order of the number of missing data. Imputation 
convergence was assessed visually and set at 70 iterations (Figure S1). Since there were no 
more than 30% missing observations for all variables, 31 complete imputed datasets were 
used in the analyses,181 and pooled results were obtained across datasets using Rubin’s 
rules.190 
Plausibility of the imputations was assessed visually via the densities of the observed 
data and that resulting from the imputed values (Figure S2). Sensitivity of results to the 
‘missing at random’ assumption was assessed with use of pattern mixture models 190-192 
assuming the original imputed values were either too high or too low by a factor of 0.1 for the 
main result of inhibition as reported by parents. Under this assumption, the obtained beta-
estimates and P-values for randomisation to Late-PN vs. Early-PN for the multivariable linear 
regression analyses performed to determine significant and independent associations 
between risk factors and inhibition as reported by the parents at 2 years’ follow-up within the 
tested patient population (Table S1-1) ranged from -2.962 (p<0.0001) to -2.396 (p=0.032). The 
effect-sizes thus remained of the same order of magnitude, sign, and statistical significance as 
were observed for the original imputed datasets, which suggested that the analyses were 
robust against the investigated ‘missing at random’ violation.  
To further evaluate the robustness of the main findings, the analyses were repeated 
after imputing a penalised test result for all severely disabled and thus non-testable patients, 
defined as the worst result in the observed patients or controls, plus or minus one, as 
appropriate for each test. In this case, the obtained beta-estimates (p-values) for 
randomisation to Late-PN vs. Early-PN for the multivariable linear regression analyses were 
respectively: A) -3.382 (p<0.0001) for inhibition as reported by parents; B) -1.928 (p=0.031) 
for meta-cognition as reported by parents; C) -1.992 (P=0.026) for working memory as 
reported by parents; D) -2.224 (p=0.014) for overall executive functioning as reported by 
parents; E) -1.668 (p=0.045) for externalising emotional and behavioural problems as reported 
by parents; and F) 0.464 (p=0.017) for visual-motor integration. These sensitivity analyses 
corresponded closely to the primary results as reported in Table 2 of the main manuscript. 
All multiple data imputation analyses were performed with R version 3.4.3 and MICE 
version 2.46.0.  
 
 
 
 
List of variables used for multiple data imputation by chained equations  
Demographics of patients and control children and patient characteristics upon PICU 
admission 
Centre, randomisation for Late-PN or Early-PN, patient vs. controls, race, gender, geographic 
origin, language, hand preference, history of malignancy, history of diabetes, a predefined 
“syndrome”, educational and occupational status of parents, diagnosis, PIM3 and PeLOD 
scores upon PICU admission, risk of malnutrition (STRONGkids category), parental smoking 
behaviour prior to PICU admission, age at randomisation, age group at randomisation. 
 
Acute effects of randomisation and post-randomisation treatments in PICU 
Acquisition of new PICU infections, duration of PICU stay, duration of mechanical ventilatory 
support, hypoglycaemia, duration of treatment with haemodynamic support, antibiotics, 
corticosteroids, opioids, benzodiazepines, hypnotics and α2-agonists. 
 
At 2-years’ follow-up 
Age, test location, height, weight, head circumference, composite endpoint “diagnosed with 
a somatic illness”, composite endpoint “diagnosed with a psychiatric illness”, composite 
endpoint “admitted to hospital for a medical or surgical reason”, clinical neurological 
examination, verbal IQ, performal IQ, total IQ, visual motor integration, reaction time left 
hand, reaction time right hand, within subject SD of reaction time left hand, within subject SD 
of reaction time left hand, number of unimanual taps right hand, number of unimanual taps 
left  hand, number of valid alternating taps, number of valid synchronous taps, delta reaction 
time inhibition, delta number of errors inhibition, delta reaction time flexibility, delta number 
of errors flexibility, numbers memory span forward, numbers working memory backward, 
word pairs learning, word pairs immediate memory, word pairs delayed memory, word pairs 
recognition, pictures, dots learning, dots immediate memory, dots delayed memory, learning 
index, executive functioning as reported by parents/caregivers (inhibition, flexibility, 
emotional control, working memory, planning and organisation, meta-cognition index, and 
total score), emotional and behavioural problems as reported by parents/caregivers 
(internalising problems, externalising problems, and total problems).  
Interactions between age group and randomization were not included in the 
imputation models. 
 
  
	 153
	LONG-TERM	DEVELOPMENTAL	EFFECTS	OF	LATE	VS	EARLY	PN	IN	PICU
6
 
 
 
Methods S4: Imputation 
 
Missing data (excluding the deceased and the severely disabled whereby non-testable 
children) were handled by multiple data imputation with chained equations under a ‘missing 
at random’ assumption. There were no missing data in the baseline variables. Predictors for 
missing values included all covariates listed below, and were retained in the predictor models 
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for meta-cognition as reported by parents; C) -1.992 (P=0.026) for working memory as 
reported by parents; D) -2.224 (p=0.014) for overall executive functioning as reported by 
parents; E) -1.668 (p=0.045) for externalising emotional and behavioural problems as reported 
by parents; and F) 0.464 (p=0.017) for visual-motor integration. These sensitivity analyses 
corresponded closely to the primary results as reported in Table 2 of the main manuscript. 
All multiple data imputation analyses were performed with R version 3.4.3 and MICE 
version 2.46.0.  
 
 
 
 
List of variables used for multiple data imputation by chained equations  
Demographics of patients and control children and patient characteristics upon PICU 
admission 
Centre, randomisation for Late-PN or Early-PN, patient vs. controls, race, gender, geographic 
origin, language, hand preference, history of malignancy, history of diabetes, a predefined 
“syndrome”, educational and occupational status of parents, diagnosis, PIM3 and PeLOD 
scores upon PICU admission, risk of malnutrition (STRONGkids category), parental smoking 
behaviour prior to PICU admission, age at randomisation, age group at randomisation. 
 
Acute effects of randomisation and post-randomisation treatments in PICU 
Acquisition of new PICU infections, duration of PICU stay, duration of mechanical ventilatory 
support, hypoglycaemia, duration of treatment with haemodynamic support, antibiotics, 
corticosteroids, opioids, benzodiazepines, hypnotics and α2-agonists. 
 
At 2-years’ follow-up 
Age, test location, height, weight, head circumference, composite endpoint “diagnosed with 
a somatic illness”, composite endpoint “diagnosed with a psychiatric illness”, composite 
endpoint “admitted to hospital for a medical or surgical reason”, clinical neurological 
examination, verbal IQ, performal IQ, total IQ, visual motor integration, reaction time left 
hand, reaction time right hand, within subject SD of reaction time left hand, within subject SD 
of reaction time left hand, number of unimanual taps right hand, number of unimanual taps 
left  hand, number of valid alternating taps, number of valid synchronous taps, delta reaction 
time inhibition, delta number of errors inhibition, delta reaction time flexibility, delta number 
of errors flexibility, numbers memory span forward, numbers working memory backward, 
word pairs learning, word pairs immediate memory, word pairs delayed memory, word pairs 
recognition, pictures, dots learning, dots immediate memory, dots delayed memory, learning 
index, executive functioning as reported by parents/caregivers (inhibition, flexibility, 
emotional control, working memory, planning and organisation, meta-cognition index, and 
total score), emotional and behavioural problems as reported by parents/caregivers 
(internalising problems, externalising problems, and total problems).  
Interactions between age group and randomization were not included in the 
imputation models. 
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Figure S1: Macronutrient doses during the first week in PICU administered to the tested 
population 
 
 
 
Daily amount of total energy in kcal/kg/day, and the daily amounts of total substrates in g/kg/day are shown 
for the first 7 days in the paediatric intensive care unit (PICU). Bars represent the mean and the whiskers 
represent the standard error of the mean (SEM). The red bars represent the Early-PN group and the green bars 
represent the Late-PN group.
 
 
 
Figure S2: Imputation convergence for selected neurocognitive test results 
Mean and standard deviation of imputed values in each of 31 datasets over 70 iterations for  
A) Executive functioning as reported by parents/caregivers - T-score: Inhibition;  
B) Meta-cognition index;  
C) Working memory;  
D) Total score;  
E) Emotional and behavioural problems as reported by parents/caregivers - T-score: Externalising problems;  
F) Visual-motor integration. 
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Figure S3: Density estimates of the observed and imputed values for selected neurocognitive 
test results 
Density estimated for observed values (in blue) and for each imputed dataset (in orange) for  
A) Executive functioning as reported by parents/caregivers - T-score: Inhibition;  
B) Meta-cognition index;  
C) Working memory;  
D) Total score;  
E) Emotional and behavioural problems as reported by parents - T-score: Externalising problems;  
F) Visual-motor integration. 
 
 
 
Figure S4: Multiple imputation predictor variables 
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Figure S4: Multiple imputation predictor variables 
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Table S1: Multivariable linear regression analyses determining significant and independent 
associations between risk factors and long-term test results within the tested patient 
population  
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Table S1: Multivariable linear regression analyses determining significant and independent 
associations between risk factors and long-term test results within the tested patient 
population  
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Table S2: Comparison of patients randomised to late parenteral nutrition during PICU stay 
with healthy control children for the tests significantly affected by the randomised 
intervention 
 
Neurocognitive function P-value 
Visual-motor integration 0.00052 
Externalising problems as reported by parents/caregivers 0.34 
Inhibition as reported by parents/caregivers 0.66 
Working memory as reported by parents/caregivers 0.032 
Meta-cognition index as reported by parents/caregivers 0.34 
Overall executive functioning as reported by parents/caregivers 0.12 
 
 
 
 
 
Table S3: Impact of late versus early parenteral nutrition in infants for tests showing a 
significant interaction P-value with age group 
 
Variable Beta-estimate Confidence interval P-value 
Overall executive functioning -3.843 -6.361 -1.325 0.0029 
Meta-cognition -3.749 -6.244 -1.254 0.0034 
Working memory -3.594 -6.052 -1.135 0.0043 
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ABSTRACT  
 
Background 
The multicentre randomised controlled PEPaNIC trial showed that withholding parenteral 
nutrition (PN) during the first week of critical illness in children was clinically superior to 
providing PN early. This study describes the cost-effectiveness of this new nutritional strategy. 
 
Methods 
Direct medical costs were calculated with use of a micro-costing approach. We compared the 
costs of late versus early initiation of PN (n=673 versus n=670) in the Belgian and Dutch study 
populations from a hospital perspective, with use of student’s t test with bootstrapping. Main 
cost drivers were identified and the impact of new infections on the total costs was assessed. 
 
Results 
Mean direct medical costs for patients receiving Late-PN (€26.680, IQR €10.090-€28.830 per 
patient) were 21% lower (€-7.180, p=0.007) than for patients receiving Early-PN (€33.860, IQR 
€11.080-€34.720). Since late PN was more effective and less costly, this strategy was superior 
to early PN. The lower costs for PN only contributed for 2.1% to the total cost reduction. The 
main cost driver was intensive care hospitalisation costs (€-4.120, p=0.003). The patients who 
acquired a new infection (14%) were responsible for 41% of the total costs. Sensitivity analyses 
confirmed consistency across both healthcare systems. 
 
Conclusions 
Late initiation of PN decreased the direct medical costs for hospitalisation in critically ill 
children, beyond the expected lower costs for withholding PN. Avoiding new infections by late 
initiation of PN yielded a large cost reduction. Hence, late initiation of PN was superior to early 
initiation of PN largely via its effect on new infections. 
 
 
 
BACKGROUND 
 
Healthcare costs are growing worldwide. Intensive care is responsible for a substantial 
proportion of all healthcare expenses, particularly prolonged intensive care and palliative 
care.98,193-195 Intensive care costs are largely dependent on length of stay (LOS) in the 
paediatric intensive care unit (PICU), which is strongly influenced by complications, such as 
hospital-acquired infections.196 
Recently, a multicentre, randomised, controlled, parallel-group, superiority trial, with 
the acronym PEPaNIC (n=1440) concluded that withholding parenteral nutrition (PN) during 
the first week of critical illness in children was clinically superior to providing PN within 24 
hours when enteral nutrition was insufficient,18 resulting in fewer patients with new 
infections. Aside from this clinical benefit, an additional economic benefit of late initiation of 
PN would be an extra argument for implementation of this new nutritional strategy.  
Currently, no studies have investigated costs of different timing of initiation of PN in 
children in the paediatric intensive care unit (PICU). Our cost-effectiveness analysis was 
predesigned, offering a unique opportunity for a micro-costing approach.197 With this method 
of calculating hospital costs, all relevant cost categories are included and costs are calculated 
at the most detailed level per patient, in contrast to the gross-costing approach, whereby the 
cost categories are highly aggregated or only hospitalisation costs are included. 
We hypothesised that withholding PN for one week is a cost saving strategy comprising 
more than merely omitting the costs of PN itself. The aims of this study were: 1) to compare 
total direct medical costs of early versus late initiation of PN in the PICU from a hospital 
perspective in an international context; 2) to provide a detailed insight into the distribution of 
cost components; and 3) to assess the impact of acquiring a new infection in the PICU on direct 
medical costs. 
 
METHODS 
 
Context  
A total of 1440 critically ill children, aged 0 (term neonates) to 17 years, from three large 
tertiary referral PICUs in three countries (University Hospitals Leuven in Belgium, Erasmus MC-
Sophia Children’s Hospital in The Netherlands, and Stollery Children’s Hospital in Canada) 
were randomly assigned to early initiation of PN (standard care) or late initiation of PN 
(intervention). Initiation and dose of enteral nutrition (EN) and the administration of trace 
elements, minerals and vitamins were identical in both groups. Patients assigned to the group 
with Late-PN (n=717) received no PN during the first week of critical illness. Patients assigned 
to the group with Early-PN (n=723) received PN within 24 hours, according to the local 
standards. After the first week, when patients were still in the PICU and EN was insufficient to 
meet nutritional goals, PN was administered equally in both groups according to standard 
nutrition protocols.18,129 The institutional ethical review boards of the participating centres in 
Leuven (ML8052), Rotterdam (NL38772.000.12) and Edmonton (Pro00038098) approved the 
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study, which was performed in accordance with the 1964 Declaration of Helsinki and its 
amendments. Written informed consent was obtained from the parents or legal guardians. 
In this study, we explored the total direct medical costs, from a hospital perspective, 
in the Belgian and Dutch study populations, as these healthcare systems are reasonably 
comparable. Including the patients from Canada would introduce a bias, as cost calculations 
and reimbursements are too differently structured in Anglo-Saxon healthcare systems. 
Therefore, we excluded this centre from the cost analyses. 
 
Healthcare systems 
In the Dutch healthcare system, hospitals are mainly paid by private insurance companies 
according to tariffs based on “Diagnosis Therapy Combination” (DBC).198 However, registered 
DBCs per patient do not represent individualised healthcare consumption. As the tariffs are 
fixed, specific healthcare activities are not presented in the patients’ invoices. Therefore, we 
used individual healthcare consumption and corresponding unit prices, which are registered 
by the hospital for reporting and stock management. 
In Belgium, healthcare costs are reimbursed by sickness funds and private insurance 
companies. Since all healthcare activities are represented in the patients’ invoices, these 
invoices can be used to accurately quantify healthcare consumption. However, total 
healthcare costs are mainly covered by advance payments to the hospital, directly by the 
government. Consequently, for healthcare activities for which the hospital receives these in 
advance payments, only 25% of the costs are represented in the patients’ invoices. When this 
is corrected to 100%, they reflect real healthcare costs from a hospital perspective.199  
 
Resource consumption 
The participating clinicians filled out standardised case report forms during PICU stay, 
including duration of PICU dependency, post-PICU hospitalisation, mechanical ventilation, 
renal replacement therapy (RRT) and mechanical hemodynamic support. LOS encompassed 
both index and transferral hospitals. PN consumption was obtained from the study database 
for Dutch patients and from the invoices for Belgian patients. Detailed information on 
diagnostic procedures, medication, blood products, surgery and consultations were obtained 
from the data management system of the hospital for Dutch patients and from the invoices 
for Belgian patients. 
Healthcare consumption was divided into ten cost categories: 1) PICU hospitalisation 
(both index and transferral hospital); 2) post-PICU hospitalisation (both index and transferral 
hospital); 3) PN; 4) medication; 5) laboratory diagnostics; 6) other diagnostics; 7) ventilator 
support; 8) RRT and mechanical haemodynamic support; 9) surgery; and 10) consultations 
from other specialists.  
 
Economic evaluation 
The cost-effectiveness analyses were based on the Dutch and Belgian guidelines for 
performing costs studies.199,200 Furthermore, this study is in line with the international 
 
 
 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.201 Real 
medical costs were calculated by multiplying the volumes of healthcare use with the 
corresponding unit prices. Costs were calculated during two periods. From randomisation 
until ready-for-discharge from PICU, or death, the costs in all aforementioned cost categories 
were calculated. Ready-for-discharge was a priori chosen to avoid bias due to availability of 
beds on regular wards and was defined as “no longer requiring or no longer at risk for requiring 
vital organ support”. From ready-for-discharge from PICU until discharge from hospital, only 
hospitalisation costs were calculated. If a patient was transferred to another hospital, only 
hospitalisation costs were included for the period from discharge from the index hospital until 
discharge from the transferral hospital or death. Since the time horizon was less than one 
year, unit prices were not discounted.  
In the Netherlands, the unit prices were available from the hospital’s financial 
database, and were adjusted to the year 2014. For hospital days (non-PICU), a national guiding 
price per day was used, because children were referred to different hospitals, charging 
different prices.200 The daily costs of mechanical ventilation and RRT were estimated based on 
published literature.202,203 Production costs of infusions for the intervention group were 
calculated by summing the costs of the PN ingredients, pharmacy compounding costs, and 
additional trial intervention costs. 
In Belgium, financial data were registered by the billing and warehousing collaborators 
of the index hospital as this is standard procedure for invoicing. The unit prices were official, 
nationally fixed prices adjusted to the year 2014, and were converted to 100%, if necessary, 
to obtain real costs from a hospital perspective.199 There were no additional trial intervention 
costs for infusions in the group receiving late initiation of PN. 
Costs of medication were categorised according to the first level of the Anatomical 
Therapeutic Chemical (ATC) classification, which is the World Health Organisation (WHO) tool 
for drug utilisation research.204 Each drug has its unique ATC code and price. Costs for ATC 
code B05BA (PN solutions) were reported separately. Since we were unable to distinguish 
costs per ATC code in Dutch patients, we excluded them from this ATC code analysis. However, 
since new infections were a primary outcome in the trial, we analysed the costs of anti-
infective drugs in both centres. 
 
Study endpoints 
The primary endpoint was the difference in total direct medical costs, from a hospital 
perspective, between early and late initiation of PN. Furthermore, the ten cost categories 
were analysed separately. In order to give insight into costs among different groups of 
patients, we compared total direct medical costs of Early-PN with Late-PN in the stratification 
groups as used for the PEPaNIC trial: “Surgical cardiac”, “Surgical other”, “Medical 
neurological” and “Medical other”, and age groups younger and older than one year 129. 
Additionally, the drugs responsible for differences in medication costs were investigated 
based on the ATC codes. Also, the impact of new infections on total costs was calculated. 
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vital organ support”. From ready-for-discharge from PICU until discharge from hospital, only 
hospitalisation costs were calculated. If a patient was transferred to another hospital, only 
hospitalisation costs were included for the period from discharge from the index hospital until 
discharge from the transferral hospital or death. Since the time horizon was less than one 
year, unit prices were not discounted.  
In the Netherlands, the unit prices were available from the hospital’s financial 
database, and were adjusted to the year 2014. For hospital days (non-PICU), a national guiding 
price per day was used, because children were referred to different hospitals, charging 
different prices.200 The daily costs of mechanical ventilation and RRT were estimated based on 
published literature.202,203 Production costs of infusions for the intervention group were 
calculated by summing the costs of the PN ingredients, pharmacy compounding costs, and 
additional trial intervention costs. 
In Belgium, financial data were registered by the billing and warehousing collaborators 
of the index hospital as this is standard procedure for invoicing. The unit prices were official, 
nationally fixed prices adjusted to the year 2014, and were converted to 100%, if necessary, 
to obtain real costs from a hospital perspective.199 There were no additional trial intervention 
costs for infusions in the group receiving late initiation of PN. 
Costs of medication were categorised according to the first level of the Anatomical 
Therapeutic Chemical (ATC) classification, which is the World Health Organisation (WHO) tool 
for drug utilisation research.204 Each drug has its unique ATC code and price. Costs for ATC 
code B05BA (PN solutions) were reported separately. Since we were unable to distinguish 
costs per ATC code in Dutch patients, we excluded them from this ATC code analysis. However, 
since new infections were a primary outcome in the trial, we analysed the costs of anti-
infective drugs in both centres. 
 
Study endpoints 
The primary endpoint was the difference in total direct medical costs, from a hospital 
perspective, between early and late initiation of PN. Furthermore, the ten cost categories 
were analysed separately. In order to give insight into costs among different groups of 
patients, we compared total direct medical costs of Early-PN with Late-PN in the stratification 
groups as used for the PEPaNIC trial: “Surgical cardiac”, “Surgical other”, “Medical 
neurological” and “Medical other”, and age groups younger and older than one year 129. 
Additionally, the drugs responsible for differences in medication costs were investigated 
based on the ATC codes. Also, the impact of new infections on total costs was calculated. 
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Finally, we explored the cost-effectiveness of Late-PN, using the number of patients with a 
new infection prevented in the PICU as an effect measure.  
 
Statistical analyses 
The PEPaNIC trial was a priori statistically powered to detect a difference in new infections. 
Therefore, the statistical power to detect differences in total direct medical costs was 
dependent on the number of patients enrolled in the original PEPaNIC trial. This cost analysis 
was an a priori planned secondary analysis. 
Costs were reported in euro (€), as mean (SD and IQR), as recommended for cost 
analyses.205 IQR was reported, as cost data is always highly skewed, and IQR reflects the 
statistical dispersion more realistically than standard deviation or standard error. Other data 
were reported as mean (SE), median (IQR) or number (%), as appropriate. In order to check 
whether the major costs were similarly distributed into the cost categories in both centres, a 
Pareto analysis was performed. This is a chart to demonstrate which factors are contributing 
most to a problem (i.e. total costs).206 
Costs were compared univariably by using Student’s one-tailed t test with 
bootstrapping (x1000),205 LOS was compared using the Mann-Whitney U test, and the 
incidence of new infection was compared using Fisher’s exact test. Based on the clinical results 
that point out clearly that late PN reduces resource consumption by reduction of new 
infections and shorter PICU stay, we have chosen to test the differences in costs one-sided, 
hypothesising that Late-PN is less costly than Early-PN. One-sided p-values <0.05 were 
considered statistically significant. Effects were reported as mean difference or odds ratio (OR) 
with the corresponding 95% confidence interval (CI). The OR for acquiring a new infection was 
adjusted for age, risk of malnutrition (STRONGkids group), treatment centre, admission 
diagnosis, and degree of organ failure (PeLOD score), in line with the PEPaNIC trial18 and also 
PIM2 score to adjust for risk of mortality. The adjusted OR was analysed using binary logistic 
regression. Analyses were conducted using IBM SPSS statistics, version 24.0.  
 
Sensitivity analyses 
Sensitivity analyses were conducted as follows: 
1. The total costs were analysed using prices from the Belgian healthcare system for all 
patients. 
2. The total costs were analysed using prices from the Dutch healthcare system for all 
patients. 
3. The total costs were analysed separately in the Belgian patients. 
4. The total costs were analysed separately in the Dutch patients. 
5. As only the hospitalisation costs of the post-PICU period were included in the primary 
analysis, the additional post-PICU costs (i.e. laboratory, medication costs) were left 
out. Since this could underestimate our results, the estimated additional post-PICU 
costs were added in the third sensitivity analysis. These additional post-PICU costs 
were estimated based on the invoices of the Belgian patients 
 
 
 
RESULTS 
 
We compared the total direct medical costs of Late-PN (n=673 patients) with those of early-
PN (n=670 patients) in the Dutch and Belgian study populations. The patients’ baseline 
characteristics and main clinical outcomes are described in Table 1.  
 
Total healthcare costs and evaluation of cost drivers 
Late-PN, as compared with Early-PN, reduced the mean total direct medical costs by €7.180 
(95%CI [€-12.920;€-1.880], p=0.007) per patient (Early-PN €33.860, Late-PN €26.680), which 
is a saving of 21% (Table 2).  
The major costs were divided into cost categories similarly for both centres (Appendix). 
Differences in mean costs between Belgian and Dutch patients were due to shorter duration 
of stay in PICU (factor 0.55) in Belgian patients (p<0.001), which might be caused by 
differences in patient populations. In contrast, the Belgian costs per day in PICU (mean costs 
of all categories summed, except hospitalisation costs post-PICU, divided by the duration of 
PICU stay) were higher (factor 1.18) than the Dutch costs (p<0.001). Almost all cost categories 
showed lower costs with Late-PN than with Early-PN. The largest reduction was found in PICU 
hospitalisation costs (€-4.120, 95%CI [€-7.590; €-1.500]), medication costs (€-650, 95%CI [€-
1.360;€100]), and ventilator support costs (€-640, 95%CI [€-1.260;€-190]) (Table 2). This 
reduction in costs is in line with the shorter PICU stay in the Late-PN group (Table 1). PN costs 
were responsible for 2.1% (-€150, 95%CI [€-200;€-110]) of the reduction in total costs. 
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Table 1: Baseline characteristics and main clinical outcomes 
 
 
Early-PN 
(n=670) 
Late-PN 
(n=673) 
 
Baseline characteristica    
Median age (IQR) - years 1.3 (0.3-6.0) 1.4 (0.2-7.0)  
Age <1 year  311 (46.4) 312 (46.4)  
Male sex  386 (57.6) 393 (58.4)  
STRONGkids risk levelb    
     Medium  593 (88.5) 600 (89.2)  
     High  77 (11.5) 73 (10.8)  
Median PeLOD score, first 24 hour in PICU (IQR)c 21 (12-32) 21 (11-31)  
Median PIM2 score (IQR)d -2.8 (-3.7;-1.3) -2.8 (-3.7;-1.6)  
Emergency admission 325 (48.5) 308 (45.7)  
Diagnostic group    
     Surgical cardiac 264 (39.4) 259 (38.5)  
     Surgical other 202 (30.1) 205 (30.4)  
     Medical neurological 44 (6.6) 50 (7.4)  
     Medical other 160 (23.9) 159 (23.5)  
Condition on admission    
     Mechanical ventilation required 596 (90.0) 587 (87.2)  
     ECMO or other mechanical hemodynamic support required 16 (2.4) 22 (3.3)  
     Infection 256 (38.2) 244 (36.3)  
Clinical primary outcome   P-valuee 
New infections - No. (%) 120 (17.9) 71 (10.6) <0.001 
Median duration of stay in PICU (IQR) – dayse 4 (2-9) 3 (2-7) 0.002 
ECMO = extracorporeal membrane oxygenation, PeLOD = Paediatric Logistic Organ Dysfunction, PIM2 = 
Paediatric Index of Mortality 2, PICU = paediatric intensive care unit, PN = parenteral nutrition, STRONGkids = 
Screening Tool for Risk on Nutritional Status and Growth. 
aThere were no significant differences in characteristics between treatment groups at baseline.  
bSTRONGkids scores range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 
indicating medium risk, and a score of 4 to 5 indicating high risk. 
cPeLOD scores range from 0 to 71, with higher scores indicating more severe illness. 
dPIM2 scores, with higher scores indicating a higher risk of mortality. 
 eThe duration of stay in the PICU was defined as the time from admission until the patient was ready for 
discharge (i.e., the patient no longer required or was no longer at risk for requiring vital-organ support). The 
duration of stay was not censored, nor adjusted for death. 
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Table 1: Baseline characteristics and main clinical outcomes 
 
 
Early-PN 
(n=670) 
Late-PN 
(n=673) 
 
Baseline characteristica    
Median age (IQR) - years 1.3 (0.3-6.0) 1.4 (0.2-7.0)  
Age <1 year  311 (46.4) 312 (46.4)  
Male sex  386 (57.6) 393 (58.4)  
STRONGkids risk levelb    
     Medium  593 (88.5) 600 (89.2)  
     High  77 (11.5) 73 (10.8)  
Median PeLOD score, first 24 hour in PICU (IQR)c 21 (12-32) 21 (11-31)  
Median PIM2 score (IQR)d -2.8 (-3.7;-1.3) -2.8 (-3.7;-1.6)  
Emergency admission 325 (48.5) 308 (45.7)  
Diagnostic group    
     Surgical cardiac 264 (39.4) 259 (38.5)  
     Surgical other 202 (30.1) 205 (30.4)  
     Medical neurological 44 (6.6) 50 (7.4)  
     Medical other 160 (23.9) 159 (23.5)  
Condition on admission    
     Mechanical ventilation required 596 (90.0) 587 (87.2)  
     ECMO or other mechanical hemodynamic support required 16 (2.4) 22 (3.3)  
     Infection 256 (38.2) 244 (36.3)  
Clinical primary outcome   P-valuee 
New infections - No. (%) 120 (17.9) 71 (10.6) <0.001 
Median duration of stay in PICU (IQR) – dayse 4 (2-9) 3 (2-7) 0.002 
ECMO = extracorporeal membrane oxygenation, PeLOD = Paediatric Logistic Organ Dysfunction, PIM2 = 
Paediatric Index of Mortality 2, PICU = paediatric intensive care unit, PN = parenteral nutrition, STRONGkids = 
Screening Tool for Risk on Nutritional Status and Growth. 
aThere were no significant differences in characteristics between treatment groups at baseline.  
bSTRONGkids scores range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 
indicating medium risk, and a score of 4 to 5 indicating high risk. 
cPeLOD scores range from 0 to 71, with higher scores indicating more severe illness. 
dPIM2 scores, with higher scores indicating a higher risk of mortality. 
 eThe duration of stay in the PICU was defined as the time from admission until the patient was ready for 
discharge (i.e., the patient no longer required or was no longer at risk for requiring vital-organ support). The 
duration of stay was not censored, nor adjusted for death. 
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Table 3: Medication costs of Belgian patients split by Anatomical Therapeutic Classification 
system classes 
 
ATC code 
Early-PN, € 
 
Late-PN, € Mean 
difference 
 [95%CI], € 
P-value  
(t test) 
Mean SD p25-p75 Mean SD p25-p75 
B (blood/blood 
forming organs) 
850 1.820 210-740 580 1.350 140-480 -270 [-510;-40] 0.02 
J (anti-infectives)a 320 2500 4-90 170 1.030 4-50 -150 [-470;80] 0.17 
A (alimentary 
tract/metabolism) 
70 250 20-70 50 80 10-40 -30 [-40;-10] <0.001 
V (various) 100 140 20-140 80 110 20-110 -20 [-40;-7] 0.004 
N (nervous system) 90 180 30-80 70 150 30-80 -20 [-40;0] 0.03 
C (cardiovascular) 55 150 3-50 45 100 1-50 -10 [-30;5] 0.07 
R (respiratory) 20 150 0-0 10 50 0-0 -10 [-30;7] 0.10 
H (hormonal) 30 110 0-30 20 60 0-30 -10 [-20;3] 0.10 
M (musculo-skeletal) 13 40 3-10 7 10 3-9 -5 [-10;-2] 0.01 
D (dermatologics) 10 70 0-8 7 30 0-8 -3 [-10;3] 0.26 
S (sensory organs) 3 5 0-4 2 3 0-4 -1 [-1;0] 0.01 
P (antiparasitic) 1 20 0-0 0 0 0-0 1 [-3;0] 0.19 
G (genito-urinary / 
sex hormones) 
1 8 0-0 1 8 0-0 0 [-1;1] 0.48 
L (antineoplasmic  / 
immunomodulating) 
25 330 0-0 45 320 0-0 20 [-30;60] 0.26 
Total 1.600 4.663 380-1.260 1.070 2.577 310-830 -500 [-1.060;20] 0.03 
Cost categories were ranked according to the mean difference between the treatment groups.  
CI = confidence interval, PN = parenteral nutrition. 
aData from both Belgian and Dutch patients. 
 
Impact of new infections 
The proportion of patients with a new infection acquired in the PICU was smaller with Late-
PN than with Early-PN (patients included for cost analysis: 10.6% and 17.9%, respectively, 
p<0.001; Table 1), with a corresponding adjusted odds ratio of 0.51 (95%CI [0.36;0.71]). In the 
whole group, 1.2% of the least expensive 50% of patients had acquired a new infection 
compared to 28.5% of the most expensive 50% of patients. Moreover, 85% (11 patients) of 
the most expensive 1% of patients (13 patients) had acquired a new infection. Figure 1 depicts 
the cost tree of patients with and without a new infection in both randomisation groups. In 
patients who acquired a new infection, costs were increased from €21.350 to €91.200 
(difference €69.850, 95%CI [€50.700;€91.560], p=0.001) with Early-PN and from €20.600 to 
€78.210 (difference €57.610, 95%CI [€41.890;€73.970], p=0.001) with Late-PN, predominantly 
caused by PICU hospitalisation costs (Early-PN group: difference €37.210, 95%CI 
[€26.200;€52.750], p=0.002; Late-PN group: difference €27.530, 95%CI [€20.660;€34.940], 
p=0.001).  
 
 
 
Late-PN was more effective and less costly than Early-PN, and falls into the south-
eastern quadrant of the cost-effectiveness plane. Interventions in this quadrant are always 
considered cost-effective.207,208 
 
Figure 1: Costs of patients with or without new infections 
 
PN = parenteral nutrition, pp = per patient. 
 
Sensitivity analyses 
The primary results were robust, as they could be reproduced with multiple sensitivity 
analyses (Table 4). Using the Dutch or Belgian unit prices for all patients showed a cost 
difference of late versus early PN of €-8.690 resp. €-6.090, which is within the 95%CI of the 
primary analysis of the base case ([€-12.920;€-1.880). Also, when analysing the Dutch and 
Belgian patients separately, the cost reduction with late PN was within the 95%CI of the 
primary analysis of the base case (Table 4). The difference in absolute costs between the 
centres was predominantly due to more resource consumption in the Dutch patients (i.e. 
longer LOS) (Appendix). In the third sensitivity analysis, total post-PICU costs were estimated 
and added to the total PICU costs. Post-PICU costs were predominantly hospitalisation costs 
(85%), which were already included in the base case. Consequently, the additional post-PICU 
costs of approximately €1.100 in this sensitivity analysis represented the 15% of post-PICU 
costs that were not included in the base case. 
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p<0.001; Table 1), with a corresponding adjusted odds ratio of 0.51 (95%CI [0.36;0.71]). In the 
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The primary results were robust, as they could be reproduced with multiple sensitivity 
analyses (Table 4). Using the Dutch or Belgian unit prices for all patients showed a cost 
difference of late versus early PN of €-8.690 resp. €-6.090, which is within the 95%CI of the 
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costs of approximately €1.100 in this sensitivity analysis represented the 15% of post-PICU 
costs that were not included in the base case. 
  
192 
CHAPTER 7
 
 
 
DISCUSSION 
 
This cost-effectiveness study of the PEPaNIC trial showed that the total direct medical costs 
were considerably lower when PN was withheld during the first week of critical illness in 
children as compared with early initiation of PN. This cost reduction was mainly due to a 
lowering of PICU hospitalisation costs, although most cost components were reduced by not 
using Early-PN. The reduction of the costs for PN was responsible for only 2.1% of the total 
cutback of costs, which supported our hypothesis that the health-economic impact of 
withholding PN encompassed more than the omission of costs for PN itself. Taking into 
account the beneficial clinical impact of Late-PN, we can conclude that withholding PN in the 
first week of critical illness is superior to Early-PN largely by preventing new infections which 
is cost-saving.207,208 
Our results confirmed previously published results of studies in critically ill adults that 
have compared early with Late-PN.123,127 The American Thoracic Society has included 
“withholding PN for one week in critically ill adults” in the top five recommendations to 
improve healthcare while reducing healthcare costs.209 One other cost analysis of the timing 
of PN in adults identified no difference in LOS, and US$ 3.170 higher costs per patient with 
late initiation of PN. However, the estimated costs in this study were based on a Monte Carlo 
simulation, in which the estimated probabilities of events, such as mechanical ventilation, 
have a large impact on cost differences.210 A micro-costing approach, used in our study, 
provides more precise and more reliable results, as this method uses the real costs that have 
been incurred.  
Three studies of PICU costs have been previously published, which allow a comparison with 
our study results. First, Harron et al. reported PICU stay and direct PICU costs that are 
comparable to those we reported here, which supports the generalisability of the findings of 
our study.211 Second, the CHiP study reported hospital costs during a 12-month period 
(£21.000)98 that were slightly lower than those found in our study. These differences could 
be explained by different study populations, with more patients included after cardiac 
surgery, which may incur lower costs than medical or non-cardiac surgical PICU patients, and 
more patients with less organ failure, reflected by mean PeLOD of 7.5 as compared with a 
median PeLOD of 21 in our study. Third, Morillo-García et al. reported higher costs for 
children with a nosocomial infection, as compared with those without a new infection,96 
which supports our conclusion that healthcare costs can be reduced by preventing new 
infections. In line with previous research,212 we observed that the duration of PICU stay had 
a major effect on the costs. This was also reflected in the finding that patients with a 
prolonged PICU stay, the minority of the total patient population that was included, 
accounted for the majority of the costs. 
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The reduction in medication costs with Late-PN versus Early-PN was mainly due to 
lower use of products in ATC categories B (blood and blood-forming organs) and J (anti-
infectives). This corroborates the finding that Late-PN reduced the proportion of patients with 
new infections, as it also does in adults.127 Additionally, patients with a new infection had 
higher total costs per patient than those without a new infection. The fact that the proportion 
of patients with new infections increased from 1.2% among the least expensive patients to 
85% among the 1% most expensive patients pointed to an effect of new infections on the total 
costs. Therefore, reducing the number of PICU days by preventing the occurrence of new 
infections by Late-PN seems to have had most influence on the cost reduction. 
The strength of this study is the micro-costing approach, reflecting real costs that 
incurred. Additionally, our findings appeared robust across two healthcare systems. We have 
carefully checked whether combining the Dutch and Belgian populations would compromise 
our results by performing sensitivity analyses, which have shown unanimously a cost 
reduction with Late-PN, which was well within the range of the confidence interval of the base 
case. These results may support that the international character of this study increased 
external validity and, possibly, applicability to other European countries.  
Some limitations should also be addressed. First, the Dutch daily costs of mechanical 
ventilation and renal replacement therapy had to be estimated, based on published literature 
on PICU costs.202,203 Second, the time horizon was limited to the hospital period and direct 
medical costs, and thus, the economic consequences could not be fully captured. One Swiss 
study, investigating out-of-pocket expenses of families with a child spending >4 days in PICU, 
reported mean 86 (±31) Franc (converted ~€137) per day, mainly on travel costs and meals.213 
As such, the full impact of Late-PN from a societal perspective could not be assessed. Third, 
quality-adjusted life years (QALYs) were not used as an outcome measure, as the time horizon 
was too short (hospital stay) to meaningfully assess long-term quality of life of critically ill 
children. It is acknowledged that a cost-utility analysis is preferred over a cost-effectiveness 
analysis, if a treatment has an impact on health-related quality of life. At this time, a long-term 
follow-up study is ongoing, with patients being evaluated 2 and 4 years after randomisation. 
This long-term follow-up study includes an assessment of quality of life. However, the aim of 
the current study was to perform a cost-effectiveness analysis and not a cost-utility analysis, 
which requires quality of life data. Finally, the lack of detailed drug costs for Dutch patients 
may have biased, and possibly underestimated, the differences in drug costs. 
 
CONCLUSIONS 
 
The cost analyses showed that Late-PN reduced the direct medical costs by 21% in critically ill 
children as compared with Early-PN, beyond the expected lower costs for the use of PN itself. 
Avoiding new infections by Late-PN yielded a large cost reduction. Withholding PN during the 
first week of critical illness in children can thus be recommended both from a clinical and a 
health-economic perspective. 
 
 
 
 
APPENDIX 
 
Figure S1: Pareto charts of the cost categories 
 
a. Belgian patients     b. Dutch patients 
 
The continuous lines reflect the cumulative total costs. 
ICU = intensive care unit, RRT = renal replacement therapy.
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Table S3: Resource utilisation and costs per centre. 
 
Centre Leuven,  
Belgium  
(n=673) 
Rotterdam,  
The Netherlands 
(n=670) 
Resource utilisation 
Duration PICU (days) – mean (SE) 5.9 (0.4) 10.8 (1.0) 
Duration post-PICU (days) – mean (SE) 9.0 (0.7) 15.7 (1.2) 
Duration ventilator support (days) – mean (SE) 3.7 (0.2) 7.4 (0.8) 
Duration renal replacement therapy (days) – 
mean (SE) 
0.2 (0.1) 0.4 (0.1) 
Duration mechanical hemodynamic support 
(days) – mean (SE) 
0.4 (0.1) 0.7 (0.2)  
Costs 
PICU hospitalisation (euro) – mean (SD, IQR) 6.650 (11.110, 1.980-6.800) 17.950 (38.650, 3.310-
18.220) 
Post-PICU hospitalisation (euro) – mean (SD, 
IQR) 
4.470 (9.220, 1.500-3.990) 9.860 (18.600, 1.880-11.600) 
PN (euro) – mean (SD, IQR) 160 (350, 20-150) 300 (470, 100-300) 
Medication (euro) – mean (SD, IQR) 1.180 (3.540, 300-850) 1.870 (7.560, 160-970) 
Laboratory diagnostics (euro) – mean (SD, 
IQR) 
1.740 (2.460, 610-1.770) 2.450 (4.900, 200-2.640) 
Other diagnostics (euro) – mean (SD, IQR) 380 (590, 110-380) 990 (2.630, 0-760) 
Ventilator support (euro) – mean (SD, IQR) 450 (690, 150-440) 2.640 (2.640, 710-2.490) 
Renal replacement therapy and mechanical 
hemodynamic support (euro) – mean (SD, 
IQR) 
150 (1460, 0-0) 2.050 (12.090, 0-0) 
Surgery (euro) – mean (SD, IQR) 4.580 (3940, 1.230-6.230) 4.400 (5.920, 0-6.980) 
Consultations (euro) – mean (SD, IQR) 500 (360, 180-710) 400 (900, 0-440) 
Total (euro – mean (SD, IQR) 20.250  
(22.550, 9.570-21.160) 
42.920  
(65.630, 13.580-43.380) 
PICU = paediatric intensive care unit, PN = parenteral nutrition. 
 
  
	 197
	COST-EFFECTIVENESS	OF	LATE	VS	EARLY	PN	IN	PICU
7
 
 
 Ta
bl
e 
S1
: T
ot
al
 h
ea
lth
ca
re
 co
st
s s
pl
it 
by
 a
ge
 
 A
ge
 g
ro
up
 
Ea
rly
-P
N,
 €
 
La
te
-P
N,
 €
 
M
ea
n 
di
ffe
re
nc
e 
[9
5%
CI
], 
€ 
P-
va
lu
e 
(t 
te
st
) 
n 
M
ea
n 
SD
 
p2
5-
p7
5 
n 
M
ea
n 
SD
 
p2
5-
p7
5 
Ag
e 
0-
1 
ye
ar
 
31
1 
39
.2
40
 
69
.0
30
 
12
.5
80
-3
8.
98
0 
31
2 
30
.7
00
 
38
.7
90
 
12
.0
00
-3
1.
13
0 
-8
.5
40
 [-
18
.5
20
;1
10
] 
0.
04
 
A
ge
 ≥
1 
ye
ar
 
35
9 
29
.2
00
 
45
.0
30
 
9.
78
0-
29
.4
20
 
36
1 
23
.2
10
 
32
.7
50
 
9.
27
0-
25
.5
80
 
-5
.9
90
 [-
12
.0
40
;-3
30
] 
0.
02
 
Co
st
 ca
te
go
rie
s w
er
e 
ra
nk
ed
 a
cc
or
di
ng
 to
 th
e 
m
ea
n 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
tr
ea
tm
en
t g
ro
up
s. 
 
CI
 =
 co
nf
id
en
ce
 in
te
rv
al
, P
N 
= 
pa
re
nt
er
al
 n
ut
rit
io
n.
 
    Ta
bl
e 
S2
: T
ot
al
 h
ea
lth
ca
re
 co
st
s s
pl
it 
by
 d
ia
gn
os
is 
gr
ou
p 
 D
ia
gn
os
is 
gr
ou
p 
Ea
rly
-P
N,
 €
 
La
te
-P
N,
 €
 
M
ea
n 
di
ffe
re
nc
e 
[9
5%
CI
], 
€ 
P-
va
lu
e 
 
(t 
te
st
) 
n 
M
ea
n 
SD
 
p2
5-
p7
5 
n 
M
ea
n 
SD
 
p2
5-
p7
5 
M
ed
ica
l -
 O
th
er
 
16
0 
52
.7
10
 
81
.9
40
 
13
.4
60
-5
3.
25
0 
15
9 
38
.0
00
 
56
.2
30
 
10
.8
10
-3
9.
30
0 
-1
4.
71
0 
[-3
0.
72
0;
13
0]
 
0.
04
 
Su
rg
er
y 
- O
th
er
 
20
2 
34
.2
80
 
66
.3
80
 
10
.7
70
-3
5.
89
0 
20
5 
24
.8
00
 
28
.4
30
 
8.
66
0-
28
.8
80
 
-9
.4
80
 [-
20
.7
20
;-1
.0
40
] 
0.
05
 
Su
rg
er
y 
- C
ar
di
ac
 
26
4 
23
.7
40
 
23
.8
40
 
11
.0
30
-2
7.
44
0 
25
9 
21
.7
30
 
21
.9
30
 
10
.6
80
-2
2.
83
0 
-2
.0
10
 [-
5.
85
0;
1.
73
0]
 
0.
16
 
M
ed
ica
l -
 N
eu
ro
lo
gi
ca
l 
44
 
24
.0
30
 
26
.0
00
 
7.
47
0-
25
.8
00
 
50
 
24
.0
90
 
31
.0
90
 
7.
63
0-
29
.5
20
 
+6
0 
[-1
0.
63
0;
11
.1
60
 
0.
50
 
Co
st
 ca
te
go
rie
s w
er
e 
ra
nk
ed
 a
cc
or
di
ng
 to
 th
e 
m
ea
n 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
tr
ea
tm
en
t g
ro
up
s. 
 
CI
 =
 co
nf
id
en
ce
 in
te
rv
al
, P
N 
= 
pa
re
nt
er
al
 n
ut
rit
io
n.
 
 
 
 
 
Table S3: Resource utilisation and costs per centre. 
 
Centre Leuven,  
Belgium  
(n=673) 
Rotterdam,  
The Netherlands 
(n=670) 
Resource utilisation 
Duration PICU (days) – mean (SE) 5.9 (0.4) 10.8 (1.0) 
Duration post-PICU (days) – mean (SE) 9.0 (0.7) 15.7 (1.2) 
Duration ventilator support (days) – mean (SE) 3.7 (0.2) 7.4 (0.8) 
Duration renal replacement therapy (days) – 
mean (SE) 
0.2 (0.1) 0.4 (0.1) 
Duration mechanical hemodynamic support 
(days) – mean (SE) 
0.4 (0.1) 0.7 (0.2)  
Costs 
PICU hospitalisation (euro) – mean (SD, IQR) 6.650 (11.110, 1.980-6.800) 17.950 (38.650, 3.310-
18.220) 
Post-PICU hospitalisation (euro) – mean (SD, 
IQR) 
4.470 (9.220, 1.500-3.990) 9.860 (18.600, 1.880-11.600) 
PN (euro) – mean (SD, IQR) 160 (350, 20-150) 300 (470, 100-300) 
Medication (euro) – mean (SD, IQR) 1.180 (3.540, 300-850) 1.870 (7.560, 160-970) 
Laboratory diagnostics (euro) – mean (SD, 
IQR) 
1.740 (2.460, 610-1.770) 2.450 (4.900, 200-2.640) 
Other diagnostics (euro) – mean (SD, IQR) 380 (590, 110-380) 990 (2.630, 0-760) 
Ventilator support (euro) – mean (SD, IQR) 450 (690, 150-440) 2.640 (2.640, 710-2.490) 
Renal replacement therapy and mechanical 
hemodynamic support (euro) – mean (SD, 
IQR) 
150 (1460, 0-0) 2.050 (12.090, 0-0) 
Surgery (euro) – mean (SD, IQR) 4.580 (3940, 1.230-6.230) 4.400 (5.920, 0-6.980) 
Consultations (euro) – mean (SD, IQR) 500 (360, 180-710) 400 (900, 0-440) 
Total (euro – mean (SD, IQR) 20.250  
(22.550, 9.570-21.160) 
42.920  
(65.630, 13.580-43.380) 
PICU = paediatric intensive care unit, PN = parenteral nutrition. 
 
  
  
 
  
General Discussion
Chapter 8
 
 
 
  
200 
CHAPTER 8
 
 
 
“PRIMUM NON NOCERE” – Hippocrates, ±400 B.C. 
 
This thesis provides insight into the short-term and long-term clinical and economic 
consequences of withholding parenteral nutrition (PN) during the first week in critically ill 
children. Based on previous studies18,20,43,127 and concerns raised by nutritional experts,71-75,166 
the main hypotheses that we tested were as follows: 
Withholding PN during the first week in critically ill children… 
- is effective and safe in neonates and undernourished children (Chapter 3 and 4); 
- does not negatively affect nutritional status (Chapter 5); 
- is effective and safe in the long term (Chapter 6); 
- is a cost-saving strategy comprising more than merely omitting the costs of PN itself 
(Chapter 7). 
 
OUTCOME PARAMETERS 
 
There is an ongoing debate about the definition of optimal nutrition in critically ill children. 
Questions concern the best timing, dose, and route of nutrition administration in relation to 
improved survival, recovery, growth, and development. Based on the current evidence there 
are still many uncertainties over how to achieve optimal nutrition in critically ill children. 
Measures of outcomes in nutritional research can be separated into surrogate outcomes and 
clinical outcomes (Chapter 1). Currently, most recommendations from international 
guidelines are based on observational research or randomised controlled trials (RCTs) with 
surrogate outcomes, such as nitrogen balance.74,99 Methodologically sound RCTs with clinical 
outcome measures, such as mortality, incidence of complications, duration of mechanical 
ventilation, stay on the paediatric intensive care unit (PICU), and hospital stay, are very scarce 
in this field (Chapter 1).69 While surrogate outcomes are important to unravel the mechanistic 
responses to a nutritional intervention, the effect of an intervention on a patient’s recovery 
should be verified with use of clinically relevant outcomes, both in the short and long term. 
However, with low mortality rates <5% nowadays,18,79 efforts to improve other clinical 
outcomes are of increasing interest. Critically ill children are at risk of acquiring brain damage 
during PICU stay, which could affect neurocognitive development.214 These neurocognitive 
deficits might increase with age, as new functions rely on undamaged tissues ─ also known as 
‘growing into deficit’ ─ which emphasizes the need for long-term assessment. As summarized 
in Chapter 1, PICU-survivors may suffer from significant and long-lasting problems,168 which 
comprises worse physical development (among others worse growth, chronic kidney disease, 
and muscle weakness),79-83 and neurocognitive developmental problems (such as lower 
academic performance, lower attention, worse memory and behavioural problems).20,87,89-95 
Furthermore, a literature review showed that children who have been critically ill had a lower 
health-related quality of life.88 Children who were treated with neonatal extracorporeal 
membrane oxygenation had a significantly lower health-related quality of life at the age of 5 
years, as reported by the mother and themselves.89 It is likely that multiple factors contribute 
 
 
 
to this long-term ‘legacy’, such as pre-existent morbidity, social factors, disease-related 
factors and treatments. Traditionally, long-term outcomes were presumed to be unmodifiable 
by treatments during PICU admission. However, tight glycaemic control has recently been 
shown to improve neurocognitive outcomes in critically ill children 4 years after PICU 
admission.20 Children in whom blood glucose levels were controlled to fasting levels 
performed better on tests for motor coordination and cognitive flexibility than children in 
whom hyperglycaemia was tolerated.20 The thyroid and somatotropic axes seemed to react 
on tight glycaemic control with a fasting response in these children, which was related to 
improved short-term outcomes.59,60 Hence, a nutritional intervention that further induces this 
fasting response might further reduce the long-term burden of critical illness. Moreover, 
enhanced recovery and improved long-term outcomes could contribute to sustainable 
healthcare. After all, with increasing healthcare expenses nowadays, cost-effectiveness is an 
important outcome measure as well.  
 
PARENTERAL NUTRITION IN THE ACUTE PHASE OF CRITICAL ILLNESS 
 
In critically ill children, the caloric targets are often not reached due to a number of barriers 
to enteral nutrition (EN) in the PICU.77 If nutritional targets cannot be reached with EN alone, 
or if it is expected that PN will be necessary, common practice worldwide is to supplement EN 
with parenteral nutrition (PN).67 However, systematic reviews have shown that there is no 
solid scientific evidence for supplementing EN with PN in critically ill children.68,69 With respect 
to clinical outcomes, recent findings provided new insights into the debate on timing of 
initiating PN in critically ill children. 
 
Late versus early initiation of PN 
A large, international RCT (the “PEPaNIC” trial), conducted by the PICUs of University Hospitals 
Leuven, Belgium;  Erasmus-MC Sophia Children’s Hospital, Rotterdam, The Netherlands; and 
Stollery Children’s Hospital, Edmonton, Alberta, Canada, investigated the effects of 
withholding PN during the first week (Late-PN) as compared with initiating PN within 24 hours 
(Early-PN) to supplement insufficient EN. In contrast to clinical practices and observational 
studies, this RCT concluded that in a heterogeneous population of critically ill children, from 
term newborns to 17 years of age, macronutrient restriction by Late-PN is superior to 
providing full nutritional intake by Early-PN on the following outcome parameters: incidence 
of new infections, duration of PICU dependency and hospital stay, duration of mechanical 
ventilatory support, and need for renal replacement therapy.18  
Despite these recent insights, about three-quarters of PICUs worldwide still administer 
PN to supplement EN during the first week, which shows that PN is still considered essential 
(Chapter 2). Of notice was the low awareness among respondents of the results from the 
PEPaNIC study, although this was a large, international, randomised study, published in an 
open access, high-impact journal (The New England Journal of Medicine), in a field with very 
limited available evidence. One could expect that these striking results would have at least 
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“PRIMUM NON NOCERE” – Hippocrates, ±400 B.C. 
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drawn the attention of the majority of PICU physicians. Despite the scarcity of (causal) 
evidence, 1 out of 3 respondents would wait for updated guidelines published by prominent 
scientific societies before deciding on their PN practices. A finding that stresses the 
importance of up-to-date guidelines. The time between the previous and current versions of 
international guidelines regarding nutrition for critically ill children is 8 to 13 years.74,99,103,104 
These updated European and American guidelines have based their recommendation 
regarding the timing of initiating PN on the PEPaNIC results. However, their interpretation and 
recommendations differ. The European guideline states that withholding PN for 1 week can 
be considered,99 while the American guideline recommends to withhold PN for 1 week only 
for patients with normal baseline nutrition state and low risk of nutrition deterioration.74 
Based on expert opinion, the American guideline suggests to start PN earlier in children 
without any EN and those who are undernourished on admission to the PICU.74 The recent 
results of Late-PN versus Early-PN in critically ill, undernourished children (Chapter 4) were 
published after the development of the current American guideline. 
Other frequently reported barriers for de-implementing Early-PN were the conviction 
that children need amino acids, concerns that withholding PN could be harmful in neonates 
and undernourished children, and that respondents were waiting for long-term results and 
replicating studies (Chapter 2). We have addressed most of these issues in the past 2 years 
(Chapter 3, 4 and 6), which might enhance de-implementation of Early-PN worldwide in the 
forthcoming years.  
 
 
 
Are amino acids essential in the acute phase 
Our survey pointed out that amino acids are the component of PN considered to be most 
essential (Chapter 2). This belief in the beneficial effect of protein comes from systematic 
reviews, including small randomised studies, showing that higher protein intake results in a 
positive protein balance.3,120 However, whether achieving a positive protein balance 
translates into prevention of muscle wasting or other clinical benefit has not been 
investigated. In preterm neonates, more research regarding amino acids has been done, 
although in this population the majority of RCTs also used surrogate outcome measures. One 
Key messages 
• Withholding PN during the first week of critical illness in children was previously 
found to be clinically superior to early initiation of PN. 
• Despite these results, initiation of supplemental PN within the first week is still 
considered essential in three-quarters of PICUs worldwide. 
• The following factors hampered de-implementation of Early-PN: low awareness 
of new results, awaiting updated international guidelines, and specific concerns 
for need for amino acids, safety in neonates and undernourished children, and 
long-term safety. 
 
 
 
 
randomised study showed that providing amino acids directly following birth resulted in 
better mental development in premature boys, but not in girls.215 However, because of 
physiological and pathophysiological differences between preterm infants and term neonates 
or older children, these results cannot be extrapolated. In a subgroup of critically ill adults 
from the randomised EPaNIC trial, lower nutrient intake by delaying PN with 1 week (including 
the delay of parenteral amino acids) did not lead to more muscle wasting as compared with 
Early-PN, but actually resulted in a decreased incidence of muscle weakness.55 Furthermore, 
a secondary analysis of the EPaNIC trial showed that it was not the cumulative dose of glucose 
or lipids, but of protein/amino acids that could explain the observed clinical harm caused by 
Early-PN.128 These harmful effects of amino acids were confirmed in critically ill children from 
the PEPaNIC study.70 Even in low doses of 20-30% of target, protein/amino acid administration 
was associated with slower recovery.70 Maximum harm was found when amino acid intakes 
increased up to 1.15 g/kg/day in children weighing up to 10 kg, 0.83 g/kg/day in children 
weighing 10 to 20 kg, and 0.75 g/kg/day in children weighing more than 20 kg,70 which are 
much lower thresholds than currently recommended.74 
A possible explanation might be related to autophagy, an efficient housekeeping 
mechanism involving the lysosomal degradation of cytoplasmic organelles or cytosolic 
components.216 Degraded contents are eliminated or recycled to maintain nutrient and energy 
homeostasis.216 Autophagy is activated by cellular stress, and plays an important adaptive role 
in cellular damage control and preservation of endogenous energy supply during critical 
illness.132,133 Importantly, this process is inhibited by nutrients.132 In rabbits, administration of 
PN early during critical illness, in particular amino acids, resulted in decreased activation of 
autophagy in muscle and liver.132 These animal models suggest that adequate activation of 
autophagy could be necessary to properly heal damaged cells or tissues, and that delaying PN 
might support autophagic activity, and thus inhibit subsequent ongoing cellular damage and 
prevent clinical complications. In fact, in critically ill adults, withholding PN for 1 week resulted 
in increased activation of autophagic quality control of myofibres and decreased muscle 
weakness as compared with initiating PN <48 hours.55 If this can be extrapolated to critically 
ill children is currently unknown. Another explanation could be that the body copes differently 
with excessive amounts of different nutrients. Whereas excessive intakes of carbohydrates 
and lipids can be stored as fat, too much intake of amino acids has to be converted into urea 
by the liver to subsequently be excreted in urine, which imposes a burden to the kidneys. 
Indeed, in critically ill children, plasma urea concentrations during the first week were higher 
if PN was initiated early (Chapter 3).70 In the acute phase of illness, protein requirements 
might differ from those during health, which could lead to an excess of amino acids if the 
targets are not being reduced. It would be interesting to investigate whether no or very low 
protein intake (enterally and parenterally) in the acute phase of critical illness would be 
beneficial as compared with current recommended intake of protein74 with a randomised 
design and clinically relevant outcome measures, such as incidence of new infections, duration 
of mechanical ventilation, length of stay, organ function, long-term physical and 
neurocognitive functioning, and quality of life.  
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Late PN in neonates and undernourished children 
Within the heterogeneous group of critically ill children, there are some subgroups of children 
who are considered susceptible to be harmed by macronutrient restriction. Because of limited 
glycogen and fat stores, neonates and undernourished children are considered more prone to 
effects of low macronutrient intake. As such, concerns were raised on the efficacy and safety 
of withholding PN in these specific patient groups (Chapter 2).71-73,75,217 
 
Critically ill, term neonates 
As nutrition and metabolism change remarkably during the first 4 weeks of life, even during 
normal physiology in a healthy neonate, we investigated the effect of Late-PN in critically ill, 
term neonates within different age groups: ≤4 weeks, ≤1 week and <1 day. In all age groups, 
Late-PN resulted in a higher likelihood of an earlier weaning from mechanical ventilation alive 
as compared with Early-PN. In neonates ≤4 weeks and ≤1 week, Late-PN led to a higher 
likelihood of an earlier discharge from PICU alive, and in neonates ≤1 week and <1 day to a 
lower risk of new infections (Chapter 3). In all age groups, Late-PN did not affect survival up 
to day 90 (Chapter 3). It should be noted that the group of neonates <1 day was small and 
that the diagnoses differed between the randomisation groups. The Early-PN group consisted 
of significantly more newborns with congenital diaphragmatic hernia than the Late-PN group, 
while the proportion of newborns with gastroschisis was lower. These baseline differences 
warrant caution when interpretating the results within this age group. Furthermore, we were 
unable to formally test an age-dependent effect, since the sample size would become too 
small if we would separate the groups. However, when comparing the hazard ratios (HR) of 
time to discharge alive in the children  older than 4 weeks (HR 1.17, 95% CI, 1.04-1.31)18 with 
those of neonates aged ≤4 weeks (HR 1.61, 95% CI 1.19-2.20) and ≤1 week (HR 1.69, 95% CI 
1.16-2.46) (Chapter 3), and the finding that the beneficial effect of Late-PN on long-term 
neurocognitive functioning was more pronounced in children who were infants on admission 
(Chapter 6), withholding PN appears to be most beneficial in the youngest patients. An 
important safety outcome in all age groups was the increased risk of hypoglycaemia with Late-
PN, although all episodes were brief and asymptomatic. This finding stresses the need for close 
monitoring of blood glucose levels when PN is withheld to detect and treat hypoglycaemia 
timely. Symptomatic, prolonged and recurrent hypoglycaemia is associated with negative 
consequences on long-term neurocognitive functioning.135 However, recent well-designed 
Key messages 
• The cumulative doses of protein/amino acids, but not glucose or lipids, could 
explain the harm caused by Early-PN. 
• Autophagy plays an important role in controlling cellular damage, which is 
suppressed by nutrients, in particular amino acids. 
 
 
 
 
studies on the long-term consequences of brief episodes of asymptomatic hypoglycaemia in 
preterm neonates and healthy newborns have shown no clear harm.19,21-23 Furthermore, 
critically ill infants and children examined 4 years after an RCT about glycaemic control did not 
show an association between hypoglycaemic incidents and neurocognitive functioning.20 In 
our 2-year follow-up, the beneficial effects of Late-PN versus Early-PN on long-term outcomes 
also did not appear to be mediated by its acute effect on exposure to hypoglycaemia (Chapter 
6). Despite the fact that brief, asymptomatic hypoglycaemia does not seem to have long-term 
repercussions, the low amount of glucose administered to neonates in the Late-PN group is of 
notice. These neonates received approximately 1.4 mg/kg/min glucose (Chapter 3), while the 
most recent European guideline advices to start with 2.5-5.0 mg/kg/min, and gradually 
increase to 5-10 mg/kg/min in 2-3 days from day 2 onwards in critically ill, term neonates.218 
In a secondary analysis of the PEPaNIC trial, it was found that higher doses of glucose in the 
first days after admission were associated with a lower the risk of new infections.70 Hence, 
future studies could consider administering higher doses of glucose then currently done in the 
PEPaNIC trial. Furthermore, higher doses of lipids beyond the first few days could also be 
beneficial.70 Although not significant, the same patterns were found in term neonates 
(Chapter 3). Furthermore, in term neonates, higher doses of protein/amino acids were 
associated with harm (Chapter 3), in line with previous findings in adults and children aged 0-
17 years.70,128 As Early-PN, containing amino acids, glucose, and lipids, was associated with 
harm, apparently, the higher amount of glucose and lipids could not offset this harm evoked 
by amino acids. 
 
 
 
Critically ill, undernourished children 
Another subgroup of vulnerable children is the group of children who are undernourished on 
admission to the PICU. Previous studies have shown an association between acute 
undernourishment and worse clinical outcomes.33,35,36 This was confirmed in the PEPaNIC 
study, showing that acute undernourishment on admission, defined as a weight Z-score <-2, 
was associated with a prolonged duration of PICU stay and hospital stay, and a higher 
incidence of hypoglycaemia during the first week as compared with well-nourished children 
(Chapter 4). However, the group of undernourished children differed from the well-nourished 
children with regard to several baseline characteristics, among others severity of illness and 
Key messages 
• Late-PN was clinically superior to Early-PN in critically ill, term neonates. 
However, clinicians should monitor blood glucose levels closely when PN is 
withheld. 
• The youngest patients appeared to benefit most from Late-PN. 
• Protein/amino acid intake was associated with harm in critically ill, term 
neonates. 
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primary diagnosis (Chapter 4), which suggests that many other, not tested, variables differ 
between the groups, for example, type and doses of medication, and co-morbidities. We have 
corrected the analyses for a few of these baseline differences, however, obviously, it is 
impossible to correct for all potential differences. Hence, it is questionable if the observed 
worse clinical outcome can be attributed to the nutritional status itself or to other factors that 
may have played a role. Current American guidelines recommend that PN might be started 
earlier in children who are undernourished on admission than in well-nourished children.74 
The rationale behind this suggestion is that higher caloric intake by PN might prevent further 
weight deterioration and subsequently improve clinical outcomes of undernourished children. 
However, it was unknown whether prevention of weight deterioration and improved 
outcomes in undernourished children can be achieved by early supplementation of PN. The 
PEPaNIC trial, with its randomised design and a large group of undernourished children, 
provided an opportunity to investigate this hypothesis. As was found in the PEPaNIC 
population as a whole, also in critically ill undernourished children, Late-PN resulted in a lower 
risk of new infections and faster recovery facilitating earlier weaning from mechanical 
ventilation alive and earlier PICU discharge alive (Chapter 4). Furthermore, Late-PN did not 
affect mortality, the risk of hypoglycaemia, and incidence of weight Z-score deterioration 
during PICU stay (Chapter 4). In severely undernourished children, Late-PN was also beneficial 
as compared with Early-PN. Possible explanations for these results in undernourished children 
remain speculative. First, as mentioned above, acute undernourishment on admission could 
be an expression of severe illness. Both in adults and children, the severity of illness and 
concomitant inflammation is considered to play a role in the development of undernutrition, 
although the precise mechanisms are largely unclear.158,159 This might explain the worse 
clinical outcome associated with undernourishment on admission. Second, it is suspected that 
undernourished children have an altered immune response as compared with well-nourished 
critically ill children, among others in cells that are involved in fasting-induced 
autophagy,149,219 which might have hindered efficient autophagy. Therefore, undernourished 
children could hypothetically be even more susceptible to the detrimental effects of Early-PN. 
More research is needed to unravel the underlying mechanisms of the interplay between 
nutritional status and immunological alterations for a better understanding how to treat these 
children. Furthermore, the optimal timing of initiating PN in undernourished critically ill 
children might differ from well-nourished children. However, currently, it is unknown whether 
PN should be initiated earlier in undernourished children to prevent further deterioration of 
their nutritional status, or later to support their immune system and autophagic activity 
longer.  
 
 
 
 
 
 
Changes in nutritional status during PICU stay  
In previous observational studies, it was found that children admitted to the PICU on average 
show a decline in several Z-scores of nutritional status parameters at different endpoints.4-
7,42,156 Improvement of a nutritional status has been associated with higher nutritional intake, 
although only in observational studies, which requires caution when interpreting these 
results.5-7,42 We investigated whether there is a relationship between withholding PN during 
the first week in PICU and change in nutritional status, and found that this did not affect the 
change in weight Z-score during PICU stay as compared with Early-PN (Chapter 5). 
Additionally, withholding PN did not affect the average change in weight Z-score per day 
(Chapter 5).  
 Possible explanations remain speculative. In a systematic review, nutritional intake 
above 57 kCal/kg/day was found to result in a positive nitrogen balance in critically ill 
children.3 However, none of the included studies investigated whether this translates into 
improved nutritional status. The acute phase of critical illness is characterised by whole body 
protein breakdown and muscle loss. In critically ill children, it was shown that muscle mass, 
measured with ultrasound as thickness of the femoral quadriceps, decreased up to 13% during 
PICU stay.49 This muscle wasting often persists because of disease related factors, but also 
iatrogenic factors, such as medication and immobilisation. In critically ill adults, supplemental 
PN during the first week did not affect muscle wasting.55,57 Hence, there seems to be no 
benefit of supplemental PN in the acute phase of illness to prevent muscle wasting. However, 
supplemental PN in the stable and recovery phase might play a role in preventing further 
deterioration.  
On admission to the PICU, the median weight Z-score was -0.72 (Chapter 5). A previous 
observational study in critically ill term neonates and older children found catch-up growth 6 
months after PICU admission.42 In line with this finding, anthropometric measurements of 
PICU-survivors 2 years after enrolment in the PEPaNIC study revealed Z-scores of height -0.07, 
weight -0.15, BMI -0.25 and head circumference -0.11, although these Z-scores were still 
significantly lower than those of matched healthy children (Chapter 6). Importantly, there 
were no differences in Z-scores between the Early-PN and Late-PN groups (Chapter 6). Also, 
the change in Z-scores between PICU admission and 2-years follow-up was similar in both 
treatment groups (Chapter 6). Altogether, although the nutritional intake was significantly 
Key messages 
• Undernourishment on admission was associated with worse clinical outcome, 
although many baseline characteristics differed between undernourished and 
well-nourished children. Therefore, we cannot preclude that other factors might 
also have played a role. 
• Undernourished children, defined as weight Z-score <-2, benefitted from 
withholding PN during the first week in PICU. 
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lower during the first week, Late-PN did not have consequences on the nutritional status 
during PICU stay and of PICU survivors 2 years after admission. Of notice, we did not correct 
the weight Z-scores for ethnicity or presence of a syndrome, which could have influenced the 
weight Z-scores. However, as there were no differences in ethnicity nor in proportions of 
patients with a (suspected) syndrome between the Late-PN and Early-PN groups, this does not 
compromise our comparisons of Late-PN versus Early-PN. Future studies could consider an 
additional assessment of body composition by use of BIA or air-plethysmography months to 
years after PICU admission, as this can give more information on the effects of nutritional 
strategies on the evolution of body composition than anthropometric measurements. Age-
dependent reference values of BIA220 and air-plethysmography221-223 are available for all 
paediatric age groups, although there is a need for updated, accurate reference values.224 
Weight Z-score deterioration was associated with a lower likelihood of an earlier 
discharge from PICU alive and with a higher risk of new infections (Chapter 5). However, since 
the change in weight Z-score was not significantly different between the treatment groups, 
deterioration of weight Z-score does not seem to be a consequence of PN intake during the 
acute phase but may reflect severe illness. In a guideline on defining paediatric malnutrition, 
the severity of inflammation is recognised to influence the occurrence or deterioration of 
disease-related malnutrition, although its exact role is not yet understood.158 In adults, 
malnutrition is also considered to be related to disease burden/inflammation.159 Given that 
withholding PN did not affect the change in weight Z-score, but still resulted in enhanced 
recovery, the value of the change in weight Z-score during the acute phase of critical illness is 
questionable. A few other measurements could be considered that could reflect the 
nutritional status better. Mid-upper arm circumference is less influenced by oedema, easy to 
obtain in critically ill children and can be used to estimate a child’s weight.32,164 Another 
measure of undernourishment is the phase angle by use of bio-electrical impedance analysis 
(BIA). The phase angle on admission and on the second day has recently been shown to be 
related to the duration of PICU stay.46 Whether the evolution of the phase angle during critical 
illness may guide nutritional interventions is currently unknown. Another important 
measurement might be the loss of muscle mass or decrease in muscle quality. Interestingly, 
in critically ill adults, CT images showed that withholding PN during the first week improved 
the muscle quality reflected by decreased amounts of adipose tissue within the muscle 
compartments, as compared with PN initiation within 48 hours.57 Muscle mass decreased 
during the first week, but this decrease was unaffected by PN.57 Moreover, muscle weakness 
was reduced in patients receiving Late-PN.55 It is unknown whether these results can be 
extrapolated to children. Little is known about critical illness related polyneuropathy in 
children as well. Muscle biopsies for scientific purposes in children are considered too 
invasive, and the evidence for reliability of ultrasonography to detect muscle wasting is 
inconsistent.49,165 However, handgrip strength tests in the long term might be feasible and 
could add value to exploring the long-term effects of nutritional interventions.225 This test can 
be done in children from the age of 4 years and age- and sex dependent reference values are 
available.225,226 
 
 
 
 
 
Long-term efficacy and safety of Late-PN 
Two years after participation in the PEPaNIC study, PICU survivors had worse developmental 
outcomes as compared with healthy matched control children in numerous domains reflecting 
growth, health status, intelligence, executive functioning and behaviour (Chapter 6). These 
observed deficits confirmed previous findings in follow-up studies of critically ill children.20,80-
82,87,89-95 Late-PN did not negatively affect survival, anthropometrics, health status, and 
neurocognitive development. Moreover, of the patients who survived, fewer were too 
disabled to be tested in the Late-PN group than in the Early-PN group (Chapter 6). 
Interestingly, Late-PN improved parent/caregiver-reported executive functioning, inhibition 
in particular, as compared with Early-PN (Chapter 6). In fact, children in the Late-PN group did 
not perform worse on inhibition tests than healthy children (Chapter 6). Executive functioning, 
which is the ability of complex decision making and goal-oriented behaviour, is important in 
many aspects of daily life.183 Thus, these long-term outcomes are relevant outcome measures 
with implications for daily life. 
Explanations for the beneficial effects of withholding PN in the long-term are 
speculative. Epigenetic alterations, which denote cellular changes that affect gene activity and 
expression, might play a role,188 since some of these changes have been associated with 
executive dysfunction.183 Furthermore, telomeres, which are located at the ends of the 
chromosomes to protect chromosomes from degradation, might be involved. Telomeres 
shorten with each cell cycle, but also under influence of oxidative stress and 
inflammation.227,228 Recently, telomeres of critically ill children were found to be shorter on 
admission to the PICU than those of healthy children, and further shortening during PICU stay 
was accelerated by Early-PN,126 which might have long-term consequences. Unraveling the 
underlying mechanisms could contribute to a better understanding of the complex situation 
of paediatric critical illness and the role of nutrition during this period, and might provide new 
insights into possible treatment options for critically ill children.  
A limitation of this study is the young age of the patients at follow-up with a median 
age of 5.7 years. The included neonates and infants, comprising half of the original study 
population, were followed-up at age 2.5 years old, as this was the lower boundary of the test 
for Intelligence Quotient (IQ). Because of their age at follow-up, the youngest children could 
not complete all tests. The most pronounced benefit of Late-PN was found in inhibition as 
reported by the parent or caregiver, but the clinical test to actually measure inhibition was 
not suitable for children younger than 4 years. Furthermore, some other significantly different 
Key messages 
• Less weight Z-score deterioration was associated with worse clinical outcomes. 
• Late-PN did not affect change in weight Z-score during PICU stay. 
• The value of change in weight Z-score to evaluate nutritional interventions in the 
acute phase of critical illness is questionable. 
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domains, such as motor coordination and memory, could not be tested in the youngest 
children as well. Since children who were infants at randomisation benefitted more from Late-
PN than older children on several parent/caregiver-reported executive functions, it could be 
expected that the beneficial, clinically tested effects of Late-PN in the whole group might have 
been larger if also the youngest children could have completed all tests.  
In this study, the Wechsler Intelligent Scales were chosen to measure Intelligent 
Quotients (IQ), which can be used from the age of 2.5 years onwards into adulthood. Given 
that a certain degree of neurodevelopmental delay was to be expected in post-PICU patients, 
it is questionable if the Wechsler Intelligent Scale is the optimal test for the youngest children 
age 2.5 years old. Perhaps, a developmental test, such as the Bayley Scales of 
Development,229,230 might have provided more information on neurodevelopment of the 
youngest children. However, an important argument to use the Wechsler Intelligent Scales in 
this setting is that it comprises comparable results on IQ along a broad age-range, which 
facilitates comparisons between age groups and, more importantly, over time. Since an even 
longer follow-up of our patients is currently ongoing, the longitudinal value was an important 
aspect to take into account.  
A few studies have looked into the IQ of children after critical illness and found a lower 
IQ compared to healthy children.20,91,93  Other studies in children with oesophageal atresia,231 
congenital diaphragmatic hernia,232 and after neonatal extracorporeal membrane 
oxygenation90 found an IQ within the normal range. Interestingly, all of these studies found 
that patients had a worse development of other cognitive functions, such as memory, 
attention, and executive functioning. Moreover, following the ‘growing into deficit’ principal, 
it can be expected that neurocognitive deficits, in particular in executive functioning, will be 
more pronounced when children grow older and demands for their neurocognitive abilities 
increase. A previous longitudinal study at 2, 5 and 8 years after neonatal extracorporeal 
membrane oxygenation found that the average IQ was within the normal range and remained 
stable over time.91 However, despite a normal IQ, a large group needed extra help in school, 
which was associated with lower attention, one of the executive functions.91 This is in line with 
the findings in our study (Chapter 6) and stresses the importance of long-term follow-up of 
PICU-survivors with an extensive neurocognitive evaluation comprising more than merely 
testing of IQ. 
The effect of Late-PN on executive functioning might point towards a protective effect 
on the cerebral frontal lobe.185 Since maturation of the prefrontal cortex continues into late 
adolescence, executive functioning is among the last brain functions that a child develops.233 
Therefore, mildly impaired executive functioning might not yet be apparent in young children. 
Moreover, this late maturation makes the prefrontal cortex particularly susceptible to 
disruption. Consequently, a child who has acquired brain damage early in life could be 
confronted with problems related to executive functions getting more pronounced with 
increasing age, such as planning and decision making. Preventing or decreasing brain damage 
due to critical illness early in life might reduce the long-term burden for these children. Since 
Late-PN already showed to have a beneficial effect on parent/caregiver-reported executive 
 
 
 
functioning 2 years after critical illness, this effect might be amplified later in life. Thus, since 
the children are older at longer follow-up, and therefore able to complete all tests, and 
because of the possibility of growing into deficit, a longer follow-up of the children would give 
more insights into the long-term ‘legacy’ of critical illness and the effect of Late-PN hereon. 
 
 
 
Cost-effectiveness of Late-PN 
Treating a severely ill child in the PICU has consequences not only for a child and a family but 
also imposes a burden on society. The intensive treatments, diagnostics, and care for these 
patients are costly. Moreover, indirect costs, such as parental absence from work, have 
financial consequences as well. With increasing healthcare expenses during the past years,234 
the cost-effectiveness of an intervention is of increasing interest. We calculated direct medical 
costs during hospital stay from a hospital perspective with a micro-costing approach and 
compared the Late-PN group with the Early-PN group. We found that Late-PN is a cost-saving 
strategy, which saves on average 7180 euro per patient, reflecting 21% of the total direct 
medical costs per patient (Chapter 7). Cost-effectiveness of a treatment can be divided into 4 
quadrants (Figure 1). If the costs of an intervention are higher but less effective (north-western 
quadrant), the treatment is always unacceptable. On contrary, if an intervention is both 
effective and cost-saving (south-eastern quadrant), the treatment is always acceptable. In 
case of a more expensive, but also more effective treatment, or cost-saving at the expense of 
reduced efficacy, the decision to accept a treatment depends on the incremental cost-
effectiveness ratio (ICER) and the willingness to pay. Thus, it depends on how much money 
the society is willing to pay for 1 unit of health benefit, which is generally expressed as quality-
adjusted life year (QALY) gained.200 
 
  
Key messages 
• Post-PICU patients had a normal IQ, but performed worse on many 
neurocognitive domains compared to healthy, matched peers, which stresses 
the need for long-term follow-up after critical illness. 
• Late-PN resulted in better inhibitory control, as reported by parents/caregivers, 
compared to Early-PN. 
• Since the youngest children were too young to complete all tests, the 
neuropsychological  effects of Late-PN should be re-evaluated when the children 
are older. 
 
	 211
	GENERAL	DISCUSSION
8
 
 
 
domains, such as motor coordination and memory, could not be tested in the youngest 
children as well. Since children who were infants at randomisation benefitted more from Late-
PN than older children on several parent/caregiver-reported executive functions, it could be 
expected that the beneficial, clinically tested effects of Late-PN in the whole group might have 
been larger if also the youngest children could have completed all tests.  
In this study, the Wechsler Intelligent Scales were chosen to measure Intelligent 
Quotients (IQ), which can be used from the age of 2.5 years onwards into adulthood. Given 
that a certain degree of neurodevelopmental delay was to be expected in post-PICU patients, 
it is questionable if the Wechsler Intelligent Scale is the optimal test for the youngest children 
age 2.5 years old. Perhaps, a developmental test, such as the Bayley Scales of 
Development,229,230 might have provided more information on neurodevelopment of the 
youngest children. However, an important argument to use the Wechsler Intelligent Scales in 
this setting is that it comprises comparable results on IQ along a broad age-range, which 
facilitates comparisons between age groups and, more importantly, over time. Since an even 
longer follow-up of our patients is currently ongoing, the longitudinal value was an important 
aspect to take into account.  
A few studies have looked into the IQ of children after critical illness and found a lower 
IQ compared to healthy children.20,91,93  Other studies in children with oesophageal atresia,231 
congenital diaphragmatic hernia,232 and after neonatal extracorporeal membrane 
oxygenation90 found an IQ within the normal range. Interestingly, all of these studies found 
that patients had a worse development of other cognitive functions, such as memory, 
attention, and executive functioning. Moreover, following the ‘growing into deficit’ principal, 
it can be expected that neurocognitive deficits, in particular in executive functioning, will be 
more pronounced when children grow older and demands for their neurocognitive abilities 
increase. A previous longitudinal study at 2, 5 and 8 years after neonatal extracorporeal 
membrane oxygenation found that the average IQ was within the normal range and remained 
stable over time.91 However, despite a normal IQ, a large group needed extra help in school, 
which was associated with lower attention, one of the executive functions.91 This is in line with 
the findings in our study (Chapter 6) and stresses the importance of long-term follow-up of 
PICU-survivors with an extensive neurocognitive evaluation comprising more than merely 
testing of IQ. 
The effect of Late-PN on executive functioning might point towards a protective effect 
on the cerebral frontal lobe.185 Since maturation of the prefrontal cortex continues into late 
adolescence, executive functioning is among the last brain functions that a child develops.233 
Therefore, mildly impaired executive functioning might not yet be apparent in young children. 
Moreover, this late maturation makes the prefrontal cortex particularly susceptible to 
disruption. Consequently, a child who has acquired brain damage early in life could be 
confronted with problems related to executive functions getting more pronounced with 
increasing age, such as planning and decision making. Preventing or decreasing brain damage 
due to critical illness early in life might reduce the long-term burden for these children. Since 
Late-PN already showed to have a beneficial effect on parent/caregiver-reported executive 
 
 
 
functioning 2 years after critical illness, this effect might be amplified later in life. Thus, since 
the children are older at longer follow-up, and therefore able to complete all tests, and 
because of the possibility of growing into deficit, a longer follow-up of the children would give 
more insights into the long-term ‘legacy’ of critical illness and the effect of Late-PN hereon. 
 
 
 
Cost-effectiveness of Late-PN 
Treating a severely ill child in the PICU has consequences not only for a child and a family but 
also imposes a burden on society. The intensive treatments, diagnostics, and care for these 
patients are costly. Moreover, indirect costs, such as parental absence from work, have 
financial consequences as well. With increasing healthcare expenses during the past years,234 
the cost-effectiveness of an intervention is of increasing interest. We calculated direct medical 
costs during hospital stay from a hospital perspective with a micro-costing approach and 
compared the Late-PN group with the Early-PN group. We found that Late-PN is a cost-saving 
strategy, which saves on average 7180 euro per patient, reflecting 21% of the total direct 
medical costs per patient (Chapter 7). Cost-effectiveness of a treatment can be divided into 4 
quadrants (Figure 1). If the costs of an intervention are higher but less effective (north-western 
quadrant), the treatment is always unacceptable. On contrary, if an intervention is both 
effective and cost-saving (south-eastern quadrant), the treatment is always acceptable. In 
case of a more expensive, but also more effective treatment, or cost-saving at the expense of 
reduced efficacy, the decision to accept a treatment depends on the incremental cost-
effectiveness ratio (ICER) and the willingness to pay. Thus, it depends on how much money 
the society is willing to pay for 1 unit of health benefit, which is generally expressed as quality-
adjusted life year (QALY) gained.200 
 
  
Key messages 
• Post-PICU patients had a normal IQ, but performed worse on many 
neurocognitive domains compared to healthy, matched peers, which stresses 
the need for long-term follow-up after critical illness. 
• Late-PN resulted in better inhibitory control, as reported by parents/caregivers, 
compared to Early-PN. 
• Since the youngest children were too young to complete all tests, the 
neuropsychological  effects of Late-PN should be re-evaluated when the children 
are older. 
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Figure 1. Cost-effectiveness plane 
 
 
ΔC = difference in costs between intervention and control; ΔE = difference in effects between intervention and 
control; R = boundary of willingness to pay. 
 
Thus, in the case of Late-PN, given the clinical benefits and lower costs of Late-PN, this 
intervention falls into the south-eastern quadrant of a cost-effectiveness plane and was thus 
highly cost-effective. Further assessments of cost-effectiveness, such as calculating the ICER, 
were redundant. The top three cost categories that contributed to the difference in costs were 
PICU hospitalisation (which included costs for personnel, electricity, et cetera), medication 
and ventilator support, which together comprised 75% of the cost reduction by Late-PN, 
although almost all cost categories were reduced by Late PN (Chapter 7). The cost reduction 
of PN itself contributed only 2.1% to the total cost reduction, which confirmed our hypothesis 
that the health-economic impact of withholding PN encompassed more than omission of the 
costs for PN itself (Chapter 7). The occurrence of new infections appeared to be an important 
factor contributing to the costs, as the proportion of patients who acquired a new infection 
was highest in the most expensive patients, even up to 85% in the 1% most expensive patients 
(Chapter 7). This is in line with a previous observational study, which reported higher costs in 
children with a new infection as compared with children without a new infection.96 Hence, 
 
 
 
reducing the duration of PICU stay by preventing the occurrence of new infections by Late PN 
seems to have had most influence on the cost reduction (Chapter 7).  
The effect measure of this cost-effectiveness analysis was a priori defined as the 
number of prevented infections. Although in cost-effectiveness analysis all types of relevant 
clinical outcomes are allowed to be used, using QALYs as effect measurement is generally 
preferable. However, the clinical value of QALY as short-term outcome measure in this specific 
study is questionable. Moreover, there are some ethical and practical obstacles to assess the 
quality of life in children shortly after they have been admitted due to critical illness. The cost-
effectiveness of treating critically ill children has been investigated in neonates who required 
surgery for congenital diaphragmatic hernia or congenital anorectal malformations.235,236 
These studies showed that the health-related quality of life during the first 4 years of life was 
lower than that of healthy children. However, in adolescence, the patients had a health-
related quality of life comparable with healthy peers. The costs of treating these children were 
approximately 2500 euro per QALY, which can be considered cost-effective.235,236 Investigating 
the health-related quality of life of the PEPaNIC participants in the long term would be 
interesting, including assessment of the cost-effectiveness of Late-PN versus Early-PN.  
 
 
  
Key messages 
• Late-PN was cost-effective in the short-term and saved approximately 7000 
euro per patient. 
• Preventing new infections was an important factor to reduce direct medical 
costs. 
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Key messages 
• Late-PN was cost-effective in the short-term and saved approximately 7000 
euro per patient. 
• Preventing new infections was an important factor to reduce direct medical 
costs. 
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CLINICAL IMPLICATIONS 
 
The studies described and discussed in this thesis have confirmed the beneficial clinical effects 
of withholding PN during the first week in critically ill term neonates and undernourished 
children, in the long term and have shown the short-term, health-economic benefits (Chapter 
3, 4, 6 and 7). Late-PN versus Early-PN was investigated while providing intravenous trace 
elements, vitamins, and minerals to children in both groups. As these micronutrients are 
usually dissolved in PN, it is required to provide them separately to prevent complications due 
to deficiencies. Furthermore, the occurrence of hypoglycaemia should be monitored closely 
to treat this appropriately and quickly. If a PICU can fulfill these requirements, based on the 
currently available evidence, it can be recommended to withhold PN during the first week of 
paediatric critical illness.  
The increased risk of hypoglycaemia with Late-PN was most pronounced in term 
neonates. Taking the risk of hypoglycaemia and the macronutrient results into account 
(Chapter 3), in term neonates it could be considered to provide a higher glucose intake than 
now provided in the Late-PN group, without administering amino acids during the first week 
of critical illness. 
In undernourished children, as well as well-nourished children, the optimal timing of 
initiating PN is currently unknown. As undernourishment on admission has consistently been 
associated with worse clinical outcomes (Chapter 4), physicians tend to start PN earlier in 
undernourished children than in well-nourished children (Chapter 2). However, up to date, 
there is no evidence showing that PN in the acute phase is capable of preventing 
undernourishment or deterioration of the nutritional status (Chapter 5). On the other hand, 
our study showed that also the children who were undernourished on admission benefitted 
from withholding PN during the first week of critical illness (Chapter 4). Therefore, withholding 
PN for a week in undernourished children seems to be the best approach with current 
knowledge. 
The results from our 2-years follow-up recognise the long-term consequences of 
paediatric critical illness that our patients can be confronted with (Chapter 6). As a large 
proportion of children was younger than 4 years old at follow-up, their neurocognitive 
function could not be assessed completely. Despite these limitations, the extensive 
neurocognitive deficits that we identified when comparing the post-PICU patients with 
matched healthy control children underline the need for clinical follow-up of these children 
after discharge. This follow-up should not only consist of a medical evaluation of growth and 
physical function, but should also address neurocognitive function, including screening for 
executive dysfunctions, emotional and behavioural problems, and memory difficulties. 
Furthermore, our study showed that including parent/caregiver-reported outcome measures 
provide added value for evaluating neuropsychological functions (Chapter 6). 
 
  
 
 
 
RECOMMENDATIONS 
 
Based on the results presented in this thesis and the available evidence with clinically relevant 
outcomes as discussed, we conclude and recommend the following: 
withholding PN during the first week of critical illness in children, while administering 
micronutrients, … 
1. can be considered, as this resulted in short-term and long-term benefits, with 
concomitant reduction of healthcare costs. 
2. is clinically beneficial in term neonates. Since the risk of hypoglycaemia is increased 
when PN is withheld, close monitoring of glucose levels is required to detect and treat 
hypoglycaemia adequately. 
3. is clinically beneficial in undernourished children, defined as weight Z-score <-2.  
 
Other recommendations are: 
4. Nutritional interventions during the acute phase of critical illness should aim at 
improving organ function and clinical outcomes.  
5. It is recommended to investigate the effect of a nutritional intervention not only in the 
short term and but also in the long term since short-term surrogate outcomes can 
contradict with clinically relevant long-term outcomes. 
6. Long-term follow-up should not only consist of a medical evaluation of growth and 
physical function, but should also address neurocognitive function, including the 
occurrence of executive dysfunction, emotional and behavioural problems, and 
memory difficulties.  
7. Due to increasing healthcare expenses, cost-effectiveness assessment should be an 
integral part of (nutritional) interventional research to enhance sustainable 
healthcare. 
8. Decreasing the duration of PICU stay by reducing new infections, is a major target to 
cut direct medical costs.  
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FUTURE PERSPECTIVES 
 
The short-term and long-term results of the PEPaNIC study underline the clinical importance 
of nutritional management. The recently published intensive care medicine clinical research 
agenda in paediatrics highlights the importance of further exploring feeding strategies in the 
next 10 years.237 The results described in this thesis have answered some important questions, 
but also raised new questions. Based on this thesis, future nutritional studies in PICU should 
focus on 3 areas:  
- unraveling underlying mechanisms of macronutrient restriction during the acute phase;  
- exploring the optimal timing and composition of (parenteral) nutrition;  
- further evaluating long-term consequences of critical illness in children. 
 
Unraveling underlying mechanisms 
Mechanistic studies provide more insight into underlying mechanisms of withholding PN, 
which in turn might reveal new opportunities to further improve outcomes. Endocrine 
responses in relation to nutritional interventions will be explored. Furthermore, the 
relationship between nutritional intervention, shortening of telomeres and long-term 
outcomes will be analysed. Finally, the role of epigenetic alterations will be explored. Early 
initiation of PN could alter an epigenetic profile, which might be related to worse long-term 
outcomes. These pre-planned mechanistic studies are currently ongoing and eagerly awaited.  
 
Exploring the optimal timing and composition of nutrition 
As with all new insights, these findings need to be confirmed with other studies. 
Furthermore, the PEPaNIC study compared initiating PN at day 1 to withholding PN during 
the first week in PICU. Such a strict and large difference in timing of initiating PN is necessary 
for scientific research to set a framework. However, this might not represent the optimal 
timing. Inevitably, there is a crossover point at which macronutrient restriction is no longer 
needed and will not be beneficial anymore. This timing is likely different per person and 
might also differ between age groups or could be depending on nutritional status. Therefore, 
an individualised approach is preferred. However, until now there is no set of biomarkers 
sufficiently sensitive and specific to predict when a patient is ready to receive PN or full EN. 
When evaluating effectiveness of such an individualised approach, this should ideally be 
compared with current nutritional practices in a randomised study using clinical outcomes. 
Assuming that a fasting response indeed is responsible for accelerated recovery from 
critical illness by withholding PN, then further amplification of this fasting response might 
result in even better clinical outcomes. Taking into account that amino acids/protein from EN 
and PN cumulative was associated with harm, a possible way to intensify the fasting response 
could be to reduce the amount of enteral protein during the acute phase while withholding 
PN. Investigating a strategy without providing any protein could be of interest.  
 Another way to support the fasting response in the acute phase could be intermittent 
enteral feeding and after the first week intermittent PN and/or EN. When investigating this 
 
 
 
strategy, the time between the periods of nutrient delivery should be sufficiently long to 
facilitate complete macronutrient uptake from EN and to induce a fasting response. Ideally, 
this intermittent feeding strategy would take into account the age-dependent circadian 
rhythm.  
 
Evaluating long-term consequences 
With regard to long-term outcomes, many questions are yet to be answered. As the youngest 
children were too young to complete all assessments, some neurocognitive domains have to 
be evaluated in these children in future studies. When children grow older, the demands for 
their neurocognitive abilities increase. Subsequently, deficits will become more clear with 
increasing age and neurocognitive tests should therefore be repeated when the children are 
older.  
 Our long-term follow-up identified the duration of treatment with benzodiazepines 
and corticosteroids as independent risk factors for worse neurocognitive outcome. Future, 
randomised studies are needed to investigate the effects of these medications in critically ill 
children. 
With all beneficial short-term and long-term effects of withholding PN as described in 
the literature and in this thesis, one could expect a positive effect on the quality of life of both 
the children and their parents as well. This will be a topic of research in the near future. 
Related to this topic is the assessment of QALYs, which can be used in long-term cost-
effectiveness analysis. When an effect is expressed as number of QALYs gained, cost-
effectiveness of different interventions can be compared with each other, which can be of 
added value in clinical decision making. 
 
 
 
CONCLUSION 
 
In critically ill children, irrespective of nutritional status or age, withholding PN during 
the first week, while administering micronutrients, was shown to be clinically beneficial 
in the short term and long term, as well as from a health economic point of view. By 
withholding PN in the acute phase of critical illness, the literal, as well as the figurative 
price to pay for paediatric critical illness can be reduced for children, their families, and 
society. 
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SUMMARY 
 
Chapter 1 
A significant proportion of critically ill children are unable to eat and drink themselves and 
therefore rely on artificial nutrition. Therefore, establishing optimal nutrition in sick children 
is generally accepted as essential therapy to enhance recovery from illness and to facilitate 
long-term growth and development. However, defining ‘optimal nutrition’ in paediatric critical 
illness is difficult because of heterogeneity in age, body composition, and the children’s 
underlying diseases and co-morbidities. Optimal nutrition differs not only between individual 
patients but also within a patient over time, during the different phases of critical illness: 
acute, stable, and recovery.  
Another problem with defining ‘optimal nutrition’ is the lack of support by high-level evidence 
to support timing, amount, and route of artificial nutrition in critically ill children. In the first 
chapter, we showed that most studies on nutrition for children admitted to the paediatric 
intensive care unit (PICU) used surrogate outcomes. We tried to provide insight on the 
imbalance between nutritional studies in critically children with surrogate and clinical 
outcome measures with help of a 5-step model consisting of surrogate outcome measures 
(step 1 biochemical indices, step 2 body composition, and step 3 organ function) and clinical 
outcome measures (step 4 short term outcome and step 5 long term and health-economic 
outcome). We summarized the current literature within each of these steps. The review in 
chapter 1 stresses the lack of well-designed, randomized trials with clinical endpoints that 
reliably validate current recommendations. This thesis focused on steps 4 and 5 to explore 
optimal nutrition in critically ill children. 
This thesis further elaborates on the results generated by the Early versus Late 
Parenteral Nutrition in the Paediatric Intensive Care Unit (PEPaNIC) randomized controlled 
trial, published in The New England Journal of Medicine in 2016, which showed that 
withholding parenteral nutrition (PN) during the first week (Late-PN) was clinically superior to 
initiation of PN at day 1 (Early-PN). Chapter 1 finishes with the aims and hypothesis of this 
thesis. 
 
Chapter 2 
Results from a worldwide survey showed that 1 year after the results of the PEPaNIC study 
were published, the majority of PICUs still administer PN during the first week of critical illness.  
However, about a quarter of the respondents opted to postpone PN beyond the first week, of 
whom half already withheld PN and half had de-implemented Early-PN. The most important 
reasons for retaining early initiation of PN were the conviction that amino acids are essential 
for critically ill children, doubts on the efficacy and safety of withholding PN for a week in 
undernourished children and neonates, and concerns on the long-term outcomes of delaying 
PN until after the first week.  These findings supported that the objectives addressed in this 
thesis are meaningful in clinical decision making, the development of new guidelines, and 
health-economic decisions.  
 
 
 
Chapter 3 
The neonatal population are a subgroup of critically ill children considered to be vulnerable to 
low nutritional intake. As many changes occur during the first month of life, we assessed the 
efficacy and safety of Late-PN in different age groups within the neonatal population included 
in PEPaNIC. In the subgroup of 290 term neonates ≤4 weeks, Late-PN was effective, except for 
the risk of new infections, which was not significantly different. However, Late-PN also 
resulted in a higher risk of hypoglycaemia. In neonates aged ≤1 week and neonates < 1 day, 
Late-PN was also effective, at the expense of a higher risk of hypoglycaemia. Interestingly, the 
effect seemed to have increasing impact for the younger children, suggesting an age-
dependent effect. Further analyses revealed that in critically ill term neonates, higher 
cumulative protein/amino acid intake was associated with a lower likelihood of an earlier 
discharge from PICU alive and a lower likelihood of an earlier weaning from mechanical 
ventilatory support alive, whereas lipids beyond the first few days were associated with a 
higher likelihood of an earlier discharge from PICU alive and an earlier weaning from 
mechanical ventilator support alive while the relation for carbohydrate intake was neutral. 
We concluded that in critically ill neonates, Late-PN was effective and the harm caused by 
Early-PN could possibly be attributed to higher protein/amino acid intake rather than lipids or 
carbohydrates. 
 
Chapter 4 
In chapter 4, we assessed the efficacy and safety of withholding PN during the first week in 
undernourished children, another important population considered to be vulnerable to 
macronutrient deficits. This pre-planned subgroup analysis of the PEPaNIC trial showed that 
in children already undernourished on admission (n=289), withholding PN during the first 
week was clinically superior as compared with initiating PN on the first day, in line with results 
of the main cohort. While Late-PN reduced the risk of new infections and increased the 
likelihood of an earlier discharge from both the PICU and hospital alive, and also the likelihood 
of an earlier weaning from mechanical ventilatory support alive, the safety outcomes were 
not significantly affected. Furthermore, the group receiving Late-PN did not suffer from more 
weight deterioration than the group with Early-PN, although this could only be investigated in 
a subset of patients (n=100). In a subgroup of severely undernourished children, the results 
were in line with those of undernourished children. In summary, there was no support for 
early initiation of PN even in undernourished children; in fact, delaying initiation of parenteral 
nutrition appeared to be beneficial. 
 
Chapter 5 
Another major concern raised by nutritional experts after the publication of the PEPaNIC 
results was the effect on weight deterioration due to reduced nutritional intake. Therefore, 
for chapter 5, we selected a subgroup of children included in PEPaNIC with longitudinal weight 
measurements available on admission and at discharge from the PICU (n=470) to evaluate 
their course of weight. Less weight Z-score deterioration during PICU stay was associated with 
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thesis are meaningful in clinical decision making, the development of new guidelines, and 
health-economic decisions.  
 
 
 
Chapter 3 
The neonatal population are a subgroup of critically ill children considered to be vulnerable to 
low nutritional intake. As many changes occur during the first month of life, we assessed the 
efficacy and safety of Late-PN in different age groups within the neonatal population included 
in PEPaNIC. In the subgroup of 290 term neonates ≤4 weeks, Late-PN was effective, except for 
the risk of new infections, which was not significantly different. However, Late-PN also 
resulted in a higher risk of hypoglycaemia. In neonates aged ≤1 week and neonates < 1 day, 
Late-PN was also effective, at the expense of a higher risk of hypoglycaemia. Interestingly, the 
effect seemed to have increasing impact for the younger children, suggesting an age-
dependent effect. Further analyses revealed that in critically ill term neonates, higher 
cumulative protein/amino acid intake was associated with a lower likelihood of an earlier 
discharge from PICU alive and a lower likelihood of an earlier weaning from mechanical 
ventilatory support alive, whereas lipids beyond the first few days were associated with a 
higher likelihood of an earlier discharge from PICU alive and an earlier weaning from 
mechanical ventilator support alive while the relation for carbohydrate intake was neutral. 
We concluded that in critically ill neonates, Late-PN was effective and the harm caused by 
Early-PN could possibly be attributed to higher protein/amino acid intake rather than lipids or 
carbohydrates. 
 
Chapter 4 
In chapter 4, we assessed the efficacy and safety of withholding PN during the first week in 
undernourished children, another important population considered to be vulnerable to 
macronutrient deficits. This pre-planned subgroup analysis of the PEPaNIC trial showed that 
in children already undernourished on admission (n=289), withholding PN during the first 
week was clinically superior as compared with initiating PN on the first day, in line with results 
of the main cohort. While Late-PN reduced the risk of new infections and increased the 
likelihood of an earlier discharge from both the PICU and hospital alive, and also the likelihood 
of an earlier weaning from mechanical ventilatory support alive, the safety outcomes were 
not significantly affected. Furthermore, the group receiving Late-PN did not suffer from more 
weight deterioration than the group with Early-PN, although this could only be investigated in 
a subset of patients (n=100). In a subgroup of severely undernourished children, the results 
were in line with those of undernourished children. In summary, there was no support for 
early initiation of PN even in undernourished children; in fact, delaying initiation of parenteral 
nutrition appeared to be beneficial. 
 
Chapter 5 
Another major concern raised by nutritional experts after the publication of the PEPaNIC 
results was the effect on weight deterioration due to reduced nutritional intake. Therefore, 
for chapter 5, we selected a subgroup of children included in PEPaNIC with longitudinal weight 
measurements available on admission and at discharge from the PICU (n=470) to evaluate 
their course of weight. Less weight Z-score deterioration during PICU stay was associated with 
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a lower risk of new infections and with a higher likelihood of earlier PICU discharge from PICU 
alive. Late-PN did not affect change in weight Z-score during PICU-stay. Thus, there appears 
to be no role for Early-PN to prevent weight Z-score deterioration during the acute phase of 
critical illness. In regard to the weight Z-score change on the short term, Late-PN can be 
considered a safe approach. 
 
Chapter 6 
As we showed in chapter 1, clinical outcomes should be primary outcome parameters in the 
evaluation of nutritional therapies. Since survival rates have increased to >95%, the long-term 
outcomes of PICU survivors have become important. Several studies in various PICU 
populations have found that PICU survivors often suffer from a long-term ‘legacy’ of critical 
illness, both in physical and neurocognitive functioning. From previous follow-up research in 
children randomized to tight glycaemic control or standard care, we have learned that a 
metabolic intervention during paediatric critical illness is able to improve long-term 
neurocognitive development.  Therefore, we followed-up the PICU survivors, assessing 
physical and neurocognitive functioning 2 years after participation in PEPaNIC, with a parallel 
group of healthy matched controls. With the results of PEPaNIC and those described in 
chapters 3 and 4 – a favorable short-term outcome with Late-PN, but higher risk of 
hypoglycaemia – in mind, these results were eagerly awaited.  
PICU survivors performed worse in a number of domains as compared with healthy 
matched controls. Furthermore, Late-PN did not negatively affect survival, growth, physical 
health status nor neurocognitive development, and even improved inhibitory control 
compared to Early-PN. There was no observed difference in the effect of Late PN for children 
who experienced a hypoglycaemic incident during the first week in PICU, compared to children 
who did not.  
 
Chapter 7 
Alongside the short- and long-term clinical consequences of withholding PN, there is also an 
economic aspect. With increasing healthcare expenses, there is a need for sustainable, 
affordable healthcare decisions. To make these decisions, the costs of an intervention have to 
be traded-off against the health benefits. We have conducted a health-economic analysis, 
using a micro-costing approach to calculate the direct healthcare costs of Early-PN versus Late-
PN, which showed that Late-PN saved, on average, approximately 7000 euro per patient. In 
considering the cost-saving elements versus the 7.3% reduction of new infections by Late-PN, 
it was undoubtedly found to be cost-effective, while further analyses, such as calculating an 
incremental cost-effectiveness ratio, were redundant. Children admitted for a medical reason 
other than neurologic disease represented the largest cost reduction, followed by children 
admitted for non-cardiac surgery.  We found that the largest reduction in costs was achieved 
in PICU hospitalization costs, medication costs, and costs for ventilator support, which 
together comprised 75% of the cost reduction. Regarding medication costs, 80% of this cost 
reduction could be attributed to medications for “blood and blood-forming organs” and anti-
 
 
 
infective agents. When further looking into the role of new infections, we found that 
preventing new infections was an important factor that contributed to reducing costs. The 
difference in costs between children with and without a new infection was on average 
approximately 70.000 euro per patient in the Early-PN group and on average approximately 
58.000 euro per patient in the Late-PN group, which was statistically significant. Thus, 
reducing the incidence of new infections by withholding PN seemed to be the key to reduce 
total direct healthcare costs. 
 
Chapter 8 
This chapter provides a reflection  on the main findings described in this thesis. Implications 
of our research for clinical practice are outlined. We conclude that withholding PN during the 
first week of paediatric critical illness can be considered, as this was beneficial in the short-
term ─ also in neonates and undernourished children ─, in the long-term, and from a health-
economic point of view. Based on our findings and currently available literature, 
recommendations for future nutritional research are made to further improve short-term and 
long-term outcomes of critically ill children. We propose that future nutritional research 
focuses on the following areas: 
- unravelling the underlying mechanisms of macronutrient restriction during the acute 
phase;  
- exploring the optimal timing and composition of (parenteral) nutrition;  
- further evaluating long-term consequences of critical illness in children. 
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it was undoubtedly found to be cost-effective, while further analyses, such as calculating an 
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together comprised 75% of the cost reduction. Regarding medication costs, 80% of this cost 
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infective agents. When further looking into the role of new infections, we found that 
preventing new infections was an important factor that contributed to reducing costs. The 
difference in costs between children with and without a new infection was on average 
approximately 70.000 euro per patient in the Early-PN group and on average approximately 
58.000 euro per patient in the Late-PN group, which was statistically significant. Thus, 
reducing the incidence of new infections by withholding PN seemed to be the key to reduce 
total direct healthcare costs. 
 
Chapter 8 
This chapter provides a reflection  on the main findings described in this thesis. Implications 
of our research for clinical practice are outlined. We conclude that withholding PN during the 
first week of paediatric critical illness can be considered, as this was beneficial in the short-
term ─ also in neonates and undernourished children ─, in the long-term, and from a health-
economic point of view. Based on our findings and currently available literature, 
recommendations for future nutritional research are made to further improve short-term and 
long-term outcomes of critically ill children. We propose that future nutritional research 
focuses on the following areas: 
- unravelling the underlying mechanisms of macronutrient restriction during the acute 
phase;  
- exploring the optimal timing and composition of (parenteral) nutrition;  
- further evaluating long-term consequences of critical illness in children. 
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SAMENVATTING 
 
Hoofdstuk 1 
Een aanzienlijk deel van de kinderen die kritiek ziek zijn kunnen niet zelf eten en drinken. 
Daarom krijgen zij kunstmatige voeding. Optimale voeding voor zieke kinderen wordt gezien 
als essentieel voor het herstel van ziekte en om (lange termijn) groei en ontwikkeling te 
bewerkstelligen. Echter, de definitie van ‘optimale voeding’ in kritiek zieke kinderen is lastig 
vanwege de grote verscheidenheid in leeftijden, lichaamssamenstellingen en onderliggende 
ziekten van de kinderen. Optimale voeding verschilt niet alleen tussen individuele patiënten, 
maar ook per persoon in de tijd tijdens de verschillende fasen van kritieke ziekte: acuut, stabiel 
en herstel. Een ander probleem bij het definiëren van optimale voeding is het gebrek aan 
wetenschappelijk bewijs met hoge kwaliteit om de beste timing, hoeveelheid en route van 
kunstmatige voeding in kritiek zieke kinderen te ondersteunen. In het eerste hoofdstuk van 
dit proefschrift hebben wij laten zien dat de meeste onderzoeken over voeding voor kinderen 
die opgenomen zijn op de kinder-intensive-care afdeling (PICU) gebruik hebben gemaakt van 
surrogaat uitkomstmaten. We hebben gepoogd om inzicht te geven in de disbalans tussen 
voedingsonderzoeken met surrogaat en klinische uitkomstmaten met behulp van een 5-staps 
model bestaande uit surrogaat uitkomstmaten (stap 1 biochemische parameters, stap 2 
lichaamssamenstelling en stap 3 orgaanfunctie) en klinische uitkomstmaten (stap 4 korte 
termijn uitkomsten en stap 5 lange termijn en gezondheids-economische uitkomsten). We 
hebben de bestaande literatuur binnen elk van deze stappen samengevat. Het overzicht in 
hoofdstuk 1 benadrukt het gebrek aan gerandomiseerde onderzoeken met klinische 
uitkomstmaten, waarmee de huidige aanbevelingen kunnen worden ondersteund. Dit 
proefschrift focust zich op stappen 4 en 5. 
Dit proefschrift bouwt verder op de resultaten van het gerandomiseerde, 
gecontroleerde onderzoek over “vroeg versus laat starten van infuusvoeding bij kritiek zieke 
kinderen” (PEPaNIC) , wat in 2016 gepubliceerd is in The New England Journal of Medicine, 
waarbij gevonden werd dat het niet geven van infuusvoeding (parenterale voeding) 
gedurende de eerste week van opname op de PICU klinisch superieur was ten opzichte van 
het vroeg starten van parenterale voeding op dag 1. Hoofdstuk 1 eindigt met de doelen en 
hypothesen van dit proefschrift. 
 
Hoofdstuk 2 
De resultaten van onze wereldwijde vragenlijst lieten zien dat, 1 jaar na bekendmaking van de 
resultaten van het PEPaNIC onderzoek, op de meerderheid van de PICU’s  nog steeds 
parenterale voeding in de eerste week van kritieke ziekte gegeven wordt. Ongeveer een kwart 
van de respondenten vulden in dat ze parenterale voeding uitstellen tot na de eerste week, 
waarvan de helft dit al deed en de andere helft het vroeg starten met parenterale voeding 
gestopt (gede-ïmplementeerd) heeft. De belangrijkste redenen die gegeven werden om vroeg 
te blijven starten met parenterale voeding waren de overtuiging dat eiwitten essentieel zijn 
voor kritiek zieke kinderen, twijfels over de effectiviteit en veiligheid van het onthouden van 
 
 
 
parenterale voeding in ondervoede kinderen en neonaten (kinderen jonger dan 1 maand) en 
zorgen over de lange termijn uitkomsten na het onthouden van parenterale voeding in de 
eerste week. Deze resultaten ondersteunden dat de onderwerpen die in dit proefschrift 
besproken worden belangrijk zijn voor nemen van beslissingen in de klinische praktijk, voor 
de ontwikkeling van nieuwe richtlijnen en bij het nemen van gezondheids-economische 
beslissingen. 
 
Hoofdstuk 3 
Een van de subgroepen van kritiek zieke kinderen die geacht worden extra kwetsbaar te zijn 
voor weinig voedingsinname is de groep neonaten. Omdat er gedurende de eerste 
levensmaand veel lichamelijke veranderingen optreden, hebben we de effectiviteit en 
veiligheid van het onthouden van parenterale voeding gedurende de eerste week in 
verschillende leeftijdsgroepen van a term geboren neonaten in het PEPaNIC onderzoek 
bekeken. In de subgroep van 209 neonaten ≤4 weken oud was het onthouden van parenterale 
voeding effectief, behalve voor het risico op nieuwe infecties, waarop geen significant effect 
werd gezien. Echter, het onthouden van parenterale voeding resulteerde ook in een hoger 
risico op lage bloedsuikers. Ook in neonaten ≤1 week en <1 dag oud was het niet geven van 
parenterale voeding effectief ten koste van een hoger risico op lage bloedsuikers. Het effect 
leek groter te worden naarmate de leeftijd jonger was, wat mogelijk wijst op een 
leeftijdsafhankelijk effect. Verdere analyses lieten zien dat in kritiek zieke a term geboren 
neonaten, hogere inname van eiwitten/aminozuren waren geassocieerd met een lagere 
waarschijnlijkheid om levend van de PICU ontslagen te worden en een lagere 
waarschijnlijkheid om levend van de ademhalingsondersteuning af te komen. Inname van 
vetten na de eerste paar dagen waren geassocieerd met een hogere waarschijnlijkheid om 
levend van de PICU ontslagen te worden en om levend van de ademhalingsondersteuning af 
te komen, terwijl de relatie tussen koolhydraten en klinische uitkomst  neutraal was. Wij 
concludeerden dat in kritiek zieke neonaten het niet geven van parenterale voeding effectief 
was en dat de schade die veroorzaakt werd door het wel geven van parenterale voeding 
mogelijk toegeschreven kon worden aan de inname van eiwitten/aminozuren, en niet vetten 
en koolhydraten. 
 
Hoofdstuk 4 
In hoofdstuk 4 hebben we de effectiviteit en veiligheid van het onthouden van parenterale 
voeding gedurende de eerste week van kritieke ziekte in ondervoede kinderen beschreven. 
Kinderen die ondervoed zijn bij opname is een belangrijke groep die geacht wordt extra 
kwetsbaar te zijn voor weinig voedingsinname. Deze geplande subgroep-analyse van het 
PEPaNIC onderzoek liet zien dat kinderen die bij opname ondervoed zijn (n=289) voordeel 
hebben van het niet geven van parenterale voeding in de eerste week als dit vergeleken wordt 
met het starten van parenterale voeding op dag 1. Deze resultaten kwamen overeen met wat 
gezien werd in de gehele groep in het PEPaNIC onderzoek. Het onthouden van parenterale 
voeding verminderde het risico op nieuwe infecties en verhoogde de waarschijnlijkheid om 
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levend van de PICU en uit het ziekenhuis ontslagen te worden en ook de waarschijnlijkheid 
om levend van de ademhalingsondersteuning af te komen. Er was geen significant effect op 
de veiligheidsuitkomsten. Bovendien had de groep kinderen die geen parenterale voeding 
kreeg niet meer achteruitgang van hun lichaamsgewicht dan de groep kinderen die wel 
parenterale voeding kreeg, hoewel dit slechts in een deel van de groep onderzocht kon 
worden (n=100). In de subgroep van ernstig ondervoede kinderen werden dezelfde resultaten 
gevonden. Samengevat, er is geen ondersteunend bewijs voor het vroeg starten van 
parenterale voeding in kinderen die ondervoed zijn bij opname op de PICU; juist het laat 
starten van parenterale voeding bleek gunstig te zijn. 
 
Hoofdstuk 5 
Een van de grote zorgen die geuit werd door voedingsdeskundigen nadat de resultaten van 
het PEPaNIC onderzoek gepubliceerd werden, was het effect van het onthouden van 
parenterale voeding op het gewichtsbeloop vanwege de verminderde voedingsinname bij 
deze strategie. Daarom hebben we voor hoofdstuk 5 een subgroep geselecteerd met kinderen 
in het PEPaNIC onderzoek die gewichtsmetingen hadden bij opname en ontslag van de PICU 
(n=470) om het gewichtsbeloop te onderzoeken. Wij vonden dat minder verslechtering van 
het gewicht geassocieerd was met een lager risico op nieuwe infecties en een hogere 
waarschijnlijkheid om levend ontslagen te worden van de PICU. Het onthouden van 
parenterale voeding had geen invloed op de mate van gewichtsverslechtering. Er lijkt dus geen 
rol voor vroege parenterale voeding in de acute fase van ziekte te zijn om 
gewichtsverslechtering te voorkomen. Wat betreft korte termijn gewichtsveranderingen kan 
het niet geven van parenterale voeding als veilig worden beoordeeld. 
 
Hoofdstuk 6 
Zoals beschreven in hoofdstuk 1 zouden klinische uitkomsten de belangrijkste uitkomstmaten 
moeten zijn bij het evalueren van (voedings-)interventies. Omdat het percentage kinderen dat 
kritieke ziekte overleeft in gestegen naar >95%, is de lange termijn uitkomst van deze PICU-
overlevenden een belangrijk aspect. Een aantal onderzoeken, gedaan in verschillende PICU 
populaties, hebben gevonden dat PICU overlevenden vaak geconfronteerd worden met lange 
termijn gevolgen, zowel in lichamelijk functioneren als ontwikkeling. Van een eerder follow-
up onderzoek hebben we geleerd dat een metabole interventie tijdens PICU opname de lange 
termijn ontwikkeling positief kan beïnvloeden. Daarom hebben de kinderen in het PEPaNIC 
onderzoek 2 jaar na opname op de PICU onderzocht op onder andere lichamelijk en mentale 
ontwikkeling, met een parallelle groep van gezonde kinderen van dezelfde leeftijd en geslacht. 
Met de bekende korte termijn resultaten van het PEPaNIC onderzoek en de resultaten zoals 
beschreven in hoofdstukken 3 en 4 in ons achterhoofd – betere korte termijn uitkomsten met 
onthouden van parenterale voeding, maar een hoger risico op lage bloedsuikers – keken wij 
uit naar deze lange termijn resultaten. 
PICU-overlevenden presteerden slechter in vele opzichten vergeleken met gezonde 
controle-kinderen. Bovendien vonden wij dat het niet geven van parenterale voeding 
 
 
 
gedurende de eerste week van opname geen negatief effect had op overlevingskansen, groei, 
lichamelijke gezondheid en neurocognitieve ontwikkeling, maar zelfs inhibitie (de capaciteit 
om primaire reacties te remmen) verbeterde in vergelijking met het vroeg starten met 
parenterale voeding. Er werden geen verschillen geobserveerd tussen kinderen die tijdens de 
eerste week van PICU-opname lage bloedsuikers hadden gehad en kinderen die geen dit niet 
hadden gehad. 
 
Hoofdstuk 7 
Naast de korte en lange termijn klinische consequenties van het onthouden van parenterale 
voeding is er ook een economisch aspect. Vanwege de stijgende zorguitgaven is er een nood 
aan duurzame en betaalbare beslissingen in de zorg. Om deze beslissingen te kunnen maken, 
moeten de kosten van een behandeling afgezet worden tegen de gezondheidswinst. Wij 
hebben een gezondheids-economische analyse gedaan, waarbij op microniveau de directe 
zorgkosten berekend werden van het vroeg versus laat starten van parenterale voeding, 
waaruit bleek dat het laat starten van parenterale voeding gemiddeld per patiënt ongeveer 
7000 euro bespaarde. Aangezien het onthouden van parenterale voeding kostenbesparend 
was, afgezet tegen 7.3% afname van nieuwe infecties, was deze strategie zonder twijfel 
kosteneffectief. Verdere analyses, zoals het berekenen van een kosten-effectiviteitsratio, 
waren dus overbodig. Kinderen die opgenomen waren vanwege een medische reden anders 
dan neurologische ziekte hadden de grootste kostenbesparing met het onthouden van 
parenterale voeding, gevold door kinderen die opgenomen waren na een operatie voor iets 
anders dan een hartafwijking. De grootste kostenbesparing werd bereikt in de categorieën 
opnamekosten van PICU ligdagen, medicatiekosten en kosten voor ademhalings-
ondersteuning, welke tezamen verantwoordelijk waren voor 75% van de kostenbesparing. 
Betreffende medicatiekosten, 80% hiervan kon toegeschreven worden aan medicatie voor 
“bloed en bloedvormende organen” en anti-infectie medicatie. Toen we de rol van nieuwe 
infecties verder onderzochten, vonden wij dat het voorkόmen van nieuwe infecties een 
belangrijke factor was in het verlagen van de kosten. Het verschil in kosten tussen kinderen 
met en zonder nieuwe infecties was ongeveer 70.000 euro per patiënt in de groep waar 
parenterale voeding vroeg werd gestart en ongeveer 58.000 euro per patiënt in de groep waar 
parenterale voeding onthouden werd, wat een statistische significant verschil was. 
Samengevat, het voorkόmen van nieuwe infecties door het niet geven van parenterale 
voeding was de sleutel tot verlaging van de totale directe zorgkosten. 
 
Hoofdstuk 8 
Dit hoofdstuk is een reflectie op de belangrijkste bevindingen beschreven in dit proefschrift. 
Implicaties van ons onderzoek voor de klinische praktijk worden beschreven. Wij concluderen 
dat het onthouden van parenterale voeding gedurende de eerste week van kritieke ziekte in 
kinderen overwogen kan worden, omdat dit voordelen had op de korte termijn ─ ook in 
neonaten en ondervoede kinderen ─, op de lange termijn en vanuit een gezondheids-
economisch oogpunt. Gebaseerd op onze bevindingen en de huidige literatuur doen wij 
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CHAPTER 9
aanbevelingen voor toekomstig voedingsonderzoek om de korte en lange termijn uitkomsten 
van kritiek zieke kinderen verder te verbeteren. Wij stellen voor dat toekomstig onderzoek 
zich richt op de volgende gebieden: 
- de onderliggende mechanismen van het beperken van voeding gedurende de acute
fase ontrafelen;
- de optimale timing en samenstelling van (parenterale) voeding uitzoeken;
- lange termijn gevolgen van kritieke ziekte in kinderen verder evalueren.
	 229
	SAMENVATTING
9
 
 
 
aanbevelingen voor toekomstig voedingsonderzoek om de korte en lange termijn uitkomsten 
van kritiek zieke kinderen verder te verbeteren. Wij stellen voor dat toekomstig onderzoek 
zich richt op de volgende gebieden: 
- de onderliggende mechanismen van het beperken van voeding gedurende de acute 
fase ontrafelen; 
- de optimale timing en samenstelling van (parenterale) voeding uitzoeken; 
- lange termijn gevolgen van kritieke ziekte in kinderen verder evalueren. 
  

Appendices
References
List of abbreviations
PhD portfolio
List of publications
About the author
Dankwoord
232 
APPENDICES	
 
 
 
REFERENCES 
 
1. Verbruggen SC, Coss-Bu J, Wu M, et al. Current recommended parenteral protein intakes do not 
support protein synthesis in critically ill septic, insulin-resistant adolescents with tight glucose 
control. Crit Care Med 2011; 39(11): 2518-25. 
2. de Betue CT, van Waardenburg DA, Deutz NE, et al. Increased protein-energy intake promotes 
anabolism in critically ill infants with viral bronchiolitis: a double-blind randomised controlled trial. 
Arch Dis Child 2011; 96(9): 817-22. 
3. Bechard LJ, Parrott JS, Mehta NM. Systematic review of the influence of energy and protein intake 
on protein balance in critically ill children. J Pediatr 2012; 161(2): 333-9 e1. 
4. Hulst JM, van Goudoever JB, Zimmermann LJ, et al. The effect of cumulative energy and protein 
deficiency on anthropometric parameters in a pediatric ICU population. Clin Nutr 2004; 23(6): 1381-
9. 
5. Bairdain S, Khan FA, Fisher J, et al. Nutritional outcomes in survivors of congenital diaphragmatic 
hernia (CDH)-factors associated with growth at one year. J Pediatr Surg 2015; 50(1): 74-7. 
6. Hong BJ, Moffett B, Payne W, Rich S, Ocampo EC, Petit CJ. Impact of postoperative nutrition on 
weight gain in infants with hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2014; 147(4): 
1319-25. 
7. Kaufman J, Vichayavilas P, Rannie M, et al. Improved nutrition delivery and nutrition status in 
critically ill children with heart disease. Pediatrics 2015; 135(3): e717-25. 
8. Mehta NM, Bechard LJ, Cahill N, et al. Nutritional practices and their relationship to clinical outcomes 
in critically ill children--an international multicenter cohort study*. Crit Care Med 2012; 40(7): 2204-
11. 
9. Mehta NM, Bechard LJ, Zurakowski D, Duggan CP, Heyland DK. Adequate enteral protein intake is 
inversely associated with 60-d mortality in critically ill children: a multicenter, prospective, cohort 
study. Am J Clin Nutr 2015; 102(1): 199-206. 
10. Joosten KF, Kerklaan D, Verbruggen SC. Nutritional support and the role of the stress response in 
critically ill children. Curr Opin Clin Nutr Metab Care 2016; 19(3): 226-33. 
11. Gielen M, Vanhorebeek I, Wouters PJ, et al. Amino acid concentrations in critically ill children 
following cardiac surgery*. Pediatr Crit Care Med 2014; 15(4): 314-28. 
12. Struijs MC, Schaible T, van Elburg RM, Debauche C, te Beest H, Tibboel D. Efficacy and safety of a 
parenteral amino acid solution containing alanyl-glutamine versus standard solution in infants: a 
first-in-man randomized double-blind trial. Clin Nutr 2013; 32(3): 331-7. 
13. de Betue CT, Joosten KF, Deutz NE, Vreugdenhil AC, van Waardenburg DA. Arginine appearance and 
nitric oxide synthesis in critically ill infants can be increased with a protein-energy-enriched enteral 
formula. Am J Clin Nutr 2013; 98(4): 907-16. 
14. van Waardenburg DA, de Betue CT, Goudoever JB, Zimmermann LJ, Joosten KF. Critically ill infants 
benefit from early administration of protein and energy-enriched formula: a randomized controlled 
trial. Clin Nutr 2009; 28(3): 249-55. 
15. Holst JJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK. Glucagon and Amino Acids Are Linked in a 
Mutual Feedback Cycle: The Liver-alpha-Cell Axis. Diabetes 2017; 66(2): 235-40. 
16. Thiessen SE, Derde S, Derese I, et al. Role of Glucagon in Catabolism and Muscle Wasting of Critical 
Illness and Modulation by Nutrition. Am J Respir Crit Care Med 2017; 196(9): 1131-43. 
17. Thiessen SE, Gunst J, Van den Berghe G. Role of glucagon in protein catabolism. Curr Opin Crit Care 
2018; 24(4): 228-34. 
18. Fivez T, Kerklaan D, Mesotten D, et al. Early versus Late Parenteral Nutrition in Critically Ill Children. 
N Engl J Med 2016; 374(12): 1111-22. 
 
 
 
19. Tin W, Brunskill G, Kelly T, Fritz S. 15-year follow-up of recurrent "hypoglycemia" in preterm infants. 
Pediatrics 2012; 130(6): e1497-503. 
20. Mesotten D, Gielen M, Sterken C, et al. Neurocognitive development of children 4 years after critical 
illness and treatment with tight glucose control: a randomized controlled trial. JAMA 2012; 308(16): 
1641-50. 
21. McKinlay CJD, Alsweiler JM, Anstice NS, et al. Association of Neonatal Glycemia With 
Neurodevelopmental Outcomes at 4.5 Years. JAMA Pediatr 2017; 171(10): 972-83. 
22. Kaiser JR, Bai S, Gibson N, et al. Association Between Transient Newborn Hypoglycemia and Fourth-
Grade Achievement Test Proficiency: A Population-Based Study. JAMA Pediatr 2015; 169(10): 913-
21. 
23. Stenninger E, Flink R, Eriksson B, Sahlen C. Long-term neurological dysfunction and neonatal 
hypoglycaemia after diabetic pregnancy. Arch Dis Child Fetal Neonatal Ed 1998; 79(3): F174-9. 
24. Nayak PP, Davies P, Narendran P, et al. Early change in blood glucose concentration is an indicator of 
mortality in critically ill children. Intensive Care Med 2013; 39(1): 123-8. 
25. Ognibene KL, Vawdrey DK, Biagas KV. The association of age, illness severity, and glycemic status in 
a pediatric intensive care unit. Pediatr Crit Care Med 2011; 12(6): e386-90. 
26. Srinivasan V, Agus MS. Tight glucose control in critically ill children--a systematic review and meta-
analysis. Pediatr Diabetes 2014; 15(2): 75-83. 
27. Jacobs BR, Nadkarni V, Goldstein B, et al. Nutritional immunomodulation in critically ill children with 
acute lung injury: feasibility and impact on circulating biomarkers. Pediatr Crit Care Med 2013; 14(1): 
e45-56. 
28. Finn KL, Chung M, Rothpletz-Puglia P, Byham-Gray L. Impact of Providing a Combination Lipid 
Emulsion Compared With a Standard Soybean Oil Lipid Emulsion in Children Receiving Parenteral 
Nutrition: A Systematic Review and Meta-Analysis. JPEN J Parenter Enteral Nutr 2015; 39(6): 656-67. 
29. Lapillonne A, Fidler Mis N, Goulet O, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric 
parenteral nutrition: Lipids. Clin Nutr 2018; 37(6 Pt B): 2324-36. 
30. Baena-Gomez MA, Aguilar MJ, Mesa MD, Navero JL, Gil-Campos M. Changes in Antioxidant Defense 
System Using Different Lipid Emulsions in Parenteral Nutrition in Children after Hematopoietic Stem 
Cell Transplantation. Nutrients 2015; 7(9): 7242-55. 
31. WHO/UNICEF/WFP/SCN. Community-based management of severe acute malnutrition; A Joint 
Statement by the World Health Organization, the World Food Programme, the United Nations 
System Standing Committee on Nutrition and the United Nations Children’s Fund, 2007. 
32. McVey L, Young D, Hulst J, et al. Development and validation of a novel paediatric weight estimation 
equation in multinational cohorts of sick children. Resuscitation 2017; 117: 118-21. 
33. de Souza Menezes F, Leite HP, Koch Nogueira PC. Malnutrition as an independent predictor of clinical 
outcome in critically ill children. Nutrition 2012; 28(3): 267-70. 
34. Prince NJ, Brown KL, Mebrahtu TF, Parslow RC, Peters MJ. Weight-for-age distribution and case-mix 
adjusted outcomes of 14,307 paediatric intensive care admissions. Intensive Care Med 2014; 40(8): 
1132-9. 
35. Bagri NK, Jose B, Shah SK, Bhutia TD, Kabra SK, Lodha R. Impact of Malnutrition on the Outcome of 
Critically Ill Children. Indian J Pediatr 2015; 82(7): 601-5. 
36. Leite HP, de Lima LF, de Oliveira Iglesias SB, Pacheco JC, de Carvalho WB. Malnutrition may worsen 
the prognosis of critically ill children with hyperglycemia and hypoglycemia. JPEN J Parenter Enteral 
Nutr 2013; 37(3): 335-41. 
37. Martinez EE, Ariagno K, Arriola A, Lara K, Mehta NM. Challenges to nutrition therapy in the pediatric 
critically ill obese patient. Nutr Clin Pract 2015; 30(3): 432-9. 
	 233
REFERENCES	
 
 
 
REFERENCES 
 
1. Verbruggen SC, Coss-Bu J, Wu M, et al. Current recommended parenteral protein intakes do not 
support protein synthesis in critically ill septic, insulin-resistant adolescents with tight glucose 
control. Crit Care Med 2011; 39(11): 2518-25. 
2. de Betue CT, van Waardenburg DA, Deutz NE, et al. Increased protein-energy intake promotes 
anabolism in critically ill infants with viral bronchiolitis: a double-blind randomised controlled trial. 
Arch Dis Child 2011; 96(9): 817-22. 
3. Bechard LJ, Parrott JS, Mehta NM. Systematic review of the influence of energy and protein intake 
on protein balance in critically ill children. J Pediatr 2012; 161(2): 333-9 e1. 
4. Hulst JM, van Goudoever JB, Zimmermann LJ, et al. The effect of cumulative energy and protein 
deficiency on anthropometric parameters in a pediatric ICU population. Clin Nutr 2004; 23(6): 1381-
9. 
5. Bairdain S, Khan FA, Fisher J, et al. Nutritional outcomes in survivors of congenital diaphragmatic 
hernia (CDH)-factors associated with growth at one year. J Pediatr Surg 2015; 50(1): 74-7. 
6. Hong BJ, Moffett B, Payne W, Rich S, Ocampo EC, Petit CJ. Impact of postoperative nutrition on 
weight gain in infants with hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2014; 147(4): 
1319-25. 
7. Kaufman J, Vichayavilas P, Rannie M, et al. Improved nutrition delivery and nutrition status in 
critically ill children with heart disease. Pediatrics 2015; 135(3): e717-25. 
8. Mehta NM, Bechard LJ, Cahill N, et al. Nutritional practices and their relationship to clinical outcomes 
in critically ill children--an international multicenter cohort study*. Crit Care Med 2012; 40(7): 2204-
11. 
9. Mehta NM, Bechard LJ, Zurakowski D, Duggan CP, Heyland DK. Adequate enteral protein intake is 
inversely associated with 60-d mortality in critically ill children: a multicenter, prospective, cohort 
study. Am J Clin Nutr 2015; 102(1): 199-206. 
10. Joosten KF, Kerklaan D, Verbruggen SC. Nutritional support and the role of the stress response in 
critically ill children. Curr Opin Clin Nutr Metab Care 2016; 19(3): 226-33. 
11. Gielen M, Vanhorebeek I, Wouters PJ, et al. Amino acid concentrations in critically ill children 
following cardiac surgery*. Pediatr Crit Care Med 2014; 15(4): 314-28. 
12. Struijs MC, Schaible T, van Elburg RM, Debauche C, te Beest H, Tibboel D. Efficacy and safety of a 
parenteral amino acid solution containing alanyl-glutamine versus standard solution in infants: a 
first-in-man randomized double-blind trial. Clin Nutr 2013; 32(3): 331-7. 
13. de Betue CT, Joosten KF, Deutz NE, Vreugdenhil AC, van Waardenburg DA. Arginine appearance and 
nitric oxide synthesis in critically ill infants can be increased with a protein-energy-enriched enteral 
formula. Am J Clin Nutr 2013; 98(4): 907-16. 
14. van Waardenburg DA, de Betue CT, Goudoever JB, Zimmermann LJ, Joosten KF. Critically ill infants 
benefit from early administration of protein and energy-enriched formula: a randomized controlled 
trial. Clin Nutr 2009; 28(3): 249-55. 
15. Holst JJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK. Glucagon and Amino Acids Are Linked in a 
Mutual Feedback Cycle: The Liver-alpha-Cell Axis. Diabetes 2017; 66(2): 235-40. 
16. Thiessen SE, Derde S, Derese I, et al. Role of Glucagon in Catabolism and Muscle Wasting of Critical 
Illness and Modulation by Nutrition. Am J Respir Crit Care Med 2017; 196(9): 1131-43. 
17. Thiessen SE, Gunst J, Van den Berghe G. Role of glucagon in protein catabolism. Curr Opin Crit Care 
2018; 24(4): 228-34. 
18. Fivez T, Kerklaan D, Mesotten D, et al. Early versus Late Parenteral Nutrition in Critically Ill Children. 
N Engl J Med 2016; 374(12): 1111-22. 
 
 
 
19. Tin W, Brunskill G, Kelly T, Fritz S. 15-year follow-up of recurrent "hypoglycemia" in preterm infants. 
Pediatrics 2012; 130(6): e1497-503. 
20. Mesotten D, Gielen M, Sterken C, et al. Neurocognitive development of children 4 years after critical 
illness and treatment with tight glucose control: a randomized controlled trial. JAMA 2012; 308(16): 
1641-50. 
21. McKinlay CJD, Alsweiler JM, Anstice NS, et al. Association of Neonatal Glycemia With 
Neurodevelopmental Outcomes at 4.5 Years. JAMA Pediatr 2017; 171(10): 972-83. 
22. Kaiser JR, Bai S, Gibson N, et al. Association Between Transient Newborn Hypoglycemia and Fourth-
Grade Achievement Test Proficiency: A Population-Based Study. JAMA Pediatr 2015; 169(10): 913-
21. 
23. Stenninger E, Flink R, Eriksson B, Sahlen C. Long-term neurological dysfunction and neonatal 
hypoglycaemia after diabetic pregnancy. Arch Dis Child Fetal Neonatal Ed 1998; 79(3): F174-9. 
24. Nayak PP, Davies P, Narendran P, et al. Early change in blood glucose concentration is an indicator of 
mortality in critically ill children. Intensive Care Med 2013; 39(1): 123-8. 
25. Ognibene KL, Vawdrey DK, Biagas KV. The association of age, illness severity, and glycemic status in 
a pediatric intensive care unit. Pediatr Crit Care Med 2011; 12(6): e386-90. 
26. Srinivasan V, Agus MS. Tight glucose control in critically ill children--a systematic review and meta-
analysis. Pediatr Diabetes 2014; 15(2): 75-83. 
27. Jacobs BR, Nadkarni V, Goldstein B, et al. Nutritional immunomodulation in critically ill children with 
acute lung injury: feasibility and impact on circulating biomarkers. Pediatr Crit Care Med 2013; 14(1): 
e45-56. 
28. Finn KL, Chung M, Rothpletz-Puglia P, Byham-Gray L. Impact of Providing a Combination Lipid 
Emulsion Compared With a Standard Soybean Oil Lipid Emulsion in Children Receiving Parenteral 
Nutrition: A Systematic Review and Meta-Analysis. JPEN J Parenter Enteral Nutr 2015; 39(6): 656-67. 
29. Lapillonne A, Fidler Mis N, Goulet O, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric 
parenteral nutrition: Lipids. Clin Nutr 2018; 37(6 Pt B): 2324-36. 
30. Baena-Gomez MA, Aguilar MJ, Mesa MD, Navero JL, Gil-Campos M. Changes in Antioxidant Defense 
System Using Different Lipid Emulsions in Parenteral Nutrition in Children after Hematopoietic Stem 
Cell Transplantation. Nutrients 2015; 7(9): 7242-55. 
31. WHO/UNICEF/WFP/SCN. Community-based management of severe acute malnutrition; A Joint 
Statement by the World Health Organization, the World Food Programme, the United Nations 
System Standing Committee on Nutrition and the United Nations Children’s Fund, 2007. 
32. McVey L, Young D, Hulst J, et al. Development and validation of a novel paediatric weight estimation 
equation in multinational cohorts of sick children. Resuscitation 2017; 117: 118-21. 
33. de Souza Menezes F, Leite HP, Koch Nogueira PC. Malnutrition as an independent predictor of clinical 
outcome in critically ill children. Nutrition 2012; 28(3): 267-70. 
34. Prince NJ, Brown KL, Mebrahtu TF, Parslow RC, Peters MJ. Weight-for-age distribution and case-mix 
adjusted outcomes of 14,307 paediatric intensive care admissions. Intensive Care Med 2014; 40(8): 
1132-9. 
35. Bagri NK, Jose B, Shah SK, Bhutia TD, Kabra SK, Lodha R. Impact of Malnutrition on the Outcome of 
Critically Ill Children. Indian J Pediatr 2015; 82(7): 601-5. 
36. Leite HP, de Lima LF, de Oliveira Iglesias SB, Pacheco JC, de Carvalho WB. Malnutrition may worsen 
the prognosis of critically ill children with hyperglycemia and hypoglycemia. JPEN J Parenter Enteral 
Nutr 2013; 37(3): 335-41. 
37. Martinez EE, Ariagno K, Arriola A, Lara K, Mehta NM. Challenges to nutrition therapy in the pediatric 
critically ill obese patient. Nutr Clin Pract 2015; 30(3): 432-9. 
234 
APPENDICES	
38. Goh VL, Wakeham MK, Brazauskas R, Mikhailov TA, Goday PS. Obesity is not associated with
increased mortality and morbidity in critically ill children. JPEN J Parenter Enteral Nutr 2013; 37(1):
102-8. 
39. Bechard LJ, Duggan C, Touger-Decker R, et al. Nutritional Status Based on Body Mass Index Is
Associated With Morbidity and Mortality in Mechanically Ventilated Critically Ill Children in the PICU. 
Crit Care Med 2016; 44(8): 1530-7. 
40. Bechard LJ, Rothpletz-Puglia P, Touger-Decker R, Duggan C, Mehta NM. Influence of obesity on
clinical outcomes in hospitalized children: a systematic review. JAMA Pediatr 2013; 167(5): 476-82. 
41. Patel L, Cowden JD, Dowd D, Hampl S, Felich N. Obesity: influence on length of hospital stay for the
pediatric burn patient. J Burn Care Res 2010; 31(2): 251-6. 
42. Hulst J, Joosten K, Zimmermann L, et al. Malnutrition in critically ill children: from admission to 6
months after discharge. Clin Nutr 2004; 23(2): 223-32. 
43. de Betue CT, van Steenselen WN, Hulst JM, et al. Achieving energy goals at day 4 after admission in
critically ill children; predictive for outcome? Clin Nutr 2015; 34(1): 115-22. 
44. Valla FV, Berthiller J, Gaillard-Le-Roux B, et al. Faltering growth in the critically ill child: prevalence,
risk factors, and impaired outcome. Eur J Pediatr 2018; 177(3): 345-53. 
45. Kraft R, Herndon DN, Williams FN, Al-Mousawi AM, Finnerty CC, Jeschke MG. The effect of obesity
on adverse outcomes and metabolism in pediatric burn patients. Int J Obes (Lond) 2012; 36(4): 485-
90. 
46. Marino LV, Meyer R, Johnson M, et al. Bioimpedance spectroscopy measurements of phase angle
and height for age are predictive of outcome in children following surgery for congenital heart
disease. Clin Nutr 2018; 37(4): 1430-6. 
47. Banwell BL, Mildner RJ, Hassall AC, Becker LE, Vajsar J, Shemie SD. Muscle weakness in critically ill
children. Neurology 2003; 61(12): 1779-82. 
48. Choong K, Al-Harbi S, Siu K, et al. Functional recovery following critical illness in children: the "wee-
cover" pilot study. Pediatr Crit Care Med 2015; 16(4): 310-8. 
49. Valla FV, Young DK, Rabilloud M, et al. Thigh Ultrasound Monitoring Identifies Decreases in
Quadriceps Femoris Thickness as a Frequent Observation in Critically Ill Children. Pediatr Crit Care
Med 2017; 18(8): e339-e47. 
50. Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of diaphragm fibers in mechanically
ventilated humans. N Engl J Med 2008; 358(13): 1327-35. 
51. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory 
distress syndrome. N Engl J Med 2003; 348(8): 683-93. 
52. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress 
syndrome. N Engl J Med 2011; 364(14): 1293-304. 
53. Field-Ridley A, Dharmar M, Steinhorn D, McDonald C, Marcin JP. ICU-Acquired Weakness Is 
Associated With Differences in Clinical Outcomes in Critically Ill Children. Pediatr Crit Care Med 2016; 
17(1): 53-7. 
54. Norman K, Stobaus N, Kulka K, Schulzke J. Effect of inflammation on handgrip strength in the non-
critically ill is independent from age, gender and body composition. Eur J Clin Nutr 2014; 68(2): 155-
8. 
55. Hermans G, Casaer MP, Clerckx B, et al. Effect of tolerating macronutrient deficit on the development 
of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med 2013; 
1(8): 621-9. 
56. den Brinker M, Dumas B, Visser TJ, et al. Thyroid function and outcome in children who survived
meningococcal septic shock. Intensive Care Med 2005; 31(7): 970-6. 
57. Casaer MP, Langouche L, Coudyzer W, et al. Impact of early parenteral nutrition on muscle and
adipose tissue compartments during critical illness. Crit Care Med 2013; 41(10): 2298-309.
58. Gottschlich MM, Jenkins ME, Mayes T, Khoury J, Kagan RJ, Warden GD. The 2002 Clinical Research
Award. An evaluation of the safety of early vs delayed enteral support and effects on clinical,
nutritional, and endocrine outcomes after severe burns. J Burn Care Rehabil 2002; 23(6): 401-15.
59. Gielen M, Mesotten D, Wouters PJ, et al. Effect of tight glucose control with insulin on the thyroid
axis of critically ill children and its relation with outcome. J Clin Endocrinol Metab 2012; 97(10): 3569-
76.
60. Gielen M, Mesotten D, Brugts M, et al. Effect of intensive insulin therapy on the somatotropic axis of
critically ill children. J Clin Endocrinol Metab 2011; 96(8): 2558-66.
61. Meersseman P, Boonen E, Peeters B, et al. Effect of Early Parenteral Nutrition on the HPA Axis and
on Treatment With Corticosteroids in Intensive Care Patients. J Clin Endocrinol Metab 2015; 100(7):
2613-20.
62. Jenniskens M, Guiza F, Haghedooren R, et al. Prevalence and Prognostic Value of Abnormal Liver Test
Results in Critically Ill Children and the Impact of Delaying Parenteral Nutrition. Pediatr Crit Care Med
2018.
63. Patterson BW, Nguyen T, Pierre E, Herndon DN, Wolfe RR. Urea and protein metabolism in burned
children: effect of dietary protein intake. Metabolism 1997; 46(5): 573-8.
64. Pollack MM, Holubkov R, Funai T, et al. The Pediatric Risk of Mortality Score: Update 2015. Pediatr
Crit Care Med 2016; 17(1): 2-9.
65. Taha AA, Badr L, Westlake C, Dee V, Mudit M, Tiras KL. Effect of early nutritional support on intensive
care unit length of stay and neurological status at discharge in children with severe traumatic brain
injury. J Neurosci Nurs 2011; 43(6): 291-7.
66. Mikhailov TA, Kuhn EM, Manzi J, et al. Early enteral nutrition is associated with lower mortality in
critically ill children. JPEN J Parenter Enteral Nutr 2014; 38(4): 459-66.
67. Kerklaan D, Fivez T, Mehta NM, et al. Worldwide Survey of Nutritional Practices in PICUs. Pediatr Crit
Care Med 2016; 17(1): 10-8.
68. Fivez T, Kerklaan D, Mesotten D, Verbruggen S, Joosten K, Van den Berghe G. Evidence for the use of
parenteral nutrition in the pediatric intensive care unit. Clin Nutr 2017; 36(1): 218-23.
69. Joffe A, Anton N, Lequier L, et al. Nutritional support for critically ill children. Cochrane Database Syst
Rev 2016; (5): CD005144.
70. Vanhorebeek I, Verbruggen S, Casaer MP, et al. Effect of early supplemental parenteral nutrition in
the paediatric ICU: a preplanned observational study of post-randomisation treatments in the
PEPaNIC trial. Lancet Respir Med 2017; 5(6): 475-83.
71. Goulet O, Jochum F, Koletzko B. Early or Late Parenteral Nutrition in Critically Ill Children: Practical
Implications of the PEPaNIC Trial. Ann Nutr Metab 2017; 70(1): 34-8.
72. Vichayavilas P, Gist K, Kaufman J. More and sooner, but not necessarily better. J Thorac Dis 2016;
8(8): 1877-9.
73. Groenendaal F. Early versus Late Parenteral Nutrition in Critically Ill Children. N Engl J Med 2016;
375(4): 384.
74. Mehta NM, Skillman HE, Irving SY, et al. Guidelines for the Provision and Assessment of Nutrition
Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American
Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr 2017; 41(5): 706-42.
75. Koletzko B, Goulet O, Jochum F, Shamir R. Use of parenteral nutrition in the pediatric ICU: should we
panic because of PEPaNIC? Curr Opin Clin Nutr Metab Care 2017; 20(3): 201-3.
76. Larsen BM, Goonewardene LA, Field CJ, et al. Low energy intakes are associated with adverse
outcomes in infants after open heart surgery. JPEN J Parenter Enteral Nutr 2013; 37(2): 254-60.
	 235
REFERENCES	
 
 
 
38. Goh VL, Wakeham MK, Brazauskas R, Mikhailov TA, Goday PS. Obesity is not associated with 
increased mortality and morbidity in critically ill children. JPEN J Parenter Enteral Nutr 2013; 37(1): 
102-8. 
39. Bechard LJ, Duggan C, Touger-Decker R, et al. Nutritional Status Based on Body Mass Index Is 
Associated With Morbidity and Mortality in Mechanically Ventilated Critically Ill Children in the PICU. 
Crit Care Med 2016; 44(8): 1530-7. 
40. Bechard LJ, Rothpletz-Puglia P, Touger-Decker R, Duggan C, Mehta NM. Influence of obesity on 
clinical outcomes in hospitalized children: a systematic review. JAMA Pediatr 2013; 167(5): 476-82. 
41. Patel L, Cowden JD, Dowd D, Hampl S, Felich N. Obesity: influence on length of hospital stay for the 
pediatric burn patient. J Burn Care Res 2010; 31(2): 251-6. 
42. Hulst J, Joosten K, Zimmermann L, et al. Malnutrition in critically ill children: from admission to 6 
months after discharge. Clin Nutr 2004; 23(2): 223-32. 
43. de Betue CT, van Steenselen WN, Hulst JM, et al. Achieving energy goals at day 4 after admission in 
critically ill children; predictive for outcome? Clin Nutr 2015; 34(1): 115-22. 
44. Valla FV, Berthiller J, Gaillard-Le-Roux B, et al. Faltering growth in the critically ill child: prevalence, 
risk factors, and impaired outcome. Eur J Pediatr 2018; 177(3): 345-53. 
45. Kraft R, Herndon DN, Williams FN, Al-Mousawi AM, Finnerty CC, Jeschke MG. The effect of obesity 
on adverse outcomes and metabolism in pediatric burn patients. Int J Obes (Lond) 2012; 36(4): 485-
90. 
46. Marino LV, Meyer R, Johnson M, et al. Bioimpedance spectroscopy measurements of phase angle 
and height for age are predictive of outcome in children following surgery for congenital heart 
disease. Clin Nutr 2018; 37(4): 1430-6. 
47. Banwell BL, Mildner RJ, Hassall AC, Becker LE, Vajsar J, Shemie SD. Muscle weakness in critically ill 
children. Neurology 2003; 61(12): 1779-82. 
48. Choong K, Al-Harbi S, Siu K, et al. Functional recovery following critical illness in children: the "wee-
cover" pilot study. Pediatr Crit Care Med 2015; 16(4): 310-8. 
49. Valla FV, Young DK, Rabilloud M, et al. Thigh Ultrasound Monitoring Identifies Decreases in 
Quadriceps Femoris Thickness as a Frequent Observation in Critically Ill Children. Pediatr Crit Care 
Med 2017; 18(8): e339-e47. 
50. Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of diaphragm fibers in mechanically 
ventilated humans. N Engl J Med 2008; 358(13): 1327-35. 
51. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory 
distress syndrome. N Engl J Med 2003; 348(8): 683-93. 
52. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress 
syndrome. N Engl J Med 2011; 364(14): 1293-304. 
53. Field-Ridley A, Dharmar M, Steinhorn D, McDonald C, Marcin JP. ICU-Acquired Weakness Is 
Associated With Differences in Clinical Outcomes in Critically Ill Children. Pediatr Crit Care Med 2016; 
17(1): 53-7. 
54. Norman K, Stobaus N, Kulka K, Schulzke J. Effect of inflammation on handgrip strength in the non-
critically ill is independent from age, gender and body composition. Eur J Clin Nutr 2014; 68(2): 155-
8. 
55. Hermans G, Casaer MP, Clerckx B, et al. Effect of tolerating macronutrient deficit on the development 
of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med 2013; 
1(8): 621-9. 
56. den Brinker M, Dumas B, Visser TJ, et al. Thyroid function and outcome in children who survived 
meningococcal septic shock. Intensive Care Med 2005; 31(7): 970-6. 
 
 
 
57. Casaer MP, Langouche L, Coudyzer W, et al. Impact of early parenteral nutrition on muscle and 
adipose tissue compartments during critical illness. Crit Care Med 2013; 41(10): 2298-309. 
58. Gottschlich MM, Jenkins ME, Mayes T, Khoury J, Kagan RJ, Warden GD. The 2002 Clinical Research 
Award. An evaluation of the safety of early vs delayed enteral support and effects on clinical, 
nutritional, and endocrine outcomes after severe burns. J Burn Care Rehabil 2002; 23(6): 401-15. 
59. Gielen M, Mesotten D, Wouters PJ, et al. Effect of tight glucose control with insulin on the thyroid 
axis of critically ill children and its relation with outcome. J Clin Endocrinol Metab 2012; 97(10): 3569-
76. 
60. Gielen M, Mesotten D, Brugts M, et al. Effect of intensive insulin therapy on the somatotropic axis of 
critically ill children. J Clin Endocrinol Metab 2011; 96(8): 2558-66. 
61. Meersseman P, Boonen E, Peeters B, et al. Effect of Early Parenteral Nutrition on the HPA Axis and 
on Treatment With Corticosteroids in Intensive Care Patients. J Clin Endocrinol Metab 2015; 100(7): 
2613-20. 
62. Jenniskens M, Guiza F, Haghedooren R, et al. Prevalence and Prognostic Value of Abnormal Liver Test 
Results in Critically Ill Children and the Impact of Delaying Parenteral Nutrition. Pediatr Crit Care Med 
2018. 
63. Patterson BW, Nguyen T, Pierre E, Herndon DN, Wolfe RR. Urea and protein metabolism in burned 
children: effect of dietary protein intake. Metabolism 1997; 46(5): 573-8. 
64. Pollack MM, Holubkov R, Funai T, et al. The Pediatric Risk of Mortality Score: Update 2015. Pediatr 
Crit Care Med 2016; 17(1): 2-9. 
65. Taha AA, Badr L, Westlake C, Dee V, Mudit M, Tiras KL. Effect of early nutritional support on intensive 
care unit length of stay and neurological status at discharge in children with severe traumatic brain 
injury. J Neurosci Nurs 2011; 43(6): 291-7. 
66. Mikhailov TA, Kuhn EM, Manzi J, et al. Early enteral nutrition is associated with lower mortality in 
critically ill children. JPEN J Parenter Enteral Nutr 2014; 38(4): 459-66. 
67. Kerklaan D, Fivez T, Mehta NM, et al. Worldwide Survey of Nutritional Practices in PICUs. Pediatr Crit 
Care Med 2016; 17(1): 10-8. 
68. Fivez T, Kerklaan D, Mesotten D, Verbruggen S, Joosten K, Van den Berghe G. Evidence for the use of 
parenteral nutrition in the pediatric intensive care unit. Clin Nutr 2017; 36(1): 218-23. 
69. Joffe A, Anton N, Lequier L, et al. Nutritional support for critically ill children. Cochrane Database Syst 
Rev 2016; (5): CD005144. 
70. Vanhorebeek I, Verbruggen S, Casaer MP, et al. Effect of early supplemental parenteral nutrition in 
the paediatric ICU: a preplanned observational study of post-randomisation treatments in the 
PEPaNIC trial. Lancet Respir Med 2017; 5(6): 475-83. 
71. Goulet O, Jochum F, Koletzko B. Early or Late Parenteral Nutrition in Critically Ill Children: Practical 
Implications of the PEPaNIC Trial. Ann Nutr Metab 2017; 70(1): 34-8. 
72. Vichayavilas P, Gist K, Kaufman J. More and sooner, but not necessarily better. J Thorac Dis 2016; 
8(8): 1877-9. 
73. Groenendaal F. Early versus Late Parenteral Nutrition in Critically Ill Children. N Engl J Med 2016; 
375(4): 384. 
74. Mehta NM, Skillman HE, Irving SY, et al. Guidelines for the Provision and Assessment of Nutrition 
Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American 
Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr 2017; 41(5): 706-42. 
75. Koletzko B, Goulet O, Jochum F, Shamir R. Use of parenteral nutrition in the pediatric ICU: should we 
panic because of PEPaNIC? Curr Opin Clin Nutr Metab Care 2017; 20(3): 201-3. 
76. Larsen BM, Goonewardene LA, Field CJ, et al. Low energy intakes are associated with adverse 
outcomes in infants after open heart surgery. JPEN J Parenter Enteral Nutr 2013; 37(2): 254-60. 
236 
APPENDICES	
 
 
 
77. Mehta NM, McAleer D, Hamilton S, et al. Challenges to optimal enteral nutrition in a multidisciplinary 
pediatric intensive care unit. JPEN J Parenter Enteral Nutr 2010; 34(1): 38-45. 
78. Herrup EA, Wieczorek B, Kudchadkar SR. Characteristics of postintensive care syndrome in survivors 
of pediatric critical illness: A systematic review. World J Crit Care Med 2017; 6(2): 124-34. 
79. Pinto NP, Rhinesmith EW, Kim TY, Ladner PH, Pollack MM. Long-Term Function After Pediatric Critical 
Illness: Results From the Survivor Outcomes Study. Pediatr Crit Care Med 2017; 18(3): e122-e30. 
80. Vergouwe FWT, Spoel M, van Beelen NWG, et al. Longitudinal evaluation of growth in oesophageal 
atresia patients up to 12 years. Arch Dis Child Fetal Neonatal Ed 2017; 102(5): F417-F22. 
81. Leeuwen L, Mous DS, van Rosmalen J, et al. Congenital Diaphragmatic Hernia and Growth to 12 Years. 
Pediatrics 2017; 140(2). 
82. Mammen C, Al Abbas A, Skippen P, et al. Long-term risk of CKD in children surviving episodes of acute 
kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis 2012; 59(4): 523-
30. 
83. Williams S, Horrocks IA, Ouvrier RA, Gillis J, Ryan MM. Critical illness polyneuropathy and myopathy 
in pediatric intensive care: A review. Pediatr Crit Care Med 2007; 8(1): 18-22. 
84. Nyaradi A, Li J, Hickling S, Foster J, Oddy WH. The role of nutrition in children's neurocognitive 
development, from pregnancy through childhood. Front Hum Neurosci 2013; 7: 97. 
85. Burkhalter TM, Hillman CH. A narrative review of physical activity, nutrition, and obesity to cognition 
and scholastic performance across the human lifespan. Adv Nutr 2011; 2(2): 201S-6S. 
86. Anjos T, Altmae S, Emmett P, et al. Nutrition and neurodevelopment in children: focus on 
NUTRIMENTHE project. Eur J Nutr 2013; 52(8): 1825-42. 
87. Kachmar AG, Irving SY, Connolly CA, Curley MAQ. A Systematic Review of Risk Factors Associated 
With Cognitive Impairment After Pediatric Critical Illness. Pediatr Crit Care Med 2018; 19(3): e164-
e71. 
88. Aspesberro F, Mangione-Smith R, Zimmerman JJ. Health-related quality of life following pediatric 
critical illness. Intensive Care Med 2015; 41(7): 1235-46. 
89. Madderom MJ, Gischler SJ, Duivenvoorden H, Tibboel D, Ijsselstijn H. Neonatal extracorporeal 
membrane oxygenation: impaired health at 5 years of age. Pediatr Crit Care Med 2013; 14(2): 183-
93. 
90. Madderom MJ, Reuser JJ, Utens EM, et al. Neurodevelopmental, educational and behavioral 
outcome at 8 years after neonatal ECMO: a nationwide multicenter study. Intensive Care Med 2013; 
39(9): 1584-93. 
91. Madderom MJ, Schiller RM, Gischler SJ, et al. Growing Up After Critical Illness: Verbal, Visual-Spatial, 
and Working Memory Problems in Neonatal Extracorporeal Membrane Oxygenation Survivors. Crit 
Care Med 2016; 44(6): 1182-90. 
92. van Zellem L, Utens EM, de Wildt SN, Vet NJ, Tibboel D, Buysse C. Analgesia-sedation in PICU and 
neurological outcome: a secondary analysis of long-term neuropsychological follow-up in 
meningococcal septic shock survivors*. Pediatr Crit Care Med 2014; 15(3): 189-96. 
93. van Zellem L, Utens EM, Madderom M, et al. Cardiac arrest in infants, children, and adolescents: 
long-term emotional and behavioral functioning. Eur J Pediatr 2016; 175(7): 977-86. 
94. Urschel S, Bond GY, Dinu IA, et al. Neurocognitive outcomes after heart transplantation in early 
childhood. J Heart Lung Transplant 2018; 37(6): 740-8. 
95. Sterken C, Lemiere J, Vanhorebeek I, Van den Berghe G, Mesotten D. Neurocognition after paediatric 
heart surgery: a systematic review and meta-analysis. Open Heart 2015; 2(1): e000255. 
96. Morillo-Garcia A, Aldana-Espinal JM, Olry de Labry-Lima A, et al. Hospital costs associated with 
nosocomial infections in a pediatric intensive care unit. Gac Sanit 2015; 29(4): 282-7. 
 
 
 
97. Rey C, Alvarez F, De-La-Rua V, et al. Intervention to reduce catheter-related bloodstream infections 
in a pediatric intensive care unit. Intensive Care Med 2011; 37(4): 678-85. 
98. Macrae D, Grieve R, Allen E, et al. A clinical and economic evaluation of Control of Hyperglycaemia 
in Paediatric intensive care (CHiP): a randomised controlled trial. Health Technol Assess 2014; 18(26): 
1-210. 
99. Joosten K, Embleton N, Yan W, Senterre T. ESPGHAN/ESPEN/ESPR guidelines on pediatric parenteral 
nutrition: Energy. Clin Nutr 2018; Jun 18. 
100. Wong JJ, Ong C, Han WM, Mehta NM, Lee JH. Survey of contemporary feeding practices in critically 
ill children in the Asia-Pacific and the Middle East. Asia Pac J Clin Nutr 2016; 25(1): 118-25. 
101. Tume LN, Balmaks R, da Cruz E, et al. Enteral Feeding Practices in Infants With Congenital Heart 
Disease Across European PICUs: A European Society of Pediatric and Neonatal Intensive Care Survey. 
Pediatr Crit Care Med 2018; 19(2): 137-44. 
102. Leong AY, Cartwright KR, Guerra GG, Joffe AR, Mazurak VC, Larsen BM. A Canadian survey of 
perceived barriers to initiation and continuation of enteral feeding in PICUs. Pediatr Crit Care Med 
2014; 15(2): e49-55. 
103. Koletzko B, Goulet O, Hunt J, et al. 1. Guidelines on Paediatric Parenteral Nutrition of the European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European 
Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of 
Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr 2005; 41 Suppl 2: S1-87. 
104. Mehta NM, Compher C, Directors ASPENBo. A.S.P.E.N. Clinical Guidelines: nutrition support of the 
critically ill child. JPEN J Parenter Enteral Nutr 2009; 33(3): 260-76. 
105. Prasad V, Ioannidis JP. Evidence-based de-implementation for contradicted, unproven, and aspiring 
healthcare practices. Implement Sci 2014; 9: 1. 
106. van Bodegom-Vos L, Davidoff F, Marang-van de Mheen PJ. Implementation and de-implementation: 
two sides of the same coin? BMJ Qual Saf 2017; 26(6): 495-501. 
107. Norton WE, Kennedy AE, Chambers DA. Studying de-implementation in health: an analysis of funded 
research grants. Implement Sci 2017; 12(1): 144. 
108. El Dib RP, Atallah AN, Andriolo RB. Mapping the Cochrane evidence for decision making in health 
care. J Eval Clin Pract 2007; 13(4): 689-92. 
109. Davidoff F. On the undiffusion of established practices. JAMA Intern Med 2015; 175(5): 809-11. 
110. Scottish Intercollegiate Guidelines Network (SIGN): SIGN 50: a guideline developer’s handbook. 2014. 
http://www.sign.ac.uk. 
111. Balas EA, Boren SA. Managing Clinical Knowledge for Health Care Improvement. Yearb Med Inform 
2000; (1): 65-70. 
112. Green LW. Making research relevant: if it is an evidence-based practice, where's the practice-based 
evidence? Fam Pract 2008; 25 Suppl 1: i20-4. 
113. Rogers E. Diffusion of Innovations. New York: Free Press; 2003. 
114. Cahill NE, Heyland DK. Bridging the guideline-practice gap in critical care nutrition: a review of 
guideline implementation studies. JPEN J Parenter Enteral Nutr 2010; 34(6): 653-9. 
115. Dodek P, Cahill NE, Heyland DK. The relationship between organizational culture and implementation 
of clinical practice guidelines: a narrative review. JPEN J Parenter Enteral Nutr 2010; 34(6): 669-74. 
116. Blair M. Getting evidence into practice--implementation science for paediatricians. Arch Dis Child 
2014; 99(4): 307-9. 
117. Olswang LB, Prelock PA. Bridging the Gap Between Research and Practice: Implementation Science. 
J Speech Lang Hear Res 2015; 58(6): S1818-26. 
118. van Puffelen E, Vanhorebeek I, Joosten KFM, Wouters PJ, Van den Berghe G, Verbruggen S. Early 
versus late parenteral nutrition in critically ill, term neonates: a preplanned secondary subgroup 
	 237
REFERENCES	
 
 
 
77. Mehta NM, McAleer D, Hamilton S, et al. Challenges to optimal enteral nutrition in a multidisciplinary 
pediatric intensive care unit. JPEN J Parenter Enteral Nutr 2010; 34(1): 38-45. 
78. Herrup EA, Wieczorek B, Kudchadkar SR. Characteristics of postintensive care syndrome in survivors 
of pediatric critical illness: A systematic review. World J Crit Care Med 2017; 6(2): 124-34. 
79. Pinto NP, Rhinesmith EW, Kim TY, Ladner PH, Pollack MM. Long-Term Function After Pediatric Critical 
Illness: Results From the Survivor Outcomes Study. Pediatr Crit Care Med 2017; 18(3): e122-e30. 
80. Vergouwe FWT, Spoel M, van Beelen NWG, et al. Longitudinal evaluation of growth in oesophageal 
atresia patients up to 12 years. Arch Dis Child Fetal Neonatal Ed 2017; 102(5): F417-F22. 
81. Leeuwen L, Mous DS, van Rosmalen J, et al. Congenital Diaphragmatic Hernia and Growth to 12 Years. 
Pediatrics 2017; 140(2). 
82. Mammen C, Al Abbas A, Skippen P, et al. Long-term risk of CKD in children surviving episodes of acute 
kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis 2012; 59(4): 523-
30. 
83. Williams S, Horrocks IA, Ouvrier RA, Gillis J, Ryan MM. Critical illness polyneuropathy and myopathy 
in pediatric intensive care: A review. Pediatr Crit Care Med 2007; 8(1): 18-22. 
84. Nyaradi A, Li J, Hickling S, Foster J, Oddy WH. The role of nutrition in children's neurocognitive 
development, from pregnancy through childhood. Front Hum Neurosci 2013; 7: 97. 
85. Burkhalter TM, Hillman CH. A narrative review of physical activity, nutrition, and obesity to cognition 
and scholastic performance across the human lifespan. Adv Nutr 2011; 2(2): 201S-6S. 
86. Anjos T, Altmae S, Emmett P, et al. Nutrition and neurodevelopment in children: focus on 
NUTRIMENTHE project. Eur J Nutr 2013; 52(8): 1825-42. 
87. Kachmar AG, Irving SY, Connolly CA, Curley MAQ. A Systematic Review of Risk Factors Associated 
With Cognitive Impairment After Pediatric Critical Illness. Pediatr Crit Care Med 2018; 19(3): e164-
e71. 
88. Aspesberro F, Mangione-Smith R, Zimmerman JJ. Health-related quality of life following pediatric 
critical illness. Intensive Care Med 2015; 41(7): 1235-46. 
89. Madderom MJ, Gischler SJ, Duivenvoorden H, Tibboel D, Ijsselstijn H. Neonatal extracorporeal 
membrane oxygenation: impaired health at 5 years of age. Pediatr Crit Care Med 2013; 14(2): 183-
93. 
90. Madderom MJ, Reuser JJ, Utens EM, et al. Neurodevelopmental, educational and behavioral 
outcome at 8 years after neonatal ECMO: a nationwide multicenter study. Intensive Care Med 2013; 
39(9): 1584-93. 
91. Madderom MJ, Schiller RM, Gischler SJ, et al. Growing Up After Critical Illness: Verbal, Visual-Spatial, 
and Working Memory Problems in Neonatal Extracorporeal Membrane Oxygenation Survivors. Crit 
Care Med 2016; 44(6): 1182-90. 
92. van Zellem L, Utens EM, de Wildt SN, Vet NJ, Tibboel D, Buysse C. Analgesia-sedation in PICU and 
neurological outcome: a secondary analysis of long-term neuropsychological follow-up in 
meningococcal septic shock survivors*. Pediatr Crit Care Med 2014; 15(3): 189-96. 
93. van Zellem L, Utens EM, Madderom M, et al. Cardiac arrest in infants, children, and adolescents: 
long-term emotional and behavioral functioning. Eur J Pediatr 2016; 175(7): 977-86. 
94. Urschel S, Bond GY, Dinu IA, et al. Neurocognitive outcomes after heart transplantation in early 
childhood. J Heart Lung Transplant 2018; 37(6): 740-8. 
95. Sterken C, Lemiere J, Vanhorebeek I, Van den Berghe G, Mesotten D. Neurocognition after paediatric 
heart surgery: a systematic review and meta-analysis. Open Heart 2015; 2(1): e000255. 
96. Morillo-Garcia A, Aldana-Espinal JM, Olry de Labry-Lima A, et al. Hospital costs associated with 
nosocomial infections in a pediatric intensive care unit. Gac Sanit 2015; 29(4): 282-7. 
 
 
 
97. Rey C, Alvarez F, De-La-Rua V, et al. Intervention to reduce catheter-related bloodstream infections 
in a pediatric intensive care unit. Intensive Care Med 2011; 37(4): 678-85. 
98. Macrae D, Grieve R, Allen E, et al. A clinical and economic evaluation of Control of Hyperglycaemia 
in Paediatric intensive care (CHiP): a randomised controlled trial. Health Technol Assess 2014; 18(26): 
1-210. 
99. Joosten K, Embleton N, Yan W, Senterre T. ESPGHAN/ESPEN/ESPR guidelines on pediatric parenteral 
nutrition: Energy. Clin Nutr 2018; Jun 18. 
100. Wong JJ, Ong C, Han WM, Mehta NM, Lee JH. Survey of contemporary feeding practices in critically 
ill children in the Asia-Pacific and the Middle East. Asia Pac J Clin Nutr 2016; 25(1): 118-25. 
101. Tume LN, Balmaks R, da Cruz E, et al. Enteral Feeding Practices in Infants With Congenital Heart 
Disease Across European PICUs: A European Society of Pediatric and Neonatal Intensive Care Survey. 
Pediatr Crit Care Med 2018; 19(2): 137-44. 
102. Leong AY, Cartwright KR, Guerra GG, Joffe AR, Mazurak VC, Larsen BM. A Canadian survey of 
perceived barriers to initiation and continuation of enteral feeding in PICUs. Pediatr Crit Care Med 
2014; 15(2): e49-55. 
103. Koletzko B, Goulet O, Hunt J, et al. 1. Guidelines on Paediatric Parenteral Nutrition of the European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European 
Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of 
Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr 2005; 41 Suppl 2: S1-87. 
104. Mehta NM, Compher C, Directors ASPENBo. A.S.P.E.N. Clinical Guidelines: nutrition support of the 
critically ill child. JPEN J Parenter Enteral Nutr 2009; 33(3): 260-76. 
105. Prasad V, Ioannidis JP. Evidence-based de-implementation for contradicted, unproven, and aspiring 
healthcare practices. Implement Sci 2014; 9: 1. 
106. van Bodegom-Vos L, Davidoff F, Marang-van de Mheen PJ. Implementation and de-implementation: 
two sides of the same coin? BMJ Qual Saf 2017; 26(6): 495-501. 
107. Norton WE, Kennedy AE, Chambers DA. Studying de-implementation in health: an analysis of funded 
research grants. Implement Sci 2017; 12(1): 144. 
108. El Dib RP, Atallah AN, Andriolo RB. Mapping the Cochrane evidence for decision making in health 
care. J Eval Clin Pract 2007; 13(4): 689-92. 
109. Davidoff F. On the undiffusion of established practices. JAMA Intern Med 2015; 175(5): 809-11. 
110. Scottish Intercollegiate Guidelines Network (SIGN): SIGN 50: a guideline developer’s handbook. 2014. 
http://www.sign.ac.uk. 
111. Balas EA, Boren SA. Managing Clinical Knowledge for Health Care Improvement. Yearb Med Inform 
2000; (1): 65-70. 
112. Green LW. Making research relevant: if it is an evidence-based practice, where's the practice-based 
evidence? Fam Pract 2008; 25 Suppl 1: i20-4. 
113. Rogers E. Diffusion of Innovations. New York: Free Press; 2003. 
114. Cahill NE, Heyland DK. Bridging the guideline-practice gap in critical care nutrition: a review of 
guideline implementation studies. JPEN J Parenter Enteral Nutr 2010; 34(6): 653-9. 
115. Dodek P, Cahill NE, Heyland DK. The relationship between organizational culture and implementation 
of clinical practice guidelines: a narrative review. JPEN J Parenter Enteral Nutr 2010; 34(6): 669-74. 
116. Blair M. Getting evidence into practice--implementation science for paediatricians. Arch Dis Child 
2014; 99(4): 307-9. 
117. Olswang LB, Prelock PA. Bridging the Gap Between Research and Practice: Implementation Science. 
J Speech Lang Hear Res 2015; 58(6): S1818-26. 
118. van Puffelen E, Vanhorebeek I, Joosten KFM, Wouters PJ, Van den Berghe G, Verbruggen S. Early 
versus late parenteral nutrition in critically ill, term neonates: a preplanned secondary subgroup 
238 
APPENDICES	
 
 
 
analysis of the PEPaNIC multicentre, randomised controlled trial. Lancet Child Adolesc Health 2018; 
2(7): 505-15. 
119. van Puffelen EH, J M; Vanhorebeek, I; Dulfer, K; Van den Berghe, G; Verbruggen, S C A T; Joosten, K 
F M. Outcomes of delaying parenteral nutrition for 1 week vs initiation within 24 hours among 
undernourished children in pediatric intensive care. JAMA Network Open 2018; 1(5): e182668. 
120. Hauschild DB, Ventura JC, Mehta NM, Moreno YMF. Impact of the structure and dose of protein 
intake on clinical and metabolic outcomes in critically ill children: A systematic review. Nutrition 
2017; 41: 97-106. 
121. Typpo KV, Kelley C. SuPPeR trial, NCT01937884. https://clinicaltrials.gov (accessed 17-05-2018 2018). 
122. ABIM Foundation: choosing wisely. http://www.choosingwisely.org/our-mission/ (accessed 14-05-
2018 2018). 
123. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. 
N Engl J Med 2011; 365(6): 506-17. 
124. Verstraete S, Verbruggen SC, Hordijk JA, et al. Long-term developmental effects of withholding 
parenteral nutrition for 1 week in the paediatric intensive care unit: a 2-year follow-up of the PEPaNIC 
international, randomised, controlled trial. Lancet Respir Med 2019 Feb;7(2):141-153. 
125. van Puffelen E, Polinder S, Vanhorebeek I, et al. Cost-effectiveness study of early versus late 
parenteral nutrition in critically ill children (PEPaNIC): preplanned secondary analysis of a multicentre 
randomised controlled trial. Crit Care 2018; 22(1): 4. 
126. Verstraete S, Vanhorebeek I, van Puffelen E, et al. Leukocyte telomere length in paediatric critical 
illness: effect of early parenteral nutrition. Crit Care 2018; 22(1): 38. 
127. Vanderheyden S, Casaer MP, Kesteloot K, et al. Early versus late parenteral nutrition in ICU patients: 
cost analysis of the EPaNIC trial. Crit Care 2012; 16(3): R96. 
128. Casaer MP, Wilmer A, Hermans G, Wouters PJ, Mesotten D, Van den Berghe G. Role of disease and 
macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis. Am J Respir Crit 
Care Med 2013; 187(3): 247-55. 
129. Fivez T, Kerklaan D, Verbruggen S, et al. Impact of withholding early parenteral nutrition completing 
enteral nutrition in pediatric critically ill patients (PEPaNIC trial): study protocol for a randomized 
controlled trial. Trials 2015; 16: 202. 
130. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for 
preterm infants. BMC Pediatr 2013; 13: 59. 
131. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-
age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods 
and development. Geneva: World Health Organization; 2006. 
132. Derde S, Vanhorebeek I, Guiza F, et al. Early parenteral nutrition evokes a phenotype of autophagy 
deficiency in liver and skeletal muscle of critically ill rabbits. Endocrinology 2012; 153(5): 2267-76. 
133. Gunst J. Recovery from critical illness-induced organ failure: the role of autophagy. Crit Care 2017; 
21(1): 209. 
134. Cinti S. Transdifferentiation properties of adipocytes in the adipose organ. Am J Physiol Endocrinol 
Metab 2009; 297(5): E977-86. 
135. Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and 
neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics 2008; 122(1): 
65-74. 
136. Lee JH, Rogers E, Chor YK, et al. Optimal nutrition therapy in paediatric critical care in the Asia-Pacific 
and Middle East: a consensus. Asia Pac J Clin Nutr 2016; 25(4): 676-96. 
137. te Braake FW, van den Akker CH, Riedijk MA, van Goudoever JB. Parenteral amino acid and energy 
administration to premature infants in early life. Semin Fetal Neonatal Med 2007; 12(1): 11-8. 
 
 
 
138. Trivedi A, Sinn JK. Early versus late administration of amino acids in preterm infants receiving 
parenteral nutrition. Cochrane Database Syst Rev 2013; (7): CD008771. 
139. van Goudoever JB, Vlaardingerbroek H, van den Akker CH, de Groof F, van der Schoor SR. Amino acids 
and proteins. World Rev Nutr Diet 2014; 110: 49-63. 
140. van den Akker CH, van Goudoever JB. Defining Protein Requirements of Preterm Infants by Using 
Metabolic Studies in Fetuses and Preterm Infants. Nestle Nutr Inst Workshop Ser 2016; 86: 139-49. 
141. Fivez T, Kerklaan D, Mesotten D, Verbruggen S, Joosten K, Van den Berghe G. Evidence for the use of 
parenteral nutrition in the pediatric intensive care unit. Clin Nutr 2015. 
142. Hulst JM, Zwart H, Hop WC, Joosten KF. Dutch national survey to test the STRONGkids nutritional risk 
screening tool in hospitalized children. Clin Nutr 2010; 29(1): 106-11. 
143. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth 
reference for school-aged children and adolescents. Bull World Health Organ 2007; 85(9): 660-7. 
144. Leteurtre S, Martinot A, Duhamel A, et al. Validation of the paediatric logistic organ dysfunction 
(PELOD) score: prospective, observational, multicentre study. Lancet 2003; 362(9379): 192-7. 
145. Slater A, Shann F, Pearson G, Paediatric Index of Mortality Study G. PIM2: a revised version of the 
Paediatric Index of Mortality. Intensive Care Med 2003; 29(2): 278-85. 
146. Dutch Growth Research Foundation. Growth Analyser Research Calculation Tool version 4.0. 
https://growthanalyser.org. Accessed April 12th, 2018. 
147. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum 
Nutr Clin Nutr 1985; 39 Suppl 1: 5-41. 
148. Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World 
Health Organ Tech Rep Ser 1985; 724: 1-206. 
149. Rytter MJ, Kolte L, Briend A, Friis H, Christensen VB. The immune system in children with 
malnutrition--a systematic review. PLoS One 2014; 9(8): e105017. 
150. Greathouse KC, Hall MW. Critical Illness-Induced Immune Suppression: Current State of the Science. 
Am J Crit Care 2016; 25(1): 85-92. 
151. Boeddha NP, Kerklaan D, Dunbar A, et al. HLA-DR Expression on Monocyte Subsets in Critically Ill 
Children. Pediatr Infect Dis J 2018. 
152. Gogos CA, Kalfarentzos F. Total parenteral nutrition and immune system activity: a review. Nutrition 
1995; 11(4): 339-44. 
153. Wanten G. An update on parenteral lipids and immune function: only smoke, or is there any fire? 
Curr Opin Clin Nutr Metab Care 2006; 9(2): 79-83. 
154. Hulst JM, van Goudoever JB, Visser TJ, Tibboel D, Joosten KF. Hormone levels in children during the 
first week of ICU-admission: is there an effect of adequate feeding? Clin Nutr 2006; 25(1): 154-62. 
155. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated 
infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 
2008; 36(5): 309-32. 
156. Eskedal LT, Hagemo PS, Seem E, et al. Impaired weight gain predicts risk of late death after surgery 
for congenital heart defects. Arch Dis Child 2008; 93(6): 495-501. 
157. Talma H. Groeidiagrammen. 2010. https://www.tno.nl/groei/. 
158. Mehta NM, Corkins MR, Lyman B, et al. Defining pediatric malnutrition: a paradigm shift toward 
etiology-related definitions. JPEN J Parenter Enteral Nutr 2013; 37(4): 460-81. 
159. Cederholm T, Jensen GL, Correia M, et al. GLIM criteria for the diagnosis of malnutrition - A consensus 
report from the global clinical nutrition community. Clin Nutr 2019 Feb;38(1):1-9.. 
160. Vanhorebeek I, Gunst J, Derde S, et al. Insufficient activation of autophagy allows cellular damage to 
accumulate in critically ill patients. J Clin Endocrinol Metab 2011; 96(4): E633-45. 
	 239
REFERENCES	
 
 
 
analysis of the PEPaNIC multicentre, randomised controlled trial. Lancet Child Adolesc Health 2018; 
2(7): 505-15. 
119. van Puffelen EH, J M; Vanhorebeek, I; Dulfer, K; Van den Berghe, G; Verbruggen, S C A T; Joosten, K 
F M. Outcomes of delaying parenteral nutrition for 1 week vs initiation within 24 hours among 
undernourished children in pediatric intensive care. JAMA Network Open 2018; 1(5): e182668. 
120. Hauschild DB, Ventura JC, Mehta NM, Moreno YMF. Impact of the structure and dose of protein 
intake on clinical and metabolic outcomes in critically ill children: A systematic review. Nutrition 
2017; 41: 97-106. 
121. Typpo KV, Kelley C. SuPPeR trial, NCT01937884. https://clinicaltrials.gov (accessed 17-05-2018 2018). 
122. ABIM Foundation: choosing wisely. http://www.choosingwisely.org/our-mission/ (accessed 14-05-
2018 2018). 
123. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. 
N Engl J Med 2011; 365(6): 506-17. 
124. Verstraete S, Verbruggen SC, Hordijk JA, et al. Long-term developmental effects of withholding 
parenteral nutrition for 1 week in the paediatric intensive care unit: a 2-year follow-up of the PEPaNIC 
international, randomised, controlled trial. Lancet Respir Med 2019 Feb;7(2):141-153. 
125. van Puffelen E, Polinder S, Vanhorebeek I, et al. Cost-effectiveness study of early versus late 
parenteral nutrition in critically ill children (PEPaNIC): preplanned secondary analysis of a multicentre 
randomised controlled trial. Crit Care 2018; 22(1): 4. 
126. Verstraete S, Vanhorebeek I, van Puffelen E, et al. Leukocyte telomere length in paediatric critical 
illness: effect of early parenteral nutrition. Crit Care 2018; 22(1): 38. 
127. Vanderheyden S, Casaer MP, Kesteloot K, et al. Early versus late parenteral nutrition in ICU patients: 
cost analysis of the EPaNIC trial. Crit Care 2012; 16(3): R96. 
128. Casaer MP, Wilmer A, Hermans G, Wouters PJ, Mesotten D, Van den Berghe G. Role of disease and 
macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis. Am J Respir Crit 
Care Med 2013; 187(3): 247-55. 
129. Fivez T, Kerklaan D, Verbruggen S, et al. Impact of withholding early parenteral nutrition completing 
enteral nutrition in pediatric critically ill patients (PEPaNIC trial): study protocol for a randomized 
controlled trial. Trials 2015; 16: 202. 
130. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for 
preterm infants. BMC Pediatr 2013; 13: 59. 
131. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-
age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods 
and development. Geneva: World Health Organization; 2006. 
132. Derde S, Vanhorebeek I, Guiza F, et al. Early parenteral nutrition evokes a phenotype of autophagy 
deficiency in liver and skeletal muscle of critically ill rabbits. Endocrinology 2012; 153(5): 2267-76. 
133. Gunst J. Recovery from critical illness-induced organ failure: the role of autophagy. Crit Care 2017; 
21(1): 209. 
134. Cinti S. Transdifferentiation properties of adipocytes in the adipose organ. Am J Physiol Endocrinol 
Metab 2009; 297(5): E977-86. 
135. Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and 
neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics 2008; 122(1): 
65-74. 
136. Lee JH, Rogers E, Chor YK, et al. Optimal nutrition therapy in paediatric critical care in the Asia-Pacific 
and Middle East: a consensus. Asia Pac J Clin Nutr 2016; 25(4): 676-96. 
137. te Braake FW, van den Akker CH, Riedijk MA, van Goudoever JB. Parenteral amino acid and energy 
administration to premature infants in early life. Semin Fetal Neonatal Med 2007; 12(1): 11-8. 
 
 
 
138. Trivedi A, Sinn JK. Early versus late administration of amino acids in preterm infants receiving 
parenteral nutrition. Cochrane Database Syst Rev 2013; (7): CD008771. 
139. van Goudoever JB, Vlaardingerbroek H, van den Akker CH, de Groof F, van der Schoor SR. Amino acids 
and proteins. World Rev Nutr Diet 2014; 110: 49-63. 
140. van den Akker CH, van Goudoever JB. Defining Protein Requirements of Preterm Infants by Using 
Metabolic Studies in Fetuses and Preterm Infants. Nestle Nutr Inst Workshop Ser 2016; 86: 139-49. 
141. Fivez T, Kerklaan D, Mesotten D, Verbruggen S, Joosten K, Van den Berghe G. Evidence for the use of 
parenteral nutrition in the pediatric intensive care unit. Clin Nutr 2015. 
142. Hulst JM, Zwart H, Hop WC, Joosten KF. Dutch national survey to test the STRONGkids nutritional risk 
screening tool in hospitalized children. Clin Nutr 2010; 29(1): 106-11. 
143. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth 
reference for school-aged children and adolescents. Bull World Health Organ 2007; 85(9): 660-7. 
144. Leteurtre S, Martinot A, Duhamel A, et al. Validation of the paediatric logistic organ dysfunction 
(PELOD) score: prospective, observational, multicentre study. Lancet 2003; 362(9379): 192-7. 
145. Slater A, Shann F, Pearson G, Paediatric Index of Mortality Study G. PIM2: a revised version of the 
Paediatric Index of Mortality. Intensive Care Med 2003; 29(2): 278-85. 
146. Dutch Growth Research Foundation. Growth Analyser Research Calculation Tool version 4.0. 
https://growthanalyser.org. Accessed April 12th, 2018. 
147. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum 
Nutr Clin Nutr 1985; 39 Suppl 1: 5-41. 
148. Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World 
Health Organ Tech Rep Ser 1985; 724: 1-206. 
149. Rytter MJ, Kolte L, Briend A, Friis H, Christensen VB. The immune system in children with 
malnutrition--a systematic review. PLoS One 2014; 9(8): e105017. 
150. Greathouse KC, Hall MW. Critical Illness-Induced Immune Suppression: Current State of the Science. 
Am J Crit Care 2016; 25(1): 85-92. 
151. Boeddha NP, Kerklaan D, Dunbar A, et al. HLA-DR Expression on Monocyte Subsets in Critically Ill 
Children. Pediatr Infect Dis J 2018. 
152. Gogos CA, Kalfarentzos F. Total parenteral nutrition and immune system activity: a review. Nutrition 
1995; 11(4): 339-44. 
153. Wanten G. An update on parenteral lipids and immune function: only smoke, or is there any fire? 
Curr Opin Clin Nutr Metab Care 2006; 9(2): 79-83. 
154. Hulst JM, van Goudoever JB, Visser TJ, Tibboel D, Joosten KF. Hormone levels in children during the 
first week of ICU-admission: is there an effect of adequate feeding? Clin Nutr 2006; 25(1): 154-62. 
155. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated 
infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 
2008; 36(5): 309-32. 
156. Eskedal LT, Hagemo PS, Seem E, et al. Impaired weight gain predicts risk of late death after surgery 
for congenital heart defects. Arch Dis Child 2008; 93(6): 495-501. 
157. Talma H. Groeidiagrammen. 2010. https://www.tno.nl/groei/. 
158. Mehta NM, Corkins MR, Lyman B, et al. Defining pediatric malnutrition: a paradigm shift toward 
etiology-related definitions. JPEN J Parenter Enteral Nutr 2013; 37(4): 460-81. 
159. Cederholm T, Jensen GL, Correia M, et al. GLIM criteria for the diagnosis of malnutrition - A consensus 
report from the global clinical nutrition community. Clin Nutr 2019 Feb;38(1):1-9.. 
160. Vanhorebeek I, Gunst J, Derde S, et al. Insufficient activation of autophagy allows cellular damage to 
accumulate in critically ill patients. J Clin Endocrinol Metab 2011; 96(4): E633-45. 
240 
APPENDICES	
 
 
 
161. Kyle UG, Earthman CP, Pichard C, Coss-Bu JA. Body composition during growth in children: limitations 
and perspectives of bioelectrical impedance analysis. Eur J Clin Nutr 2015; 69(12): 1298-305. 
162. Elberg J, McDuffie JR, Sebring NG, et al. Comparison of methods to assess change in children's body 
composition. Am J Clin Nutr 2004; 80(1): 64-9. 
163. Zamberlan P, Feferbaum R, Doria Filho U, Brunow de Carvalho, Figueiredo Delgado. Bioelectrical 
Impedance Phase Angle and Morbidity and Mortality in Critically Ill Children. Nutr Clin Pract 2019; 
34(1): 163-71. 
164. WHO. Guideline updates on the management of severe acute malnutrition in infants and children. 
Geneva: World Health Organization, 2013. 
165. Fivez T, Hendrickx A, Van Herpe T, et al. An Analysis of Reliability and Accuracy of Muscle Thickness 
Ultrasonography in Critically Ill Children and Adults. JPEN J Parenter Enteral Nutr 2016; 40(7): 944-9. 
166. Jimenez L, Mehta NM, Duggan CP. Timing of the initiation of parenteral nutrition in critically ill 
children. Curr Opin Clin Nutr Metab Care 2017; 20(3): 227-31. 
167. Porter ME. What is value in health care? N Engl J Med 2010; 363(26): 2477-81. 
168. Verstraete S, Van den Berghe G, Vanhorebeek I. What's new in the long-term neurodevelopmental 
outcome of critically ill children. Intensive Care Med 2018; 44(5): 649-51. 
169. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab 2014; 
19(2): 181-92. 
170. Kincaid B, Bossy-Wetzel E. Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and 
neurodegeneration. Front Aging Neurosci 2013; 5: 48. 
171. van der Heijden KB, Suurland J, De Sonneville LM, Swaab H. Vragenlijst voor executieve functies voor 
2- tot 5-jarigen: Handleiding. Amsterdam: Hogrefe; 2013. 
172. Huizinga M, Smidts D. BRIEF Vragenlijst executieve functies voor 5- tot 18-jarigen: Handleiding. 
Amsterdam: Hogrefe; 2012. 
173. Achenbach TM, Rescorla LA. Manual for the ASEBA Preschool Forms and Profiles. Burlington: 
University of Vermont: Research Center for Children, Youth, and Families; 2000. 
174. Verhulst FC, Van der Ende J. Handleiding ASEBA. Vragenlijsten voor leeftijden 6 tot en met 18 jaar 
[ASEBA Manual Questionnaires for ages 6 to 18 years]. Rotterdam: ASEBA Nederland; 2013. 
175. Hendriksen J HP. WPPSI-III-NL Wechsler Preschool and Primary Scale of Intelligence: Handleiding. 
Amsterdam: Pearson; 2010. 
176. Wechsler D. WISC-III Nederlandstalige bewerking. Handleiding. Amsterdam: Pearson; 2005. 
177. Wechsler D. WAIS-IV-NL Nederlandstalige Bewerking. Amsterdam: Pearson; 2012. 
178. Beery KE, Buktenica NA, Beery NA. The Beery-Buktenica Developmental Test of Visual-Motor 
Integration, 6th edn (BEERY™ VMI). Amsterdam: Pearson; 2010. 
179. De Sonneville L. Handboek Amsterdamse Neuropsychologische Taken. Amsterdam: Boom test 
uitgevers; 2014. 
180. Cohen MJ. Children Memory Scale Manual. Amsterdam: Pearson; 1997. 
181. Wulff J, Jeppesen L. Multiple imputation by chained equations in praxis: guidelines and review. 
Electron J Bus Res Methods 2017; 15: 41-56. 
182. Jaber L, Halpern GJ, Shohat M. The impact of consanguinity worldwide. Community Genet 1998; 1(1): 
12-7. 
183. Ibrahim O, Sutherland HG, Haupt LM, Griffiths LR. An emerging role for epigenetic factors in relation 
to executive function. Brief Funct Genomics 2018; 17(3): 170-80. 
184. Utendale WT, Hubert M, Saint-Pierre AB, Hastings PD. Neurocognitive development and 
externalizing problems: the role of inhibitory control deficits from 4 to 6 years. Aggress Behav 2011; 
37(5): 476-88. 
 
 
 
185. Chambers CD, Garavan H, Bellgrove MA. Insights into the neural basis of response inhibition from 
cognitive and clinical neuroscience. Neurosci Biobehav Rev 2009; 33(5): 631-46. 
186. Sonneville R, den Hertog HM, Guiza F, et al. Impact of hyperglycemia on neuropathological 
alterations during critical illness. J Clin Endocrinol Metab 2012; 97(6): 2113-23. 
187. de Rooij SR, Caan MW, Swaab DF, et al. Prenatal famine exposure has sex-specific effects on brain 
size. Brain 2016; 139(Pt 8): 2136-42. 
188. Qureshi IA, Mehler MF. Understanding neurological disease mechanisms in the era of epigenetics. 
JAMA Neurol 2013; 70(6): 703-10. 
189. Little RJA. Missing-data adjustments in large surveys. J Bus Econ Stat 1988; 6: 287–96. 
190. Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987. 
191. Little RJ. Comments on: Missing data methods in longitudinal studies: a review. Test 2009; 18: 47–
50. 
192. Collins CT, Makrides M, McPhee AJ, et al. Docosahexaenoic Acid and Bronchopulmonary Dysplasia in 
Preterm Infants. N Engl J Med 2017; 376(13): 1245-55. 
193. Conte T, Mitton C, Trenaman LM, Chavoshi N, Siden H. Effect of pediatric palliative care programs on 
health care resource utilization and costs among children with life-threatening conditions: a 
systematic review of comparative studies. CMAJ Open 2015; 3(1): E68-75. 
194. Smith AG, Andrews S, Bratton SL, et al. Pediatric palliative care and inpatient hospital costs: a 
longitudinal cohort study. Pediatrics 2015; 135(4): 694-700. 
195. Heikkila P, Forma L, Korppi M. Hospitalisation costs for infant bronchiolitis are up to 20 times higher 
if intensive care is needed. Acta Paediatr 2015; 104(3): 269-73. 
196. Dominguez TE, Chalom R, Costarino AT, Jr. The impact of adverse patient occurrences on hospital 
costs in the pediatric intensive care unit. Crit Care Med 2001; 29(1): 169-74. 
197. Gold MR SJ, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford 
University Press; 1996. 
198. Nederlandse Zorgautoriteit. Prestaties en tarieven medisch specialistische zorg. 
https://www.nza.nl/regelgeving/beleidsregels/BR_CU_2147__Prestaties_en_tarieven_medisch_sp
ecialistische_zorg, 2016. 
199. Cleemput I NM, Van de Sande S, Thiry N. Belgische richtlijnen voor economische evaluaties en budget 
impact analyses: tweede editie. Health Technology Assessment (HTA). Brussel: Federaal 
Kenniscentrum voor de Gezondheidszorg (KCE), 2012. 
200. Hakkaart-van Roijen LvdL, N.; Bouwmans, C.; Kanters, T.; Tan, S.S. Kostenhandleiding: Methodologie 
van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. 
https://www.zorginstituutnederland.nl/binaries/zinl/documenten/publicatie/2016/02/29/richtlijn-
voor-het-uitvoeren-van-economische-evaluaties-in-de-
gezondheidszorg/Richtlijn+voor+het+uitvoeren+van+economische+evaluaties+in+de+gezondheidsz
org+%28verdiepingsmodules%29.pdf, 2015. 
201. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) statement. Value Health 2013; 16(2): e1-5. 
202. Zorgautoriteit N. Prestaties en tarieven medisch specialistische zorg. 
https://www.nza.nl/1048076/1048090/BR_CU_2136__Prestaties_en_tarieven_medisch_specialisti
sche_zorg.pdf, 2015. 
203. Tan SS, Hakkaart-van Roijen L, Al MJ, et al. A microcosting study of intensive care unit stay in the 
Netherlands. J Intensive Care Med 2008; 23(4): 250-7. 
204. Methodology WCCfDS. ATC/DDD Index 2016. 12-16-2015 2015. 
http://www.whocc.no/atc_ddd_index (accessed 6-15-2016 2016). 
	 241
REFERENCES	
 
 
 
161. Kyle UG, Earthman CP, Pichard C, Coss-Bu JA. Body composition during growth in children: limitations 
and perspectives of bioelectrical impedance analysis. Eur J Clin Nutr 2015; 69(12): 1298-305. 
162. Elberg J, McDuffie JR, Sebring NG, et al. Comparison of methods to assess change in children's body 
composition. Am J Clin Nutr 2004; 80(1): 64-9. 
163. Zamberlan P, Feferbaum R, Doria Filho U, Brunow de Carvalho, Figueiredo Delgado. Bioelectrical 
Impedance Phase Angle and Morbidity and Mortality in Critically Ill Children. Nutr Clin Pract 2019; 
34(1): 163-71. 
164. WHO. Guideline updates on the management of severe acute malnutrition in infants and children. 
Geneva: World Health Organization, 2013. 
165. Fivez T, Hendrickx A, Van Herpe T, et al. An Analysis of Reliability and Accuracy of Muscle Thickness 
Ultrasonography in Critically Ill Children and Adults. JPEN J Parenter Enteral Nutr 2016; 40(7): 944-9. 
166. Jimenez L, Mehta NM, Duggan CP. Timing of the initiation of parenteral nutrition in critically ill 
children. Curr Opin Clin Nutr Metab Care 2017; 20(3): 227-31. 
167. Porter ME. What is value in health care? N Engl J Med 2010; 363(26): 2477-81. 
168. Verstraete S, Van den Berghe G, Vanhorebeek I. What's new in the long-term neurodevelopmental 
outcome of critically ill children. Intensive Care Med 2018; 44(5): 649-51. 
169. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab 2014; 
19(2): 181-92. 
170. Kincaid B, Bossy-Wetzel E. Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and 
neurodegeneration. Front Aging Neurosci 2013; 5: 48. 
171. van der Heijden KB, Suurland J, De Sonneville LM, Swaab H. Vragenlijst voor executieve functies voor 
2- tot 5-jarigen: Handleiding. Amsterdam: Hogrefe; 2013. 
172. Huizinga M, Smidts D. BRIEF Vragenlijst executieve functies voor 5- tot 18-jarigen: Handleiding. 
Amsterdam: Hogrefe; 2012. 
173. Achenbach TM, Rescorla LA. Manual for the ASEBA Preschool Forms and Profiles. Burlington: 
University of Vermont: Research Center for Children, Youth, and Families; 2000. 
174. Verhulst FC, Van der Ende J. Handleiding ASEBA. Vragenlijsten voor leeftijden 6 tot en met 18 jaar 
[ASEBA Manual Questionnaires for ages 6 to 18 years]. Rotterdam: ASEBA Nederland; 2013. 
175. Hendriksen J HP. WPPSI-III-NL Wechsler Preschool and Primary Scale of Intelligence: Handleiding. 
Amsterdam: Pearson; 2010. 
176. Wechsler D. WISC-III Nederlandstalige bewerking. Handleiding. Amsterdam: Pearson; 2005. 
177. Wechsler D. WAIS-IV-NL Nederlandstalige Bewerking. Amsterdam: Pearson; 2012. 
178. Beery KE, Buktenica NA, Beery NA. The Beery-Buktenica Developmental Test of Visual-Motor 
Integration, 6th edn (BEERY™ VMI). Amsterdam: Pearson; 2010. 
179. De Sonneville L. Handboek Amsterdamse Neuropsychologische Taken. Amsterdam: Boom test 
uitgevers; 2014. 
180. Cohen MJ. Children Memory Scale Manual. Amsterdam: Pearson; 1997. 
181. Wulff J, Jeppesen L. Multiple imputation by chained equations in praxis: guidelines and review. 
Electron J Bus Res Methods 2017; 15: 41-56. 
182. Jaber L, Halpern GJ, Shohat M. The impact of consanguinity worldwide. Community Genet 1998; 1(1): 
12-7. 
183. Ibrahim O, Sutherland HG, Haupt LM, Griffiths LR. An emerging role for epigenetic factors in relation 
to executive function. Brief Funct Genomics 2018; 17(3): 170-80. 
184. Utendale WT, Hubert M, Saint-Pierre AB, Hastings PD. Neurocognitive development and 
externalizing problems: the role of inhibitory control deficits from 4 to 6 years. Aggress Behav 2011; 
37(5): 476-88. 
 
 
 
185. Chambers CD, Garavan H, Bellgrove MA. Insights into the neural basis of response inhibition from 
cognitive and clinical neuroscience. Neurosci Biobehav Rev 2009; 33(5): 631-46. 
186. Sonneville R, den Hertog HM, Guiza F, et al. Impact of hyperglycemia on neuropathological 
alterations during critical illness. J Clin Endocrinol Metab 2012; 97(6): 2113-23. 
187. de Rooij SR, Caan MW, Swaab DF, et al. Prenatal famine exposure has sex-specific effects on brain 
size. Brain 2016; 139(Pt 8): 2136-42. 
188. Qureshi IA, Mehler MF. Understanding neurological disease mechanisms in the era of epigenetics. 
JAMA Neurol 2013; 70(6): 703-10. 
189. Little RJA. Missing-data adjustments in large surveys. J Bus Econ Stat 1988; 6: 287–96. 
190. Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987. 
191. Little RJ. Comments on: Missing data methods in longitudinal studies: a review. Test 2009; 18: 47–
50. 
192. Collins CT, Makrides M, McPhee AJ, et al. Docosahexaenoic Acid and Bronchopulmonary Dysplasia in 
Preterm Infants. N Engl J Med 2017; 376(13): 1245-55. 
193. Conte T, Mitton C, Trenaman LM, Chavoshi N, Siden H. Effect of pediatric palliative care programs on 
health care resource utilization and costs among children with life-threatening conditions: a 
systematic review of comparative studies. CMAJ Open 2015; 3(1): E68-75. 
194. Smith AG, Andrews S, Bratton SL, et al. Pediatric palliative care and inpatient hospital costs: a 
longitudinal cohort study. Pediatrics 2015; 135(4): 694-700. 
195. Heikkila P, Forma L, Korppi M. Hospitalisation costs for infant bronchiolitis are up to 20 times higher 
if intensive care is needed. Acta Paediatr 2015; 104(3): 269-73. 
196. Dominguez TE, Chalom R, Costarino AT, Jr. The impact of adverse patient occurrences on hospital 
costs in the pediatric intensive care unit. Crit Care Med 2001; 29(1): 169-74. 
197. Gold MR SJ, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford 
University Press; 1996. 
198. Nederlandse Zorgautoriteit. Prestaties en tarieven medisch specialistische zorg. 
https://www.nza.nl/regelgeving/beleidsregels/BR_CU_2147__Prestaties_en_tarieven_medisch_sp
ecialistische_zorg, 2016. 
199. Cleemput I NM, Van de Sande S, Thiry N. Belgische richtlijnen voor economische evaluaties en budget 
impact analyses: tweede editie. Health Technology Assessment (HTA). Brussel: Federaal 
Kenniscentrum voor de Gezondheidszorg (KCE), 2012. 
200. Hakkaart-van Roijen LvdL, N.; Bouwmans, C.; Kanters, T.; Tan, S.S. Kostenhandleiding: Methodologie 
van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. 
https://www.zorginstituutnederland.nl/binaries/zinl/documenten/publicatie/2016/02/29/richtlijn-
voor-het-uitvoeren-van-economische-evaluaties-in-de-
gezondheidszorg/Richtlijn+voor+het+uitvoeren+van+economische+evaluaties+in+de+gezondheidsz
org+%28verdiepingsmodules%29.pdf, 2015. 
201. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) statement. Value Health 2013; 16(2): e1-5. 
202. Zorgautoriteit N. Prestaties en tarieven medisch specialistische zorg. 
https://www.nza.nl/1048076/1048090/BR_CU_2136__Prestaties_en_tarieven_medisch_specialisti
sche_zorg.pdf, 2015. 
203. Tan SS, Hakkaart-van Roijen L, Al MJ, et al. A microcosting study of intensive care unit stay in the 
Netherlands. J Intensive Care Med 2008; 23(4): 250-7. 
204. Methodology WCCfDS. ATC/DDD Index 2016. 12-16-2015 2015. 
http://www.whocc.no/atc_ddd_index (accessed 6-15-2016 2016). 
242 
APPENDICES	
 
 
 
205. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 
2000; 320(7243): 1197-200. 
206. Montgomery D. Introduction to Statistical Quality Control. 6 ed: John Wiley & Sons, Inc; 2009. 
207. Drummond M.F. S, M.J. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed: 
Oxford University Press; 2005. 
208. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability 
curves: an example using data from a trial of management strategies for atrial fibrillation. BMC 
Health Serv Res 2006; 6: 52. 
209. Halpern SD, Becker D, Curtis JR, et al. An official American Thoracic Society/American Association of 
Critical-Care Nurses/American College of Chest Physicians/Society of Critical Care Medicine policy 
statement: the Choosing Wisely(R) Top 5 list in Critical Care Medicine. Am J Respir Crit Care Med 
2014; 190(7): 818-26. 
210. Doig GS, Simpson F, Early PNTIG. Early parenteral nutrition in critically ill patients with short-term 
relative contraindications to early enteral nutrition: a full economic analysis of a multicenter 
randomized controlled trial based on US costs. Clinicoecon Outcomes Res 2013; 5: 369-79. 
211. Harron K, Mok Q, Dwan K, et al. CATheter Infections in CHildren (CATCH): a randomised controlled 
trial and economic evaluation comparing impregnated and standard central venous catheters in 
children. Health Technol Assess 2016; 20(18): vii-xxviii, 1-219. 
212. Smeets IA, Tan EY, Vossen HG, et al. Prolonged stay at the paediatric intensive care unit associated 
with paediatric delirium. Eur Child Adolesc Psychiatry 2010; 19(4): 389-93. 
213. Wasserfallen JB, Bossuat C, Perrin E, Cotting J. Costs borne by families of children hospitalized in a 
pediatric intensive care unit: a pilot study. Swiss Med Wkly 2006; 136(49-50): 800-4. 
214. Schiller RM, van den Bosch GE, Muetzel RL, et al. Neonatal critical illness and development: white 
matter and hippocampus alterations in school-age neonatal extracorporeal membrane oxygenation 
survivors. Dev Med Child Neurol 2017; 59(3): 304-10. 
215. van den Akker CH, te Braake FW, Weisglas-Kuperus N, van Goudoever JB. Observational outcome 
results following a randomized controlled trial of early amino acid administration in preterm infants. 
J Pediatr Gastroenterol Nutr 2014; 59(6): 714-9. 
216. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40(2): 
280-93. 
217. Mehta NM. Parenteral Nutrition in Critically Ill Children. N Engl J Med 2016; 374(12): 1190-2. 
218. Mesotten D, Joosten K, van Kempen A, Verbruggen S, nutrition EEECwgopp. ESPGHAN/ESPEN/ESPR 
guidelines on pediatric parenteral nutrition: Carbohydrates. Clin Nutr 2018. 
219. Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Annu Rev 
Immunol 2012; 30: 611-46. 
220. Brantlov S, Jodal L, Lange A, Rittig S, Ward LC. Standardisation of bioelectrical impedance analysis for 
the estimation of body composition in healthy paediatric populations: a systematic review. J Med 
Eng Technol 2017; 41(6): 460-79. 
221. Butte NF, Hopkinson JM, Wong WW, Smith EO, Ellis KJ. Body composition during the first 2 years of 
life: an updated reference. Pediatr Res 2000; 47(5): 578-85. 
222. Fomon SJ, Haschke F, Ziegler EE, Nelson SE. Body composition of reference children from birth to age 
10 years. Am J Clin Nutr 1982; 35(5 Suppl): 1169-75. 
223. Wells JC, Williams JE, Chomtho S, et al. Pediatric reference data for lean tissue properties: density 
and hydration from age 5 to 20 y. Am J Clin Nutr 2010; 91(3): 610-8. 
224. Delisle Nystrom C, Soderstrom E, Henriksson P, Henriksson H, Poortvliet E, Lof M. The paediatric 
option for BodPod to assess body composition in preschool children: what fat-free mass density 
values should be used? Br J Nutr 2018; 120(7): 797-802. 
 
 
 
225. Silva C, Amaral TF, Silva D, Oliveira BM, Guerra A. Handgrip strength and nutrition status in 
hospitalized pediatric patients. Nutr Clin Pract 2014; 29(3): 380-5. 
226. van den Beld WA, van der Sanden GA, Sengers RC, Verbeek AL, Gabreels FJ. Validity and 
reproducibility of the Jamar dynamometer in children aged 4-11 years. Disabil Rehabil 2006; 28(21): 
1303-9. 
227. Nilsson PM. Genetics: telomere length and the metabolic syndrome-a causal link? Nat Rev Endocrinol 
2014; 10(12): 706-7. 
228. Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, Willeit P. Leucocyte telomere 
length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2014; 349: 
g4227. 
229. Bayley N. Bayley scales of infant and toddler development, third edition. San Antonio, TX: Harcourt 
Assessment, Inc., 2006. 
230. van der Meulen BF, Ruiter SAJ, Lutje Spelberg HC, Smrkovsky M. Bayley Scales of Infant Development-
II-Nederlandse Versie. Handleiding. Amsterdam: Harcourt Test Publishers; 2004. 
231. Harmsen WJ, Aarsen FJ, van der Cammen-van Zijp MHM, et al. Developmental problems in patients 
with oesophageal atresia: a longitudinal follow-up study. Arch Dis Child Fetal Neonatal Ed 2017; 
102(3): F214-F9. 
232. Madderom MJ, Toussaint L, van der Cammen-van Zijp MH, et al. Congenital diaphragmatic hernia 
with(out) ECMO: impaired development at 8 years. Arch Dis Child Fetal Neonatal Ed 2013; 98(4): 
F316-22. 
233. Teffer K, Semendeferi K. Human prefrontal cortex: evolution, development, and pathology. Prog 
Brain Res 2012; 195: 191-218. 
234. CBS. https://www.cbs.nl/nl-nl/nieuws/2016/20/zorguitgaven-stijgen-langzamer. 2016. 
235. Poley MJ, Stolk EA, Langemeijer RA, Molenaar JC, Busschbach JJ. The cost-effectiveness of neonatal 
surgery and subsequent treatment for congenital anorectal malformations. J Pediatr Surg 2001; 
36(10): 1471-8. 
236. Poley MJ, Stolk EA, Tibboel D, Molenaar JC, Busschbach JJ. The cost-effectiveness of treatment for 
congenital diaphragmatic hernia. J Pediatr Surg 2002; 37(9): 1245-52. 
237. Peters MJ, Argent A, Festa M, et al. The intensive care medicine clinical research agenda in 
paediatrics. Intensive Care Med 2017; 43(9): 1210-24. 
 
	 243
REFERENCES	
 
 
 
205. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 
2000; 320(7243): 1197-200. 
206. Montgomery D. Introduction to Statistical Quality Control. 6 ed: John Wiley & Sons, Inc; 2009. 
207. Drummond M.F. S, M.J. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed: 
Oxford University Press; 2005. 
208. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability 
curves: an example using data from a trial of management strategies for atrial fibrillation. BMC 
Health Serv Res 2006; 6: 52. 
209. Halpern SD, Becker D, Curtis JR, et al. An official American Thoracic Society/American Association of 
Critical-Care Nurses/American College of Chest Physicians/Society of Critical Care Medicine policy 
statement: the Choosing Wisely(R) Top 5 list in Critical Care Medicine. Am J Respir Crit Care Med 
2014; 190(7): 818-26. 
210. Doig GS, Simpson F, Early PNTIG. Early parenteral nutrition in critically ill patients with short-term 
relative contraindications to early enteral nutrition: a full economic analysis of a multicenter 
randomized controlled trial based on US costs. Clinicoecon Outcomes Res 2013; 5: 369-79. 
211. Harron K, Mok Q, Dwan K, et al. CATheter Infections in CHildren (CATCH): a randomised controlled 
trial and economic evaluation comparing impregnated and standard central venous catheters in 
children. Health Technol Assess 2016; 20(18): vii-xxviii, 1-219. 
212. Smeets IA, Tan EY, Vossen HG, et al. Prolonged stay at the paediatric intensive care unit associated 
with paediatric delirium. Eur Child Adolesc Psychiatry 2010; 19(4): 389-93. 
213. Wasserfallen JB, Bossuat C, Perrin E, Cotting J. Costs borne by families of children hospitalized in a 
pediatric intensive care unit: a pilot study. Swiss Med Wkly 2006; 136(49-50): 800-4. 
214. Schiller RM, van den Bosch GE, Muetzel RL, et al. Neonatal critical illness and development: white 
matter and hippocampus alterations in school-age neonatal extracorporeal membrane oxygenation 
survivors. Dev Med Child Neurol 2017; 59(3): 304-10. 
215. van den Akker CH, te Braake FW, Weisglas-Kuperus N, van Goudoever JB. Observational outcome 
results following a randomized controlled trial of early amino acid administration in preterm infants. 
J Pediatr Gastroenterol Nutr 2014; 59(6): 714-9. 
216. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40(2): 
280-93. 
217. Mehta NM. Parenteral Nutrition in Critically Ill Children. N Engl J Med 2016; 374(12): 1190-2. 
218. Mesotten D, Joosten K, van Kempen A, Verbruggen S, nutrition EEECwgopp. ESPGHAN/ESPEN/ESPR 
guidelines on pediatric parenteral nutrition: Carbohydrates. Clin Nutr 2018. 
219. Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Annu Rev 
Immunol 2012; 30: 611-46. 
220. Brantlov S, Jodal L, Lange A, Rittig S, Ward LC. Standardisation of bioelectrical impedance analysis for 
the estimation of body composition in healthy paediatric populations: a systematic review. J Med 
Eng Technol 2017; 41(6): 460-79. 
221. Butte NF, Hopkinson JM, Wong WW, Smith EO, Ellis KJ. Body composition during the first 2 years of 
life: an updated reference. Pediatr Res 2000; 47(5): 578-85. 
222. Fomon SJ, Haschke F, Ziegler EE, Nelson SE. Body composition of reference children from birth to age 
10 years. Am J Clin Nutr 1982; 35(5 Suppl): 1169-75. 
223. Wells JC, Williams JE, Chomtho S, et al. Pediatric reference data for lean tissue properties: density 
and hydration from age 5 to 20 y. Am J Clin Nutr 2010; 91(3): 610-8. 
224. Delisle Nystrom C, Soderstrom E, Henriksson P, Henriksson H, Poortvliet E, Lof M. The paediatric 
option for BodPod to assess body composition in preschool children: what fat-free mass density 
values should be used? Br J Nutr 2018; 120(7): 797-802. 
 
 
 
225. Silva C, Amaral TF, Silva D, Oliveira BM, Guerra A. Handgrip strength and nutrition status in 
hospitalized pediatric patients. Nutr Clin Pract 2014; 29(3): 380-5. 
226. van den Beld WA, van der Sanden GA, Sengers RC, Verbeek AL, Gabreels FJ. Validity and 
reproducibility of the Jamar dynamometer in children aged 4-11 years. Disabil Rehabil 2006; 28(21): 
1303-9. 
227. Nilsson PM. Genetics: telomere length and the metabolic syndrome-a causal link? Nat Rev Endocrinol 
2014; 10(12): 706-7. 
228. Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, Willeit P. Leucocyte telomere 
length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2014; 349: 
g4227. 
229. Bayley N. Bayley scales of infant and toddler development, third edition. San Antonio, TX: Harcourt 
Assessment, Inc., 2006. 
230. van der Meulen BF, Ruiter SAJ, Lutje Spelberg HC, Smrkovsky M. Bayley Scales of Infant Development-
II-Nederlandse Versie. Handleiding. Amsterdam: Harcourt Test Publishers; 2004. 
231. Harmsen WJ, Aarsen FJ, van der Cammen-van Zijp MHM, et al. Developmental problems in patients 
with oesophageal atresia: a longitudinal follow-up study. Arch Dis Child Fetal Neonatal Ed 2017; 
102(3): F214-F9. 
232. Madderom MJ, Toussaint L, van der Cammen-van Zijp MH, et al. Congenital diaphragmatic hernia 
with(out) ECMO: impaired development at 8 years. Arch Dis Child Fetal Neonatal Ed 2013; 98(4): 
F316-22. 
233. Teffer K, Semendeferi K. Human prefrontal cortex: evolution, development, and pathology. Prog 
Brain Res 2012; 195: 191-218. 
234. CBS. https://www.cbs.nl/nl-nl/nieuws/2016/20/zorguitgaven-stijgen-langzamer. 2016. 
235. Poley MJ, Stolk EA, Langemeijer RA, Molenaar JC, Busschbach JJ. The cost-effectiveness of neonatal 
surgery and subsequent treatment for congenital anorectal malformations. J Pediatr Surg 2001; 
36(10): 1471-8. 
236. Poley MJ, Stolk EA, Tibboel D, Molenaar JC, Busschbach JJ. The cost-effectiveness of treatment for 
congenital diaphragmatic hernia. J Pediatr Surg 2002; 37(9): 1245-52. 
237. Peters MJ, Argent A, Festa M, et al. The intensive care medicine clinical research agenda in 
paediatrics. Intensive Care Med 2017; 43(9): 1210-24. 
 
244 
APPENDICES	
 
 
 
LIST OF ABBREVIATIONS 
 
€ Euro 
ANT  Amsterdam Neuropsychological Tests 
ATC classification Anatomical therapeutical chemical classification 
BIA Bio-electrical impedance 
BRIEF Behaviour Rating Inventory of Executive Function  
CBCL Child Behaviour Checklist 
CI Confidence interval 
CMS Children's Memory Scale 
DBC ‘Diagnosis Therapy Combination’ (translation from Dutch) 
DXA Dual X-ray absorptiometry 
ECMO Extracorporeal membrane oxygenation 
EN Enteral nutrition 
EPaNIC Early versus Late Parenteral Nutrition in Critical Illness 
HDL High-density lipoproteins 
HR Hazard ratio 
ICU Intensive care unit 
IQ Intelligence quotient 
IQR Interquartile range 
LDL Low-density lipoproteins 
LOS Length of stay 
NTI Non-thyroidal illness 
OR Odds ratio 
PeLOD Paediatric Logistic Organ Dysfunction 
PEPaNIC Paediatric Early versus Late Parenteral Nutrition in Critical Illness 
PICU Paediatric intensive care unit 
PIM2 Paediatric Index of Mortality 2 
PN parenteral nutrition 
RCT Randomised controlled trial 
RRT Renal replacement therapy 
SD Standard deviation 
SE Standard error 
STRONGkids Screening Tool for Risk on Nutritional Status and Growth 
US$ American Dollar 
VLDL  Very-low-density lipoproteins 
VMI Visual-motor integration 
WAIS Wechsler Adult Intelligence Scale 
WHO World health organisation 
WISC-III-NL Wechsler Intelligence Scale for Children 
WPPSI Wechsler Preschool and Primary Scale of Intelligence 
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